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Probiotics and prebiotics are a hot topic in pediatric research. Human milk oligosaccharides
have been recognized to enhance the development of a bifidogenic microbiome in infants. In this
issue, many different clinical conditions are discussed in which probiotics and prebiotics can interfere
with the microbiome. This editorial for a special issue of Nutrients contains 17 papers, a mixture of
reviews and original research, reflecting the broad and evolving interest and researches in this topic,
such as diarrhea, atopic diseases, infantile colic, celiac, necrotizing enterocolitis, constipation. However,
in the pediatric age, manipulation of that microbiome still leads to inconclusive results as studies
provide often contradictory data. The inconclusive data may be explained by the fact that dysbiosis is
likely to be only one of several interfering factors causing these different conditions. In conclusion,
the manuscripts in this issue raise a lot of aspects and questions and offer challenges for future research.
The evolution of knowledge on this topic in recent years has allowed us to conclude that there
is currently sufficient enough evidence to conclude that the role of the gastro-intestinal microbiome
during the first month of life is crucial for a balanced development of the immune system. The interest
in the human microbiome and its interplay with the host has exploded and provided new insights
on its role in conferring host protection and regulating host physiology, including the correct
development of immunity [1,2]. Bifidobacterium breve is the dominant species in the gut of breast-fed
infants and it has also been isolated from human milk. It has antimicrobial activity against human
pathogens, it does not possess transmissible antibiotic resistance traits, it is not cytotoxic and it has
immuno-stimulating abilities [3]. Probiotic supplementation during pregnancy and in the neonatal
period might reduce some maternal and neonatal adverse outcomes [4]. The current evidence on the
efficacy of probiotics for the management of pediatric functional abdominal pain disorders, such as
functional constipation, irritable bowel syndrome, functional abdominal pain is rather disappointing
as no single strain, the combination of strains or synbiotics can be recommended for the management
of these conditions [5].
Allergic individuals have a different microbiome than non-allergic. The “microbiota hypothesis”
ties the increase in allergy rates observed in highly developed countries over the last decades to
disturbances in the gut microbiota [6]. Diaz et al showed that infants with non-IgE mediated allergy
have a different microbiome compared to healthy infants, while being on an elimination diet [7].
Moreover, the protein source (formula of vegetable origin, casein or whey hydrolysate) result in a
different composition of the microbiome [7]. The clinical relevance of these findings needs to be
further investigated. Lactobacillus (L.) administration might also be of interest in children with chronic
immune disorders, such as asthma [8]. Results of a prospective, double blind, randomized Chinese
study with four groups (L. paracasei, L. fermentum, their combination and placebo) showed lower asthma
severity and better Childhood Asthma Control Test scores [8]. The group treated with both probiotics
improved most, as increased peak expiratory flow rates and decreased IgE levels were shown [8].
Thus, lactobacillus administration, at least the strains tested, can contribute the clinical improvement
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in children with asthma [8]. A meta-analysis showed that L. rhamnosus GG was ineffective in the
reduction of atopic dermatitis [9].
Infantile colic is a common condition, occurring in about 20 % of all infants, of unknown
pathogenesis that causes frustration and anxiousness in families, which then seek effective
management [10]. Dysbiosis and chronic inflammation are likely to be part of the pathophysiologic
mechanisms of infantile colic [11]. A study from Ukraine showed that a combination of L. rhamnosus
19070-2 and L. reuteri and a small amount of a prebiotic, fructo-oligosaccharide (FOS), resulted in
a significant decrease of crying time compared to the natural evolution in the placebo group [12].
These data confirm previous literature, mainly using L. reuteri alone, showing that lactobacilli decrease
infantile colic in exclusively breastfed infants [13]. A probiotic mixture was also shown to reduce
crying time in exclusively breastfed infants compared to placebo, although no differences between the
groups were found regarding anthropometric data, bowel movements, stool consistency or microbiota
composition [14]. Unfortunately, data on the outcome of probiotic administration in formula fed
infants presenting with infantile colic are still missing. L. reuteri DSM 17938 may be considered for
the management of breastfed colic infants, while data on other probiotic strains, probiotic mixtures or
synbiotics are limited in infantile colic [5].
The ESPGHAN working group on probiotics and prebiotics recommended considering the
addition of some probiotic strains to oral rehydration therapy in the management of infants with acute
gastroenteritis [15]. The additional benefit of L. reuteri DSM 17938 and zinc was evaluated compared
to oral rehydration alone in a study, including 51 children with acute gastroenteritis [16]. Although
there was a trend that the probiotic and zinc supplemented group did better, the outcome was not
statistically significant better [16]. Two other large trials, with L. rhamnosus GG reported also a negative
outcome [17,18]. Bacillus clausii was tested in six randomized controlled trials, including 1298 [19].
Data arising from the pooled analysis showed that Bacillus clausii significantly reduced the duration
of diarrhea with a mean difference of -9.12 hours only compared with control. Stool frequency was
not significantly different after Bacillus clausii administration compared with the control group [19].
A randomized trial in India with Bacillus clausii compared to placebo reported a statistically significant
difference in duration of diarrhea of only six hours, with a difference of one defecation per day at
day 4 [20]. These findings question the importance of the selection of patients, and the strain selection
of the probiotic. Shortening of the duration of diarrhea might have been shown to be statistically
reduced, but may lack clinical significance of benefit [19].
The use of probiotics among very low-birth-weight infants is constantly increasing, as probiotics
are believed to reduce the incidence of severe diseases, such as necrotizing enterocolitis (NEC) and
late-onset sepsis and to improve feeding tolerance [21]. According to feeding type, the beneficial
effect of probiotics was confirmed only in exclusively human milk-fed preterm infants [22]. Fifty-one
randomized controlled trials were included in a review by the ESPGHAN working group on pre- and
probiotics, involving 11,231 preterm infants [23]. Most strains or combinations of strains were only
studied in one or a few trails [23]. Only 3 of 25 studied probiotic treatment combinations showed a
significant reduction in mortality rates [23]. Seven treatments reduced NEC incidence, two reduced
late-onset sepsis, and three reduced time until full enteral feeding [23]. Among human milk fed infants,
only probiotic mixtures, and not single-strain products, were effective in reducing late onset sepsis [22].
Human milk oligosaccharides (HMO) have a strong prebiotic effect, and stimulate the development of
a bifidogenic microbiome in breastfed infants.
HMOs may support immune function development and provide protection against infectious
diseases directly through the interaction of the gut epithelial cells or indirectly through the modulation
of the gut microbiota, including the stimulation of the bifidobacteria [24,25]. The limited clinical data
suggest that the addition of HMOs to infant formula seems to be safe and well tolerated, inducing
a normal growth and suggesting a trend towards health benefits [24]. Gut immaturity in preterm
infants leads to difficulties in tolerating enteral feeding and bacterial colonization and high sensitivity
to NEC, particularly when breast milk is insufficient [26]. The HMOs diversity and the levels of
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Lacto-N-difucohexaose I were found to be lower in samples from mothers of infants that developed
NEC, as compared to non-NEC cases at all sampling time points [27]. Lacto-N-difucohexaose I is
only produced by secretor and Lewis positive mothers. This is significant, but inconsistent with
associations between 3’-sialyllactose and 6’-sialyllactose, and culture-proven sepsis; and consists
of weak correlations between several HMOs and growth rate [27]. However, the benefit of HMO
supplementation in preterm infants is debated [26]. These findings highlight once more that a priority
research topic is the understanding why about 20% of the mothers are "non-secretors", since all data
suggest that infants of secretor mothers have a better health outcome than there of non-secretors.
Constipation is still a frequent functional gastro-intestinal disorder in infants, occurring in about
10 % [10]. In a Brazilian, randomized, placebo-controlled, double blind trial, fructo-oligosaccharides
(FOS) or placebo was given at a dosage of 6, 9 or 12 g daily based on the infants’ weight groups of
6.0–8.9 kg, 9.0–11.9 kg or over 12.0 kg, respectively [28]. Therapeutic success occurred in 83.3% of the
FOS group infants and in as much as 55.6% of the control group [28]. The placebo effect in this trial
was very high, suggesting again that reassurance is the cornerstone of the management of functional
disorders in infants. But, compared with the control group, the FOS group exhibited a higher frequency
of softer stools and fewer episodes of straining and/or difficulty passing stools [28]. Further, after one
month, the Bifidobacterium sp. count was higher in the FOS group [28].
Celiac disease is a chronic autoimmune enteropathy triggered by dietary gluten exposure in
genetically predisposed individuals [2]. Despite ascertaining that gluten is the trigger in celiac disease,
evidence has indicated that also intestinal microbiota is somehow involved in the pathogenesis,
progression, and clinical presentation of the disease [2]. Patients with celiac disease have an increased
abundance of Bacteroides spp. and a decrease in Bifidobacterium spp. [2]. A six-week multispecies
probiotic treatment improved the severity of irritable bowel syndrom-type symptoms, in celiac patients
on a strict glutenfree diet and was associated with a modification of gut microbiota, characterized
by an increase of bifidobacteria [28]. The role of prebiotics in the nutritional management of chronic
conditions, such as celiac disease in patients on a glutenfree diet is a different area of interest.
Iron deficiency anemia occurs in up to almost half of the patients diagnosed with celiac disease.
A randomised trial with an oligofructose enriched inulin administered during three months to celiac
patients failed to show a clear benefit of a bifidogenic microbiome on nutritional (ferritin, hemoglobin)
and inflammatory (C-reactive protein) parameters, although a decrease in hepcidin was shown [29].
Hepcidin is a key regulator of the entry of iron into the circulation and considered to be an interesting
and useful marker.
Different aspects of pro- and prebiotics in pediatrics are presented and discussed in this special
issue. The overall conclusion suggests that although there is a physiologic and patho-physiological
ground regarding the impact of a balanced microbiome on different health aspects in infants and
children, clinical outcomes are often contradictory. Future research and trials must reveal relevant
outcomes about which there is a consensus regarding. It should be mandatory to report the specific
strains of probiotics. Studies should be done with commercial products. Therefore, further research
on the impact of manipulation with probiotic and prebiotic of the gastrointestinal microbiome in
pediatrics is still needed.
Conflicts of Interest: The author declares no conflict of interest.
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Abstract: Acute diarrhea is a burdensome disease with potentially harmful consequences, especially
in childhood. Despite its large use in clinical practice, the efficacy of the probiotic Bacillus clausii in
treating acute childhood diarrhea remains unclear. Our objective was to systematically review the
efficacy of Bacillus clausii in the treatment of acute childhood diarrhea. The following electronic
databases were systematically searched up to October 2017: MEDLINE (via PubMed/OVID),
EMBASE (via OVID), Cochrane Central Database of Controlled Trials (via CENTRAL), Google
Scholar, and ClinicalTrials.gov. Only randomized controlled trials were included. The overall effect
for the meta-analysis was derived by using a random effects model. Six randomized controlled
trials (1298 patients) met the eligibility criteria. Data arising from pooled analysis showed that
Bacillus clausii significantly reduced the duration of diarrhea (mean difference = −9.12 h; 95%
confidence interval [CI]: −16.49 to −1.75, p = 0.015), and the duration of hospitalization (mean
difference = −0.85 days; 95% CI: −1.56 to −0.15, p = 0.017), compared with control. There was a trend
of decreasing stool frequency after Bacillus clausii administration compared with the control group
(mean difference = −0.19 diarrheal motions; 95% CI: −0.43 to −0.06, p = 0.14). Bacillus clausii may
represent an effective therapeutic option in acute childhood diarrhea, with a good safety profile.
Keywords: acute diarrhea; children; Bacillus clausii; efficacy; randomized controlled trials
1. Introduction
Diarrhea refers to the abrupt onset of three or more loose or liquid stools per day [1]. More
specifically, acute diarrhea is defined as an abnormally frequent discharge of semi-solid or fluid fecal
matter from the bowel, lasting less than 14 days [2]. Although it is a preventable disease, acute
diarrhea remains a major cause of morbidity and mortality in children worldwide, resulting in 525,000
deaths per year among those younger than five years. Most of these mortalities occur in developing
countries [1]. Other direct consequences of diarrhea in children include growth faltering, malnutrition,
and impaired cognitive development [3]. Acute diarrhea in children is caused by a wide range of
pathogens—including viral, bacterial, and protozoal pathogens—which makes overcoming the high
disease burden a large challenge [4].
Currently, the World Health Organization (WHO) recommends treatment of acute childhood
diarrhea with oral rehydration salts (ORS) and continued feeding for the prevention and treatment of
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dehydration, as well as zinc supplementation to shorten the duration and severity of the diarrheal
episode [1]. Probiotics are living micro-organisms that, upon ingestion in certain numbers, exert health
benefits beyond inherent general nutrition [5]. It has been suggested that probiotics modulate the
immune response, produce antimicrobial agents, and compete in nutrient uptake and adhesion sites
with pathogens [6–8].
Bacillus clausii is a rod-shaped, non-pathogenic, spore-forming, aerobic, Gram-positive bacterium
that is able to survive transit through the acidic environment of the stomach and colonize the intestine
even in the presence of antibiotics [9]. Prospective clinical trials conducted in adult subjects found
Bacillus clausii to be effective and safe in the treatment and prevention of acute diarrhea [10,11].
In a prospective, Phase II clinical trial of Bacillus clausii in 27 adult patients with acute diarrhea,
the mean ± standard deviation (SD) duration of diarrhea decreased from 34.81 ± 4.69 min at baseline
to 9.26 ± 3.05 (p < 0.0001) minutes per day after 10 days of Bacillus clausii therapy. The mean ± SD
frequency of defecation also decreased from 6.96 ± 1.05 to 1.78 ± 0.50 (p < 0.0001) times per day,
abdominal pain decreased from 3.22 ± 0.93 (severe) to 0.74 ± 0.71 (absent) (p < 0.0001), and stool
consistency improved from 3.93 ± 0.38 (watery) to 1.22 ± 0.42 (soft) (p < 0.0001). No significant change
in safety parameters was observed during treatment with Bacillus clausii. Thus, the study concluded
that Bacillus clausii can potentially be effective in alleviating the symptoms of diarrhea without causing
any adverse effects [11].
The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)
and the European Society of Pediatric Infectious Diseases (ESPID) currently recommend the use of
Lactobacillus rhamnosus GG and Saccharomyces boulardii in the management of children with acute
diarrhea as an adjunct to rehydration therapy, whereas a recommendation for Bacillus clausii is missing
due to limited data [12]. The aim of this paper is to systematically review randomized controlled trials
that assessed the efficacy and safety of Bacillus clausii in the treatment of acute childhood diarrhea.
According to our knowledge, no systematic reviews with meta-analyses addressing the effectiveness
of Bacillus clausii in acute pediatric diarrhea have yet been published. We will focus only on studies
using Bacillus clausii as a probiotic, because critics of using a meta-analytical approach to assess the
efficacy of probiotics argue that beneficial effects of probiotics seem to be strain-specific.
2. Methods
2.1. Criteria for Considering Studies for this Review
We included randomized controlled trials conducted among children under 18 years of age with
acute diarrhea (≤14 days). Patients in the experimental groups had to receive Bacillus clausii at any dose
and in the following four bacterial stains: O/C, SIN, N/R, and T. Patients in the control groups had
to receive either a placebo, an appropriate standard of care for acute diarrhea in lieu of the probiotic,
or no treatmentcontrol. The designations of these bacterial strains are derived from their resistance to
diverse antibiotics: O/C is resistant to chloramphenicol, SIN to neomycin and streptomycin, N/R to
novobiocin and rifampin, and T to tetracycline [13].
The primary outcome measures were duration of diarrhea, stool frequency after intervention, and
hospitalization duration. The secondary outcome measures were vomiting episodes, quality of life,
and adverse events. All randomized controlled trials regardless of language or publication date or state
(published, unpublished, in press, and in progress) were included in the review. Studies investigating
probiotics other than Bacillus clausii (including synthetic microbiota suspensions), as well as those
conducted in adult subjects or in children receiving Bacillus clausii for indications other than acute
diarrhea were excluded. In vitro/vivo studies, observational studies, narrative/systematic reviews,
case reports, letters, editorials, and commentaries were also excluded, but read to identify potential
additional studies.
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2.2. Search Strategy for Identification of Studies
The following electronic databases were systematically searched up to October 2017 for relevant
studies: MEDLINE (via PubMed/OVID), EMBASE (via OVID), Cochrane Central Database of
Controlled Trials (via CENTRAL), Google Scholar, and ClinicalTrials.gov (https://clinicaltrials.gov).
The last literature search was conducted on 23 October 2017. The text word terms used were:
Bacillus clausii; Enterogermina; probiotic; probiotics; diarrhea; diarrhoea; acute diarrhea; acute
diarrhoea; diarrh *; children; child *; pediatric; and pediatr *. In addition, we hand-searched the
bibliographies of papers of interest to provide additional references. Relevant meeting abstracts via
EMBASE and the International Probiotic Conference were also hand-searched. When needed, we
contacted the authors for additional data and clarification of study methods. Finally, the pharmaceutical
company Sanofi-Aventis Group (Paris, France), which manufactures Bacillus clausii was contacted to
identify further published and unpublished studies. No limit was imposed regarding the language
of publication, and both studies published as full text or as abstracts at conferences/proceedings of
scientific meetings were included in the review.
2.3. Study Selection
Titles and abstracts of publications identified according to the above described search strategy
were independently screened by two reviewers (G.I. and G.R.). All potentially relevant articles were
retained and the full text of these studies were examined to determine which studies satisfied the
inclusion criteria. In the case of any differences of opinion or disagreements between the two reviewers,
an adjudicator (A.G.) was consulted.
2.4. Data Extraction
Data extraction was carried out independently by two reviewers (G.I. and G.R.), using a data
collection form designed for this review prepared in Microsoft Excel 2013 (Microsoft, Redmond, WA,
USA). Discrepancies between the two reviewers were resolved by discussion. Information about
the study design and outcomes was verified by all reviewers. Authors’ names, publication year,
study design, study location, study duration, inclusion and exclusion criteria, interventions, type of
comparator, number of patients, age and gender of included patients, outcomes, and adverse events
were extracted from each study. To keep track of study references, EndNote version X7.71 (Thomson
Reuters, New York, NY, USA) was used.
2.5. Quality Assessment
To assess the methodological quality of each study included in the review, two reviewers (G.I. and
G.R.) independently performed a risk of bias assessment using the criteria (generation of allocation
sequence; allocation concealment; blinding of investigators, participants, outcome assessors, and data
analysts; intention-to-treat (ITT) analysis; and comprehensive follow-up) described by the Center
for Reviews and Dissemination (CRD)’s guidance for undertaking reviews in health care (2009) [14].
For each criterion, the risk of bias was assessed answering the respective questions with ‘yes’, ‘no’,
or ‘unclear’ and the overall quality of each study was rated « good », « fair » or «poor ».
2.6. Statistical Methods
Mean values and SDs of diarrhea duration, number of stools, and hospitalization duration were
extracted to calculate the mean difference between the treatment and control groups for each of these
outcomes. Overall effect for each meta-analysis was derived by using a random effects model, which
takes between-study variation into account [15]. We also reported the corresponding 95% confidence
intervals (CI) and p-values. Statistical heterogeneity between studies was assessed by using Cochran’s
Q test and I-squared [16]. An I2 value of 0% indicates no observed heterogeneity, and larger values
show increasing heterogeneity.
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The risk of publication bias was assessed by visual inspection of Begg’s funnel plots. Formal
statistical assessment of funnel plot asymmetry was also done using Egger’s regression asymmetry
test and Begg’s adjusted rank correlation test [17]. All statistical analyses were conducted by using the
metafor package (Maastricht University, Maastricht, NL, USA) [18]. p-Values < 0.05 were considered
statistically significant.
3. Results
3.1. Characteristics of Included Studies
The literature search retrieved 2165 potential relevant citations. After carefully reviewing the titles
and abstracts, 2154 citations were excluded. For the remaining 11 citations, full papers were obtained
and reviewed. After a full-text assessment, six citations were included in the final database, and five
excluded for the following reasons: two studies were non-randomized, one study was conducted in an
adult population, one was a review article, and one was a commentary. The flow diagram of the study
selection process is given in Figure 1.
Figure 1. Flow diagram of the study selection process.
Table 1 summarizes the characteristics of the six randomized controlled trials included in the
review, which were published between 2007 and 2015. Of these, one was performed in Italy [19],
one in Kenya [20], one in the Philippines [21], and three in India [22–24]. Three of the included
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studies were published as original articles [19,23,24], one as a meeting abstract [21], one as a Master’s
dissertation [20], and one as a clinical study report [22]. Of the six studies, two were conducted
in a multicentric setting [19,22]. All six studies included an outcome for diarrhea duration, four
included an outcome for stool frequency [19,20,22,24], and three included an outcome for duration of
hospitalization [20,21,23].
Overall, 1298 patients were enrolled in the six selected studies. Among these, 467 patients were
treated with Bacillus clausii. In the Canani et al. (2007) study [19], patients were allocated to six different
groups: a control group (n = 92), a group treated with Bacillus clausii (n = 100), a group treated with
Lactobacillus casei (n = 100), a group treated with Saccharomyces boulardii (n=91), a group treated with
Lactobacillus delbrueckii var bulgaricus, Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium
bifidum (n = 97), and a group treated with Enterococcus faecium (n = 91). All groups, with the exception
of the control group and the group receiving Bacillus clausii were excluded from this meta-analysis.
Thus, in total, 919 patients were included in the meta-analysis (467 in the experimental group and 452
in the control group). The age of the patients ranged from 3 months to 12 years. Four studies enrolled
inpatients [20,21,23,24], whereas two enrolled outpatients [19,22].
In all six clinical trials, the control group was treated with ORS. In the Canani et al. (2007)
study [19], the control group (n = 92) was given an oral rehydration solution for 3 to 6 h and then fed
with a full-strength milk formula containing lactose or cows’ milk, depending on age. In the three
Indian studies, the control group (n = 132 in the Lahiri trial [22]; n = 80 in the Lahiri, D’Souza et al.
trial [24]; and n = 62 in the Lahiri, Jadhav et al. trial [23]) received ORS with zinc supplementation.
The control group in the Urtula and Dacula (2008) study (n = 35) received ORS alone [21]. Finally,
the control group in the Maugo (2012) study (n = 51) received in addition to zinc sulfate and ORS,
one vial twice daily of a placebo packaged in identical looking vials containing sterile water [20].
Concerning the interventions in the experimental group, in one study, the daily dosage of Bacillus clausii
was 1 × 109 colony-forming units (CFU) administrated twice daily [19], while in four other studies,
children were administered 2 × 109 CFU of Bacillus clausii twice daily [20,22–24], and in the Urtula and
Dacula (2008) trial, 2 × 109 or 4 × 109 CFU of Bacillus clausii were administrated per day, depending on
the age of the children [21]. In all studies, the experimental group received ORS in addition to Bacillus
clausii therapy. Moreover, zinc supplementation was also added to the treatment of the experimental
group in four studies [20,22–24]. The duration of the interventions was five days in all clinical trials,
with the exception of the Urtula and Dacula (2008) trial [21] which treated patients for three days.
3.2. Risk of Bias within Included Studies
The methodological quality of the clinical trials varied (Table 2). Three studies [19–21] were
rated as adequate for both generation of the allocation sequence and allocation concealment. In the
remaining three studies, the method used for allocation sequence and allocation concealment was
unclear [22–24]. In only one study [20], care providers, participants, and outcome assessors were
blind to treatment allocation. In the Canani et al. (2007) study [19] and in the Lahiri (2008) trial [22],
analyses were conducted on an ITT basis. Three studies [21,23,24] were unclear for an ITT analysis,
and the Maugo (2012) trial [20] did not include an ITT analysis. Loss to follow-up was adequate in two
studies [20,22], and was unclear in the remaining four studies [19,21,23,24]. The overall quality was
assessed, with two studies [19,20] rated as ‘good’ (low risk for bias), two other studies [21,22] which
were susceptible to some bias rated as ‘fair’, and the remaining two studies [23,24] were rated as ‘poor’
(high risk for bias).
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3.3. Primary Findings
All six studies contained data on the duration of diarrhea. Compared to the control group (n = 441),
the change in diarrhea duration in patients treated with Bacillus clausii (n = 457) ranged from −24.4 to
+2.5 h among included studies. In the Canani et al. (2007) trial [19], duration of diarrhea was expressed
as median (interquartile range [IQR]) duration, whereas in three studies [20–22], it was expressed as
mean (SD) duration, and in two studies [23,24], it was simply expressed as mean duration. According
to the Cochrane Reviewers’ Handbook 4.2.2 (2004) [25] and assuming normal distribution, median
duration of diarrhea in the Canani et al. (2007) study [19] was treated as a mean value, and the width
of IQR was considered as 1.35 × SD. After this conversion, a meta-analysis of the six randomized
controlled trials (898 participants) showed a significant reduction in the duration of the diarrhea (mean
difference = −9.12 h, 95% CI: −16.49 to −1.75) for those treated with Bacillus clausii compared to
ORS with or without zinc supplementation (p = 0.015) (Figure 2). The heterogeneity test for diarrhea
duration showed a substantial heterogeneity between the six studies (Cochrane’s Q test, p = 0.02,
I2 = 63.4%).
Figure 2. Forest plot showing effect of Bacillus clausii on mean duration of diarrhea. CI, confidence
interval, RE, random effects.
Four studies (697 participants) evaluated stool frequency after intervention [19,20,22,24]. In the
Canani et al. (2007) trial [19], daily stool frequency was expressed as median (IQR), and it was evaluated
from the first day of Bacillus clausii administration up to day 7. In the Maugo (2012) study [20], daily
diarrheal output was expressed as mean (SD), and it was also evaluated from day 1 of Bacillus clausii
administration up to day 7. In the Lahiri (2008) trial [22], daily diarrheal output was expressed as both
mean (SD) and median (range) values, and it was evaluated from day 1 of Bacillus clausii administration
up to day 6. Finally, in the Lahiri, D’Souza et al. (2015) study [24], stool frequency was expressed as
a mean value, and it was assessed before and after treatment with Bacillus clausii. Similarly to the
duration of diarrhea, median stool frequency in the Canani et al. (2007) study [19] was treated as a
mean value, and the width of IQR was considered as 1.35 × SD [25]. Pooling the results of the four trials
showed that Bacillus clausii reduces the stool frequency after intervention (mean difference = −0.19
diarrheal motions, 95% CI: −0.43 to −0.06, p = 0.14) compared with the control group which received
ORS with or without zinc supplementation (Figure 3). The heterogeneity test for stool frequency
after intervention revealed a slight heterogeneity between the four trials (Cochrane’s Q test, p = 0.22,
I2 = 32.9%).
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Figure 3. Forest plot showing effect of Bacillus clausii on mean stool frequency. CI, confidence interval,
RE, random effects.
Finally, duration of hospitalization was assessed in three studies [20,21,23] among 291 patients.
In the Maugo (2012) study [20], hospitalization duration was expressed as mean (SD), whereas in
the two other trials [21,23], it was simply expressed as mean. Based on the results of these three
clinical trials [20,21,23], there was a significant reduction in the duration of hospitalization (mean
difference = −0.85 days, 95% CI: −1.56 to −0.15) for those treated with Bacillus clausii compared to
ORS with or without zinc (p = 0.017) (Figure 4). The heterogeneity test for duration of hospital stay
showed a substantial heterogeneity between the three studies (Cochrane’s Q test, p = 0.03, I2 = 71.3%).
Figure 4. Forest plot showing effect of Bacillus clausii on mean duration of hospitalization. CI, confidence
interval, RE, random effects.
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3.4. Secondary Findings
Two clinical trials [19,22] included an outcome related to the incidence and/or duration of
vomiting episodes among 447 patients. In the Canani et al. (2007) trial [19], both median (IQR)
duration of vomiting and the number (%) of children experiencing vomiting episodes were similar
in the group treated with Bacillus clausii (n = 100) and in the control group (n = 92). In the control
group, 34 children (37%) experienced vomiting episodes versus 32 children (32%) in the Bacillus clausii
group (p = 0.47). Similarly, the median (IQR) vomiting duration was 2 (1–2) days in the control group
versus 1.5 (1–2) days in the group treated with Bacillus clausii (p = 0.25). In the Lahiri (2008) study [22],
the mean ± SD number of vomiting episodes on day 4 of treatment was 0.1 ± 0.6 in the Bacillus clausii
+ ORS group (n = 129) versus 0.2 ± 0.6 in the ORS group (n = 126). Hence, the difference in the mean
number of vomiting episodes was not statistically significant between the two groups (p = 0.79).
The studies [19,22] did not report any serious adverse effects related to Bacillus clausii. According
to Canani and colleagues [19], treatment by Bacillus clausii was well tolerated, and no adverse events
were observed. In the Lahiri (2008) trial [22], 40/129 patients (31%) from the Bacillus clausii + ORS
group and 39/126 patients (31%) from the ORS group experienced undesirable side effects. There was
no statistically significant difference in the number of patients experiencing adverse events between
the two groups (p = 0.48). Vomiting was the most reported adverse event in both the Bacillus clausii +
ORS group (20/129; 15.5%) and the ORS group (17/126; 13.5%).
Outcomes related to quality of life were not reported in any of the studies included in
the meta-analysis.
3.5. Publication Bias
The publication bias was assessed by using a funnel plot depicting the mean differences in
duration of diarrhea, stool frequency, and duration of hospital stay against their effect sizes as a measure
of precision. A slight asymmetry was seen in Begg’s funnel plot for duration of diarrhea, resulting in
evidence of publication bias (Egger’s test, p = 0.02). In contrast, duration of hospital stay and stool
frequency showed neither asymmetry nor evidence for publication bias (Egger’s test, p = 0.55 for
hospitalization duration and p = 0.11 for stool frequency).
4. Discussion
We conducted a systematic review and a meta-analysis of randomized controlled trials to estimate
the efficacy of Bacillus clausii in the treatment of acute diarrhea in children. Results of this systematic
review indicate that Bacillus clausii combined with ORS might significantly reduce the duration of
acute childhood diarrhea and the duration of hospital stay compared to ORS alone.
To our knowledge, this is the first systematic review focusing on randomized controlled trials of
Bacillus clausii in acute childhood diarrhea. In this review, the duration of diarrhea was reduced by
a mean of 9.12 h with Bacillus clausii treatment compared to controls (p = 0.015). These findings were
replicated in a prospective, phase II, Indian clinical study conducted among 27 adult patients with
acute diarrhea treated with 2×109 CFU of Bacillus clausii twice daily for a duration of 10 days, in which
mean ± SD duration of diarrhea decreased from 34.81 ± 4.69 min at baseline to 9.26 ± 3.05 (p < 0.0001)
minutes per day after 10 days of Bacillus clausii administration [11]. In contrast, in the Canani et al.
(2007) trial [19], it was found that the duration of diarrhea in patients receiving Bacillus clausii was
similar to that in the group receiving only oral rehydration, with an estimated difference of one hour
between the control group and the group treated with Bacillus clausii (p = 0.76). The difference between
the overall results of our meta-analysis and the results of the Canani et al. (2007) trial [19] may be
due to the difference in the prescribed dosage of Bacillus clausii in the different randomized controlled
trials and the zinc supplementation provided in some study protocols [20,22–24]. In the other studies,
children were administered 4 × 109 CFU of Bacillus clausii per day [20,22–24], while in the Canani et al.
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(2007) trial [19], children received 2 × 109 CFU of Bacillus clausii per day, which also corresponds to the
prescribed dosage of Bacillus clausii in the younger children of the Urtula and Dacula (2008) study [21].
Our results also showed that administration of Bacillus clausii preparations significantly reduced
the duration of hospitalization by a mean of 0.85 days compared to controls (p = 0.017). The reduction
of hospital stay by Bacillus clausii is important considering that in low-income countries, children
under three years old experience on average three episodes of diarrhea every year [1]. Moreover,
a 2008 study set in in Vellore, India, in 439 children under the age of five years found that median
household expenditures incurred per diarrheal episode ranged from 2.2% to 5.8% of the household’s
annual income [26]. Similarly, a 2013 cross-sectional study set in Bolivia and conducted among 1107
caregivers of pediatric patients (<5 years of age) with diarrhea found that 45% of patients’ families
paid ≥1% of their annual household income for a single diarrheal episode [27]. Thus, diarrheal disease
in children constitutes a considerable worldwide economic burden. The results of this systematic
review are of particular importance, since these reductions in the length of hospital stay and duration
of diarrhea that were obtained with Bacillus clausii in our analysis may offer significant social and
economic benefit in the treatment of acute childhood diarrhea, particularly in low- and middle-income
countries. In addition, in the Lahiri, Jadhav et al. (2015) study [23], treatment with Bacillus clausii
reduced total treatment costs by 472 Indian rupees compared to ORS alone. Further studies may
be needed to clarify the cost-effectiveness of Bacillus clausii preparations in treating children with
acute diarrhea.
The effect of Bacillus clausii on stool frequency reduction compared to ORS alone did not reach
statistical significance after pooling the results of four clinical trials (p = 0.14). This result could have
different explanations. First, assessing such a specific outcome, as stool frequency can be challenging.
Moreover, these four studies [19,20,22,24] differed in sample size, study design, and treatment protocols.
Consequently, large studies might be needed to clarify the efficacy of Bacillus clausii on stool frequency
reduction in acute pediatric diarrhea.
Our systematic review suggested that treatment with Bacillus clausii is well tolerated, without
causing serious adverse events. This finding is consistent with the safety results of the prospective,
Phase II clinical trial conducted in 27 adult patients with acute diarrhea which found no significant
change in safety parameters during treatment with Bacillus clausii [11]. Additionally, in a 2004
single-center, double-blind, prospective, randomized, placebo-controlled study performed in 120
consecutive Helicobacter pylori-positive adult patients free from gastrointestinal symptoms, it was
found that Bacillus clausii treatment during and after a standard seven-day anti-Helicobacter pylori
regimen was also associated with lower incidence of self-reported side-effects and a better tolerability
to multiple antibiotic treatment when compared with placebo (p < 0.05) [10].
Between-trial heterogeneity was detected for diarrhea duration and duration of hospital stay.
This heterogeneity among the included studies could be partially explained by trials at high/unclear
risk of bias for sequence generation, allocation concealment, and/or blinding. Indeed, only one
included study was double-blinded [20], whereas the five other studies were either single-blinded [19],
open-label [22–24], or had unclear blinding [21]. However, a slight heterogeneity for stool frequency
after intervention was detected, reflecting an apparent effect of Bacillus clausii administration on stool
frequency reduction compared with the control group.
Several mechanisms have been proposed to explain the effect of Bacillus clausii against acute
childhood diarrhea. Urdaci and colleagues found Bacillus clausii to possess antimicrobial and
immunomodulatory activities. Moreover, Bacillus clausii strains were found to release antimicrobial
substances in the medium, and this was observed during stationary growth phase and coincided
with sporulation. These substances were active against Gram-positive bacteria, in particular against
Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile. The antimicrobial activity of Bacillus
clausii was resistant to subtilisin, proteinase K, and chymotrypsin treatment, whereas it was sensitive
to pronase treatment [28]. The ability of Bacillus clausii spores to germinate during gastrointestinal
transit and grow as vegetative cells both in the presence of bile and under limited oxygen availability
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was also described in an experimental study by Cenci et al. (2006) [29]. Additionally, Bacillus clausii
O/C supernatant was found to reduce the cytotoxic effects of Clostridium difficile and Bacillus cereus
toxins through the secreted alkaline serine M-protease [30]. Finally, the production of vitamin B2
by Bacillus clausii (strains O/C, N/R, SIN, and T) was compared with that of other probiotics in an
in vitro agar-diffusion assay, and it was found that only Bacillus clausii and Bacillus subtilis permitted
the growth of MS0057, a riboflavin-auxotrophic mutant of Bacillus cereus, which indicates secretion
and diffusion of vitamin B2 in the solid medium [31]. These results are consistent with the beneficial
effects evidenced for Bacillus clausii preparations in our study.
Our review had limitations that must be considered while interpreting our results. Three studies
had unclear sequence generation and allocation concealment, five had inadequate or unclear blinding,
and four were unclear for or had no ITT analysis. In addition, the definition of diarrhea, the
termination of diarrhea, and inclusion and exclusion criteria varied among the included studies.
In our meta-analysis, we also noticed publication bias detected for diarrhea duration. A key strength of
the study comes from the fact that only a clearly defined probiotic micro-organism mix of four Bacillus
clausii strains was assessed. Moreover, all treatments received by the control groups in the included
studies were standardized consisting of ORS with or without zinc supplementation. Only the control
group in the Maugo (2012) study received a placebo [20].
In summary, our results indicate that Bacillus clausii might represent an effective therapeutic
option in acute childhood diarrhea, with a good safety profile. One limitation of this meta-nalysis is
represented by the heterogeneity we found among studies, that prevent us from drawing definitive
conclusions. Further, well designed studies are needed to confirm our findings.
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Abstract: The authors reviewed the published evidence on the presence of oligosaccharides in
human milk (HMO) and their benefits in in vitro and in vivo studies. The still limited data of trials
evaluating the effect of mainly 2′-fucosyllactose (2′-FL) on the addition of some of HMOs to infant
formula were also reviewed. PubMed was searched from January 1990 to April 2018. The amount
of HMOs in mother’s milk is a dynamic process as it changes over time. Many factors, such as
duration of lactation, environmental, and genetic factors, influence the amount of HMOs. HMOs may
support immune function development and provide protection against infectious diseases directly
through the interaction of the gut epithelial cells or indirectly through the modulation of the gut
microbiota, including the stimulation of the bifidobacteria. The limited clinical data suggest that
the addition of HMOs to infant formula seems to be safe and well tolerated, inducing a normal
growth and suggesting a trend towards health benefits. HMOs are one of the major differences
between cow’s milk and human milk, and available evidence indicates that these components do
have a health promoting benefit. The addition of one or two of these components to infant formula is
safe, and brings infant formula closer to human milk. More prospective, randomized trials in infants
are need to evaluate the clinical benefit of supplementing infant formula with HMOs.
Keywords: breast feeding; formula feeding; human milk oligosaccharide; 2′-fucosyllactose;
Lacto-N-neotetraose; microbiota; bifidobacteria
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1. Introduction
Breast milk is the natural and ideal food for infants, providing the energy and nutrients that
every infant needs during the first four to six months of life in the correct quality and amount. Infants
who are breastfed for shorter periods or are not breastfed suffer more infectious diseases, such as
gastroenteritis and acute otitis media, more immune-mediated diseases, have a lower intelligent
quotient (IQ) and are likely to have a higher risk of being overweight and type 2 diabetes in later
life [1,2]. However, any breastfeeding is beneficial. In a pooled analysis of 24 studies from the USA
and Europe, for example, any form of breastfeeding was found to be protective for acute otitis media
in the first two years of life, but exclusive breastfeeding for the first six months was associated with
the greatest protection [3].
The composition of breast milk is unique. Aside from nutrients for the infant’s healthy growth and
development, it contains thousands of bioactive substances [4], including human milk oligosaccharides
(HMOs) [5]. HMOs are non-digestible carbohydrates [6]. Although they have little nutritional value
for the infant, HMOs are the third largest solid component in human milk after lactose and lipids [7,8].
More than 200 free oligosaccharide structures have so far been identified from human milk samples [9].
Compared to human milk, oligosaccharide concentrations in the milk of farm animals, such as cows,
goats, and sheep are 100–1000-fold lower. In fact, these unique complex carbohydrate structures in
human milk are virtually absent in cow’s milk or any other farmed animal milk, and their variety is
much lower [10]. The difference in oligosaccharide content on human milk and cow milk, and, thus,
cow milk-based infant formula, is likely to explain, at least in part, the differences in health outcomes
between formula and breastfed infants.
2. Human Milk Oligosaccharides
Around 1900, infant mortality rate (deaths in the first year of life per 1000 live births) in Europe
was very high at up to and above 20% [11,12]. Mortality was especially high in non-breastfed infants
and was seven times greater in bottle-fed than breastfed infants [11,13]. It was around this time
that differences in stool bacterial composition were discovered between breastfed and formula-fed
infants and both breastfeeding and the resulting gut microbiota were linked to the better health of
the infants [11,13]. In the 1930s, oligosaccharides were identified as the most important bifidogenic
factor in human milk [11]. The most abundant oligosaccharides in human milk were discovered
in 1954. However, it was only recently that scientists and industry were able to produce the first
oligosaccharides structurally identical to those in human milk [14]. It is important to note that HMOs
resist cold and heat and are not affected by pasteurization and freeze-drying [15,16].
The amount of HMOs is 20–25 g/L in colostrum and 10–15 gram per liter (g/L) in mature milk,
or 1.5–2.3 g/100 kcal assuming an energy density of human milk of 64 kcal/100 mL [13,17]. Three major
HMO categories are present in breast milk: (i) fucosylated neutral HMOs (35–50%); (ii) sialylated acidic
HMOs (12–14%), and (iii) non-fucosylated neutral HMOs (42–55%) [18,19]. Neutral HMOs account for
more than 75% of the total HMOs in human breast milk. 2′-fucosyllactose (2′-FL) is part of the fucosylated,
while Lacto-N-neotetraose (LNnT) is part of the non-fucosylated neutral HMOs. In women who are
“secretors”, 2′-FL is by far the most abundant HMO and constitutes nearly 30% of all HMOs.
All HMOs are synthesized in the mammary gland [20]. The amount and composition of HMOs
vary between women and over the course of lactation. HMO concentration is higher during the early
stages of lactation and decreases gradually over time [21–23]. The Lewis antigen system is a human
blood group system based upon two genes on chromosome 19: fucosyltransferase-3 (FUT3), or Lewis
gene; and FUT2, or Secretor gene. FUT2 has a dominant allele which codes for an enzyme and
a recessive allele which does not produce a functional enzyme. Similarly, FUT3 has a functional
dominant allele and a non-functional recessive allele. A recent study could not confirm the observation
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that the content of HMOs is also higher after a term than preterm delivery [24]. The most extreme
intra individual variation in HMO fucosylation is based on the maternal secretor and Lewis blood
group status [13,20,24]. Both the FUT2 or secretor gene and the FUT3 or Lewis gene are expressed in
glandular epithelia. The secretor (Se) gene encodes for the FUT2 which is necessary for the synthesis
of 2′-FL and other Fucosyl-HMOs and is expressed in the lactating mammary gland. The milk
of secretor (Se+) women is, therefore, characterized by an abundance of α1-2-fucosylated HMOs,
especially 2′-FL [6,13,24]. Non-secretors, by contrast, lack the FUT2 enzyme and, therefore, their milk
does not contain 2′-FL and other α1-2-fucosylated HMOs, or is in only minimal amounts [6,25].
The absence of 2′-FL and other α1-2-fucosylated HMOs explains the lower total amount of HMOs
in “non-secretor” milk [20]. For example, a recent study found approximately 35% to 45% less total
HMOs in the milk of non-secretor Lewis-positive women than in the milk of Lewis-positive secretor
women [20]. The acidic HMOs do not depend on secretor status [20].
Based on the expression of FUT2 and FUT3, breast milk can be assigned to one of four groups
(Table 1) [13]:
Group 1: Secretors, Lewis-positive, (Se+Le+) (FUT2 active, FUT3 active)
Group 2: Non-secretors, Lewis-positive, (Se−Le+) (FUT2 inactive, FUT3 active)
Group 3: Secretors, Lewis-negative (Se+Le−) (FUT2 active, FUT3 inactive)
Group 4: Non-secretors, Lewis-negative (Se−Le−) (FUT2 inactive, FUT3 inactive)
Table 1. Diversity of human milk oligosaccharides (HMO) based on genetic background of the mother.
Gene Lewis Gene + Lewis Gene −
Secretor gene +
Lewis positive secretors Lewis negative secretors
Secrete all HMOs Secrete 2′-FL, 3′-FL, LNFP-I, LNFP-III
Secretor gene −
Lewis positive non-secretors Lewis negative non-secretors
Secrete 3′-FL, LNFP-II and
LNFP III Secrete 3
′-FL, LNFP-III and LNFP-V
2′-FL: 2′-fucosyllactose; 3′-FL: 3′-fucosyllactose; LNFP: Lacto-N-fucopentaose.
About 80% of the European and American women are secretors [26]. About 70% of the populations
are Lewis-positive secretors (Se+Le+) and around 5–10% are Lewis-negative secretors (Se+Le−) [27].
However, other factors also influence HMO synthesis. A recent study showed that HMO content and
profiles vary geographically, even when secretor and Lewis blood group genes were considered [20,28].
Findings on HMO concentrations over time of lactation and clusters bas ed on 2′-FL concentrations
suggest that LNnT and Lacto-N-Tetraose (LNT) are ‘co-regulated’ with the FUT2 dependent 2′-FL
concentration, with LNnT showing a positive and LNT a negative relation to the amount of 2′-FL [6].
Mothers’ milk with low levels of 2′-FL also contains low levels of LNnT but high levels of LNT [6].
The clinical impact of these findings still needs to be unraveled.
The European Union (EU) considers two HMOs, 2′-FL and LNnT, novel foods (Commission
Implemented Regulation (EU) 2017/2470). Today, the USA’s FDA considers three HMOs to be
Generally Regarded as Safe (GRAS notice no 650). On 29 June 2015, the European Food Safety
Authority (EFSA), based on the scientific and technical information provided, concluded that 2′-FL is
safe for infants up to one year of age when added to infant and follow-on formulae, in combination
with LNnT, at concentrations up to 1.2 g/L of 2′-FL and up to 0.6 g/L of LNnT, at a ratio of 2:1 in
the reconstituted formulae. 2′-FL is safe for young children (older than one year of age) when added to
follow-on and young-child formulae, at concentrations up to 1.2 g/L of 2′-FL (alone or in combination
with LNnT, at concentrations up to 0.6 g/L, at a ratio of 2:1) (EFSA-Q-2015-00052, EFSA Journal 2015).
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3. Health Benefit of Human Milk Oligosaccharides
Secretor milk (due to its high levels of 2′-FL and other Fucosyl-HMOs) may have advantages
for the infant because it more effectively promotes an early high Bifidobacteria-dominated
gut microbiota [29] and provides better protection against specific diarrheal diseases [30] than
non-secretor milk.
Several studies have documented beneficial effects of HMOs, including modification of the intestinal
microbiota, anti-adhesive antimicrobial effects, modulation of intestinal epithelial cell response, effects on
immune development and on brain development.
4. Preclinical and Observational Studies
4.1. Modification of the Intestinal Microbiota
In vitro studies have shown that HMOs promote the growth of certain, but not all,
bifidobacteria [13]. Bifidobacterium longum subsp. infantis (B. infantis) grows well on HMOs (including
2′-FL) as the sole source of carbohydrates [31–34]. Compared to B. infantis, Bifidobacterium bifidum
grows slightly slower on HMOs [33]. Recent literature showed in strains from other bifidobacterial
species that the metabolic capacity to utilize HMOs is not restricted to B. infantis [35–37].
Observational studies showed that 2′-Fucosyl-HMOs are associated with bifidobacteria dominated
early gut microbiota in breastfed infants [29,35,38].
The fact that HMOs are a preferred substrate for B. infantis and other bifidobacteria strains may
reduce the nutrients available for potentially harmful bacteria and keep their growth under control.
In addition, B. infantis produces short-chain fatty acids (SCFA), which help create an environment
favoring the growth of commensal bacteria instead of potential pathogens [39].
An in vitro study evaluated HMOs’ utilization by Enterobacteriaceae, which has been linked to
the onset of necrotizing enterocolitis (NEC) in preterm infants [40]. The study showed that none
of the Enterobacteriaceae strains grow on 2′-FL, 6-siallylactose (6′-SL), and LNnT, whereas several
Enterobacteriacea strains, including pathogens, grew well on galacto-oligosaccharides (GOS) [40].
The influence of secretor status and breastfeeding on gut microbiota composition persists up to two to
three years [38].
4.2. Anti-Adhesive Antimicrobial
Many viruses, bacterial pathogens or toxins need to adhere to mucosal surfaces to colonize or
invade the host and cause disease [13,41,42]. Some HMOs are structurally similar to the intestinal
epithelial cell surface glycan receptors and serve as decoy receptors to prevent pathogen binding
and enhance pathogen clearance [13]. This unique beneficial effect of HMOs is highly dependent on
their structure.
Evidence for an anti-adhesive effect of specific HMOs comes from in vitro and ex vivo studies.
For instance, Ruiz-Palacios et al. demonstrated that human milk oligosaccharides inhibited Campylobacter
jejuni (C. jejuni) adherence to epithelial cells in vitro [43], one of the major causes of bacterial diarrhea
worldwide. A second study conducted by the same group confirmed that fucosylated human milk
oligosaccharides inhibit Campylobacter colonization of human intestinal mucosa ex vivo [43]. Yu et al.
tested the ability of 2′-FL to inhibit C. jejuni infection of the intestinal epithelium and C. jejuni-associated
mucosal inflammation [44]. In an in vitro model, 2′-FL attenuated 80% of C. jejuni invasion (p < 0.05) and
decreased the release of mucosal pro-inflammatory signals. In a mouse model, ingestion of 2′-FL reduced
C. jejuni colonization by 80%, weight loss by 5%, intestinal inflammation (shown by histologic features),
and induction of inflammatory signaling molecules (p < 0.05) [44].
In infants, observations from a prospective study conducted by Morrow et al. suggested
a beneficial effect of α1-2-fucosylated HMO on reducing episodes of C. jejuni-associated diarrhea [30].
In Mexican breastfed infants, Campylobacter diarrhea occurred less often in those infants whose
mother’s milk contained a high percentage of milk oligosaccharides of 2′-FL than in those infant whose
24
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mother’s milk contained a lower percentage of 2′-FL oligosaccharides. There was a dose-dependent
association with higher rates of moderate-to-severe diarrhea of all causes. The association between
milk oligosaccharides measured during the first months and diarrhea in breastfed infants persisted
through the course of lactation but not after cessation of breastfeeding [30].
Other observational studies of breastfed infants also suggested beneficial effects of fucosyl-HMOs
in breast milk. They showed that fucosyl-HMOs in breast milk are related to lower morbidity in
Gambian infants at four months of age [45] and fewer respiratory and enteric problems in US infants
at three months of age [46].
The influence of 2′-FL and 6′-SL on adhesion of Escherichia coli and Salmonella fyris to Caco-2 cells
was tested with positive results for E. coli but not for Salmonella [47].
HMOs have also been suggested to possibly protect against important systemic infections of
the newborn. For instance, LNnT reduces Streptococcus (S.) pneumoniae load in lungs in a rabbit
model [48]. A clinical study with infants older than six months, however, could not achieve a reduction
in the colonization of the oropharynx with S. pneumoniae through a synthetic LNnT-supplemented infant
formula [49].
HMOs may function as an alternative substrate to modify a group B Streptococcus component in a
manner that impairs growth kinetics [50]. There is a unique antibacterial role for HMOs against this
leading neonatal pathogen [50].
There is increasing evidence that HMOs could reduce infant mortality and morbidity in preterm
infants, for example by shaping a favorable gut microbiome protecting against NEC, candidiasis,
and several other immune-related diseases [51]. In support of this, a lower concentration of the HMO
disialyllacto-N-tetraose (DSNLT) was shown to predict the risk of NEC in preterm infants. This finding
has been demonstrated by a recent multicenter clinical cohort study including 200 mothers and their
very low birthweight infants who were predominantly human milk-fed [52]. DSLNT concentrations
were significantly lower in almost all milk samples in NEC cases compared with controls, and its
abundance could identify NEC cases before onset, i.e., DSLNT content in breast milk is a potential
non-invasive marker to identify infants at risk of developing NEC, and screen high-risk donor milk.
Beneficial effects on NEC have also been reported for 2′-FL. Good et al. demonstrated that 2′-FL
attenuates the severity of the experimental NEC by enhancing mesenteric perfusion in the neonatal
intestine on an experimental mouse model of NEC [53].
4.3. Modulators of Intestinal Epithelial Cell Response
HMOs are able to reduce cell growth, induce differentiation, apoptosis and maturation, and
increase the barrier function in vitro [54–57]. Intestinal health and intestinal barrier function constitute
the first defense line in innate immunity.
Zehra et al. demonstrated that the HMOs 6′-siallyllactose and 2′-FL modulate human epithelial
cell responses related to allergic disease in different ways [58]. 6′-Sialyllactose inhibited chemokine
(Interleukin (IL)-8 and CCL20) release from T-84 and HT-29 cells stimulated with antigen-antibody
complex tumor necrosis factor-alfa (TNF-α) or prostaglandin-E2 (PGE-2); an effect that was PPARy
dependent and associated with decreased activity of the transcription factors AP-1 and nuclear factor
kappa-light-chain-enhancer of activated B cells) NF-κB. In contrast, 2′-FL selectively inhibited CCL20
release in response to the antigen-antibody complex in PPARy dependent manner. These findings
reinforce the concept that structurally different oligosaccharides have distinct biological activities and
identifies, and for the first time, that the HMOs, 6′-SL, and 2′-FL, modulate human epithelial cell
responses related to allergic diseases. This encourages further investigation of the therapeutic potential
of specific HMOs in food allergy [58].
4.4. Immune Modulators
Among the multiple functions of HMOs, immunomodulation is one of the most remarkable [59].
HMOs directly affect intestinal epithelial cells and modulate their gene expression, which leads to
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changes in cell surface glycans and other cell responses. HMOs modulate lymphocyte cytokine
production, potentially leading to a more balanced TH1/TH2 response.
An increasing number of in vitro studies suggest that HMOs not only affect the infant’s immune
system indirectly by changing gut microbiota but also directly modulate immune responses by
affecting immune cell populations and cytokine secretion [5]. HMOs may either act locally on cells of
the mucosa-associated lymphoid tissues or on a systemic level [13].
Dietary HMOs were more effective than non-human prebiotic oligosaccharides in altering
systemic and gastrointestinal immune cells in pigs [60]. These altered immune cell populations
may mediate the effects of dietary HMOs on rotavirus infection susceptibility [60]. Daily oral treatment
with 2′-FL attenuated food allergy symptoms in a mouth model by induction of IL-10+ T-regulatory
cells and indirect stabilization of mast cells [61].
In vitro studies have shown that 2′-FL directly inhibits lypopolysaccharide-mediated
inflammation during enterotoxigenic E. coli (ETEC) invasion of T84 (modeling mature) and
H4 (modeling immature) intestinal epithelial cells through attenuation of CD14 induction [62].
CD14 expression mediates lypoplysaccharide-TLR4 (toll-like receptor 4) stimulation of portions of
the ‘macrophage migration inhibitory factors’ inflammatory pathway via suppressors of cytokine
signaling 2/signal transducer and activator of transcription 3/NF-κB.
In an animal model, early life provision for a period of 6 weeks of 1% authentic HMOs delayed and
suppressed Type 1 diabetes development in non-obese diabetic mice and reduced the development
of severe pancreatic insulitis in later life [63]. In a murine influenza vaccination model dietary
2′-FL improved both humoral and cellular immune responses to vaccination in mice, enhancing
vaccine specific delayed-type hypersensitivity responses accompanied by increased serum levels of
vaccine-specific immunoglobulin proliferation. Vaccine-specific CD4+ and CD8+ T-cells, as well as
interferon-gamma production, were significantly increased in spleen cells of mice receiving 2′-FL
leading to the conclusion that dietary intervention with 2′-FL improved both humoral and cellular
immune responses to vaccination in mice [64].
4.5. Brain Development
Metabolic products of HMOs such as sialic acid promote brain development,
neuronal transmission, and synaptogenesis. HMOs provide sialic acid as potentially essential
nutrients for brain development and cognition [65,66]. Application of L-fucose and 2′-FL increases
the potentiation of the population spike amplitude (POP-spike) and the field excitatory postsynaptic
potential (fEPSP) after tetanization of the Schaffer collaterals of the rat hippocampus [67]. Dietary
2′-FL interferes with cognitive domains and improves learning and memory in rodents [68]. HMOs,
3′-Sialyllactose and 6′-Sialyllactose, support normal microbial communities and behavioral responses
during stressor exposure, potentially through effects on the gut microbiota–brain axis [69].
4.6. Improved Gut Adaptation after Resection
Patients with short bowel syndrome require parental nutrition and may require frequent treatment
with antibiotics that modify intestinal microbiota and have an adverse effect on gastrointestinal
function [70]. The hypothesis that 2′-FL contributes to the adaptive response after intestinal resection
was confirmed on the basis of a murine model of intestinal adaptation. Modulating of gut microbiota
following intestinal resection improved the outcome of short bowel syndrome in an experimental
setting. Supplementation with 2′-FL increased weight gain following ileo-cecal resection and promoted
histological changes in gut mucosa suitable for adaptation [71].
5. Clinical Studies with 2′-fucosyllactose
One prospective, randomized, controlled study tested the tolerance and safety in relation
to growth of an infant formula containing 2′-FL (0.2 g/L or 1.0 g/L) in combination with
galacto-oligosaccahrides (2.2 g/L or 1.4 g/L) in healthy full-term infants from 28 sites across USA [72].
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No differences in growth parameters and adverse events were found between the infants fed
the formula with 2′-FL from enrolment (0–5 days of age) up to the age of four months compared to
infants fed a control formula containing only galacto-oligosaccharides and between both formula-fed
groups and the breastfed reference group. This study was the first publication showing that growth
of infants consuming a formula containing 2′-FL was similar to that of human milk-fed infants [72].
Both formulas with 2′-FL and galacto-oligosaccharides were well tolerated and did not influence stool
frequency or consistency.
The effects of feeding formulas supplemented with 2′-FL on biomarkers of immune function
were investigated in a subgroup of this study population [73]. Infants fed formulas with 2′-FL and
galacto-oligosaccharides had 29–83% lower concentrations of plasma inflammatory cytokines and
TNF-α than infants fed the control formula with galacto-oligosaccharides only [73]. There were no
differences in plasma inflammatory cytokines and TNF-α between infants fed formulas with 2′-FL
and galacto-oligosaccharides and infants breastfed. These findings indicate that supplementation of
infant formula with 2′-FL supports aspects of immune development and regulation similar to that of
breastfed infants; while supplementation with galacto-oligosachairdes alone does not [73].
Another prospective, randomized, controlled study tested the gastrointestinal tolerance of
an infant formula containing 2′-FL (0.2 g/L) in combination with fructo-oligosaccharides (2 g/L)
compared to a control formula without oligosaccharides [74]. The formula with 2′-FL and
fructo-oligosaccharides fed from less than eight days of age for approximately one month was well
tolerated; stool consistency, anthropometric data, and frequency of feedings with spitting up/vomiting
and was similar to that of infants given formula without oligosaccharides or to infants breastfed [74].
Puccio et al. conducted the first clinical trial with an infant formula supplemented with two
HMOs [75]. In this prospective, randomized, controlled multicenter study, healthy term infants
received a formula with 2′-FL and LNnT or the same formula without HMOs from enrolment at
≤14 days of age to age six months and for at least four months as the exclusive diet [75]. The formula
with 2′-FL and LNnT was well-tolerated and supported age-appropriate growth. Gastrointestinal
symptoms (flatulence, spitting up, and vomiting) were similar between the groups. Infants receiving
formula with 2′-FL and LNnT had significantly softer stools and fewer episodes of night-time wake-ups
at age two months, and infants born by caesarian section also had a lower incidence of colic at four
months of age. Puccio et al. also analyzed the incidence of different health outcomes as secondary
outcomes. Infants fed the formula with 2′-FL and LNnT compared to infants fed the formula without
HMOs had significantly fewer parental reports of bronchitis (at 4, 6, and 12 months), reduced incidence
of lower respiratory tract infections (through 12 months), reduced use of antipyretics (through four
months) and reduced use of antibiotics (through 6 and 12 months) with protective effects that continued
after the six months intervention period [75].
In the same trial, infants fed the formula with 2′-FL and LNnT developed a gut microbiota that
was closer to the microbiota observed in breastfed infants [76]. At three months of age, the stool
microbiota was characterized by an increased quantity of beneficial bifidobacteria and decreased
abundances of taxa with potentially pathogenic members. Moreover, the supplementation of infant
formula with these two HMOs promoted the growth of a distinct fecal bacteria community, typical
of breastfed infants and showing a very high density of bacteria. Formula-fed infants carrying this
fecal community type had a two times decreased risk of requiring antibiotics during the first year of
life [76]. Therefore, this study suggests that the association between consuming formula with 2′-FL
and LNnT and lower parent-reported morbidity and medication use may be linked to gut microbiota
community types [76].
Today, the amount of data available on HMO supplementation in infant formula from clinical
trials in infants is still limited. More data are definitely needed. According to the data from the few
studies, differences in clinical outcome of supplemented vs. non-supplemented formula are not yet
conclusive [72–76]. The different primary outcomes of the different trials contribute to a lack of coherent
results. The cost-benefit ratio also needs further evaluation. In addition, the optimal concentration of
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HMO added needs further adjustment. And of course, there is the fact that only one or two HMOs are
added to infant formula, while mother’s milk contains 200 different oligosaccharides. Supplementation
with more HMOs could result in further evidence of benefit.
6. Conclusions
HMOs act as soluble decoy receptors that block the attachment of specific viral, bacterial or
protozoan parasite pathogens to epithelial cell surface sugars, which may, in turn, help prevent
infectious diseases in the gut, respiratory, and urinary tracts. In addition, HMOs alter host epithelial
and immune cell responses with potential benefits for the neonate, beyond protection against
infectious diseases.
Although the functions of HMOs have been known for many years, it was not possible to
synthesize them on an industrial scale until recently. With the goal of imitating their effect, non-human
milk oligosaccharides, mainly fructo and galacto-oligosaccharides have been added to infant formula.
In recent years it has, to a certain extent, become technically possible to add 2′-FL and LNnT to
infant formula.
The addition of one HMO, namely 2′-FL, is a step forward in bringing formula feeding closer to
the gold standard: Mother’s milk. No adverse effects have been reported for 2′-FL and in vitro and
animal studies have shown benefits of supplementation of infant formula with 2′-FL. The first clinical
data in infants show a normal growth pattern and normal defecation and suggest clinical benefit.
More prospective, randomized trials in infants comparing formula without and with HMOs are still
needed to evaluate the clinical effects of this supplementation. It can, therefore, be concluded that
2′-FL is a safe supplementation of infant formula.
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Abstract: The efficacy of oral rehydration solution (ORS) enriched with Lactobacillus reuteri DSM
17938 and zinc in infants with acute gastroenteritis, is poorly defined. The aim of this double-blind,
randomized, placebo-controlled study, was to assess the efficacy of an ORS enriched with Lactobacillus
reuteri DSM 17938 and zinc (ORS+Lr&Z) in well-nourished, non-hospitalized infants with acute
diarrhoea. Fifty one infants with acute diarrhoea were randomly assigned to receive either ORS+Lr&Z
(28 infants, mean ± SD age 1.7 ± 0.7 years, 21 males), or standard ORS (ORS−Lr&Z; 23 infants,
mean ± SD age 1.8 ± 0.7 years, 16 males). Stools volume and consistency were recorded pre- and
posttreatment using the Amsterdam Infant Stool Scale and were compared between the two groups,
as well as lost work/day care days, drug administration and need for hospitalization. Both groups
showed reduction in the severity of diarrhoea on day two (p < 0.001) while, all outcomes showed
a trend to be better in the ORS+Lr&Z group, without reaching statistical significance, probably due
to the relatively small number of patients. No adverse effects were recorded. In conclusion, both
ORS were effective in managing acute diarrhoea in well-nourished, non-hospitalized infants. ORS
enriched with L. reuteri DSM 17938 and zinc was well tolerated with no adverse effects.
Keywords: acute gastroenteritis; children; Lactobacillus reuteri; oral rehydration solution;
probiotics; zinc
1. Introduction
Oral rehydration solution (ORS) is recommended in infants and children with acute diarrhoea
for the treatment or the prevention of dehydration [1]. Zinc supplementation is beneficial in infants
and children with acute diarrhoea living in developing countries [2], however, its efficacy in those
living in developed countries is poorly defined. Furthermore, selected strains of probiotics have
been shown to reduce the duration and the severity of diarrhoea in children with acute diarrhoea
and the effect is greater if the probiotics are given within 60 hours from the onset of symptoms [3–8].
Lactobacillus reuteri (L. reuteri) ATCC 55730 was reported to have a beneficial effect in reducing the
duration and severity of acute gastroenteritis of both bacterial and viral (rotavirus) origin in infants
and toddlers aged 6–36 months [6–8]. However, the above strain was found to carry transferable
resistance traits for tetracycline and lincomycin, and for this reason it was replaced by a new
strain—L. reuteri DSM 17938—by removal of two potentially transferable plasmid-borne resistances.
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Furthermore, L. reuteri DSM 17938 was assessed in hospitalized and non-hospitalized children with
acute diarrhoea with varied results. The administration of L. reuteri DSM 17938 at a dose of 4 × 108
CFU in hospitalized 69 Italian children aged six months to three years for acute diarrhoea, reduced
significantly the frequency and the duration of diarrhoea on days 2 and 3, and also the number of
children with diarrhoea on days 2 and 3, compared to the placebo without though affecting the duration
of hospital stay [9]. In another multicenter, randomized, single-blinded, case control clinical trial [10]
in 64 hospitalized children with acute watery diarrhoea, the administration of L. reuteri DSM 17938 at
a dose of 1 × 108 CFU for five days was associated with reduction of the duration of diarrhoea and of
the hospital stay as well as with better success rate on day 2 compared to 63 controls while, the same
strain at a subsequent study in 60 children with acute diarrhoea presented at outpatients clinics, showed
reduced duration of diarrhoea and better success rate on day two but no differences from the third day
between the two groups [11]. Although the above strain has been solitary studied in childhood acute
diarrhoea, the efficacy of the combined supplementation of ORS with L. reuteri DSM 17938 and zinc in
infants with acute diarrhoea, has not been studied so far.
The aim of the present study therefore, was to assess whether an ORS enriched with
L. reuteri DSM 17938 and zinc (ORS+Lr&Z) would be superior or equivalent to ORS without added
probiotic and zinc (ORS−Lr&Z) in managing acute diarrhoea in well-nourished non-hospitalized
infants and toddlers, and its effects on child’s and family’s normal activities
2. Patients and Methods
2.1. Study Design
The study was a randomized, double-blind, placebo-controlled study, conducted in patients
with acute diarrhoea who were followed up at outpatient paediatric clinics in Athens, Greece during
30 months. The study protocol was approved by the ethics committee of the hospital and the study
was registered at ClinicalTrials.gov (NCT 01886755), before the enrolment of the first patient. Informed
consent was obtained from at least one parent or legal guardian prior to study inclusion.
2.2. Patients
Infants aged 6–36 months with acute diarrhoea defined as three or more watery or soft stools per
day for the past 24–48 h and with mild to moderate degree of dehydration defined as one to four scores
on Baily’s clinical dehydration scale [12], seen as outpatients were recruited. The exclusion criteria
included the following: diarrhoea lasting more than 48 hours, clinical signs of severe dehydration
defined as Bailey scale scores = or > 5, malnutrition defined as weight/height ratio below the 5th
percentile, clinical signs of a coexisting severe acute systemic illness (meningitis, sepsis, pneumonia),
immunodeficiency, severe chronic disease including cystic fibrosis, food allergy diagnosed by physician
or other chronic gastrointestinal diseases, use of pre-/probiotics in the previous two weeks, use of
antibiotics or any anti-diarrhoeal medication in the previous four weeks.
2.3. Methods
The patients were randomly assigned to receive either ORS+Lr&Z or ORS−Lr&Z of similar
composition and osmolality (Table 1) both provided by BioGaia AB, Sweden. Oral rehydration
took place over the first four hours while ongoing losses were replaced by administering 10 mL/kg
of ORS using a graduated bottle provided by the sponsor, after each loose/watery stool or vomit
until diarrhoea ceased or up to five days from the enrolment. Patients were allocated to each group
according to a computer—generated randomisation using Random Allocation Software version 2.3.8
(StatsDirect Ltd., Chesire, UK). Treatment allocation was concealed to maintain the double-blind status.
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Table 1. Composition of the study products.
ORS Enriched with L. reuteri DSM 17938 and
Zinc (1 Sachet)
ORS without L. reuteri DSM 17938 and Zinc
(1 Sachet)
Protein <0.1 g <0.1 g
Carbohydrates 3.75 g 3.75 g
of which glucose 3.75 g 3.75 g
Fat <0.1 g <0.1 g
Sodium 0.35 g/15 mmol 0.35 g/15 mmol
Chloride 0.4 g/11 mmol 0.4 g/11 mmol
Potassium 0.2 g/5 mmol 0.2 g/5 mmol
Citrate 0.5 g/3 mmol 0.5 g/3 mmol
Zinc 1.5 mg/0.02 mmol 0 mg/0 mmol
Osmolality 220 mOsm/kg H2O 220 mOsm/kg H2O
L. reuteri DSM 17938 1 × 109 CFU (Colony Forming Units) 0
The parents/legal guardians of the enrolled children were instructed to make daily records of the
stools in a specific form using the Amsterdam stool scale (ISS) [13], the vomiting episodes, the volume
of ORS consumed by the child on each day, other treatments or medications during the study period,
adverse events, missed number of workdays for the parents and days at day care/nursery for the
child, as well as any hospital admissions.
2.4. Outcome Measures
The primary outcome measures included the proportion of children without watery or soft (type
A3–4 or B3–4 ISS) stools on day 2 of treatment, as well the time from the start of treatment up to the
day of recording the last watery or soft stool. The secondary outcome measures included the reduction
in the severity of diarrhoea assessed by the following: (a) the number of watery and soft (type A3–4
or B3–4 ISS) stools on each of the days during the study period; (b) the percentage of patients with
watery or soft (type A3–4 or B3–4 ISS) stools on each day during the study period; and (c) the decrease
in the diarrhoea severity score consisting of the sum of the points of three variables according to ISS:
(i) number of bowel movements; (ii) type (A, B, C, and D) of stools and (iii) volume (1, 2, 3 and 4) of
stools (Table 2); the number of vomiting episodes; the volume of ORS intake during the first day of
treatment; the need for hospitalization; the loss of workdays for the parents; the loss of days from the
day care/nursery for the children as well the need for medication administration due to diarrhoea.
Table 2. Total score of severity of diarrhoea based on Amsterdam stool scale.
Variable
Consistency Volume
Category A B C D 1 2 3 4
Points 1 point for each bowel movement 2 1 0 0 1 2 3 4
The total score consists of the sum of the product of the points of three variables: (i) number of bowel movements;
(ii) Type (A, B, C, and D) of stools and iii) Volume (1, 2, 3, and 4) of stools.
2.5. Statistical Analysis
Continuous parameters are presented as mean and standard deviation (SD) and compared
by non-parametric tests (Mann-Whitney) due to the small sample sizes and the extremely skewed
distributions of outcome variables which are discrete and with relatively narrow range. Categorical
variables are presented as absolute (n) and relative (%) frequencies and compared by the Fisher exact
test. Mean differences (MD) of continuous outcomes between the two groups and 95% confidence
intervals (CI) are reported, whereas absolute risk difference (ARD) with 95% CI were estimated
for categorical outcomes. The level of statistical significance was set to 0.05. In cases of multiple
comparisons, the Bonferroni correction was applied (0.05 divided by the number of comparisons).
Data were analysed with Stata 11.2 MP statistical software (StataCorp, TX, USA).
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3. Results
Fifty-eight children were randomly allocated to receive either ORS+Lr&Z (n = 30) or ORS−Lr&Z
(n = 28) seven of whom (two from the ORS+Lr&Z and five from the ORS-Lr&Z group) were lost from
follow up. A total of 51 children mean ± SD age 1.8 ± 0.7, 1.7 (1.3, 2.3), 37 males, 14 females, received
either ORS+Lr&Z (n = 28, aged 1.7 ± 0.7, 21 males, seven females) or ORS−Lr&Z (n = 23, mean ± SD
age 1.8 ± 0.7, 16 males, seven females) and were included in the analysis. The CONSORT flow diagram
of the study is shown in Figure 1.
Figure 1. CONSORT flow diagram.
Age and gender were comparable between the two groups at baseline, as well as the severity of
diarrhoea before recruitment (Table 3).
Table 3. Baseline characteristics in the two study arms.
ORS−Lr&Z ORS+Lr&Z p-Value
Age (years) * 1.8 ± 0.7, 1.8 (1.3, 2.4) 1.7 ± 0.7, 1.6 (1.3, 2.1) 0.5 **
Severity of diarrhoea (score) * 4.7 ± 3.6, 5 (2, 6) 4.3 ± 3.1, 3.5 (2.0, 6.5) 0.6 **
Gender, males/females, n (%) 16/7(69.6%/30.4%)
21/7
(75.0%/25%) 0.8 ***
* Mean ± SD, median (IQR); ** Mean (95% confidence interval); *** Mann-Whitney test, level of significance after
Bonferroni correction: 0.01.
The proportion of children without diarrhoea on day two after the start of treatment did not differ
significantly between the two groups: ORS−Lr&Z 13/23 (56.5%), ORS+Lr&Z 18/28 (64.3%), p = 0.8,
ARD: 7.7% (−19.2%, 34.7%).
All of the outcomes in the intention to treat analysis showed a trend to be better in the ORS+Lr&Z
group, however statistical significance was not reached in any of them. Both groups showed
comparable improvement in the severity of diarrhoea on day two following the start of treatment
(Table 4, Figure 2) as well as during the study period (Table 4, Figure 3).
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Both ORS with or without supplementation with L. reuteri DSM 17938 and zinc managed to
decrease significantly the severity of diarrhoea on day 2, based on the severity score that took into
account both stool consistency and volume according to ISS (Figure 2).
Figure 2. Improvement of the severity score of diarrhoea at day 2 compared to baseline (day−1).
At each time point, the results are presented with means and 95% confidence intervals. Comparisons
within groups were performed by the Wilcoxon signed-rank test for paired data, whereas data between
groups were compared by the Mann-Whitney U test. Comparisons in the ORS+Lr&Z arm on day two
versus day−1 (p < 0.001). Comparisons in the ORS−Lr&Z arm on day two versus day−1 (p < 0.001).
Furthermore, although the ORS supplemented with L. reuteri DSM 17938 and zinc had a tendency
to achieve a greater decrease in the 6-day severity score of diarrhoea, the difference between the two
groups did not reach statistical significance (Figure 3).
Figure 3. Total six-day severity score of diarrhoea. Results are presented with means and 95%
confidence intervals. Comparisons between the ORS+Lr&Z and the ORS-Lr&Z arms were performed
by the Mann-Whitney U test (p > 0.5).
Similarly, although a tendency was seen in the group receiving ORS supplemented with
L. reuteri DSM 17938 and zinc to have smaller duration of watery diarrhoea as well as of soft stools
compared to the group which received non-supplemented ORS, again, the difference did not reach
statistical significance (Figure 4A,B).
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Figure 4. (A): Number of days with watery stools. (B): Number of days with soft stools. Results are
presented with means and 95% confidence intervals. Comparisons between the ORS+Lr&Z and the
ORS-Lr&Z arms were performed by the Mann-Whitney U test (p > 0.5).
The same was true for the number of days lost from the day care for the infants and from
work for the parents, which tended to be less in the group which received ORS supplemented
with L. reuteri DSM 17938 and zinc, but again, the differences did not reach statistical significance
(Figure 5A,B).
Figure 5. (A): Number of lost day care/nursery days for patients. (B): Number of lost work days for
parents. Results are presented with means and 95% confidence intervals. Comparisons between the
ORS+Lr&Z and the ORS-Lr&Z arms were performed by the Mann-Whitney U test (p > 0.5).
The number of vomiting episodes was comparable between the ORS−Lr&Z and the ORS+Lr&Z
groups at baseline: mean ± SD, median (IQR) 0.09 ± 0.28, 0 (0, 0) vs. 0.07 ± 0.26, 0 (0, 0) respectively,
p = 0.4, while no vomiting episodes were recorded during the study period in any of the two groups.
The consumed volume of ORS during the first 24 h did not differ between the ORS+Lr&Z and
the ORS−Lr&Z groups: mean ± SD, median (IQR) 309.8 ± 235.3, 265 (120, 415) vs. 326.5 ± 195.9
respectively, 300 (170, 490), p = 0.5.
None of the patients was hospitalized during the study period and no other medications for
diarrhoea or antibiotics were administered by any of the patients.
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4. Discussion
This study is the first study assessing the efficacy of an ORS supplemented with L. reuteri DSM 17938
and zinc in infants with acute diarrhoea. Furthermore, this is the first study that uses for the assessment of
the efficacy of the above ORS supplementation, an objective measure (ISS), that takes into account both
consistency and volume of the infant’s stools. In addition, this is the first study assessing the effects of
the above combination, on child’s and family’s normal activities during acute diarrhoea. We showed that
ORS+Lr&Z and ORS−Lr&Z were both associated with reduction in the severity of diarrhoea two days
following the start of treatment in a group of well-nourished, non-hospitalized infants and toddlers with
acute gastroenteritis. Furthermore, we showed that all of the outcomes including the severity of diarrhoea
based on ISS, the duration of watery diarrhoea, the percentages of infants with no diarrhoea on days 3
and 5 as well as the number of absences from the day care for the infants and the parents from the work,
all showed a trend to be better in the ORS+Lr&Z group without though reaching statistical significance,
probably due to the relatively small number of recruited patients.
Other studies using probiotic strains such as L. reuteri ATCC 55730, Lactobacillus rhamnosus 19070-2
and L. reuteri DSM 12246, reported beneficial effects in children with acute gastroenteritis [3–7,14].
Lactobacillus rhamnosus 19070-2 and L. reuteri DSM 12246 were both effective in reducing the duration of
diarrhoea after intervention in hospitalized and non-hospitalized children with mild diarrhoea while,
a greater efficacy was noted in case of early (<60 hours after the start of diarrhoea) intervention [4,5].
Furthermore, L. reuteri DSM 17938 and L. reuteri ATCC 55730 were reported in one meta-analysis in
hospitalized children 3 to 60 months (n = 196 and n = 156 respectively), to reduce significantly the
duration of diarrhoea compared to placebo or no treatment respectively [15].
The mechanisms of the effect of L. reuteri in acute diarrhoea are not fully understood. It has been
shown that L. reuteri can produce reuterin, a broad-spectrum antimicrobial agent [16], which may
be responsible for the inhibition of pathogenic microorganisms in the gastrointestinal tract, but also,
it can decrease intestinal permeability [17,18] and stimulate the intestinal immune responses [19,20].
Furthermore, L. reuteri DSM 17938 and ATCC PTA 6475 were shown in a model of rotavirus infection
in new-born mice, to increase the early mucosal rotavirus-specific IgA as well as the diversity of the
distal gut microbiome, attenuating rotavirus induced enteritis and reducing the duration of diarrhoea
by one day. In our study, we did not perform gut microbiome analysis in the recruited infants with
acute diarrhoea. Therefore, we cannot draw any conclusions from this study on the possible effects of
the supplemented ORS with L. reuteri DSM 17938 and zinc on infants distal gut microbiome during
acute diarrhoea. Other preliminary studies suggested that L. reuteri 17938 increased the number of
villus goblet cells bearing markers of intestinal stem cell activity [21–23].
Based on the available evidence, the European Society for Pediatric Gastroenterology,
Hepatology and Nutrition recommended the use of Lactobacillus rhamnosus GG, Saccharomyces boulardii,
L. reuteri DSM 17938, and the heat-inactivated Lactobacillus acidophilus LB as a supplement of the ORS
for the management of childhood acute gastroenteritis [24].
With regards to zinc supplementation of ORS in children with acute diarrhoea, it has been
shown to be beneficial in malnourished children [25] but has been poorly studied in well-nourished
ones. The postulated mechanisms include improved absorption of water and electrolytes by the
intestine [26–28], regeneration of gut epithelium [29], increased levels of enterocyte brush-border
enzymes [30], and enhanced immunologic mechanisms. Therefore, WHO recommended early oral
rehydration therapy and zinc supplementation to treat acute diarrhoea in children [1]. Our study failed
to show superiority of the enriched with zinc ORS in the study group consisting of well-nourished
infants with mild diarrhoea not requiring hospitalization, probably due to the fact that the study was
underpowered due to the relatively small number of recruited patients.
The main limitation of the study was, therefore, the relatively small number of the recruited
children. The fact, however, that the study was a well-designed, double blind, placebo-controlled
trial, the first that assessed an ORS enriched with L. reuteri DSM 17938 and zinc in infants with acute
gastroenteritis, and also used for the assessment of the severity of diarrhoea an objective method
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(ISS), make the results a valuable contribution to the meta-analyses on the topic, which has clinical
importance for health professionals, including general practitioners, general pediatricians, pediatric
gastroenterologists, and nutritionists.
5. Conclusions
This randomised, double blind, placebo-controlled trial showed that ORS supplemented with
L. reuteri DSM 17938 and zinc had comparable efficacy with ORS of similar composition and osmolality
without added probiotic and zinc, in managing acute diarrhoea, in well-nourished, non-hospitalised
infants and toddlers with acute diarrhoea. ORS enriched with L. reuteri DSM 17938 and zinc was well
tolerated without adverse effects.
Author Contributions: M.M. made substantial contributions to the data acquisition, as well as drafting the
manuscript and revising it critically. G.C. made substantial contributions to the data analysis and interpretation,
as well as revising the manuscript critically. A.M. made substantial contributions to the recruitment of patients
and data acquisition, as well as revising the manuscript critically. A.O. made substantial contributions to the
recruitment of patients and data acquisition as well as revising the manuscript critically. A.T. made substantial
contributions to the recruitment of patients and data acquisition as well as revising the manuscript critically.
A.P. made substantial contributions to the design of the study, data acquisition and interpretation, drafting the
manuscript, and revising it critically.
Funding: The study was funded by BioGaia AB, Sweden. The sponsor was not involved in the data collection,
analysis and interpretation, in the writing of the manuscript, as well as in the decision to submit the article
for publication.
Conflicts of Interest: M.M., G.C., A.M., A.O. and A.P. received research grants from BioGaia, the manufacturer
of the ORS enriched with Lactobacillus reuteri DSM 17938 and zinc and the ORS without enrichment. A.T. had
nothing to declare.
Abbreviations
ORS Oral rehydration solution
L. reuteri Lactobacillus reuteri
ORS+Lr&Z ORS enriched with L. reuteri DSM 17938 and zinc
ORS−Lr&Z ORS of similar composition and osmolality without added probiotic and zinc
MD Mean differences
SD Standard deviation
95% CI 95% confidence intervals
References
1. World Health Organization, Dept. of Child and Adolescent Health and Development & UNICEF. Clinical
Management of Acute Diarrhoea: WHO/UNICEF Joint Statement; World Health Organization: Geneva,
Switzerland, 2004.
2. Castillo Duran, C.; Vial, P.; Uauy, R. Trace mineral balance during acute diarrhea in infants. J. Pediatr. 1988,
113, 452–457. [CrossRef]
3. Allen, S.J.; Martinez, E.G.; Gregorio, G.V.; Dans, L.F. Probiotics for treating acute infectious diarrhoea.
Cochrane Database Syst. Rev. 2010. [CrossRef] [PubMed]
4. Rosenfeldt, V.; Michaelsen, K.F.; Jakobsen, M.; Larsen, C.N.; Møller, P.L.; Pedersen, P.; Tvede, M.;
Weyrehter, H.; Valerius, N.H.; Paerregaard, A. Effect of probiotic Lactobacillus strains in young children
hospitalized with acute diarrhea. Pediatr. Infect. Dis. J. 2002, 21, 411–416. [CrossRef] [PubMed]
5. Rosenfeldt, V.; Michaelsen, K.F.; Jakobsen, M.; Larsen, C.N.; Møller, P.L.; Tvede, M.; Weyrehter, H.;
Valerius, N.H.; Paerregaard, A. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of
non-hospitalized children attending day-care centers. Pediatr. Infect. Dis. J. 2002, 21, 417–419. [CrossRef]
[PubMed]
6. Shornikova, A.V.; Casas, I.A.; Isolauri, E.; Mykkanen, N.; Vesikari, T. Lactobacillus reuteri as a therapeutic
agent in acute diarrhoea in young children. J. Pediatr. Gastroenterol. Nutr. 1997, 24, 399–404. [CrossRef]
[PubMed]
41
Nutrients 2018, 10, 1189
7. Shornikova, AV.; Casas, I.A.; Mykkanen, N.; Salo, E.; Vesikari, T. Bacteriotherapy with Lactobacillus reuteri in
rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 1997, 16, 1103–1107. [CrossRef] [PubMed]
8. Eom, T.H.; Oh, E.Y.; Kim, Y.H.; Lee, H.S.; Yang, P.S.; Kim, D.U.; Kim, J.-T.; Lee, B.-C. The therapeutic effect of
Lactobacillus reuteri in acute diarrhea in infants and toddlers. Korean J. Pediatr. 2005, 48, 986–989.
9. Francavilla, R.; Lionetti, E.; Castellaneta, S.; Ciruzzi, F.; Indrio, F.; Masciale, A.; Fontana, C.; La Rosa, M.M.;
Cavallo, L.; Francavilla, A. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. Placebo in children
with acute diarrhea—A double-blind study. Aliment. Pharmacol. Ther. 2012, 36, 362–369. [CrossRef] [PubMed]
10. Dinleyici, E.C.; PROBAGE Study Group; Vandenplas, Y. Lactobacillus reuteri DSM 17938 effectively reduces
the duration of acute diarrhoea in hospitalised children. Acta Paediatr. 2014, 103, e300–e305. [PubMed]
11. Dinleyici, E.C.; Dalgic, N.; Guven, S.; Metin, O.; Yasa, O.; Kurugol, Z.; Turel, O.; Tanir, G.; Yazar, A.S.;
Arica, V.; et al. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient
setting. J. Pediatr. 2015, 91, 392–396. [CrossRef] [PubMed]
12. Bailey, B.; Gravel, J.; Goldman, R.D.; Friedman, J.N.; Parkin, P.C. External validation of the clinical
dehydration scale for children with acute gastroenteritis. Acad. Emerg. Med. 2010, 17, 583–588. [CrossRef]
[PubMed]
13. Bekkali, N.; Hamers, S.L.; Reitsma, J.B.; Van Toledo, L.; Benninga, M.A. Infant stool form scale: Development
and results. J. Pediatr. 2009, 154, 521–526. [CrossRef] [PubMed]
14. Chmielewska, A.; Ruszczynski, M.; Szajewska, H. Lactobacillus reuteri strain ATCC 55730 for the treatment
of acute infectious diarrhea in children: A meta-analysis of randomized controlled trials. Pediatr. Wspolczesna
2008, 10, 33–37.
15. Szajewska, H.; Urbanska, M.; Chmielewska, A.; Weizman, Z.; Shamir, R. Meta-analysis. Lactobacillus reuteri
strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children.
Benef. Microbes 2014, 5, 285–293. [PubMed]
16. Brunser, O.; Araya, M.; Espinoza, J.; Guesry, P.R.; Secretin, M.C.; Pacheco, I. Effect of an acidified milk on
diarrhea and the carrier state in infants of low socio-economic stratum. Acta Paediatr. Scand. 1989, 78, 259–264.
[CrossRef] [PubMed]
17. Isolauri, E.; Majamaa, H.; Arvola, T.; Rantala, I.; Virtanen, E.; Arvilommi, H. Lactobacillus casei strain GG
reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993, 105,
1643–1650. [CrossRef]
18. Isolauri, E.; Kaila, M.; Arvola, T.; Majamaa, H.; Rantala, I.; Virtanen, E.; Arvilommi, H. Diet during rotavirus
enteritis affects jejunal permeability to macromolecules in suckling rats. Pediatr. Res. 1993, 33, 548–553.
[CrossRef] [PubMed]
19. Perdigon, G.; Alvarex, S.; Nader De Macias, M.; Roux, M.; Pesce de Ruiz Holgado, A. The oral administration
of lactic acid bacteria increases the mucosal intestinal immunity in response to enteropathogens. J. Food Prot.
1990, 53, 404–410. [CrossRef]
20. Perdigon, G.; Medici, M.; BibasBonet de Jorrat, M.E.; Valverde de Budeguer, M.; Pesce de Ruiz Holgado, A.
Immunomodulating effects of lactic acid bacteria on mucosal and humoral immunity. Int. J. Immunother.
1993, 9, 29–52.
21. Preidis, G.A.; Saulnier, D.M.; Blutt, S.E.; Mistretta, T.A.; Riehle, K.P.; Major, A.M.; Venable, S.F.; Finegold, M.J.;
Petrosino, J.F.; Conner, M.E.; et al. Probiotics stimulate enterocyte migration and microbial diversity in the
neonatal mouse intestine. FASEB J. 2012, 26, 1960–1969. [CrossRef] [PubMed]
22. Preidis, G.A.; Saulnier, D.M.; Blutt, S.E.; Mistretta, T.A.; Riehle, K.P.; Major, A.M.; Venable, S.F.; Barrish, J.P.;
Finegold, M.J.; Petrosino, J.F.; et al. Host response to probiotics determined by nutritional status of
rotavirus-infected neonatal mice. J. Pediatr. Gastroenterol. Nutr. 2012, 55, 299–307. [CrossRef] [PubMed]
23. Preidis, G. Mechanisms of probiosis by Lactobacillus reuteri in Acute Rotaviral Gastroenteritis. Translational
Biology and Molecular Medicine. Ph.D. Thesis, Baylor College of Medicine, Houston, TX, USA, 2011.
24. Szajewska, H.; Guarino, A.; Hojsak, I.; Indrio, F.; Kolacek, S.; Shamir, R.; Vandenplas, Y.; Weizman, Z.;
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for
management of acute gastroenteritis: A position paper by the ESPGHAN Working Group for Probiotics and
Prebiotics. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 531–539.
25. Ghishan, F.K. Transport of electrolytes, water, and glucose in zinc deficiency. J. Pediatr. Gastroenterol. Nutr.
1984, 3, 608–612. [CrossRef] [PubMed]
42
Nutrients 2018, 10, 1189
26. Patrick, J.; Golden, B.E.; Golden, M.H. Leucocyte sodium transport and dietary zinc in protein energy
malnutrition. Am. J. Clin. Nutr. 1980, 33, 617–620. [CrossRef] [PubMed]
27. Patrick, J.; Michael, J.; Golden, M.N.; Golden, B.E.; Hilton, P.J. Effect of zinc on leucocyte sodium transport
in vitro. Clin. Sci. Mol. Med. 1978, 54, 585–587. [PubMed]
28. Roy, S.K.; Behrens, R.H.; Haider, R.; Akramuzzaman, S.M.; Mahalanabis, D.; Wahed, M.A.; Tomkins, A.M.
Impact of zinc supplementation on intestinal permeability in Bangladeshi children with acute diarrhoea and
persistent diarrhoea syndrome. J. Pediatr. Gastroenterol. Nutr. 1992, 15, 289–296. [CrossRef] [PubMed]
29. Gebhard, R.L.; Karouani, R.; Prigge, W.F.; McClain, C.J. The effect of severe zinc deficiency on activity of
intestinal disaccharidases and 3-hydroxy-3-methylglutaryl coenzyme A reductase in the rat. J. Nutr. 1983,
113, 855–859. [CrossRef] [PubMed]
30. Galvao, T.F.; Thees, M.; Pontes, R.F.; Silva, M.T.; Pereira, M.G. Zinc supplementation for treating diarrhea in
children: A systematic review and meta-analysis. Rev. Panam. Salud Publica 2013, 33, 370–377. [CrossRef]
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Lactobacillus rhamnosus GG in the Primary
Prevention of Eczema in Children: A Systematic
Review and Meta-Analysis
Hania Szajewska * and Andrea Horvath
Department of Paediatrics, The Medical University of Warsaw, Żwirki i Wigury 63A, 02-091 Warsaw, Poland;
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Abstract: Current guidelines recommend the use of probiotics to reduce the risk of eczema.
It remains unclear which strain(s) to use. We systematically evaluated data on the efficacy of
Lactobacillus rhamnosus GG (LGG) supplementation prenatally and/or postnatally for the primary
prevention of eczema. The Cochrane Library, MEDLINE, and EMBASE databases were searched
up to August 2018, with no language restrictions, for systematic reviews of randomized controlled
trials (RCTs) and RCTs published afterwards. The primary outcome was eczema. For dichotomous
outcomes, we calculated the risk ratio (RR) and 95% confidence interval (CI). A random-effects model
was used to pool data. Heterogeneity was explored using the I2 statistics. The GRADE criteria were
used to assess the overall quality of evidence supporting the primary outcome. Seven publications
reporting 5 RCTs (889 participants) were included. High to moderate certainty in the body of evidence
suggests that LGG supplementation (regardless of the timing of administration) did not reduce the
risk of eczema. There was also no consistent effect on other allergic outcomes. This meta-analysis
shows that LGG was ineffective in reducing eczema. It does not support the general recommendation
to use probiotics for preventing eczema, unless specific strains would be indicated.
Keywords: probiotics; allergy; infants; pediatrics
1. Introduction
Allergic diseases are a major public health concern in many countries [1]. Among other
factors, disturbances in gut microbiota composition and/or activity (dysbiosis) may contribute to the
pathogenesis of allergic diseases [2]. If so, gut microbiota may be a target for improving outcomes
in subjects affected or at risk for allergic diseases. To date, modification of gut microbiota via the
provision of probiotics and/or prebiotics is the most extensively studied strategy.
Probiotics are live microorganisms that, when administered in adequate amounts, confer a
health benefit on the host [3]. The mechanisms of action of probiotics remain unclear. However,
protolerogenic action of probiotics in the gastrointestinal tract has been suggested [4]. First, probiotics
compete with pathogenic organisms for nutrients and binding sites on the intestinal epithelium.
Second, they may secrete bacteriocins and induce intestinal epithelium to secrete defensins, natural
antimicrobial peptides. Third, through fermenting fibers, probiotics stimulate the production of
metabolites such as short-chain fatty acids, the majority of which are acetate, propionate, and butyrate.
Short-chain fatty acids activate G protein-coupled receptors that stimulate colonic dendritic cells and
macrophages to secrete interleukin-10 (IL-10) and promote development of regulatory T lymphocytes
(Tregs) in the mesenteric lymph nodes. Tregs are a source of tolerogenic cytokines such as IL-10 and
transforming growth factor-beta (TGF-beta) that inhibit allergic and inflammatory responses [4].
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A 2014 guideline by the World Allergy Organization (WAO) [5] did not recommend use of
probiotics for reducing the risk of allergy in children. However, the WAO considered that there is
a likely net benefit from using probiotics for preventing eczema. Specifically, the WAO suggests:
“(a) using probiotics in pregnant women at high risk for having an allergic child; (b) using probiotics in women
who breastfeed infants at high risk of developing allergy; and (c) using probiotics in infants at high risk of
developing allergy”. All recommendations were conditional and supported by a very low quality of
evidence. Since the beginning, these guidelines raised a debate [6], mainly because of the lack of
answers to practical questions such as: Which probiotic(s) should be used to reduce the risk of eczema?
When should one start the administration of probiotics with proven efficacy? When should one stop?
What is the dose of an effective probiotic [7]? Our aim was to systematically evaluate evidence on the
efficacy of Lactobacillus rhamnosus GG (LGG) supplementation during the prenatal and/or postnatal
period for the reducing the risk of eczema. The effect on other allergic diseases was also evaluated.
LGG is widely available and commonly used in the pediatric population. It is also the first probiotic
for which a reduction in the risk of atopic eczema has been documented [8].
2. Materials and Methods
The methodology was similar to one followed in our earlier systematic review on allergy
prevention [9]. The guidelines from the Cochrane Collaboration for undertaking and reporting
the results of this systematic review and meta-analysis were followed [10].
2.1. Criteria for Considering Studies for This Review
2.1.1. Type of Studies
Randomized controlled trials (RCTs) were considered for inclusion.
2.1.2. Type of Participants
Participants had to be healthy (1) pregnant women at high risk for having an allergic child;
(2) breastfeeding mothers of infants at high risk of developing allergy; or (3) healthy term infants at
high risk of developing allergy.
2.1.3. Type of Interventions
We included trials that compared use of the LGG compared with placebo or no intervention.
If other experimental arms were available, they were not considered.
2.1.4. Type of Outcomes
Our primary outcome was eczema. However, we also focused on the other allergic manifestations
such as wheezing/asthma, allergic rhinitis, food allergy (all as defined by the authors of the original
publications), and adverse events. We report outcomes at time intervals reported by the authors of the
original publications (or as close as possible).
2.2. Search Methods for Identification of Studies
First, we identified RCTs via reviewing previously completed systematic reviews [11,12]. As there
was no discrepancy between two recent reviews with regard to LGG studies, we only searched for
RCTs published subsequently to these reviews. The Cochrane Central Register of Controlled Trials
(CENTRAL, the Cochrane Library), MEDLINE, and EMBASE databases were searched for relevant
studies from December 2014 (end date of last search in the first systematic review [9]) to August 2018.
There were no language restrictions. The search was carried out independently by two reviewers.
In brief, the following search terms were used: (“infant, newborn”(MeSH Terms) OR (“infant”(All
Fields) AND “newborn”(All Fields)) OR “newborn infant”(All Fields) OR “neonat*”(All Fields) OR
“infant”(MeSH Terms) OR “infant”(All Fields) OR “pediatric”(All Fields) OR “paediatric”(All Fields))
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AND (“hypersensitivity”(MeSH Terms) OR “hypersensitivity”(All Fields) OR “allergy”(MeSH Terms)
OR “allergy”(All Fields) OR “allergy and immunology”(All Fields) OR “food allergy”(All Fields) OR
“milk allergy”(All Fields) OR “eczema”(MeSH Terms) OR “eczema”(All Fields) OR “wheezing”(All
Fields)) OR “asthma”(MeSH Terms) OR “asthma”(All Fields)) AND (Lactobacillus (All Fields)).
Additionally, we searched reference lists from identified studies and key review articles. Experts
in the field were contacted for additional references.
2.2.1. Selection of Studies
Two reviewers initially screened the title, abstract, and keywords of every record identified with
the search strategy, and they retrieved the full texts of potentially relevant trials and of records for
which the relevance was unclear. The same reviewers independently applied the inclusion criteria to
each potentially relevant trial to determine its eligibility. If differences in opinion existed, they were
resolved by discussion until a consensus was reached.
2.2.2. Data Extraction and Management
Data extraction was performed using standard data-extraction forms. In addition to data such as
methods, participants, interventions, and outcomes (including the definitions of the primary outcome
of interest used in the study), we collected information about sample size calculation and the funding
of each study. One reviewer extracted the data from the included studies, and the second author
checked the extracted data. Discrepancies between the reviewers were resolved by discussion until
a consensus was reached. Participants, interventions, comparisons, and outcomes were taken into
consideration to determine whether they were similar enough to allow pooling of data.
2.2.3. Assessment of Risk of Bias in Included Studies
The Cochrane Collaboration’s tool for assessing risk of bias was used. The risk of bias parameters
included the type of randomization method (selection bias), allocation concealment (selection bias),
blinding of participants and personnel (performance bias), blinding of outcome assessment (detection
bias), and incomplete outcome data (attrition bias). Additionally, selective reporting (reporting bias)
and other types of bias were considered. If an item could not be evaluated due to missing information,
it was rated as having an unclear risk of bias [13].
2.2.4. Dealing with Missing Data
We assessed pooled data using intention-to-treat analysis, i.e., an analysis in which data are
analyzed for every participant for whom the outcome was obtained (also known as available case
analysis), rather than intention-to-treat analysis with imputation [14].
2.2.5. Assessment of Heterogeneity
Heterogeneity was quantified by χ2 and I2. A value for I2 of 0% indicates no observed
heterogeneity, and larger values show increasing heterogeneity. All analyses were based on the
random effects model.
2.2.6. Assessment of Reporting Biases
To test for publication bias, a test for asymmetry of the funnel plot, as proposed by Egger et al. [15],
was planned; however, sufficient (≥10) eligible trials were not available for any given outcome.
2.2.7. Data Synthesis
The data were entered into Review Manager (RevMan), Computer program, Version 5.3.
(The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) for analysis.
The results for individual studies and pooled statistics are reported as the risk ratio (RR) between the
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experimental and control groups with 95% confidence intervals (95% CI). RR is significant when the
95% CI does not include 1.0.
2.2.8. Subgroup Analysis
Subgroup analysis was based on the timing of the intervention (prenatally only, prenatally and
postnatally, postnatally only).
2.2.9. Quality of Evidence
For assessing the quality of evidence (also known as certainty in the evidence or confidence
in the effect estimates) for the primary outcome, we chose to use the GRADE methodology and
GradePro software, GRADEpro GDT: GRADEpro Guideline Development Tool (Software). (McMaster
University, Evidence Prime, Inc., Hamilton, ON, Canada). This software is available from gradepro.org.
The GRADE system offers 4 categories of the quality of the evidence (i.e., high, moderate, low, and
very low).
3. Results
3.1. Description of Studies
We identified seven publications [8,16–21] reporting on 5 RCTs (Table S1), which involved 889
participants at enrollment (443 in the LGG group and 446 in the control group). Compared to
previously published systematic reviews that identified 8 publications on LGG, we excluded the
study by Rautava et al. [22], as it reported data on a subset of the population from the study by
Kalliomaki et al. [8]. For a flow diagram documenting the identification process for eligible trials,
see Figure S1.
All studies were carried out in high-income countries such as Australia (one), Finland (one),
Germany (one), Taiwan (one), and the US (one). One trial reported data on the administration of LGG
during late pregnancy only [17]. Three trials [8,20,21] reported data on the administration of LGG
during pregnancy and to infants (duration of intervention prior to delivery ranged from 14–18 weeks
to 2–4 weeks, and in all trials was for 6 months after delivery). One RCT [18] reported data on the
administration of LGG to infants only (the duration of intervention was 6 months). The risk of allergy
was assessed in the included trials by a family history (the presence of allergy in at least one parent
and/or sibling) and/or other markers.
The daily doses of LGG ranged from 1.0 × 109 colony forming units (CFU) to 1.8 × 1010 CFU.
The sample size ranged from 105 to 250. Four RCTs were placebo-controlled. In one trial, inulin was
administered in both study groups, thus, any effect, if it exists, may be attributable to LGG. All included
RCTs evaluated eczema. However, various definitions were used. Atopic eczema IgE-associated was
reported separately in one trial only [16]. Other allergic manifestations were reported inconsistently.
In case of wheezing and asthma, the definitions were often overlapping, hence, our decision to present
these data jointly.
Risk of Bias in Included Studies
The included studies are described with respect to their risk of bias across the included RCTs in
Figures 1 and 2. Only one trial [17] had a low risk of bias. The remaining trials had some methodological
limitations. Sample size calculations were performed in all 5 trials. Funding was reported in 4 trials.
The GRADE assessment for the primary outcome related to use of LGG is presented in Table S2.
Using the GRADE methodology, the overall quality of evidence was rated as high to moderate.
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Figure 1. Risk of bias graph.
Figure 2. Risk of bias summary.
3.2. Effects of Interventions
3.2.1. Eczema
For data on eczema, see Figure 3.
LGG Administration during Late Pregnancy
Only 1 RCT (n = 242) [17] reported the effect of use of LGG administration during pregnancy on
the cumulative incidence of eczema and found a similar risk in both study groups (RR 0.88 (95% CI:
0.63, 1.22)).
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Figure 3. Primary outcome: Effect of LGG supplementation on eczema (data presented based on the
timing of LGG administration and the timing of assessment).
LGG Administration during Pregnancy and after Delivery
Three RCTs [8,20,21] reported the effect of LGG administration during pregnancy and to infants
on the cumulative incidence of eczema. The pooled results of data up to 2 years of age showed no
reduction in the risk of eczema (3 RCTs, n = 352, RR. 0.93 (0.49, 1.76)). Significant heterogeneity was
found (I2 = 72%). There also was no difference between groups in the risk of eczema in children up to
3–4 years (2 RCTs, n = 236, RR 0.74 (0.43, 1.26); I2 = 44%). Only one RCT (n = 115) reported a significant
reduction in the risk of eczema in children up to 7 years in favor of the LGG group (RR 0.66 (0.46,
0.94)) [19]. However, only 72% (115 of 159) of participants were followed up at 7 years.
LGG Administration to Infants Only
One 1 RCT [18] in which LGG was administered to infants only reported no significant difference
between groups in the risk of eczema up to 2 years of age (RR 0.93 (0.59, 1.45)).
The pooled results of 5 RCTs [8,17,18,20,21] (n = 778) showed no difference between the
LGG-supplemented and control groups in the risk of eczema, regardless of the timing of LGG
administration, up to 2 years (RR 0.90 (0.67, 1.21), I2 = 45%).
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3.2.2. Wheezing/Asthma
For data on wheezing/asthma, see Figure 4.
Figure 4. Secondary outcome: Effect of LGG supplementation on wheezing/asthma (data presented
based on the timing of LGG administration and the timing of assessment).
LGG Administration during Late Pregnancy
One RCT [17] in which LGG was administered only during late pregnancy reported no effect of
LGG administration on the risk of wheezing in children up to 2 years of age (RR 0.92 (0.58, 1.45)).
LGG Administration during Pregnancy and after Delivery
Four publications reporting on 3 RCTs [16,19–21] reported the effect of LGG administration during
pregnancy and to infants on the cumulative incidence of wheezing/asthma at various time intervals.
At 7 years, an increase in the risk of asthma in the LGG group compared with placebo group was
observed; however, this difference was of a borderline significance (RR 3.51 (1.00, 12.30)). Furthermore,
in addition to the previously stated high attrition rate in this trial (28%), the very wide confidence
intervals call for caution when interpreting these findings. For other time intervals, there were no
significant differences between the study groups.
LGG Administration to Infants Only
One RCT [18] in which LGG was administered only to infants reported no significant difference
between groups in the risk of asthma at 5 years (RR 0.56 (0.26, 1.21)).
50
Nutrients 2018, 10, 1319
3.2.3. Allergic Rhinitis/Sneezing
For data on allergic rhinitis/sneezing, see Figure 5.
Figure 5. Secondary outcome: Effect of LGG supplementation on allergic rhinitis (data presented based
on the timing of LGG administration and the timing of assessment).
LGG Administration during Pregnancy and after Delivery
Three publications [16,19,21] in which LGG was administered during pregnancy and to infants
reported data on allergic rhinitis at various time intervals; no significant differences between the study
groups were found.
LGG Administration to Infants Only
One RCT [18] in which LGG was administered only to infants reported no significant difference
between groups in the risk of allergic rhinitis at 5 years (RR 0.80 (0.22, 2.88)).
3.3. Food Allergy
None of the trials reported data on food allergy.
3.4. Adverse Events
Only 2 RCTs reported data on adverse events. [17] found a non-significant reduction in the risk of
adverse event in the LGG group compared with the placebo group (RR 0.66 (0.4, 1.1)). [20] found no
difference between the groups (data were not shown).
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4. Discussion
4.1. Summary of Findings
This meta-analysis adds to two recently published meta-analyses [9,10] by focusing on a single,
specific probiotic strain. We found no consistent effect of the administration of LGG for reducing
the risk of eczema up to 4 years of age, regardless of the timing of LGG administration (during
pregnancy and/or during breastfeeding or to infants only). One trial reported a reduced risk of
eczema at 7 years of age in the LGG group. However, the 7-year follow-up was completed by only a
subset of participants initially randomized into the study (115 of 159, i.e., 72%); hence, this finding
had to interpreted with caution. There was no effect of LGG administration on reducing the risk of
wheezing/asthma, with the exception of one trial that reported an increased risk of asthma at 7 years
in the LGG group compared with the placebo group. However, the high attrition rate in this trial
(as mentioned earlier), the borderline statistical significance, and wide confidence intervals around the
estimate call for caution in interpreting these findings. There was no effect of LGG administration on
allergic rhinitis. Adverse events were similar in both study groups.
4.2. Comparison with Other Reviews
Two previously published meta-analyses pooled data on different probiotics [9,10]. A 2015
systematic review (search date: December 2014) by Cuello-Garcia et al. [9] identified 29 publications in
which 12 various probiotics, single or in combinations, were used. The authors concluded that there are
significant benefits of probiotic supplementation in reducing the risk of eczema when used by women
during the last trimester of pregnancy (RR 0.71, 95% CI 0.60 to 0.84), when used by breastfeeding
mothers (RR 0.57, 95% CI 0.47 to 0.69), or when given to infants (RR 0.80, 95% CI 0.68 to 0.94). Based
on this systematic review, the WAO guidelines were published [5].
A 2018 systematic review (search date: December 2015) concluded that, overall, probiotic
supplementation during pregnancy and breastfeeding reduced the risk of both eczema (19 studies;
RR 0.78; 95% CI 0.68 to 0.90; substantial heterogeneity was found (I2 = 61%)) and “atopic” eczema
(11 studies; RR 0.78; 95% CI 0.65 to 0.92; no heterogeneity was found (I2 = 0%) at age ≤ 4 years.
However, there was no reduction in the risk of eczema in children aged 5 to 14 years. Subgroup
analysis for eczema showed a significant difference between studies that supplemented mothers
during the postnatal period (9 interventions; RR 0.64; 95% CI 0.51 to 0.80) and studies that just
supplemented infants during the postnatal period (11 interventions; RR 0.93; 95% CI 0.81 to 1.06) [10].
For both meta-analyses, the risk is that pooling data from different genera, species, strains, and doses
of probiotics obtained in different settings and/or populations, presumably with variations in their
native intestinal microbiota, may result in misleading conclusions. The results could be erroneously
extrapolated to other probiotics, including those that have not been adequately studied.
4.3. Strengths and Limitations
Our meta-analysis focused exclusively on one type of a clearly defined, single-organism,
probiotic microorganism, specifically LGG. Thus, it provides an answer to the question as to whether
current evidence should change practice. Nevertheless, several limitations must be emphasized.
First, our search depended on the studies identified via reviewing previously completed systematic
reviews. However, as the results were consistent, we decided to rely on these searches. Available data
were too limited to allow an examination as to whether the timing of probiotic administration matters
(i.e., during pregnancy only, or during pregnancy and to infants, or to infants only), even if each timing
was assessed separately. All trials were conducted in high-income countries, thus, the generalizability
of these findings to less privileged settings remains unclear. Overall, the quality of studies was sound.
Still, some methodological issues should be considered when interpreting the results. For example,
the high attrition bias in the trial by Kalliomaki et al. [17] is one methodological limitation. However,
this was unavoidable in a trial with a 7-year follow-up. Included trials used different definitions
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of eczema, and atopic eczema was assessed separately in only one trial [15] As the definitions of
wheezing and asthma were often overlapping, these data were presented jointly. However, not all
cases of early life wheezing will progress into asthma later on. Most children will eventually grow
out of the symptoms and will never develop asthma [23]. Regardless, as some trials have indicated
an increased risk of wheezing/asthma, more data are needed to evaluate this potentially harmful
effect of using probiotics. This is important as a 2018 systematic review found that of nearly 400 RCT
interventions aimed at modifying microbiota, only 6% adequately reported harms [24]. Consequently,
the safety and potential harms of using probiotics, particularly very early in life and for a prolonged
period, remains questionable. Trials included in our review did not report differences in adverse effects.
However, only limited data were available.
5. Conclusions
This meta-analysis does not support the use of LGG for reducing the risk of eczema. Our findings
indicate that current guidelines on the use of probiotics for preventing eczema in infants at high risk
for this allergic disease should be revised and be more specific with regard to which strain(s) to use.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/9/1319/
s1, Figure S1: Identification process for eligible trials, Table S1: Characteristics of the included studies, Table
S2: GRADE evidence profile summarizing the effect of Lactobacillus GG supplementation vs. placebo or no
intervention on eczema.
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Abstract: This review focuses on the evidence for health benefits of human milk oligosaccharides
(HMOs) for preterm infants to stimulate gut adaptation and reduce the incidence of necrotizing
enterocolitis (NEC) in early life. The health benefits of breastfeeding are partly explained by the
abundant HMOs that serve as prebiotics and immunomodulators. Gut immaturity in preterm infants
leads to difficulties in tolerating enteral feeding and bacterial colonization and a high sensitivity to
NEC, particularly when breast milk is insufficient. Due to the immaturity of the preterm infants,
their response to HMOs could be different from that in term infants. The concentration of HMOs
in human milk is highly variable and there is no evidence to support a specifically adapted high
concentration in preterm milk. Further, the gut microbiota is not only different but also highly variable
after preterm birth. Studies in pigs as models for preterm infants indicate that HMO supplementation
to formula does not mature the gut or prevent NEC during the first weeks after preterm birth and
the effects may depend on a certain stage of gut maturity. Supplemented HMOs may become more
important for gut protection in the preterm infants when the gut has reached a more mature phase.
Keywords: human milk oligosaccharides; human milk; infant formula; necrotizing enterocolitis;
preterm infant
1. Introduction
Preterm birth (<37 weeks’ gestation) is a major health concern and the leading cause of neonatal
mortality. Rates of preterm delivery remain high and even increase in some countries but medical
advancements have greatly improved survival rates, even for the extremely and very preterm infants
(<28 and <32 weeks’ gestation, respectively) [1]. Transition to enteral feeding at birth poses a great
challenge for the immature gastrointestinal tract of very preterm infants due to their compromised
digestive and immune functions. Diet-related neonatal diseases for very preterm infants include
sepsis and necrotizing enterocolitis (NEC). The NEC is a devastating intestinal inflammatory disease
that leads to necrosis and perforation of the gut epithelium. The NEC complications may relate to
morbidities later in life, including compromised neurodevelopment, atopic diseases and retinopathy [2].
Improved long-term survival of preterm infants also reflect improvements in nutritional care and
it is now widely recognized that mother’s own milk is the optimal diet for preterm new-borns [1].
Mother’s own milk reduces morbidity and mortality [3,4], protects against NEC [5–8] and sepsis [9]
and is trophic to the gastrointestinal tract [10]. Donor human milk is considered the best alternative to
mother’s own milk but donor milk is mature-derived milk and pasteurized and the content of bioactive
components are therefore reduced [11]. Comparisons of donor human milk with preterm formula,
as a supplement to mother’s own milk for the first 10 days, did not improve protection against severe
infections and mortality in very low-birth-weight infants [12].
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Human milk oligosaccharides (HMO) are highly abundant in human milk. With the unique and
complex carbohydrate structure, they resist gastrointestinal hydrolysis and digestion by pancreatic
and brush-border enzymes and are therefore not absorbed in significant amounts. Instead, they serve
as prebiotic substrates for specific commensal bacteria in the gut. Thus, HMOs help to shape the
developing microbiome and the innate immune system in the infant gut, as documented from
mother-infant cohort studies [13,14]. Several beneficial effects have been associated with HMOs,
based on preclinical studies. These HMO effects include antiadhesive properties, modulation of
intestinal epithelial cell responses, microbiota and immune modulation, protection against NEC and
improved brain development. Reviews on the metabolism and effects of HMOs, mainly in term
infants, are available [15–18]. Much less information is available about HMO effects in preterm infants.
With the recent industrial capacity to isolate HMOs or synthesize HMO analogues in bulk amounts,
the first clinical trials in healthy infants receiving formula have been performed. It is documented that
supplementation of 2’-fucosyllactose (2’-FL) and lacto-N-neo-tetraose (LNnT) is tolerable and stimulate
normal growth within the first 4–6 months of life [19,20]. In general, the number of publications on
HMO effects is increasing with the capacity to isolate or produce HMOs in bulk amounts within the
recent years, both as regards infant trials and preclinical studies in larger animals. These results now
warrant clinical trials to investigate effects of specific HMO interventions for special groups of infants,
such as preterm infants.
The prebiotic and immunomodulatory effects of HMOs may be particularly important for the
population of very preterm infants to improve their intestinal maturation and protection. On the
other hand, it is possible that the physiologically immature intestine in preterm infants hinders or
changes the normal HMO-related improvements in gut functions, microbiota composition and immune
modulation. This review highlights the current documentation for effects of HMOs to prevent gut
dysfunction and NEC in the very preterm infants. The review is based on evidence from clinical trials
and cohort studies in infants, preclinical animal models and in vitro studies.
2. Oligosaccharides in Human Milk after Preterm Birth
The HMOs are composed of the monosaccharides glucose (Glc), galactose (Gal), N-acetyl
glucosamine (GlcNAc), fucose (Fuc) and sialic acid, which in humans is found exclusively as
N-acetylneuraminic acid (Neu5Ac) [16]. Selected HMOs and their abbreviations are listed in Table 1.
Table 1. Selected human milk oligosaccharide structures and abbreviations [21,22].
Neutral Oligosaccharides Acidic Oligosaccharides
2’-Fucosyllactose 2’-FL Disialyllacto-N-tetraose DSLNT
Lactodifucotetraose LDFT Siallylacto-N-neo-tetraose b LST b
Lacto-N-tetraose LNT Siallylacto-N-neo-tetraose c LST c
Lacto-N-neo-tetraose LNnT Siallylacto-N-tetraose a LST a
Lacto-N-hexaose LNH 3′-Sialyllactose 3’SL
3-Fucosyllactose 3FL 6′-Sialyllactose 6’SL
Lacto-N-fucopentaose I LNFP I
Lacto-N-fucopentaose II LNFP II
Lacto-N-fucopentaose III LNFP III
Lacto-N-fucopentaose V LNFP V
Lacto-N-difucohexaose I LNDFH I
Lacto-N-difucohexaose II LNDFH II
The HMO composition in human milk is determined by genetic factors and dependent on the
mother’s Secretor (Se) and Lewis (Le) blood group characteristics. The blood group characteristics
determine the expression of the specific α1-2-fucosyltransferase (FUT2) and α1-3/4-fucosyltransferase
(FUT3), which gives rise to four different milk groups (Table 2). Group 1 are the Secretor Lewis-positive
(Se+/Le+) and derives from the most common phenotype. They comprise approximately 70% of
the European population and contains the highest concentration of total and fucosylated HMOs,
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primarily 2’-FL [23]. Group 2 are Nonsecretor Lewis-positive (Se−/Le+) and Group 3 are Secretor
Lewis-negative (Se+/Le−). Group 4 are Nonsecretor Lewis-negative (Se−/Le−), which have the lowest
levels of total oligosaccharides [24].




Secretor Lewis Secretor Lewis
1 Se/- Le/- Secretor Lewis positive
2’-FL, LNDFH I + II, LNFP I + II
+ III, 3FL, LDFT, LNnT, LNT,
LNH, MFNLH II
2 se/se Le/- Non-secretor Lewis positive LNDFH I + II, 3FL, LNFP II + III,LNnT, LNT, LNH, MFNLH II
3 Se/- le/le Secretor Lewis negative 3FL, LNFP I + III, LDFT, 2’-FL,LNnT, LNT, LNH, MFNLH II
4 se/se le/le Non-secretor Lewis negative 3FL, LNFP III, MFLNH II, LNnT,LNT, LNH
* All sialyl-oligosaccharides are present in all the milk groups, including DSLNT, LST, 3’SL, 6’SL.
The different HMOs in the four milk groups have been characterized in preterm milk during
the first month of lactation [24]. The total amounts of HMOs were highest in Group 1 milk at day
4 (23.4 g/L) and lowest in Group 4 (11.3 g/L), with important decreases in concentrations in these
groups within the first month of lactation (15% and 22%, respectively). Although reduced over time,
the levels in Group 1 continued to be highest within the first month, also relative to Groups 2 and
3 (~17 g/L). Therefore, the concentration of total HMOs is not particularly high in colostrum and
depends more on the blood characteristics of the mother. LNT and LNnT together constituted >90% of
the core oligosaccharides in all 4 groups. Group 1 milk was dominated by 2’-FL, LNDFH and LNFP
I, Group 2 by LDFNH, LNFP II and 3’-FL, Group 3 by 2’-FL and LNFP I and Group 4 by MFLNH
II and LNFP III. The identified fucosyl-oligosaccharides are listed in Table 2. No differences in the
average levels of sialyl-oligosaccharides were observed among the groups but levels were reduced
during the first month of lactation in Groups 1, 2 and 4 [24]. Thus, considerable differences in HMO
contents were found within the milk groups and were primarily related to the presence or absence of
specific fucosyl-oligosaccharides. In another study, LNT was found to be more abundant and with
higher variability in preterm milk [25]. Further, 2′-FL was not consistently present across lactation in
milk from mothers delivering preterm, which added to the variation in concentrations of fucosylated
HMOs. The variation was found both between individuals and during lactation in women delivering
preterm compared to women delivering at term. Fucosylation may therefore not be as well-regulated
in preterm milk as in term milk [25].
When looking at the total HMO concentration in preterm versus term milk, the total HMO
concentration in breast milk from Group 1 mothers delivering preterm [26] was higher than that from
mothers delivering at term [27] and decreased during the first month. In another study, the content
of neutral HMOs in milk from mothers delivering preterm was not different to milk from mothers
delivering at term during the first month of lactation but HMO concentrations varied over time
from mother to mother [28]. A recent study found similar levels of HMOs in milk from mothers
delivering preterm and term, also with large individual variations [22]. For sialic acid, the content in
milk from mothers delivering preterm was higher than in milk from mothers delivering at term and
decreased within the first three months of lactation [29]. This may correlate to the total number of
acidic HMOs. The varying levels and specificity of HMOs in the milk maintained over time may have
significant impact on the biological and clinical effects on preterm infants during the breastfeeding
period. The infants of non-secretor, Lewis negative mothers are most likely not compensated by
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improved gut utility and metabolization and a random factor related to the mother’s or the donor
blood group genetics may thereby impact gut homeostasis and clinical outcome in the infant.
The difference in total HMO levels between the different studies most likely reflects the lack
of standardized methods for obtaining quantitative data on HMO content in milk and the number
of subjects included in the studies [22]. From the present studies, there is no clear evidence for a
higher total concentration of HMOs in preterm versus term milk. Variation in HMO concentrations
among mothers may relate more to high individual differences based on genetic variation. This may
or may not influence the susceptibility of preterm infants to NEC, late onset sepsis and related
neurodevelopmental impairments.
3. Human Milk Oligosaccharides and Necrotizing Enterocolitis
The high prevalence of NEC in preterm infants is closely related to their immature gut and is
affected by the diet and bacterial colonization. With HMOs serving as prebiotics and possibly also
as antiadhesive antimicrobials and modulators of intestinal epithelial cell and immune responses,
they may have a significant impact on NEC by modulating the immune system and gut microbiota in
a more appropriate direction. Currently, no randomized clinical trials in preterm infants have been
conducted to document direct effects of supplemented HMOs on NEC outcome. Most indications for
HMO effects are based on the lower incidence of NEC in breast-fed infants compared to formula-fed
infants [6]. Evidence is also found from mother-infant cohort studies correlating HMO concentration
in mother’s milk with infant outcomes on NEC related parameters such as microbiota modulation [30].
In a multicentre clinical prospective cohort study, correlation between HMO composition in breast
milk and NEC outcome in very low-birth-weight infants showed no differences between NEC cases
and total HMO concentration in their milk diet. Only DSLNT-concentrations were lower in almost all
milk samples in NEC cases compared with controls [31].
The efficacy of HMOs to prevent NEC has mainly been assessed in preclinical NEC animal
models. In neonatal rats, formula supplemented with HMOs (10 mg/mL) showed improved survival
(73 to 95%) and reduced pathology scores (1.98 to 0.45). Within the pool of HMOs, DSLNT was
identified to exert the NEC protective effect [32]. Both 2’-FL and synthesized DSLNT analogues
have been documented to improve NEC protective effects, although not to the same extent as pooled
HMOs [33,34]. The neonatal rat studies hereby document beneficial effects of specific HMOs to reduce
NEC-related intestinal lesions. The rat NEC models are based on term-delivered pups exposed to
various insults (e.g., hypoxia and hypothermia) to induce NEC and not to the prematurity of the
organs, which is the main driver of NEC in infants. In rodents, gut development occurs relatively
rapidly after birth, while the gut of infants matures gradually from the foetal period and into the
neonatal period [35]. After preterm birth, the immature gut has to adapt slowly to cope with the
challenges of feeding and bacterial colonization. This situation may differ markedly from the rapid
postnatal gut development in rodents. Lipopolysaccharide stimulation of foetal murine intestinal
epithelial cells ex vivo results in intracellular cell signalling, transcriptional activation and chemokine
secretion, whereas cells from new-born and adult mice are non-responsive [36,37]. This indicates that
the intestine acquires immunological tolerance to endotoxin after birth and only in the prenatal state
the intestine is hyper-responsive and therefore potentially more NEC-sensitive. The neonatal rats as
NEC models are suitable and well-recognized to identify potential dietary effector substrates related to
NEC but as common for many models, the effect may be more extreme than what would be observed
in infants. This needs to be taken into account when translating the results to infants.
Pigs have the same gastrointestinal structure as humans with similar dietary habits and preterm
piglet delivery at 88–95% gestation is associated with clinical complications and degrees of gut
immaturity similar to those in infants born at 70–90% gestation, such as impaired respiratory,
nutritional, immunological and metabolic responses after preterm birth [35]. The high spontaneous
susceptibility to enteral feeding and bacterial colonization closely resemble that in infants. This makes
the preterm pig model relevant as a large animal model for studies on clinical complications of preterm
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birth such as NEC. Novel technologies have now made it possible to generate several of the complex
HMOs in larger amounts. This makes it feasible to test single and more complex blends of HMOs as
dietary supplements in a clinically relevant NEC model with preterm pigs.
Supplementation with 2’-FL (5 g/L) to formula has only shown minimal short-term effects on
NEC and gut maturation in preterm pigs within 5 days. Here, eight 2’-FL pigs (50%) and twelve control
pigs (71%) developed NEC with no difference in NEC lesion scores (p = 0.35). Further, several intestinal
functional parameters were not affected by 2’-FL [38]. Also, blends of 4 and >25 HMOs have been
investigated as a supplement to formula at 5–10 g/L for 5 or 11 days after preterm birth in pigs.
All HMOs were identified in urine and faeces of the HMO-treated pigs. After 5 days, NEC lesions
were similar between HMO supplemented and control pigs. Only after 11 days, supplementation with
the 4-HMO blend showed minor tendencies towards reduced NEC relative to control pigs (56 vs. 79%,
p = 0.2). At the same time dehydration and diarrhoea was increased. The diarrhoea is likely induced
by infant formula maldigestion and subsequent high intraluminal osmolarity that may be enhanced
by non-digested HMOs in the lumen [39].
4. Human Milk Oligosaccharides and the Preterm Gut Microbiota
The microbiota of preterm infants is different from their healthy term counterparts. This is mainly
due to organ immaturity, frequent use of antibiotics and hospital stay in the neonatal intensive care
units [40]. The microbiota of healthy term infants is dominated by Bifidobacteria and Bacteroidetes,
which are also the primary consumers of HMOs. These bacteria are only present at low abundance
in preterm infants. Instead, the preterm infants show low diversity with increased colonization of
potentially pathogenic bacteria from the gram-negative family Enterobacteriaceae of the Proteobacteria
phylum [30,40–42]. Several Proteobacteria are positively associated with development of NEC,
whereas the relative abundances of Firmicutes and Bacteroidetes are decreased [43–45]. In the piglet
model, Enterobacteriaceae and Lachnospiraceae were predominant in both preterm and term pigs at
11 days after birth and only in the low abundant genera differences were observed between preterm
and term pigs [46]. Proteobacteria and Firmicutes phyla have also been identified as predominant
in preterm and term pigs at day 5 but in the preterm pigs, the relative abundance of Proteobacteria
decreased and Firmicutes increased at day 26, where also Lactobacillus was predominant (Shamrul et al.,
JPGN in press). As for infants, the Bifidobacteria and Bacteroidetes are found in low numbers in the
preterm pigs. Instead the Enterobacteriaceae are dominant. In new-born rats, considerable diversity of
bacterial populations has been observed but lactobacilli have often been identified as the most common
first colonizers in both formula-fed and breast-fed rats [47,48].
Only few studies have investigated the influence of the different HMOs in mother’s milk on the gut
microbiota pattern in preterm infants. The HMO composition in milk and stools from mother-preterm
infant dyads have shown high variability in the content of HMOs between individuals but similar
within mother-infant pairs and secretor status of the mother correlated with specific HMO structures
in faecal content of the infant [30]. Further, there was a trend towards higher levels of Proteobacteria
and lower levels of Firmicutes in preterm infants of non-secretor mothers. This indicated that HMOs
influence the intestinal microbiota in preterm infants. Infants of secretor mothers may be protected by
fucosylated HMOs that decrease the levels of pathogens related to NEC and sepsis, for example LDFT
and LNFP V and structures that are both fucosylated and sialylated. Other structures, such as LNnH
and HMOs that contain neither fucose nor sialic acid, may on the other hand lead to dysbiosis [30,49].
In a new-born pig diarrhoea model, the level of Enterococcus was reduced in 2’-FL supplemented
pigs within the first eight days after birth. When inoculating the pigs with enterotoxigenic Escherichia
coli F18, 2’-FL tended to reduce the abundance of Enterobacteriaceae and increased the relative abundance
of an unclassified Lachnospiraceae genus [50]. Also, a mix of HMOs (75% neutral and 25% acidic)
have shown to reduce Rotavirus-induced diarrhoea in new-born pigs, with increased number of
Lachnospiraceae and modulation of the mucosal immunity [51]. In the preterm pig NEC model,
only minor microbiota effects were observed in 2’-FL supplemented pigs within 5 days. The pigs tended
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to have less anaerobic bacteria in caecal contents and only Enterococcus differed in proportions between
2’-FL and control pigs [38]. In an 11-day study, the overall bacterial adherence and diversity was not
changed after supplementation with a mixture of 4 HMOs in the preterm pig model. The short-chain
fatty acids, acetic acid, butyric acid and pentanoic acid, did though tend to be higher in the 4-HMO
supplemented pigs [39]. Only Fusobacterium were reduced in the 4-HMO supplemented pigs and the
number of Fusobacterium tended to be related to NEC development. Interestingly, although found in
lower amounts, Bifidobacteria correlated with total HMO content and specifically with 2’-FL levels in
colon contents in 11-day old preterm pigs fed the 4-HMO blend (Rudloff et al. manuscript in review).
In contrary, DSLNT did not correlate with bacterial colonization or NEC, although NEC preventive
effects of DSLNT have been observed in rats [34]. The effects of the sialylated oligosaccharide, SL, in a
bovine based milk supplement has been investigated in preterm pigs for 19 days (Obelitz-Ryom et al.
manuscript in review). Even within this slightly longer study period, supplementation of SL-enriched
bovine milk oligosaccharides in amounts similar to what is found in mature human milk (380 mg
SL/L) did not change either the overall microbiota density or composition nor the short chain fatty
acid levels in the gut. Many of the pigs were clinically compromised with diarrhoea during the
study period related to their prematurity and the oligosaccharide supplementation was not able to
improve the clinical conditions of the piglets, as also observed earlier [39]. Overall, only minor effects
of HMOs on gut microbiota has been observed in preterm pigs, including limited effects of 2’-FL on
Bifidobacteria. In contrast to the preterm models, models of undernutrition in new-born infants have
shown a relationship between sialylated bovine milk oligosaccharides and growth. Here, gnotobiotic
5-week old mice and 3-day old piglets were inoculated with faecal microbiota from a 6-month old
stunted Malawian infant [52].
5. Human Milk Oligosaccharide Effects on Gastrointestinal Maturation
Whereas clinical outcomes such as diarrhoea and NEC are common endpoints in clinical infant
trials, gut functional and structural changes are more difficult to investigate. The preclinical animal
models and in vitro cell models may give insight into more specific functional gastrointestinal effects,
such as gut structure and morphology, epithelial differentiation, mucus production, permeability and
digestive and absorptive capacity.
The HMO supplemented formula-fed rat pups have shown normal, healthy microscopic
architecture of the ileum, comparable to dam fed pups, whereas some ileal sections from formula-fed
and galacto-oligosaccharide supplemented pups showed complete destruction of the tissue [32].
Although tissue architecture was improved with HMO supplementation, no effects were observed on
weight gain, where only the dam-fed pups improved weight gain compared to formula-fed pups [32].
No other gut parameters have been documented in the identified rodent HMO studies [32,34].
In the preterm pig NEC studies, no major effects on gut parameters have been observed from
HMO supplementation within 5 and 11 days. For 2’-FL supplementation, no effects were found on
any of the investigated gut parameters [38]. For 4 and >25 HMO blends, only minor effects on the gut
were observed [39]. Overall, no effects were observed on daily weight gain, relative organ weights,
mucosa proportion of the small intestine, hexose absorption, gut permeability, or plasma citrulline,
reflecting enterocyte mass and function. Minor changes were observed for the brush-border enzyme
activities. The activities of lactase, aminopeptidase A, aminopeptidase N and dipeptidyl peptidase IV
were higher only in the ileum of piglets supplemented with 25-HMO compared to non-supplemented
piglets after 5 days. No changes were observed for maltase and sucrase. The same was observed for the
piglets supplemented with 4-HMO, which only showed lower villus heights. Supplementary studies
in an intestinal epithelial cell model with IPEC-J2 cells showed reduced proliferation with 25-HMO,
2’FL, LNnT, 6’SL and SA, indicating differentiation towards more mature intestinal cells [39], in line
with earlier observations in HT-29, Caco-2 and HIEC cells [53]. Overall, only minor effects have been
observed from HMO supplementation to formulas on a wide range of investigated parameters related
to gut function and maturation in preterm piglets. In contrast, other diets or dietary components have
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induced significant improvements in both growth, organ weights and brush-border enzyme activities.
For example, porcine or bovine colostrum and donor human milk in comparison to infant formula in
preterm pigs [11,54–56]. Also supplements like bioactive whey protein concentrate and lactose [57]
and amniotic fluid [58] have documented effects.
6. Immunomodulatory Effects of Human Milk Oligosaccharides
The immature mucosal immune system in the intestine of preterm infants is hyper-
inflammatory [59] and the disturbance of the development in controlling inflammatory processes
potentially contributes to NEC [60]. The bioactive components in human milk are highly important for
the quenching of inflammatory processes after birth, by facilitating appropriate immune responses
and antigenic memory [61–63].
So far, randomized controlled trials with HMO interventions have only been conducted in healthy
term infants. In a randomized multicentre trial, the effects of supplementation of infant formula with
2’-FL (1.0 g/L) and LNnT (0.5 g/L) on growth, tolerance and morbidity in new-born healthy infants has
been investigated during the first 6 months of life. Infants receiving HMOs had lower parent-reported
morbidity, particularly bronchitis and fewer medication use, such as antipyretics and antibiotics [20].
A randomized controlled study on growth and tolerance was conducted in healthy new-born infants
fed formula supplemented with 2’-FL (0.2 and 1.0 g/L) for 114 days. The 2’-FL supplemented formula
was well tolerated and comparable to formula-fed infants for average stool consistency, number of
stools per day and percent of feedings associated with spitting up or vomit [19]. In a sub-study
nested within this clinical trial, effects on biomarkers of immune function were investigated [64]. Here,
infants fed 2’-FL supplemented formula had lower levels of plasma (IL-1ra, IL-1a, IL-1b, IL-6, TNF-α)
and ex vivo (TNF-α, IFN-γ) inflammatory cytokines than formula-fed infants. The levels were similar
to those of breast-fed infants.
The HMOs from human colostrum have shown to modulate mucosal signalling in the immature
human intestine by the use of human foetal intestinal explants. The human foetal intestinal epithelial
cells overexpressed innate inflammatory genes, such as NFkB, MyD88, TLR2, TLR4 and TRAF,
with inadequate expression of negative feedback regulator genes. Accordingly, the immature intestinal
mucosa of foetal tissues is prone to exaggerated responses to pro-inflammatory stimuli, increasing the
risk of inflammatory diseases of the intestine in the infant. The HMO stimulation enhanced expression
of genes involved in immune cell trafficking, proliferation and recruitment of immune cells to the
mucosal surface. This could explain the clinical association between human milk consumption
and reduced risk of preterm gut inflammation [65]. The HMOs and particularly 2’-FL, have also
been shown to suppress CD14 expression in human intestinal epithelial cells, thereby attenuating
lipopolysaccharide-induced inflammation. The inhibition of inflammation supports the role HMOs in
the innate immune system to protect the infant through the milk [66].
In vitro studies have associated HMOs to systemic immune functions. In leukocytes isolated from
human peripheral blood, sialylated HMOs have shown to reduce selectin-mediated platelet-neutrophil
complex formation [67] and inhibit adhesion of monocytes, lymphocytes and neutrophils to endothelial
cells [68]. Excessive leukocyte infiltration has been linked to the host’s immune system involved in NEC
pathogenesis [69] but evidence from preterm infants is lacking. Further, the systemic effects require
the presence of HMOs in the circulation, which is minor due to the low absorption of HMOs [70–72].
In the preterm pig studies investigating blends of 4 and >25 HMOs, no changes in the levels
of IL-8 and IL-1β in the small intestine and colon were observed from HMO supplementation.
Supplementation with 4-HMO for 11 days increased the expression of IL10, IL12, TGFβ and TLR4 [39].
The upregulation of specific immune genes related to the Th1 and Treg balance may represent an ability
of the HMOs to control mucosal immune responses to the diet and the bacterial colonization. This may
help to educate the immature immunological pathways in the gut. The systemic immunity has been
investigated in preterm pigs supplemented with SL-enriched bovine milk oligosaccharides for 19 days.
The levels of blood leukocyte subsets remained unchanged and similar neutrophil phagocytotic
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capacity of Staphylococcus aureus was observed in the SL and control group (Ryom-Obelitz et al.
manuscript in review). The lacking effects of HMOs to stimulate mucosal and systemic immune
maturation in the preterm pigs may be related to their prematurity. In comparison to term pigs with
a well-developed immune system, the preterm pigs may not be able to respond appropriately to
bioactive immune-stimulating factors in milk to facilitate an appropriate immune response before
their immune system is more mature. Even in pigs with NEC, which should have a significant
increase in the activation of innate immune parameters, the immune response of the preterm pigs is
moderate [73,74]. The low dietary modulation of the immune system in preterm neonates may be
particularly compromising when feeding formula diets that predispose to NEC [6].
7. Human Milk Oligosaccharides for the Preterm Newborns
An overview of HMO effects in the compromised preterm neonates is presented in Figure 1,
together with the mechanisms of action in healthy term infants as reviewed earlier [15,17].
Reduced peristalsis, lowered digestive and absorptive function, impaired intestinal epithelial barrier
and a dysregulated mucosal immune system leads to the uncontrolled cycle of maldigestion,
bacterial invasion, immune activation and inflammation in the preterm neonate. This is particularly
evident following formula feeding. As reviewed here, there seem not to be a specifically adapted high
concentration of HMOs in preterm versus term milk. Rather, the content is related to high individual
differences based on genetic variation. Beneficial effects of individual and pooled HMOs on NEC
resistance has been documented in neonatal rat studies. The preterm piglets are highly sensitive to
dietary interventions and the pig studies support the beneficial effects of feeding optimal diets such as
donor human milk for improved health outcome and NEC prevention [11,55,56]. Nonetheless, it has
not been possible to document any significant effects of HMOs supplementation of infant formula
on NEC prevention [38,39,50]. This indicates that immune parameters and microbial colonization
and fermentation may only to a limited extent be modified by HMOs in a formula base in the early
life of the very preterm neonates. Either the effects are minor in the new-born immature gut, or the
detrimental effects induced by formula feeding, such as food intolerance and NEC, may override
any beneficial effects of HMOs. Other milk components may have a higher impact on gut health
in the preterm intestine within the first weeks’ of life. Several milk diets with optimized protein
bioactivity have proven to be beneficial in the preterm pig intestine by modulating the innate immune
defence system and improving gut functional parameters and growth [11,55,57,75–77]. These results
indicate that bioactive proteins may be more important than prebiotic oligosaccharides for preterm
gut development.
The preterm infants are particularly sensitive with immature organs and although HMOs are
thought to stimulate gut and immune maturation and appropriate colonization, the undeveloped gut
may not be able to tolerate a high microbial load to the same extent as term infants, regardless the
composition [78,79]. Reducing the total load of bacteria, rather than stimulating bacterial colonization,
may hinder NEC development more efficiently in the early life of very preterm infants [80,81].
Biological effects of HMOs may likely be more effective to improve the immature gastrointestinal
functions in preterm neonates beyond the immediate neonatal period. In a later and more robust
period of prenatal development and growth, preterm infants who do not have access to human
milk may benefit from HMO supplemented bovine milk-based infant formula. This has though not
yet been investigated. At least in healthy new-born term infants, the supplementation of 2’-FL and
LNnt to infant formula starting <14 days after birth until 6 months of age has proven to be well
tolerated without changing weight gain and associated with lower parent-reported morbidity such
as bronchitis [19,20]. In general, the number of publications on HMO effects is increasing with the
capacity to isolate or produce HMOs in bulk amounts within the recent years, both as regards infant
trials and preclinical studies in larger animals. This will add important information to the generated
knowledge from breast-fed infants over the years.
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Figure 1. Schematic overview of the suggested mechanisms of action of human milk oligosaccharides
(HMOs) in the intestine of term infants (left panel) and in the immature intestine of preterm
new-born neonates (right panel). In the term intestine, appropriate peristalsis, milk digestion and
absorption and epithelial barrier protection with well-developed mucus and mature and responsive
enterocytes maintain gut and immune homeostasis. Here, HMOs may serve as prebiotics, act as decoy,
modify epithelial glycan receptor expression, stimulate epithelial restitution and immune modulation
to further secure proper response to feeding. In preterm neonates, gut prematurity may outweigh or
hinder the beneficial effects of HMOs. Reduced peristalsis, lowered digestive and absorptive function,
a dysregulated mucosal immune system and impaired intestinal epithelial barriers with reduced mucus
and epithelial restitution all lead to an imbalance between epithelial cell injury and repair. The HMOs
may still serve as a prebiotic substrate for bifidogenic bacteria and support short chain fatty acid
(SCFA) production and may also serve as receptor-mediated decoys for specific pathogenic bacteria
but the underlying immaturity of the gut with compromised absorptive functions and restitution seem
unresponsive to HMOs, with no maturational effects on the basic functions. This is of particularly
concern if the HMOs are supplemented to infant formula, where over-fermentation and proliferation of
bacteria are inevitable in the preterm gut. Thereby, a vicious cycle of maldigestion, bacterial invasion,
immune activation and uncontrolled inflammation appears that does not seem to be hindered by HMO
supplementation (indicated with yellow stars).
The preclinical animal studies do not fully represent the NEC pathology of infants and the milk
oligosaccharide and gut microbial patterns differ to some extent. Concentrations of oligosaccharides
in porcine colostrum is in the range 7.38 to 29.35 g/L and the corresponding value for bovine milk
oligosaccharides is about 1 g/L [82]. These data showed big variation among sows, which is similar
to observations in humans. The observed range of concentrations is though not very distinct from
concentrations in human milk. The highest levels in sows’ colostrum correspond to the concentrations
found in Group 1 milk and the lowest concentrations similar to the concentrations in Group 4 milk.
However, contrary to in humans, the content is significantly reduced (−43%) within the first week after
delivery. This may represent the faster ontogeny and shorter time to weaning of the piglet compared
to infants. For specific milk oligosaccharides, LNT is highly abundant in human milk and one of
the primary drivers of infant colonization with bifidobacteria. In contrary, these bacteria have minor
influence in the new-born preterm pig intestine. Human milk is considered unique, as it contains type
I oligosaccharides (LNT, LNFP-I, LNFP-II and LNDFH-I), which have not been identified in bovine
milk. Unlike bovine milk, LNDFH-I has also been identified in porcine milk and Neu5Gc containing
oligosaccharides that are found in bovine milk are absent in porcine milk. Although natural levels of
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oligosaccharides in porcine milk after the first week is lower than human milk, the higher abundance
of fucosylated versus sialylated oligosaccharide structures places porcine milk structurally far closer to
human milk than previously assumed [82–84]. From birth, piglets also have endogenous production
of fucosylated structures in the gut such as α1,2’-fucose [50]. This may to some extent compensate for
the lower levels in the milk. Although the microbial fingerprint in the piglet is different from that of
the new-born infants, the presence of fucosylated structures both in the porcine milk and in the gut
of the new-born piglets may indicate an impact of these oligosaccharide structures in managing gut
homeostasis also in pigs. In both infants and piglets, a balanced milk oligosaccharide composition
may be needed to shape the gut microbiome for optimal trophic and protective effects and to keep
dysbiosis in check, not only by stimulating bifidobacteria but also by regulating other bacteria such as
Enterobacteriaceae that are implicated in NEC.
8. Conclusions
As a major constituent of human milk, HMOs are probably significant contributors to general
infant health during breastfeeding. This could be due to their ability to stimulate the immune system
and to provide substrates for development of a beneficial gut microbiota. Very preterm infants are born
with an immature gut and immune system. Whether the health effects ascribed to HMOs also benefit
these neonates in their first difficult weeks of life, when the immature gut needs to adapt to enteral
feeding and microbial colonization, is unclear. Reflections on when to introduce HMO supplementation
to preterm infants are necessary (e.g., when feeding donor human milk or infant formula). Fortification
of donor human milk is often needed to provide enough protein for appropriate growth to the very
preterm infant and addition of HMOs in combination with protein supplements may be feasible.
Based on the preclinical studies reviewed here, there is limited evidence that addition of HMOs to
a milk formula diet of very sensitive preterm neonates in the first weeks of life will reduce NEC
sensitivity. Later introduction of HMOs to the preterm neonates, when the gut has adapted to feeding
and bacterial colonization may be more beneficial for improved gut health. Larger cohort studies as
well as randomized clinical trials with NEC as outcome are needed to validate preclinical findings
of HMOs and the discrepancies between preterm and term adaptation and tolerance. Furthermore,
the mechanistic actions of HMOs should be tested further in appropriate preclinical animal studies,
where specific HMO structures and optimal timing of supplementation should be addressed.
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Abstract: The use of probiotics among very low-birth-weight infants is constantly increasing,
as probiotics are believed to reduce the incidence of severe diseases such as necrotizing enterocolitis
and late-onset sepsis and to improve feeding tolerance. However, despite the enthusiasm towards
these products in neonatal medicine, theoretical knowledge and clinical applications still need to be
improved. The purpose of this review is to give an overview of the most important gaps in the current
literature about potential uses of probiotics in preterm infants, highlighting promising directions for
future research. Specifically, further well-designed studies should aim at clarifying the impact of
the type of feeding (mother’s milk, donor milk, and formula) on the relationship between probiotic
supplementation and clinical outcome. Moreover, future research is needed to provide solid evidence
about the potential greater efficacy of multi-strain probiotics compared to single-strain products.
Safety issues should also be addressed properly, by exploring the potential of paraprobiotics and
risks connected to antibiotic resistance in preterm infants. Last, in light of increasing commercial
and public interests, the long-term effect of routine consumption of probiotics in such a vulnerable
population should be also evaluated.
Keywords: preterm infant; probiotic; human milk; probiotic strain; safety
1. Introduction
Despite continuous improvements in neonatal medicine, prematurity represents the leading cause
of both neonatal and childhood mortality through age five years worldwide [1]. Diseases such as
necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) pose a serious threat for preterm infants,
and are included among the leading causes of morbidity and mortality in this population [2].
There is a growing body of literature directed towards the implementation of preventive measures
which could reduce the incidence and severity of these diseases, possibly leading to an improvement
in neonatal short- and long-term outcomes [3]. Among these interventions, probiotics appear to be
very promising; they have been recently described as living “a golden age” in neonatal medicine [4].
Despite such enthusiasm, it is still difficult to make precise recommendations on the use of
probiotics in preterm infants. Recent systematic reviews and meta-analyses of the literature have
suggested a beneficial role of probiotics for preventing NEC [5–7] and LOS [8,9], and for improving
feeding tolerance by shortening the time to achieve full enteral feeding (FEF) [10,11]; furthermore,
it has been suggested that probiotic administration might lead to a global improvement in neonatal
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health by reducing mortality rates and length of hospital stay [12–14]. However, most of the studies
included in these systematic reviews and meta-analyses have not properly addressed all of the potential
confounding factors which might interfere in shaping the relationship between probiotic administration
and clinical outcomes, thus failing to provide to the clinician a meaningful answer as to which probiotic
strain should be used, how long probiotic supplementation should be continued, and which group(s)
of infants would likely benefit from the intervention.
Despite concerns about the efficacy and, more importantly, the safety of available probiotic
products [15], a recent survey of US Neonatal Intensive Care Units (NICUs) participating to the Vermont
Oxford Network has shown that probiotic use among very low-birth-weight (VLBW) infants is increasing,
and that there is a wide variability in their indications and in the probiotic products themselves [16].
The purpose of this review is to give an overview of the most important gaps in the current
literature about potential uses of probiotics in preterm infants, highlighting promising directions for
future research.
2. Defining the Target: Gut Microbiota vs. Clinical Outcomes
In infants, as well as in children and adults, the rationale for using probiotics to treat or prevent
any disease relies on their potential ability to restore a healthy gut microbiota. Probiotic action in
the gut is mediated through several mechanisms, which include the up- and down-regulation of
genes involved in inflammation and cytoprotection, improvement of gut barrier function, production
of metabolites such as short-chain fatty acids which modulate the growth of pathogenic bacteria,
and competition with other microorganisms [17].
When talking about preterm infants, a clear definition of this probiotic target is challenging, as the
characterization of a healthy gut microbiota in these infants is not univocal, being influenced by several
factors such as place of birth, mode of delivery, feeding characteristics, antibiotic use, and NICU
environment [18]. In addition, despite a generally clear association between dysbiosis and disease,
the causality and reversal of disease in response to probiotic-induced changes in gut microbiota have
not yet been demonstrated [19]. For this reason, the target for probiotic intervention in preterm infants
at present cannot be exclusively microbiological (in other words, a gut microbiota with distinctive
“healthy” features), but still needs to be clinical.
Given this premise, a clear definition of clinical outcomes whose improvement might be related
to probiotic administration is fundamental. In most clinical trials, sample size calculation is based
on single pre-specified outcomes (i.e., mortality, NEC, LOS, feeding tolerance), but other outcomes,
for which these studies are probably underpowered, are often analyzed and their results are included
among relevant conclusions. This constitutes a limitation of these studies’ conclusions, which hopefully
should be overcome in the future by calculating the sample size on multiple outcomes.
3. Exploring Feeding Contribution: Human Milk vs. Formula
Infant nutrition in early life has been recognized to play a key role in shaping future health [20].
Specifically, human milk (HM) is known to exert a series of beneficial effects for the infant,
including improved neurological, immunological, and metabolic outcomes [21]. In this respect,
exclusive HM-feeding appears to be even more important for preterm infants, especially for those
born with a VLBW [22]. The beneficial effects of HM are related to its peculiar nutritional and
functional components, such as long-chain polyunsaturated fatty acids, immunomodulatory proteins
(i.e., lactoferrin, immunoglobulin), and HM oligosaccharides (HMOs) [23]. Some of these HM
components have been also related to the decrease in NEC incidence and severity documented in
infants receiving exclusive HM [24]. The unique composition of HM possibly confers protection against
NEC through several mechanisms implicated in the pathogenesis of the disease, such as reduction in
gastric pH, improvement in intestinal motility, and decrease in epithelial permeability. In addition,
immunoglobulin A and lactoferrin, contained in HM, might modulate gut inflammation, and HMOs
are thought to prevent bacterial adhesion to the intestinal mucosa and exert a prebiotic action on
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gut microbiota [25]. Furthermore, it is well recognized that HM itself harbors a specific microbiota,
which contributes to drive the establishment of the infant gut bacterial community [26]. In this regard,
features of gut microbiota in breastfed vs. formula-fed infants are quite different: breastfed infants have
a higher abundance of Bifidobacterium spp., Staphylococcus spp., and Streptococcus spp., while Bacteroides
spp., Clostridium spp., Enterobacteriaceae, and Lachnospiraceae dominate in formula-fed infants [27].
A recent systematic review examined the effect of different enteral feeding strategies, including
feeding type and probiotic supplementation, on the establishment of gut microbiota in preterm
infants [28], with the aim of identifying feeding factors which would promote gut colonization with
beneficial bacteria. Both mother’s own milk (MOM) and probiotics were found to promote a healthy
gut microbiota, by increasing microbial diversity and promoting colonization with Bifidobacteria.
Since the effects of both HM and probiotics on gut microbiota and clinical outcomes such as
NEC and LOS have been advocated in so many clinical trials and literature reviews, it is quite
surprising that the two interventions have not been examined together. It is plausible that nutrition
and supplemental probiotics could act together in the preterm infant’s gut, leading to a differential
effect of exogenous bacteria depending on type of feeding. Despite the theoretical likeliness of this
hypothesis, type of feeding is rarely detailed or considered among confounding factors in trials
about probiotics. One might speculate that probiotics would act preferentially in formula-fed infants,
as they would counterbalance the negative effect of formula feeding on gut microbiota. However,
unexpectedly even for the authors themselves, one clinical trial reported that a combination of probiotic
strains (Lactobacillus acidophilus and Bifidobacterium bifidum) was effective on NEC only in VLBW infants
who were exclusively breastfed, but not in those receiving formula [29]. Similarly, two meta-analyses
of randomized controlled trials (RCTs) documented a reduction in the incidence of LOS and in the
time to achieve FEF only in HM-fed preterm infants [9,11]. More recently, the effect of probiotics
on NEC was found to be more pronounced in cohorts where higher proportions of neonates were
exclusively breastfed [30].
The available literature does not offer a clear justification for these findings: one hypothesis is
that VLBW infants exposed to formula might have a higher baseline risk for diseases such as NEC
and feeding intolerance, because intact bovine proteins in infant formula can contribute to intestinal
inflammation [25]. Furthermore, it is plausible that the effect of probiotics on clinical outcomes could be
mediated by functional HM components such as prebiotic HMOs, immunological factors, and probiotic
bacteria [31]. In this respect, recent data suggest that a low abundance of a specific HMO in MOM
(disialyllacto-N-tetraose, DSLNT) could represent a marker of the susceptibility of preterm infants to
NEC [32], thus highlighting the fundamental role of the crosstalk between HM prebiotic components,
gut and HM microbiota, and probiotics in the development of the disease.
While the role of MOM in the prevention of NEC has been established, less is known about
donor HM (DHM). In a multicenter clinical trial, the availability of DHM was associated with a 10%
increase in MOM availability and a 2.6% decrease in the rate of NEC [33]. Similarly, the introduction
of DHM and probiotic supplementation in two clinical settings was linked to a significant reduction
in neonatal mortality and to a non-significant decrease in NEC rates [34]. On the contrary, the use of
DHM as a supplement to MOM was not associated with any significant benefit in terms in mortality
and morbidity indexes, nor in neurodevelopment at 18 months corrected age [35].
The interaction between DHM and probiotic supplementation in shaping neonatal clinical
outcomes in far from clear. The manipulation process of DHM, which includes several steps such as
freezing, thawing, pooling, and pasteurization, is likely to have a major impact on HM functional
components [36]. Whether the changes in DHM composition induced by its manipulation translate
into a clinically relevant effect is yet to be demonstrated. Recently, the effect of different feeding
types, including MOM, DHM, and formula, on the features of gut microbiota in preterm infants
was analyzed: compared to DHM-fed infants, gut microbiota in MOM-fed infants was richer in
Bifidobacteriaceae and poorer in Staphylococcaceae, Clostridiaceae, and Pasteurellaceae. Despite these
differences, gut microbiota profiles in MOM-fed and DHM-fed infants were more similar than those
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observed in formula-fed infants [37]. The clinical significance of these observations deserves to be
assessed in further trials.
In summary, given the differential effect of MOM, DHM, and formula on both gut microbiota and
neonatal clinical outcomes, it is fundamental that further studies exploring probiotic supplementation
in preterm infants will plan to describe in greater detail and adjust their data for feeding characteristics
of included infants, in order to limit potential confounding factors (i.e., percentage of MOM, duration
of exclusive MOM, characteristics of HM fortification, etc.). Even better, it would be ideal to restrict
inclusion criteria to infants fed homogeneously (MOM, DHM, or formula), thus overcoming the
impracticability of randomizing preterm infants according to type of feeding.
4. Choosing the Probiotic: Is There Strength in (Strain) Numbers?
The strain-specificity of the probiotic effect has been accepted for decades as a pivotal principle of
probiotic science and regulation [38]. More than 20 years from the first RCT showing that probiotics
could be effective in reducing NEC, several RCTs and cohort studies reporting on NEC, LOS,
and/or mortality in preterm infants receiving probiotic supplementation have been conducted.
Multiple different probiotic strains or combinations have been used and some of them have been shown
to exert beneficial effects. However, it has not been clarified whether a single probiotic or a mixture
of probiotics would be more effective in improving preterm infants’ outcome, and which probiotic
strain or mixture should be better used. Numerous meta-analyses summarizing currently available
data have recently been published [4,6,9,11,13,14,30,39–42]: data from these meta-analyses suggest
that, beyond the overall benefit, a combination of different strains or species may have advantages
over single probiotic organisms [6,9,14,30,39]. Since the same probiotic strain was used in very few
studies, strain-specific sub-meta-analyses are difficult to perform, and strain-specific meta-analyses
have been conducted only twice [40,41]. In order to provide an overview on the use of probiotics in
preterm infants at a strain level and to identify strains with the greatest efficacy, van den Akker et al.
carried out a network meta-analysis, combining evidence from direct and indirect comparison across
several competing interventions [7]. Single- or multi-strain studies reporting on NEC, LOS, time to FEF,
or overall mortality were included. Only a minority of the studied interventions, both single-strain
and multi-strain/multi-species, was found to be effective. There was no clear overlap of certain strains
which were significantly effective on multiple outcome domains. Most strains or combinations of strains
only showed trends towards efficacy, whereas other strains did not demonstrate any. The authors
suggested that a lack of effect might be either due to understudied species or to a true lack of effect of
certain strains.
The extreme variety of probiotics used in neonatology might lead to conflicting conclusions.
The variability of the strains and protocols in the trials included in various meta-analyses is often
presented as a weakness. However, given the consistently decreased risk of NEC in RCTs using
different probiotic regimens, it could be argued that most of the investigated interventions improve the
health of the participants beyond any placebo effect. This evidence might indicate that the concept of
strain-specific effects of probiotics may not be relevant to certain outcomes such as NEC [43]. Because of
the complexity of the normal gut microbiome and of various cascades involved in the pathogenesis
of NEC, different strains may exert their beneficial effect by different pathways. Thus, some authors
suggested that commonly used probiotic strains share core benefits providing ‘non-specific’ or ‘generic’
protection [44–46]. While some specific mechanisms are rare and present in only a few strains of
commonly studied probiotic species, some mechanisms might be frequently observed at a species
and even a genus level [45,47]. Shared mechanisms exist among taxonomic groups that include many
different strains [48]. On these bases, a multi-strain or multi-species probiotic [49] could be more
effective than a single-strain product: more strains give more chances of success for a beneficial effect,
provide a greater microbiota diversity and thus more potential niches in combination with individually
determined host factors, allow a broader efficacy spectrum, and may exert additive or synergistic effects.
However, a combination of probiotic strains does not necessarily ensure, in itself, a greater efficacy
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than a single-strain probiotic, as different probiotic strains may exert mutual inhibitory properties
through the production of antimicrobial substances or differential gene expression [50,51].
Further structured research is needed to address the benefits of single-strain versus multi-strain or
multi-species probiotic products in preterm infants. Head-to-head human intervention studies should
be performed comparing a multi-strain product with its single-strain components and a placebo.
Furthermore, in vitro and animal studies should aim to identify safe probiotic combinations that show
additive or synergistic properties, avoiding potential antagonistic effects.
5. Addressing Safety Concerns: Time for Ghost Probiotics?
The routine administration of probiotics to preterm infants is hindered by concerns about the
safety of commercially available products. Reasons of concern include fear of probiotic-related sepsis,
transmission of antibiotic resistance, and non-availability of high-quality products.
Although none of the meta-analyses on probiotic supplementation in preterm infants reported
any serious adverse events in infants receiving probiotics, there are several reports describing the
occurrence of probiotic-related infections such as sepsis, pneumonia, and meningitis [31]. In addition,
the genome of probiotic bacteria is known to contain genetic elements which confer resistance
to several broad-spectrum antibiotics, such as glycopeptides, aminoglycosides, mono-bactams,
and fluoroquinolones [52]; these resistant genes are themselves not harmful, but they can be transferred
to other gut bacteria and eventually to opportunistic pathogens, leading to an uncontrolled increase in
antibiotic-resistance [53], which might lead to longer-term consequences that outweigh the immediate
benefits of probiotic supplementation. Furthermore, in many countries probiotics are considered as
food supplements, and thus lack the strict quality regulation of other pharmaceuticals [31]. This is
linked to a high risk of product contamination which can have serious consequences, especially
when probiotics are administered to vulnerable individuals with weak immune systems, enhanced
inflammatory responses, and/or compromised gut barrier, such as preterm infants.
To address the safety issues related to currently available probiotics, research is focusing on
inactivated products, the so-called “paraprobiotics”. The concept of paraprobiotics, or ghost probiotics,
was developed by Taverniti et al. [54], who defined them as “non-viable microbial cells or crude
cell extracts, which, when administered in adequate amounts, confer a benefit on the human or
animal consumer”. Inactivation of probiotics has been performed through several methods (i.e., heat,
chemical, gamma or ultraviolet rays, sonication), each one having a different effect on cell structure
and function [54].
A “probiotic paradox” has been described in relation to paraprobiotics, and is related to the fact
that both live and dead microbial cells might exert beneficial responses in the host [55]. Mechanisms
of action of paraprobiotics involve the modulation of various steps of the inflammatory and gut
immune responses, and theoretical advantages over viable products include enhanced safety and
longer shelf-life.
Results of the studies comparing viable vs. non-viable probiotic products on a variety of clinical
outcomes have been summarized by Lahtinen et al. The authors concluded that, while it is clear that
live bacteria are overall more effective than non-viable ones, there might be some cases where viability
is not essential for the health benefit, as suggested by some clinical reports [56]. The evaluation of
viable probiotics vs. non-viable ones is further complicated by the fact that, during storage, part of the
probiotic population may become “dormant” [57].
At present, few probiotic species, including strains of both Lactobacillus and Bifidobacterium, have
been studied in their inactivated form [58]; current evidence about their potential applications in
preterm infants is limited, but it is likely that further research will give new insight into mechanisms
of action, most effective and safe probiotic strains to be used in their inactivated form, and most
promising clinical applications in preterm infants [59].
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6. Choosing the Study Design: The Challenge of Cross-Colonization
Cross-colonization, or cross-contamination, occurs when a microorganism, including a probiotic,
is transferred from one individual or environment to another. Early clinical trials on probiotic
supplementation to preterm infants reported some cases of cross-colonization with the probiotic
organism. Millar et al. documented transient colonization with Lactobacillus GG of one infant, whose twin
was receiving probiotic supplementation and was being nursed in an adjacent cot [60]. One RCT
investigating the colonization with Bifidobacterium breve detected the probiotic bacteria in the feces
of 44% of the control infants at six weeks [61]. More recently, Hickey et al. [62] assessed the rate of
cross-colonization of specific probiotic organisms within a multicenter RCT [63]. The authors reported
a low occurrence of probiotic cross-colonization (7.9%) and environmental contamination, suggesting
that this phenomenon may be related to physical proximity to infants receiving probiotics, as well as
NICU length of stay. In contrast, the Probiotic in Preterm Infants Study (PiPS), the largest multicenter
RCT about probiotics in preterm infants, demonstrated that cross-contamination occurred in 49% of
the infants in the placebo arm in all study sites. Furthermore, rates of the primary outcomes did not
differ significantly between the probiotic and placebo groups [64]. Nonetheless, further analysis based
on the colonization status suggested benefits in the colonized infants irrespective of their allocation to
the probiotic or placebo treatment groups [65,66].
Mechanisms of cross-contamination in the NICU have not been satisfactorily explored. They likely
include transmission through the contamination of NICU surfaces and the body/hands of caregivers [67].
Even if cross-colonization may not result in ingestion of the probiotic bacteria at beneficial doses in
the control group, it may be enough to alter the outcomes. The challenges of cross-contamination
include both the potential impact on NICU infants and limitations in assessing the true effect of
probiotic supplementation in clinical trials. In order to avoid infant-to-infant probiotic dissemination,
Totsu et al. [68] performed a cluster RCT involving 19 NICUs, reporting benefits of single-strain
Bifidobacterium bifidum OLB6378 supplementation in preterm infants. Taking these findings together,
cross-colonization should be considered when designing further RCTs. Cluster or cross-over cluster
randomized trials in which the NICU is randomized rather than the infant should be considered [40,47,64],
as well as more standardized hygiene policies and NICU layouts.
7. Conclusions
The interaction between probiotics and the preterm host is extremely complex, due to particular
intrinsic and environmental factors. Despite the enthusiasm towards probiotics in neonatal medicine,
theoretical knowledge and clinical applications still need to be improved. This review highlights the
need for further well-designed studies aimed at clarifying the impact of the type of feeding, as well
as related confounding factors, on the relationship between probiotic supplementation and clinical
outcome. Furthermore, future research is needed to provide solid evidence about the potential greater
efficacy of multi-strain/multi-species probiotics compared to single-strain products. According to
recent observations, paraprobiotics could represent an answer to safety concerns related to the routine
administration of probiotics in preterm infants, and pre-clinical and clinical studies should be targeted
to explore this new frontier. Further RCTs exploring probiotic supplementation in preterm infants
should also consider a cluster design to avoid the issue of cross-contamination. Last, in light of
increasing commercial and public interests, the long-term effect of the routine consumption of
probiotics and the risk connected to antibiotic resistance in this vulnerable population should be
explored in ad hoc studies.
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Abstract: Cow’s milk protein allergy (CMPA) is the most common food allergy in infancy. Non-IgE
mediated (NIM) forms are little studied and the responsible mechanisms of tolerance acquisition
remain obscure. Our aim was to study the intestinal microbiota and related parameters in the fecal
samples of infants with NIM-CMPA, to establish potential links between type of formula substitutes,
microbiota, and desensitization. Seventeen infants between one and two years old, diagnosed
with NIM-CMPA, were recruited. They were all on an exclusion diet for six months, consuming
different therapeutic protein hydrolysates. After this period, stool samples were obtained and
tolerance development was evaluated by oral challenges. A control group of 10 age-matched healthy
infants on an unrestricted diet were included in the study. Microbiota composition, short-chain
fatty acids, calprotectin, and transforming growth factor (TGF)-β1 levels were determined in fecal
samples from both groups. Infants with NIM-CMPA that consumed vegetable protein-based formulas
presented microbiota colonization patterns different from those fed with an extensively hydrolyzed
formula. Differences in microbiota composition and fecal parameters between NIM-CMPA and
healthy infants were observed. Non-allergic infants showed a significantly higher proportion of
Bacteroides compared to infants with NIM-CMPA. The type of protein hydrolysate was found to
determine gut microbiota colonization and influence food allergy resolution in NIM-CMPA cases.
Keywords: fecal microbiota; protein hydrolyzed formulas; cow’s milk protein; tolerance acquisition;
non-IgE mediated allergy
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1. Introduction
Cow’s milk protein (CMP) is the main cause of food allergy in the first year of life. Based on the
involvement of IgE antibodies, CMP allergy (CMPA) is classified as classic IgE-mediated, non-IgE
mediated (NIM), and mixed pathophysiology [1]. Typically, clinical presentation is delayed, and
digestive symptoms are more frequent, with NIM-CMPA than with IgE-mediated CMPA [2]. In both
types, treatment involves the avoidance of cow’s milk formula and the use of a therapeutic formula as
a substitute. Clinical guidelines recommend the use of an extensively hydrolyzed formula (EHF) as the
first choice, while amino acid-based formulas are reserved for those cases not responding to an EHF [3].
Soy formulas represent an option in infants older than six months [4], and rice formulas have been
safely used during the last few years [5]. Nowadays, a wide number of articles highlight the importance
of the correct establishment/development of gut microbiota in early life and its impact on allergic
diseases, including food allergies [6,7]. Although some studies have related intestinal microbiota and
allergy resolution in IgE-mediated CMPA [8,9], research on gut microbiota exclusively in NIM-CMPA
has been hampered by the difficulty of diagnosis [10]. However, differences in microbial composition
between infants with IgE-mediated and non-IgE mediated food allergies have been reported [11].
The present study was designed to evaluate intestinal microbiota and fecal associated parameters
in infants with NIM-CMPA, under a milk elimination diet, compared to healthy infants, with an
unrestricted conventional diet, with the aim of establishing potential links among microbiota, main
feeding sources, and tolerance acquisition.
2. Materials and Methods
2.1. Subjects
Infants 12 to 24 months old diagnosed with NIM-CMPA (n = 17) were prospectively recruited
for study participation at three different regional hospitals in Asturias (Northern Spain): Hospital
Universitario Central de Asturias, Hospital Universitario de Cabueñes, and Hospital Universitario San Agustín.
All participants had symptoms suggestive of CMPA, a negative skin prick test, values lower than
0.35 kU/L cow’s milk-specific IgE determined in their blood, and a clear positive standardized oral
challenge (SOC), performed under medical supervision following the European Society for Pediatric
Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines. Infants that were exclusively
breastfed at the diagnosis, and those that had used antibiotics or had symptoms of an infectious disease
in the four weeks prior to the stool sample collection, were excluded from the study.
The study was approved by the Regional Ethics Committee for Clinical Research of Principality of
Asturias (Ref. number 105/15, approved on 22 June 2015). Personal data of the children that provided
stool samples conformed to the ethical guidelines outlined in the Declaration of Helsinki and its
amendments. Individual signed informed consents were obtained from all the families participating in
the study.
2.2. Study Design
This was a prospective cohort study. A detailed medical history, including type of feeding and
formula used, were recorded by the clinicians. All infants were on a cow’s-milk-free diet for at least
six months before a new SOC was performed. Following the elimination diet period, and before the
new SOC, stool samples were collected. A control group of 10 age-matched healthy infants (range
12–24 months old), with a normal diet consuming CMP, were included in the study and provided
stool samples. Feces from all the participants were collected by their parents in sterile containers and
immediately frozen at −20 ◦C. All samples were thawed on ice once they had been delivered to the
laboratory and processed accordingly for different analyses.
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2.3. Intestinal Microbial Community Analysis
Extraction of DNA from feces was based on the method of Zoetendal et al. [12] using the
QIAamp DNA Stool mini kit (Qiagen, Hilden, Germany), with some modifications as previously
described [13]. Partial 16S rRNA gene sequences were amplified from the DNA of the samples
according to previous reports [14]. Samples were submitted to 2 × 250 bp paired-end sequencing by
an Illumina MiSeq System (Illumina, San Diego, CA, USA). All Illumina quality-approved, trimmed,
and filtered sequences were processed using a custom script based on the QIIME software suite [15].
Sequences were classified to the lowest possible taxonomic rank considered (i.e., genus level), using
QIIME and the SILVA database as reference. Weighted UniFrac was employed to assess the similarity
of the microbial communities between infants. The raw sequences data were deposited in the Sequence
Read Archive (SRA) of the NCBI (https://www.ncbi.nlm.nih.gov/sra) under accession numbers
SRR6884553 to SRR6884580.
2.4. Analysis of Short-Chain Fatty Acids (SCFAs)
A chromatographic system, composed of 6890N gas chromatography (GC) apparatus (Agilent
Technologies, Santa Clara, CA, USA) connected to a flame ionization detector (FID), was used.
All samples were analyzed in duplicate and SCFAs were quantified as previously described [16].
2.5. Calprotectin Assays
Calprotectin levels were determined using the commercially available enzyme-linked
immunosorbent assay (ELISA) kit CALPROLABTM (Calpro, Lysaker, Norway) according to the
manufacturer’s instructions.
2.6. Transforming Growth Factor-β1 (TGF-β1) Determination
The concentration of TGF-β1 in the feces was determined by using a Bio-Plex 200 system
instrument and the Bio-Plex ProTM TGF-β Assay (both from Bio-Rad, Hercules, CA, USA). Analysis of
samples was carried out as previously described [17].
2.7. Statistical Analysis
Statistical analysis of microbiological sequences was performed with the Metastats statistical
method [18]. Multiple hypothesis tests were adjusted using a false discovery rate (FDR) correction of
0.25. Multivariable statistical analysis was performed by principal coordinates analysis (PCoA) and the
plot was visualized in the EMPeror Visualization Program [19]. Differences in the microbial distribution
between infants were sought by analysis of molecular variance (AMOVA). Biochemical fecal data
were analyzed using IBM SPSS 23 statistic software. Normality was checked by the Shapiro–Wilk
test. As the variables were not normally distributed, medians and interquartile ranges (Q1 and Q3)
were calculated, and comparisons were performed, by using the non-parametric Mann–Whitney test.
The level of significance was set at p values of <0.05. Finally, the Spearman correlation method was
conducted to elucidate the relationship between the variables of the study.
3. Results
Seventeen infants (nine male and eight female) were recruited into the NIM-CMPA group and
10 infants into the control group. No statistically significant differences were found with respect to sex
and age between the two groups: median of 17 (13–23) months in the NIM-CMPA group vs. 18 (14.3–24)
months in the control group. Infants in the NIM-CMPA group were fed with EHFs (12 patients, 70.6%),
soy protein-based formulas (two patients, 11.8%), and hydrolyzed rice formulas (three patients, 17.6%).
All of them developed tolerance to CMP by the end of the study with the exception of the three infants
fed a rice formula.
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3.1. Microbiota Analysis in NIM-CMPA in Relation to Tolerance and Diet
The three infants who did not develop tolerance to CMP, after the exclusion diet for six months,
presented a clear distinct microbiota colonization pattern characterized by a low abundancy of
sequences of Actinobacteria, in particular the genus Bifidobacteria (Table 1). Distinctively, the infant
that reported the quickest and severest gastrointestinal (GI) symptoms after the SOC presented a clear
dysbiotic pattern, with a marked presence of sequences belonging to the phylas Verrucomicrobia
and Proteobacteria (infant code 12; Figure S1). The PCoA plot showed that the samples from the
three non-tolerant infants did not clearly cluster and were separated from the infants who acquired
desensitization to CMP (Figure 1). However, when AMOVA was used to assess the statistical
significance of the spatial separation, significant differences in the microbial clustering between tolerant
and non-tolerant infants (the latter ones consuming rice formula) were revealed (p value = 0.02).
Table 1. Significant differences (at different taxonomic ranks) in fecal microbial abundances (%) between
tolerant and non-tolerant infants with non-IgE mediated cow’s milk protein allergy (NIM-CMPA) after
a period with a diet free of cow’s milk protein (CMP).






Actinobacteria 0.002 0.428 ± 0.200 21.775 ± 15.731
Family
Bifidobacteriaceae 0.002 0.087 ± 0.141 17.705 ± 15.513
Coriobacteriaceae 0.009 0.266 ± 0.224 3.990 ± 4.087
Genus
Bifidobacterium 0.002 0.087 ± 0.141 17.680 ± 15.506
a Significance was considered below a p value of 0.05, multiple hypothesis test correction of Benjamini and Hochberg
was applied with a false discovery rate (FDR) of 0.25. b Mean relative abundance ± standard deviation.
Figure 1. Principal coordinates analysis (PCoA) plot. For its construction, the weighted Unifrac
method was used to compare the bacterial communities among samples from non-tolerant (n = 3) and
tolerant (n = 14) infants with non-IgE mediated cow’s milk protein allergy (NIM-CMPA), based on
their phylogenetic relationship. Percentages shown in the axes represent the explained variance. Blue
circles illustrate samples from tolerant infants whereas red circles illustrate those that maintain active
hypersensitivity after the standardized oral challenge (SOC). Analysis of molecular variance (AMOVA)
was used to assess the statistical significance of the spatial separation between both groups (p = 0.02).
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Other members of the Actinobacteria phylum, in particular the family Coriobacteriaceae, was
significantly diminished in the infants with NIM-CMPA that consumed vegetable protein-based
formulas (n = 5; mean of 0.64% of total assigned reads; range 0.02–2.38%), both rice and soy, compared
to those infants fed with an EHF (mean of 4.45%; range 0.08–13.44%).
3.2. Microbiota Analysis Comparison between the NIM-CMPA and Control Groups
Differences in the composition of the gut microbial communities between the infants with
NIM-CMPA and the infants in the control group were observed. The non-allergic group, following an
unrestricted diet, showed a significantly higher proportion of sequences of the phylum Bacteroidetes,
the family Bacteroidaceae, and the genus Bacteroides compared to the NIM-CMPA group (Figure 2).
In contrast, some members of the Clostridiales order, such as the Eubacterium fissicatena group
(of the family Lachnospiraceae), were significantly higher in allergic infants, which also included
the aforementioned Coriobacteriaceae family (mean of 3.33% of assigned reads, ranging from 0.02% to
13.44%, in the NIM-CMPA group versus 0.86% of assigned reads, ranging from 0.01% to 4.12%, in the
control group).
Figure 2. Differences in relative abundances (%) of sequences belonging to the phylum Bacteriodetes,
the family Bacteroidaceae, and the genus Bacteroides in fecal samples of infants with non-IgE mediated
cow’s milk protein allergy (NIM-CMPA) (n = 17) and non-allergic control infants (n = 10). Comparisons
were corrected with a false discovery rate (FDR) of 0.25.
3.3. Fecal Excreted SCFAs
Regarding the quantification of the SCFAs in the feces, there were no statistically significant
differences in the acetic, butyric, and propionic levels between the NIM-CMPA and control groups
(Table 2). For butyric acid, levels were higher in the infants with NIM-CMPA; however, the difference
was borderline and not statistically significant (p = 0.06). There was a positive correlation (Spearman
correlation coefficient r = 0.48, p = 0.01) between butyric acid levels and fecal Coriobacteriaceae, both of
which were higher in the allergic group (see Figure S2).
Conversely, the branched chain fatty acids (BCFAs), isobutyric and isovaleric acids, presented
significantly higher levels in the infants with NIM-CMPA than in the control group (p = 0.03).
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Table 2. Levels of main short-chain fatty acids (SCFAs), branched chain fatty acids (BCFAs),
transforming growth factor-β1 (TGF-β1), and calprotectin excreted in feces of infants with non-IgE




NIM-CMPA (n = 17) Control (n = 10)
BCFAs (μmol/g) 5.13 (3.08–6.52) 2.59 (1.94–3.37) 0.03
Acetic (μmol/g) 54.88 (48.05–89.63) 68.61 (50.49–69.96) 0.90
Propionic (μmol/g) 16.19 (13.09–21.48) 15.64 (11.66–24.06) 0.94
Butyric (μmol/g) 17.59 (12.74–21.41) 12.88 (6.14–14.3) 0.06
TGF-β1 (pg/mL) 1774.79 (1153.10–3810.88) 1496.29 (382.23–5820.20) 0.73
Calprotectin (μg/g) 47.25 (28.80–106.10) 68.40 (30.38–76.73) 1.00
a Concentrations represent median and interquartile ranges (IQR). b Mann–Whitney U test. Significance was set at
p = 0.05.
3.4. Inflammatory Parameters
The levels of the TGF-β1 in feces of infants with NIM-CMPA were quite similar compared with
values obtained in the control group, and statistical differences between both groups were not found
(Table 2). In one infant of the control group and in three of the NIM-CMPA group, the levels of TGF-β1
were below the lower limit of quantification (0.62 pg/mL). A significant negative correlation between
fecal levels of butyric acid and excretion of TGF-β1 was observed (r = 0.53, p = 0.04), but only in the
group of infants with NIM-CMPA (Figure S3).
Fecal calprotectin concentrations in allergic infants did not show statistical differences with those
found in control infants (Table 2). Calprotectin levels in the samples from the three infants that did not
acquire tolerance, after the elimination diet, were no different from the levels found in the remaining
NIM-CMPA patients, nor in the infants in the control group.
4. Discussion
NIM-CMPA is difficult to diagnose because clinical symptoms appear with a delayed onset and
no specific diagnostic tests are available [20]. For this reason, there are only a few studies focusing
on non-IgE mediated cases [10], and almost none of them consider the description of gut microbiota.
The development of the intestinal microbiota and immune system could be playing a critical role in this
condition, which affects children during their first two years of life. The important association between
GI microbiota and food allergies in early infancy has been clearly pointed to in recent years [6,7,21],
although the precise mechanisms of desensitization and interaction with the host remains poorly
understood in most cases.
Our study was designed to evaluate intestinal microbiota and fecal associated parameters in
infants with NIM-CMPA, under a milk elimination diet, compared to healthy infants, on an unrestricted
diet, in an effort to establish potential links among microbiota and its metabolites, main feeding
sources, and tolerance acquisition. The importance of formula selection for the management of infants
with CMPA (both IgE and non-IgE mediated) and the acquisition of tolerance has been previously
stated in studies by Berni Canani and colleagues, who demonstrated that an EHF supplemented
with a probiotic (Lactobacillus rhamnosus GG) was able to accelerate tolerance acquisition in infants
with CMPA [22,23]. However, the microbiota was not analyzed in these works. In our study, we
observed that only those infants who were consuming rice hydrolyzed formulas did not develop
clinical tolerance after six months of an exclusion diet, and presented significant differences in their
microbiota with respect to those who outgrew their CMPA. To the best of our knowledge, this is the
first study focusing exclusively on NIM-CMPA. A recent work has also been published in NIM-CMPA
patients, but in that case, in suspected not challenge-proven cases [10]. In that interventional study,
only a few groups of fecal microorganisms (bifidobacteria and Clostridium coccoides group (reclassified
now as Blautia coccoides, belonging to the clostridial cluster XIVa)) were evaluated by fluorescence
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in situ hybridization. In our study, we obtain detailed insights into the microbiota composition
using next-generation sequencing (NGS) techniques. We found that infants with NIM-CMPA that
consumed vegetable protein-based formulas had less Coriobacteriaceae. Specifically, those fed with
rice formulas presented low abundances of representatives of Coriobacteriaceae and Bifidobacteriaceae in
their fecal samples. Members of Bifidobacteriaceae (in particular Bifidobacterium) and Coriobacteriaceae
(mainly Collinsella) have been reported to be highly prevalent from the early years of life [21,24].
Coriobacteriaceae, and certainly the genus Collinsella, were present in higher rates in infants with
NIM-CMPA that consumed an EHF in our study. Although the biology of these bacteria is still
largely ignored [21], experiments in vitro in human models showed that both Collinsella spp. and
Bifidobacterium spp. are the major lactose utilizers in the human gut [24]. In fact, lactose is present is
some of the commercial EHFs, but not in vegetable ones. In our work, a positive correlation was found
between Coriobacteriaceae and butyrate levels. This may be explained by the stimulation of certain
butyrate producers, such as members of the C. coccoides group, through cross-feeding mechanisms [25]
that are triggered by end fermentation metabolites, which are produced by Coriobacteriaceae.
We also observed statistically higher levels of BCFAs (isobutyric and isovaleric acids) in infants
with NIM-CMPA as compared with infants in the control group. These minor SCFAs have often
been associated with protein breakdown [26]. Previous studies of IgE-mediated CMPA revealed fecal
concentrations and percentages of butyric acid and BCFAs higher in infants with CMPA than in healthy
infants [27].
The most outstanding difference between allergic and healthy infants, in terms of fecal microbiota
composition, in our study was the reduction in the relative proportions of the phylum Bacteroidetes,
especially the family Bacteroideaceae and the genus Bacteroides, in the infants with NIM-CMPA (both
tolerant and non-tolerant) after the restricted diet period. Bacteroidetes perform metabolic conversions
that are essential for the host, often related to the degradation of proteins [24]. Some species may
play an important role in protein metabolism since they have proteolytic activity. The association
of Bacteroides with a high consumption of fat and proteins of animal origin has been previously
mentioned [28,29]. It has been described that in the mature intestine of the child, by two to three years
of age, the microbiota composition mainly consists of Bacteroideaceae, as well as Lachnospiraceae and
Ruminococcaceae members [30]. Other conditions during infancy, such as antibiotic exposure, preterm
birth, or cesarean section delivery, have been related with reduced abundance of Bacteroidetes [31–33].
Furthermore, in adults, this group of microorganisms has been reported to be affected in some digestive
pathologies, such as irritable bowel syndrome [34].
The precise mechanisms leading to tolerance in NIM-CMPA cases are not yet elucidated. Several
immunological mechanisms may be responsible for the non-IgE reactions. Th1/Th2 imbalances are
assumed to have an impact, but both humoral and/or cell-mediated mechanisms may be implicated
and induce symptoms [35]. The regulatory cytokine TGF-β1 is known to induce T-cell suppression,
contributing to the downregulation of inflammatory processes. The expression of this growth factor
in the intestinal mucosa increases with age during infancy [35]. In the present study, significant
differences in the fecal levels of TGF-β1 between infants diagnosed with NIM-CMPA and healthy
infants were not found. Additionally, the three infants with persistent CMPA after the second SOC
showed values in the same range as those that acquired tolerance. In a previous study of patients with
NIM-CMPA, a higher frequency of circulating regulatory T (Treg) cells were found in children who,
after a milk-free period, outgrew their allergy compared to those who maintained clinically active
hypersensitivity [36]. The authors suggested that the suppressive action of cow’s milk-specific Treg
cells was exerted partly by direct cell–cell contact, and partly by production of TGF-β. In our study,
it should be taken into consideration that fecal samples were taken after a period of six months of a
dairy-free diet, during which most of the participants became tolerant, indicating that the underlying
inflammatory condition of the gut may have normalized. Contrary to what we expected, we found
a moderate, but significant, negative correlation between butyric acid and TGF-β1 fecal levels in the
group of infants with NIM-CMPA. Although we do not have a clear explanation at this stage, we
86
Nutrients 2018, 10, 1481
postulate that the relationship between butyric acid levels and TGF-β1 might be related to the role
of the TGF-β receptor. Although this needs to be explored further in future studies, the activity of
the type 1 receptor for TGF-β, rather than the cytokine itself, has already been suggested as being
related with the pathogenesis of NIM-CMPA [37]. Furusawa and colleagues demonstrated, for the first
time in 2013, that butyrate induce differentiation of colonic Treg cells, which have a central role in the
suppression of inflammatory and allergic responses [38]. Butyrate exerts anti-inflammatory effects,
through epigenetic mechanisms, influencing immune system development and function. The positive
role of butyrate epigenetic effects on children’s health has been previously highlighted [39].
Calprotectin levels vary with age, and therefore different studies on children have used diverse
cut-off values [40]. As observed previously by others [41], differences in calprotectin concentrations
between healthy and allergic infants after a CMP elimination diet were not found in our study,
probably due to most of the patients outgrowing their allergy after the therapeutic diet restriction
stabilization period.
Patterns of formula selection in infants with CMPA are changing with an increased use of
soy and rice hydrolyzed formulas [23,42]. Actually, more information is needed for the choice of
formula substitutes for children with CMPA [5]. Our findings support the recommendations of the
GI Committee of ESPGHAN [3], and show that the use of a vegetable dietary regimen may not be
conducive to achieving oral tolerance, due to the absence of exposure to immunomodulatory peptides
and the shaping of the gut microbial communities. We realize the limitations of the study, namely the
small number of patients included in each group. Therefore, the data found in this pilot study need to
be confirmed in a larger population, especially since some studies in the past did not find differences
in tolerance acquisition rates between the choice of different vegetable (rice, soy, and protein) formulas
with respect to EHFs [43,44].
Our results indicate that the type of formula consumed in early life can determine the composition
and diversity of the microbiota established. These preliminary data on NIM-CMPA still have to be
taken with caution due to the high inter-individual variability in the microbiota among infants in this
age period [21]. Although, with the present data, we hypothesize that differences in a child’s main diet
may influence the intestinal microbiota and its metabolic products, and, ultimately, influence tolerance
acquisition, which has an important impact on clinical practice in NIM-CMPA.
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Abstract: The “microbiota hypothesis” ties the increase in allergy rates observed in highly developed
countries over the last decades to disturbances in the gut microbiota. Gut microbiota formation
depends on a number of factors and occurs over approximately 1000 days of life, including the
prenatal period. During this period the microbiota helps establish the functional immune phenotype,
including immune tolerance. The development of immune tolerance depends also on early exposure
to potential food allergens, a process referred to as nutritional programming. This article elaborates
on the concepts of microbial and nutritional programming and their role in the primary prevention
of allergy.
Keywords: microbiome; intestinal microbiota; microbial programming; nutritional programming;
allergy; prevention
1. Introduction
Allergies are one of the key medical problems in highly developed countries, where the proportion
of those affected exceeds 30% and continues to grow [1]. The observed increase in allergy rates is
associated with the type of lifestyle and involves excessive cleanliness and antibiotic use, small families,
increased Cesarean section (CS) rates, altered dietary habits (increased use of processed foods,
ready meals), rapid urbanization, and increasingly limited contact with nature [2,3]. These factors
immensely affect the composition of the gut microbiota, which is currently believed to be essential
for immune system functioning and the development of immune tolerance. The gut microbiota
establishes itself over approximately 1000 initial days of life. During this time, the microbiota
programs the baby’s immature immune system [4]. Another key factor determining the composition
of gut microbiota is nutrition. The baby’s diet affects the composition of microbiota (e.g., in the
breastfed infants, predominantly bifidobacteria occur) and is a source of exposure to potential allergens.
Studies show that the diet of both the mother (during pregnancy and lactation) and the baby influence
the development of allergies later in life [5].
This article presents the role of the gut microbiota and controlled exposure to food allergens
in allergy development as well as the possible preventive measures intended to stem the rise in
allergy rates.
2. Gut Microbiota and Allergic Conditions
The gut microbiota is a complex of microorganisms colonizing the mucous membranes (mainly
the intestinal mucosa) and constitutes an integral part of the human body. The number of bacteria
colonizing the gastrointestinal tract (1014 cells) is comparable to that of all the cells in the body and,
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as demonstrated by recent calculations, exceeds the number of nucleated human cells 10-fold [6].
However, the microbiome (all the genetic material within the microbiota, i.e., the microbiota genome)
is over a hundred-fold bigger than that of the human genome [7]. Modern molecular methods show the
intestinal microbiome to be very diverse and individually specific [8,9]. In addition, the composition
of the intestinal microbiome undergoes short- and long-term changes throughout life, which are
induced by numerous factors such as diet, antibiotic therapy, stress, infections etc. However, the largest
modifications of the microbiome, which seem to be permanent, occur during the period of intestinal
biocenosis formation [9]. Studies by Lozupone et al. comparing the microbiomes of the citizens
of the Republic of Malawi and the United States showed considerable differences in microbiota
composition between developing and highly developed countries [10]. By comparing the microbiome
of Malavians (Malawi-born individuals who emigrated to the US) and citizens of United States,
the study demonstrated that the “Westernized” diet had limited effects on the microbiome established
in early childhood. This confirms the theory that the window of opportunity for changing the intestinal
microbiome extends over no more than the first two years of a child’s life and any microbiome
disturbances (dysbiosis) occurring in this period may result in an abnormal immune system activation
and development of pathological conditions such as allergy [3,4].
Studies show that the microbiota in children with allergies are less diversified, with the observed
bacterial colonization (predominantly with Bacteoidetes, and Bifidobacterium and Lactobacillus species)
reportedly delayed and less numerous in this age group [11,12]. One important fact in microbial
programming is that the differences in microbiota composition between children with allergies
and healthy children occur during early infancy, even before the first signs of allergy. Assessing
3-week-old neonates who developed allergic symptoms during their first year of life, Kalliomaki et al.
demonstrated an increased number of Clostridium species, with a concurrent decrease in Bifidobacterium
genera, compared with healthy children [13]. Moreover, a reduced biodiversity of gut-colonizing
bacteria at the age of 1 year was associated with increased allergy rates at age 6 years and the
development of asthma at age 7 years [14,15]. Furthermore, a reduced colonization with Bifidobacterium
and Lactobacillus species at the age of 1–2 months induced the development of allergy by the age of
5 years [16].
3. The Impact of Gut Microbiota on Immune System Development
Despite developed lymphatic organs, the immune system of neonates is immature. Neonatal
lymphocytes are referred to as naïve, i.e., never before exposed to external antigens [17]. Gut-colonizing
bacteria are among the first antigens to activate the body’s defense mechanisms, and help seal the
intestinal barrier, establish immune tolerance, and modify the body’s response to potential allergens [18].
The gut microbiota forms the first line of defense against pathogens, activates the synthesis of secretory
immunoglobulins A (IgA), and increases the expression of the proteins (e.g., zonulin, occludin) that
form intraepithelial junctions.
Studies carried out on gnotobiotic experimental models demonstrated that in contrast to
conventionally raised mice, germ-free (GF) mice have hypoplastic Peyer’s patches and decreased
number of both IgA-secreting plasma cells and lymphocytes located in the lamina propria [19,20].
Colonization of GF animals with components of the gut microbiota induced production of secretory
IgA, which are natural antibodies reacting with a wide spectrum of microorganisms and food molecules
including allergens. Recently, using transmission electron microscopy we have presented that the gut
microbiota improves the immature intestinal epithelium of GF mice [20]. Brush borders of GF-mouse
enterocytes were irregularly arranged with decreased numbers of cytoskeletal microfilaments and a
lack of elongation into the terminal web. Colonization of GF mice with Lactobacillus species obtained
from the stool of healthy infants significantly improved this condition. In addition, the adherens
junctions of Lactobacillus colonized mice were significantly elongated and narrow compared with
those in the GF mice and resembled those found in mice colonized with physiological microbiota.
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This fortification of the intestinal barrier was further evident from the increased levels of the zonulin
and occludin proteins in Lactobacillus-colonized animals [20].
Gut-colonizing bacteria, which react with Toll-like receptors located on the intestinal epithelium
and dendritic cells, stimulate also signaling pathways that activate a number of immune effector cells,
such as macrophages, B cells, NK cells, helper T cells (Th1 and Th2), cytotoxic T cells, and regulatory
T (Treg) cells [18]. Treg cells regulate the immune response and are characterized by a specific cytokine
profile. They produce interleukin (IL)-10 and transforming growth factor (TGF)-beta 1. Treg cells
are responsible for maintaining Th1/Th2 cytokine equilibrium and the development of immune
tolerance [21]. Our results obtained in gnotobiotic animals showed that stimulation of the immune
system by defined components of the intestinal microbiota in early ontogeny is followed by the
induction of regulatory mechanisms that maintain the stability of both the local mucosal and systemic
immunity [19,20]. This is especially important during the infancy period, as the T cell cytokine
profile during early life is pro-allergenic (Th2-like), while Th1 capacity to produce cytokines (IL-12,
IFN-gamma) is impaired during this period [17].
4. Factors Affecting Gut Microbiota Formation
Despite reports demonstrating the presence of bacteria in the amniotic fluid and placenta,
which could indicate the formation of the gut microbiota already in the prenatal period [22,23], in 2017
a study contradicting this theory was published [24]. The assertion that the fetal gastrointestinal tract
is sterile and the first gut-colonizing bacteria appear during delivery is believed to be true, and the
delivery is the time when the newborn is in direct contact with the microorganisms of the mother
or environment [24]. However, the child’s intestinal ecosystem may be affected by the mother’s
microbiota as early as during the prenatal period, e.g., via low-molecular-weight metabolites, such as
butyric acid. During the prenatal period, butyric acid can induce colonocyte proliferation and growth
as well as activate adhesion receptors (on the intestinal epithelium) for the bacteria constituting the
newborn’s microbiome [25].
In newborns 98% of intestinal bacteria belong to one of these four phyla: Firmicutes, Bacteroidetes,
Proteobacteria, and Actinobacteria [9]. From the second week of life, the gastrointestinal tracts of breastfed
infants contain predominantly bifidobacteria. As the child develops and solids are introduced into
its diet, the microbiota composition becomes more diversified [26]. At the age of approximately
2 years, the gut microbiota stabilizes and the proportion of individual types of bacteria is similar to that
observed in adults (i.e., predominantly Bacteroidetes). There are a number of factors that shape the infant
gut microbiota: the mother’s microbiome, gestational age, mode of delivery, hospital environment,
diet (both of the mother and the child), hospitalization period, medication, e.g., antibiotics [26–28].
The optimal microbiota composition that may reduce the risk of developing an allergy is observed
in infants whose mothers are healthy, did not take antibiotics during pregnancy or lactation, as well
as infants who were delivered vaginally, breastfed, living in contact with nature, animals, peers,
and siblings, with no antibiotics or excessively sanitized living conditions [27].
The 1000-day pre- and postnatal period of gut ecosystem formation marks the formation of the
microbiome—a new organ, which programs mainly the function of the immature immune system but
also metabolism and the gut–brain axis [29].
5. The Impact of the Mode of Delivery on the Gut Microbiome and Allergy Development
During vaginal delivery, the baby is in contact with the microbiota of the mother’s gastrointestinal
tract and birth canal and this microbiota is the main source of microorganisms colonizing the
newborn [9]. During the first day of life, neonatal intestines are colonized predominantly by facultative
anaerobic bacteria (Escherichia coli and enterococci), which proliferate in an oxygen-rich infant gut and
prepare the conditions for further colonization with bacteria of the genera: Bifidibacterium, Lactobacillus,
Bacteroides, and Clostridium [26]. One beneficial effect observed in vaginally delivered newborns
is a decrease in the number of Clostridium bacteria in favor of Bifidobacterium bacteria as early as
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on day 3 of life [30]. Newborns delivered via a CS are deprived of any contact with the mother’s
intestinal microbiota, which results in dysbiosis (an imbalance in the composition of the gut microbiota)
observed as early as in the first few hours after birth and over the next days. One-day-old CS-born
neonates were shown to be colonized predominantly by the microorganisms colonizing the mother’s
skin [31]. These 1-day-old neonates had also a smaller number of Escherichia coli and Bacteroides
fragilis, with higher rates of Clostridium difficile isolates and hospital-derived bacteria (including
antibiotic-resistant strains) [30]. Despite being breastfed, 3-day-old CS-born neonates exhibited no
bifidobacteria [31]. It seems that neonatal period dysbiosis observed after CS delivery may lead to
disturbances in microbiotic homeostasis in the subsequent months and years of life. Children delivered
via CS demonstrated microbiotic abnormalities such as reduced microbiotic biodiversity, delayed and
reduced colonization with Bacteroidetes also at the age of 3, 6, 12, and even 24 months [32]. Our studies
confirmed an absence of Bacteroidetes in the gut of preterm, CS-born neonates one week after birth,
with this absence persisting for a period of at least 8 weeks independently on supplementation with
Saccharomyces boulardii [33].
Disturbances of gut microbiota resulting from CS may affect the development of allergies in the
future, which is suggested by epidemiological studies. These studies show that CS deliveries correlate
with higher incidence of food allergy and asthma [34–37]. American cohort studies conducted in
136,098 children indicated that the risk of developing asthma by children aged 4.5–6 years was over
seven-fold higher (odds ratio (OR) = 7.77, 95% confidence interval (CI): 6.25–9.65) in the presence of
additional factors (besides CS), which negatively affect the gut microbiome. These additional factors
included antibiotic therapy during pregnancy and infancy as well as a lack of siblings [38].
6. The Effect of Gut Microbiome and Breastfeeding on Allergy Development
Breast milk is the best food for infants, providing the child with all essential nutrients (except
vitamins D and K), supporting the function of immature gastrointestinal and immune systems and
optimally shaping the development of the gut microbiota [39]. The gut of breastfed infants is colonized
predominantly by bifidobacteria [26]. The microbiota of formula-fed children is more diversified and
includes Enterobacteriaceae, Enterococcus species, and Bacteroides species [9,26].
The most important component of breast milk (absent from cow’s milk) responsible for the
formation of the microbiome are human milk oligosaccharides (HMOs) [40]. There are more than
200 currently known HMOs (resistant to digestive enzymes) which become a selective medium for
Bifidobacteria, inducing their proliferation in the gut, increasing short-chain fatty acid (e.g., butyric
acid) levels, and lowering stool pH. HMOs can also bind to specific intestinal epithelial receptors,
which prevents the adhesion of pathogenic bacteria.
Recent studies demonstrated that apart from natural prebiotics (HMOs), breast milk also
contains live probiotic bacteria from the genera Lactobacillus and Bifidobacterium [41,42]. The most
commonly isolated Bifidobacterium species found in breast milk was Bifidobacterium breve, and the
most commonly isolated Lactobacilli were Lactobacillus salivarius and Lactobacillus fermentum. Therefore,
breast milk is a natural synbiotic containing both probiotics and prebiotics. However, not all mothers’
breastmilk contains probiotic bacteria. The breastmilk of over 50% of women yields no bifidobacterial
isolates; moreover, the breastmilk of approximately 30% of women contains no Lactobacillus species.
The microbiotic profile of breastmilk depends on a number of factors, including the composition of the
woman’s gut and skin microbiota, the woman’s health, medication (mainly antibiotics), and the type of
delivery [43–45]. Antibiotic therapy during pregnancy and lactation dramatically lowers the number
of Lactobacillum and Bifidobacterium genera in breastmilk [43]. The breastmilk of women who delivered
via CS contains a lower number of bifidobacteria compared with that of women after a vaginal
delivery [44]. The breastmilk of obese mothers was shown to contain a lower number of bifidobacteria
and higher number of Staphylococcus species as well as to exhibit an altered immunomodulatory
capacity, which was associated with lowered levels of such immunostimulating factors as TGF-beta2
and soluble CD14 [45].
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Despite the observed differences in the composition of breast milk, studies demonstrate that
breast-feeding has a beneficial effect on the occurrence of many diseases associated with the improper
functioning of the immune system. Reduced immunity, immaturity of the intestinal barrier and
intestinal dysbiosis is primarily associated with premature births. Thus, preterm infants are particularly
vulnerable to severe infections such as necrotizing enterocolitis and sepsis. It is now believed that
mother’s milk is the optimal diet for such newborns. Human milk has been shown to reduce morbidity
and mortality in preterm newborns [46] and protects against necrotizing enterocolitis in early life [47].
In studies on the impact of breast feeding on occurrence of allergies exclusive breastfeeding for
3 months was proven to reduce the risk of atopic dermatitis in genetically predisposed children as well
as in those without genetic predisposition [48]. The CHILD (Canadian Healthy Infant Longitudinal
Development Birth Cohort) study involving 3296 children showed that, compared with exclusive
breastfeeding for the first three months, other diets (such as formula feeding (OR = 2.14; 95% CI
1.37–3.35) or mixed feeding (OR = 1.73; 95% CI 1.17–2.57)) increase the risk of developing asthma at the
age of 3 years [49]. Moreover, studies by Chu et al. indicated that breastfeeding for the first 6 months
may lower the elevated risk of asthma in children born via CS [50].
7. Infant Formulas Supplemented with Prebiotics and Probiotics in Allergy Prevention
Formula-fed or mixed-fed children are more prone to developing allergy. Infant formulas are
based on cow’s milk, whose composition is fundamentally different from that of human breast milk.
This is why, manufacturers supplement infant formulas with bioactive ingredients present in human
breast milk, including substances directly affecting the baby’s microbiome, such as oligosaccharides
with prebiotic properties or probiotic bacteria derived from human breast milk (e.g., Bifidobacterium
breve). There are also synbiotic formulas containing both oligosaccharides and probiotic bacteria.
The most thoroughly studied oligosaccharides are a mixture of short-chain galacto-oligosaccharides
(scGOS) and long-chain fructo-oligosaccharides (lcFOS) in a 9:1 ratio, at a dose of 8 g per liter.
It was demonstrated that supplementation of infant formulas with a scGOS/lcFOS mixture shifts
the microbiotic profile in formula-fed infants towards the profile observed in breastfed infants [51,52].
Consequently, these infants were shown to bear an increased number of bacteria from the genera
Bifidobacterium and Lactobacillus. In addition, formula supplementation with scGOS/lcFOS helped
resolve post-antibiotic-therapy dysbiosis, lowered stool pH (the pH reached the values similar to those
observed in breastfed infants), and made the short-chain fatty acid profile similar to that present in
breastfed infants. The use of a synbiotic formula supplemented with scGOS/lcFOS and the probiotic
bacteria Bifidobacterium breve M-16V in infants born via CS induced elimination of dysbiosis by increasing
the number of bifidobacteria [53]. In older, healthy children aged 1–3 years, a 3-month-long diet of
synbiotic formula also resulted in an increase in bacteria of the genus Bifidobacterium [54].
Moro et al. are the authors of the first randomized placebo-controlled clinical study on the use of
scGOS/lcFOS-supplemented infant formulas conducted in infants at risk of developing allergy [55].
The study group was fed with a partially hydrolyzed whey formula supplemented with scGOS/lcFOS
at 8 g/L for 6 months. After this period, the risk of developing atopic dermatitis was halved in the
group fed a scGOS/lcFOS-supplemented formula. This beneficial effect persisted for at least 2 years.
A 2-year-long prospective study by Arslanoglu et al. demonstrated that feeding infants formulas
containing extensively hydrolyzed whey and supplemented with scGOS/lcFOS for 6 months not
only lowers the rates of atopic dermatitis, but also significantly reduces the number of children with
wheezing and urticaria in comparison with those rates in the group receiving formula without prebiotic
supplementation [56]. A 5-year follow-up confirmed persistent, long-term benefits of the evaluated
dietary intervention [57].
In 2016, World Allergy Organization (WAO) experts issued their guidelines on the use of prebiotics
in allergy prevention [58]. These guidelines suggest that all formula-fed infants should receive formulas
supplemented with prebiotics. This WAO guideline was based on an analysis of 18 randomized
placebo-controlled trials, which demonstrated that supplementing the diet of healthy formula-fed
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infants with prebiotics during the first year of life lowers the risk of asthma and recurrent wheezing
(relative risk (RR): 0.37; 95% CI 0.17–0.80) as well as the risk of food allergy (RR 0.28; 95% CI 0.08–1.00).
The published guidelines emphasized that there is no need to provide prebiotic supplementation either
to breastfed infants or to lactating mothers.
One year earlier, by analyzing randomized placebo-controlled studies, WAO experts issued a
statement suggesting the potential use of probiotics in primary prevention of allergy in high-risk families
(in pregnant women, breastfeeding women, and infants) [59]. A 2013 meta-analysis of 25 randomized
placebo-controlled clinical studies involving 4031 children showed probiotics administered both pre-
and postnatally to be the most effective [60]. Probiotic supplementation was demonstrated to reduce
total IgE levels over a long-term (at least 2-year) follow-up and to lower the risk of allergy, but they had
no effect on reducing the incidence of asthma. The WAO guideline does not recommend specific strains
for primary prevention of allergy. The authors emphasize that the recommendations are conditional
and depend on the results of the further research. Recently, Szajewska and Horvath published a
meta-analysis of randomized double blind placebo controlled studies, which presented that pre- and/or
postnatal supplementation with Lactobacillus rhamnosus GG strain does not affect the occurrence of
atopic dermatitis, and this strain should not be recommended in allergy prevention [61]. However, it is
necessary to remember that probiotic effects are both strain- and population-specific. Thus, the clinical
efficacy may be dependent on the strain, but also on a mode of birth (CS or vaginal delivery) or
geographical place of birth (northern or southern countries), and these determinants were not taken
into account in the meta-analysis. On the other hand, it should be emphasized that the Lactobacillus
rhamnosus GG strain does not originate from breast milk, only from the intestine. How much it can
affect the specific action of probiotics we do not know, and further research is necessary.
8. The Effect of Nutritional Programming on Allergy Development
A baby’s diet affects the development of allergies by acting at least bi-directionally (Figure 1).
On the one hand food influences the composition of the gut microbiota influencing the development
and functioning of the immune system. On the other hand an induction of immune tolerance can
be achieved by direct exposure to potential allergens during pregnancy, lactation, and weaning.
The contact of the immune system with small doses of allergens activates the formation of Treg
lymphocytes [21]. The 20th century was an era of eliminating potential allergens from the diet of both
the mother (during pregnancy and lactation) and child (late—often over the age of 1 year—introduction
of allergenic foods). The advent of the 21st century completely altered our attitudes toward exposure
to potential allergens. The PASTURE study (Protection against Allergy: Study in Rural Environments)
of 2014 demonstrated that the less varied the diet during the first year, the higher the risk of developing
food allergy at the age of 4, 5, and 6 years [62]. This study also showed a significant reduction of 26% for
the development of asthma, with each additional food item introduced in the first year of life. Likewise,
a study called LEAP (Learning Early about Peanut Allergy) demonstrated that introducing a potential
allergen (in this case: peanuts) at small doses into the diet early (at the age of 4–6 months) reduced the
incidence of allergy to this allergen by 80% [63]. Recent studies confirmed that allergen introduction
reduced peanut allergy incidence most effectively when peanuts were introduced into the mother’s
diet during pregnancy and lactation and then into the infant’s diet [64]. Thus, dietary interventions
during gestation and lactation period include a balanced diet without elimination of potential allergens
(Table 1). In the postnatal period breastfeeding for a minimum of 4–6 months, the introduction of solid
foods according to the recent recommendation of the European Society for Paediatric Gastroenterology
Hepatology and Nutrition from week 17 and no later than at week 26 including potential allergens
may also have a positive impact on allergy development [65].
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Figure 1. Immune tolerance development in children. Regulatory (Treg) T lymphocytes are activated
by the gut microbiota and contact with potential food allergens.
Table 1. Dietary intervention in pre- and postnatal period which could play role in induction of
immune tolerance.
Prenatal Period Postnatal Period
• Balanced and varied diet
• No elimination of potential allergens
• The use of probiotics may be considered in
families at risk of allergy
• Breastfeeding for a minimum 4–6 months
• Introduction of solid foods starting from week 17; no later than at week 26
• No elimination of potential allergens
• Formulas supplemented with prebiotic oligosaccharides may be
considered in formula-fed and non-exclusively fed infants
• Partially hydrolyzed formulas, optionally supplemented with prebiotics
and/or probiotics may be considered in formula-fed and non-exclusively
fed infants in families at risk of allergy
The development of cow’s milk (CM) allergy in formula-fed infants may depend on the degree of
CM protein hydrolysis [66,67]. Formulas with extensively hydrolyzed proteins and amino acid-based
elemental formulas are not intended for healthy infants. Instead, they are for infants with symptomatic
allergy to CM proteins. In contrast, partially hydrolyzed formulas (pHF), also called hypoallergenic
formulas, which contain partially broken down proteins are especially recommended for children from
families at risk of allergy (i.e., when the parents and/or siblings have allergies). It seems that partially
hydrolyzed CM proteins can be more effective in induction of specific Treg cells. Gouw et al. identified
specific peptides with tolerogenic potential in a whey-based pHF [68]. They presented that partial
hydrolysis induced the occurrence of peptides overlapping the specific regions of beta-lactoglobulin,
which were found to contain T-cell epitopes with tolerogenic potential. In experimental mice studies
partially hydrolyzed whey proteins increased the percentage of Treg cells in the mesenteric lymph
nodes leading to a significantly reduced acute allergic skin response to whey [69]. Also, in a clinical
trial performed by Boyle et al. the effect of whey-based pHF on Treg cells was investigated. In this
randomized, placebo-controlled study after 6 months of intervention, increased percentages of
CD4+CD25highFoxp3high Treg lymphocytes were detected in infants who received pHF compared to
the ones who received a standard infant formula. In spite of positive effects on T reg cells, pHF did
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not prevent eczema in the first year in high-risk infants [70]. In contrast, an update meta-analysis
performed by Szajewska and Horvath in 2017 showed that 100% whey-based pHF (manufactured by
a single manufacturer), given to infants at risk of allergy development decreased the occurrence of
eczema, and reduced the risk of eczema and all allergic diseases among children at high risk of allergy
at different time points [66]. Although the certainty of the evidence is low, as the authors underline,
such intervention could have beneficial effects in primary prevention of allergies. In a review article
by Vandeplas, it is suggested that pHF may be used for all infants, irrespective of family history of
allergy [67]; however, at this time, there are no studies confirming the effectiveness of such action.
9. Conclusions and Recommendations
Current preventive measures intended to stem the development of allergies focus on inducing
immune tolerance via microbial and nutritional programing. Primary prevention of allergies is focused
on dietary intervention during both pre- and postnatal periods, and includes a balanced diet without
elimination of potential allergens in pregnant and lactating mothers as well as promoting breast feeding
for a minimum of 4–6 months, with early introduction of solid foods in the infant diet. To prevent
dysbiosis in infants, CS should be only performed when medically indicated, and antibiotic therapy
should be limited in both pregnant/lactating women and in infants. In formula- or non-exclusively fed
infants, the introduction of synbiotic formulas or those supplemented with prebiotic oligosaccharides
can have positive effects on allergy development; however, additional research in this field would be
still needed.
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HMOs Human milk oligosaccharides
IgA (E) immunoglobulins A (E)
IL interleukin
lcFOS long chain fructo-oligosaccharides
OR Odds ratio
pHF partially hydrolyzed formula
RR Relative risk
scGOS short chain galacto-oligosaccharides
TGF transforming growth factor
Th T helper
Treg regulatory T cells
WAO World Allergy Organization
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Abstract: Difference in human milk oligosaccharides (HMO) composition in breast milk may
be one explanation why some preterm infants develop necrotizing enterocolitis (NEC) despite
being fed exclusively with breast milk. The aim of this study was to measure the concentration
of 15 dominant HMOs in breast milk during the neonatal period and investigate how their levels
correlated to NEC, sepsis, and growth in extremely low birth weight (ELBW; <1000 g) infants
who were exclusively fed with breast milk. Milk was collected from 91 mothers to 106 infants at
14 and 28 days and at postmenstrual week 36. The HMOs were analysed with high-performance
anion-exchange chromatography with pulsed amperometric detection. The HMOs diversity and the
levels of Lacto-N-difucohexaose I were lower in samples from mothers to NEC cases, as compared to
non-NEC cases at all sampling time points. Lacto-N-difucohexaose I is only produced by secretor
and Lewis positive mothers. There were also significant but inconsistent associations between
3′-sialyllactose and 6′-sialyllactose and culture-proven sepsis and significant, but weak correlations
between several HMOs and growth rate. Our results suggest that the variation in HMO composition
in breast milk may be an important factor explaining why exclusively breast milk fed ELBW infants
develop NEC.
Keywords: neonatal; preterm; breast milk; oligosaccharides; diversity; necrotizing enterocolitis;
sepsis; growth
1. Introduction
While the care of premature infants has improved dramatically during the last decades, still about
30% of the extremely low birth weight (ELBW, birth weight < 1000 g) infants die [1]. Severe infections
and necrotizing enterocolitis (NEC) are common causes of death in this population, and there are
clear links between nutrition and the risk of NEC, infection, and mortality [2]. Definite NEC (Bell’s
stage II-III [3]) remains among the most devastating diseases encountered in premature infants. It is
associated with an excessive inflammatory process in the intestinal mucosa that presents clinically
with feeding intolerance, abdominal distension, and bloody stools [4]. The incidence among ELBW
infants is approximately 10% [5], but varies in different neonatal settings between 4 to 15% depending
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on factors such as breastfeeding rates and use of milk banks [6]. The surgical intervention rate is as
high as 50% [4], and the mortality rate in affected infants is 15–30%. It is increasingly recognized that
NEC is a major adverse factor for subsequent lower intelligence quotient (IQ), motor impairment,
visual impairment, and cerebral palsy [7]. Finding new measures to identify and treat infants at-risk is
urgently needed.
Exclusive enteral feeding with human breast milk remains the most important prevention strategy
for NEC [2]. However, in Scandinavian countries, despite exclusive feeding with breast milk being
employed routinely for at least 20 years, the incidence of NEC in ELBW infants is still as high as 10%
according to the most recent data available in the Swedish Neonatal Quality Register (www.snq.se).
Breast milk not only provides the necessary nutrients for growth and development, it also
contains numerous immunological components that compensate the immature and inexperienced
mucosal immune system [8]. Such components include immune cells, IGA antibodies, and pro and
anti-inflammatory cytokines such as TNF and IL-10 [8,9].
Difference in the composition of bioactive components in breast milk may explain why some
preterm infants still develop NEC despite being fed exclusively with breast milk. Among these,
non-digestible human milk oligosaccharides (HMOs) are highly abundant (5–15 g/L) as constituents.
Besides stimulating beneficial microbes, such as bifidobacteria, in the infant intestinal tract [10],
HMOs mimic carbohydrate-binding motifs of certain enteric pathogens, such as enteropathogenic
E. coli, by acting as a receptor decoy, and thereby prevent adhesion of these pathogens to the apical
surface of enterocytes [11]. Certain HMOs also stimulate anti-inflammatory responses in the intestinal
epithelium [12,13]. A growing body of evidence suggests that the HMO composition in breast milk
influences the risk of developing NEC in preterm infants [14–16]. Supplementation with the HMOs
disialyllacto-N-tetraose (DSLNT) [14] and 2′-fucosyllactose (2FL) were identified to be protective
against NEC in an experimental murine model. Low DSLNT levels preceded NEC development in
very low birth weight preterm infants (VLBW; <1500 g) in a human trial [16]. Interestingly, there was
a high variation of DSLNT in different countries in a world-wide study in which Swedish mothers
had the lowest levels [17]. HMO levels have also been associated with growth [18] and the risk of
infections in infants [19,20].
The aim of this study was to investigate the composition of 15 dominant HMOs in breast milk
during the neonatal period and examine how this correlated to NEC, sepsis, and growth in ELBW
infants who were exclusively fed with breast milk. The analyses revealed low HMO diversity and low
levels of the HMO Lacto-N-difucohexaose (LNDH I) in infants that developed NEC.
2. Materials and Methods
2.1. Study Design and Participants
The present study was a part of the prospective, randomized-controlled, multi-centre trial
“Prophylactic Probiotics to Extremely Low Birth Weight Premature Infants” (PROPEL) evaluating the
effect of probiotic Lactobacillus reuteri DSM 17938 on feeding tolerance, growth, severe morbidities,
and mortality in ELBW premature infants (ClinicalTrials.gov ID NCT01603368). A detailed study
design and the clinical outcomes have been published elsewhere [21]. Briefly, in total 134 infants born
between gestational week (gw) 23 + 0 and 27 + 6 with a birth weight below 1000 g were enrolled
between 2012 and 2015 at two level III neonatal intensive care units (Astrid Lindgren Children’s
Hospital, Stockholm, and Linköping University Hospital, Linköping, Sweden). Exclusion criteria were
major congenital or chromosomal anomalies, no realistic hope of survival, the infant could not be
fed and thus not receive the study product within three days, or the infant was included in another
intervention trial on growth, feeding intolerance, or severe morbidity. Participating infants received
daily oral administration of 1.25 ×108 L. reuteri DSM 17938 or placebo from birth to postmenstrual
week 36 + 0. Written informed consent was obtained from both parents and the study was approved by
the Ethics Committee for Human Research at Linköping University (Dnr 2012/28-31, Dnr 2012/433-32).
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Due to the 100% coverage of breast milk donor banks, all infants were fed exclusively with breast
milk until they had reached a weight of at least 2000 g. Protein and lipid fortification was based
individually on analyses of the macronutrient and energy content of the breast milk given to each
infant. Oral feeding started during the first day of life and increased gradually at a rate specified
in clinical guidelines. Breast milk fortification with bovine protein fortifier started when the enteral
feeds had reached 100 mL/kg/day. Breast milk samples were collected from 91 mothers to 106 infants
at 14 (n = 78) and 28 (n = 71) days after delivery and at postmenstrual week (PMW) 36 + 0 (n = 51).
The milk was frozen in sterile tubes at −20 ◦C (short-term) and subsequently at −70 ◦C. The median
time until the analysed breast milk was given to the infant was five days (inter-quartile range [IQR]
1–7). Samples were only obtained if the infant was exclusively fed mother´s own milk. All infants to
mothers from whom samples were available were included in the present study. Mother´s own milk
was not pasteurised before feeding at the neonatal intensive care units (NICUs) at the time of the trial.
Analytic staff was blinded to the clinical metadata until the laboratory analyses were concluded.
2.2. Clinical Outcomes
The infants were characterized using comprehensive clinical data including perinatal data, growth,
antibiotics, and mild to severe morbidities collected daily in a study specific case report form until
gestational week 36 + 0. Necrotizing enterocolitis (NEC) was staged according to Bell’s criteria [3],
and all cases of stage II or greater were recorded. A diagnosis of culture-proven sepsis required a
positive blood culture, clinical deterioration, and a laboratory inflammatory response. Weight, length
and head circumference were recorded at birth, at 14 and 28 days, and at PMW 36 + 0. In order to adjust
for gestational age, the standard deviation score (z-score) for each measurement was calculated using
Niklasson’s growth chart, which is based on information of normal deliveries from gestational week
24 to full term in the Swedish medical birth registry, 1990–1999 [22]. The growth rate was calculated
using the difference in z-score between the later measurements and birth.
2.3. Purification of Human Milk Oligosaccharides
HMOs were purified from each milk sample by the following method. To remove lipids, 1 mL
of the milk sample was centrifuged at 20,000 g for 30 min. Thereafter, 0.5 mL of the infranatant
fluid was transferred to another tube and 50 μL of the internal standard was added. The internal
standard consisted of 2.4 mg/mL galacturonic acid (Sigma-Aldrich, St Louis, MO, USA) and 12 mg/mL
stachyose (Sigma-Aldrich). To precipitate proteins, 1 mL of refrigerated 99.5 % ethanol was added,
and the mixture was kept at 4 ◦C for one hour and subsequently centrifuged at 20,000 g for 10 min at
4 ◦C. The sample was further purified by applying 1 mL of the supernatant fluid to an Isolute C18
column (Biotage, Uppsala, Sweden), preconditioned with 2 mL of ethanol followed by 2 mL of water.
The eluate was collected and then ultra-filtrated using Amicon Ultra-4 (Merck Millipore, Cork, Ireland)
with a 3 kDa molecular cut off. The tube was centrifuged at 4000 g for 40 min and the filtered sample
was collected. To remove ethanol, the filtrate was evaporated with compressed air for one hour at
40 ◦C. Neutral oligosaccharides were further purified by applying 50 μL of the sample to an anion
exchange bonded silica cartridge (LC-SAX, Supelco, Bellefonte, PA, USA), preconditioned according to
instructions. Thereafter, 500 μL of Milli-Q water was added to the column and the eluate was collected.
2.4. Analysis of Human Milk Oligosaccharides
High-performance anion-exchange chromatography (HPAEC) with pulsed amperometric
detection (PAD) was used to separate and quantify the major 15 oligosaccharides in human milk
(Table 1). The analysis was based on previous published methods [23–25], but adopted to the following
system to achieve optimal separation of the measured oligosaccharides.
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Table 1. Median human milk oligosaccharides (HMO) levels (μmol/L) in breast milk from mothers to































































































PMW = Postmenstrual week. IQR = Interquartile range. HMO = human milk oligosaccharides.
The high-performance anion-exchange chromatography with pulsed amperometric detection
(HPAEC-PAD) system ICS-3000 (Dionex, Sunnyvale, CA, USA) was equipped with a thermostated
CarboPac PA-200 column (3 × 50 mm guard column and 3 × 250 mm analytical column),
an electrochemical Au detector and an Ag/AgCl reference electrode. The flow rate was 0.5 mL/min and
the injection volume 20 μL. Separation was achieved using different gradient programs. For neutral
oligosaccharides a constant concentration of 20 mM NaOH and a gradient with sodium acetate
(NaOAc) from 0 to 25 mM at 5 to 30 min (30 ◦C) or 6 to 37 min (25 ◦C) were used. For acidic
(sialylated) oligosaccharides a constant concentration of 0.1 M NaOH and a two-step gradient of
NaOAc from 20 mM to 80 mM at 5 to 30 min and from 80 mM to 150 mM at 30 to 40 min were
used. HPAEC was performed at both 30 and 40 ◦C for acidic oligosaccharides, to achieve optimal
separation [26]. The different HMOs were identified by comparing their retention times to those of
known milk oligosaccharide standards that were analysed in each run. All oligosaccharide standards
were from Dextra Laboratories (Reading, UK), except for DSLNT, 3SL and 6SL, which were from
Sigma-Aldrich. The oligosaccharide concentrations were calculated from the individual HMOs peak
areas in relation to the area of the internal standard (galacturonic acid for acidic and stachyose for
neutral oligosaccharides). The results were further corrected for the response factor of each individual
oligosaccharide, as determined by the analysis of standards with known concentrations.
2.5. Statistical Analyses
The primary outcome and other continuous variables with skewed distributions were analysed
with Mann-Whitney U test, while t-test for independent samples were employed for continuous
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variables with normal distributions. Fisher’s exact test was used for categorical outcome variables.
Baseline characteristics were summarized by means and standard deviations (SDs) for continuous
data and counts and percentages for categorical data. Primary and secondary outcome variables were
summarized by means and SD or medians with IQR for continuous data and counts and percentages
for categorical data. The analysis of similarity (ANOSIM) was applied to test if HMOs composition
was more similar within the same mother over time than between mothers [27]. ANOSIM provides
an R-value where R close to 1 indicates dissimilarity and R close to 0 indicates even distribution
(of high and low ranks) within and between groups. As a complement to ANOSIM, permutation
analysis of variance (PERMANOVA) was also applied to test if HMO composition differed among the
mothers and over time. The distribution of HMOs composition across mothers and sampling times
were observed by Non-metric Multi-dimensional Scaling (NMDS) plots. NMDS maps the pair-wise
(dis)similarity of ranked distances to a k-dimensional ordination space, where the distance between
objects corresponds to their (dis)similarity [28]. The statistical discrimination was at a significance
level of 0.05. No adjustments for multiple comparisons were made for those outcomes, for which there
were separate hypotheses, such as NEC, sepsis, and growth rate parameters. All statistical analyses
were performed using IBM SPSS Statistics software, version 25 (IBM Corp, Armonk, NY, USA), except
for Shannon diversity index, ANOSIM, PERMANOVA, and NMDS that were performed in R version
3.3.0 [29].
3. Results
3.1. Description of the Study Population
Breast milk samples were collected from 91 mothers to 106 infants at 14 (78 mothers to 89 infants)
and 28 (71 mothers to 83 infants) days after delivery and at PMW 36 + 0 (56 mothers to 65 infants).
Baseline characteristics of the ELBW infants are displayed in Table 2.
Table 2. Background characteristics in extremely low birth weight (ELBW) infants with and without
necrotising enterocolitis (NEC) during the neonatal period.
No NEC (n = 96) NEC (n = 10) p *
Gestational age, weeks + days, mean (SD) 25 + 4 (9 days) 25 + 1 (9 days) 0.3
Birth weight, g, mean (SD) 749 (136) 681 (123) 0.1
Birth weight zscore, mean (SD) −1.1 (1.2) −1.4 (1.6) 0.6
Birth length, cm, mean (SD) 32.7 (2.5) 32.0 (2.2) 0.4
Birth length z-score, mean (SD) −1.5 (1.8) −1.4 (2.0) 0.9
Birth head circumference, cm, mean (SD) 23.0 (1.5) 22.8 (1.2) 0.5
Birth head circumference z-score, mean (SD) −0.8 (0.8) −0.6 (0.7) 0.4
Small for gestational age, n (%) 22 (23) 2 (20) 0.8
Caesarean section, n (%) 62 (65) 6 (60) 0.8
Apgar score 5 min, mean (SD) 6.2 (2.6) 7.0 (2.4) 0.3
Apgar score 10 min, mean (SD) 7.8 (1.9) 8.4 (1.6) 0.3
Male, n (%) 49 (51) 9 (90) <0.01
Infants from multiple pregnancy, n (%) 35 (36) 4 (40) 0.8
Maternal smoking, n (%) 2 (2) 1 (10) 0.5
Maternal preeclampsia, n (%) 10 (10) 1 (10) 1.0
Preterm premature rupture of membranes, n (%) 30 (30) 4 (40) 0.6
Maternal chorioamnionitis, n (%) 20 (21) 3 (30) 0.6
Maternal prepartal antibiotics, n (%) 51 (53) 5 (50) 0.9
Prenatal steroids, n (%) 94 (81) 10 (100) 0.2
Received surfactant, n (%) 78 (81) 9 (90) 0.4
Antibiotics during first week, n (%) 95 (99) 10 (100) 1.0
Antibiotics during second week, n (%) 76 (79) 10 (100) 0.2
Probiotic supplementation, n (%) 50 (52) 5 (50) 1.0
Patent ductus arteriosus treated, n (%) 70 (73) 7 (70) 1.0
* t-test for independent samples to compare means. Fisher’s exact test to compare proportions.
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3.2. Development of the HMOs Over Time
Concentrations of the 15 HMOs in breast milk samples from 14 and 28 days after delivery and at
PMW 36 + 0 are displayed in Table 1. ANOSIM analyses including the 41 cases with samples from all
three time points indicated a higher variability in HMOs composition between mothers (R-value = 0.04;
p = 0.01) than within the same mother over time (R-value = 0.7; p = 0.001). The HMO composition was
clearly separated by the secretor status (R-value = 0.9; p = 0.001), which was also revealed in the NMDS
plot (Figure 1). The PERMANOVA analyses showed that the secretor status explained 63% (p = 0.001)
of the variance in HMO composition, the mother explained 26% (p = 0.001) and sampling time point
only 0.07% (p = 0.001). When adjusting for secretor status, the mother explained 70% (p = 0.001),
while the sampling time point explained 17% (p = 0.001) of the variance for both, secretor-positive,
and secretor-negative cases.
Figure 1. Non-metric multidemension scaling (NMDS) plot of the HMO composition among the
41 mothers with samples from all three time points. Each mother is indicated by a number from 1 to 41.
PMW 36 + 0: postmenstrual week 36 + 0. Stress level: 0.08
3.3. Clinical Outcomes in Relation to the HMO Levels
The HMO composition at day 14 in each NEC case is shown in Figure 2, and the levels of the 15
HMOs in samples from mothers to infants who did and did not developed NEC and culture-proven
sepsis, respectively, are displayed in Table 3 and 4 (day 14), S1 and S2 (day 28), and S3 and S4 (PMW
36 + 0). NEC development was associated with low levels of the neutral oligosaccharide LNDH
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I at all three sampling time points. This HMO is only produced by mothers that are both secretor
and Lewis-positive (Table 1). NEC development was also associated with low levels of LSTa and
LNnT at 28 days. The diversity of all 15 HMOs was lower in all three samples from mothers to NEC
cases as compared to non-NEC cases (Figure 3a), while there was no difference between NEC and
non-NEC cases in the total content of HMO in the samples (Table 3, Tables S1 and S3). There was also a
trend towards less NEC among infants to secretor and Lewis-positive mothers (Figure S1). The HMO
diversity in NEC and non-NEC cases stratified by the different secretor groups is displayed in Figure
S2. Male gender was significantly more common among the NEC-cases (Table 2), but there were no
differences in HMO diversity in breast milk from mothers of singleton boys and girls (p = 0.43 at
14 days, p = 0.76 at 28 days, and p = 0.84 at postmenstrual week 36 + 0). The incidence of NEC was not
associated with probiotic supplementation (Table 2).
Figure 2. Human milk oligosaccharide (HMO) content in the first breast milk sample from mothers of
all NEC-cases, stratified according to secretor (Se) and Lewis (Le) status, and median HMO levels in
milk samples from day 14 from the non-NEC cases of the respective Se/Le groups
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Figure 3. Human milk oligosaccharide (HMO) diversity in breast milk samples and the incidence of
NEC (a) and culture proven sepsis (b). Boxes indicate 25th, 50th and 75th percentiles; whiskers indicate
min and max values. t-test for independent samples was used to compare means. N indicates the
number of patients in each group. PMW=postmenstrual week.
Table 3. Comparison of human milk oligosaccharide (HMO) concentrations (μmol/L) in milk samples
from day 14 to infants who developed or did not develop necrotising enterocolitis (NEC).
Secreted by
NEC (n = 9)
Median (IQR)
No NEC (n = 80)
Median (IQR)
p *
3SL All 318 (231–376) 321 (254–395) 0.8
6SL All 1437 (1220–1635) 1159 (919–1585) 0.2
LSTa All 9 (7–17) 10 (5–14) 0.6
LSTb All 49 (29–144) 68 (42–128) 0.4
LSTc All 138 (103–196) 130 (85–198) 0.7
DSLNT All 572 (401–1193) 674 (498–1038) 0.4
2FL Se+ 6331 (0–8026) 5390 (3374–7223) 0.9
3FL All 675 (436–3004) 1255 (575–1841) 0.6
LDFT Se+ 45 (0–651) 410 (28–686) 0.2
LNT All 3507 (1277–4320) 2294 (1710–2990) 0.7
LNnT All 129 (90–208) 187 (111–273) 0.2
LNFP I Se+ 797 (0–3903) 1165 (441–1789) 0.5
LNFP II Le+ 124 (0–1996) 413 (191–880) 0.6
LNFP III All 363 (332–437) 351 (267–526) 0.8
LNDH I Se+ Le+ 0 (0–213) 882 (0–1279) <0.01
Σ analyzed HMO 15889 (11623–18311) 15770 (13405–17274) 0.8
* Mann Whitney U-test for independent samples used to compare distributions.
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High levels of 6SL at 14 days (Table 4) and low levels of 3SL and at 28 days of life (Table S2) were
significantly associated with the development of culture-proven sepsis, although HMO diversity was
not (Figure 3b).
Table 4. Comparison of human milk oligosaccharide (HMO) concentrations (μmol/L) in milk samples
from day 14 to infants who developed or did not develop culture-proven sepsis.
Secretedby
Sepsis (n = 32)
Median (IQR)
No Sepsis (n = 57)
Median (IQR)
p *
3-SL All 283 (236–336) 331 (268–399) 0.2
6-SL All 1313 (1088–1647) 1142 (876–1503) <0.05
LSTa All 7 (4–12) 11 (7–14) 0.1
LSTb All 62 (34–154) 72 (42–114) 0.5
LSTc All 134 (102–174) 127 (79–199) 0.8
DSLNT All 622 (426–941) 644 (502–1093) 0.2
2FL Se+ 4829 (0–7674) 5944 (3429–7467) 0.3
3FL All 1367 (595–2983) 1227 (524–1833) 0.4
LDFT Se+ 386 (0–664) 404 (22–690) 0.7
LNT All 2459 (1481–3630) 2194 (1768–2710) 0.5
LNnT All 202 (100–273) 177 (110–257) 0.9
LNFP I Se+ 957 (0–1625) 1490 (475–2042) 0.2
LNFP II Le+ 494 (171–1348) 372 (123–749) 0.3
LNFP III All 363 (269–468) 351 (255–531) 0.8
LNDH I Se+ Le+ 632 (0–1194) 821 (0–1231) 0.5
Σ analyzed HMO 15723 (13137–17176) 15972 (13008–17512) 0.8
* Mann Whitney U-test for independent samples used to compare distributions.
The correlation between growth indices and the 15 HMOs are displayed in Figure 4 (14-days
sample) Figure S3 (28-days sample) and Figure S4 (PMW-36 + 0 sample). There were many statistically
significant but weak correlations, but some of them were consistent throughout the neonatal period.
The sialylated oligosaccharide LSTa correlated positively to the growth of weight and length at all
three time points and also to head growth at day 14 of life, while the sialylated oligosaccharides 6SL,
LSTb and LSTc correlated negatively to weight and head growth at 14 and 28 days of life.
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Figure 4. Correlations between concentrations of individual human milk oligosaccharide (HMO)
(micromol/litre) in milk samples from day 14 and infant growth (change in z-score from birth to
measurement on the 14th or 28th day of life or at 36 postmenstrual week (PMW), analysed using
Spearman´s rho correlation coefficient. Significant correlations are highlighted with green for positive
and red for negative correlations.
4. Discussion
This study in preterm ELBW infants supports the hypothesis that HMO composition in breast
milk affect the risk of developing NEC, which is consistent with animal models [14,15,30] and a
previous human trial in preterm VLBW infants [16]. The main finding in the present trial was the low
diversity of the 15 dominant HMOs in infants developing NEC, which has not been reported in any of
the previous trials [14–16]. The study could not confirm the preventive effect of the sialylated HMO
DSLNT on NEC found in previous studies [14–16], but instead NEC was associated with low levels of
112
Nutrients 2018, 10, 1556
LNDH I, which is a fucosylated HMO that can only be produced by mothers that are both secretor and
Lewis positive.
The HMO composition reflects the mother´s secretor status and Lewis blood group and
depends on genetic variation causing different expression of fucosyltransferases. As a consequence,
secretor-negative and Lewis-negative mothers cannot produce some of the HMOs. One of them,
2FL, is the most abundant HMO in milk from secretor-positive mothers and has been associated with
preventive effects on both NEC [15,30] and infections [31]. There was a trend of lower NEC in infants to
secretor and Lewis-positive, as compared to negative, mothers in the present study, and the difference
in HMO diversity between NEC and non-NEC cases remained when the material was stratified to
include only secretor and Lewis-positive mothers, but disappeared when only secretor and Lewis
negative individuals were included. Interestingly, the two infants developing NEC despite high levels
of DSLNT had received breast milk from either a secretor-negative or a Lewis-negative mother.
Diversity is crucial for resilience in biological systems [32]. For instance, high microbial diversity
in the gut has been associated with reduced risk of developing NEC in preterm infants [33] and
asthma in school-age children [34]. The fact that such a high variety of HMOs are produced in human
breast milk also suggests that the diversity and composition of the HMOs is more important than
single HMOs. However, this does not preclude a preventive effect of administration of a single HMO
such as DSNLT [14,15], 2FL [30], or LNDH I in preterm infants, but such an effect still needs to be
confirmed in a randomised-controlled trial. The different findings in the human trial on VLBW infants
by Autran et al. [16] with a significant correlation between NEC and low DSLNT, but not with total
diversity, might be explained by cohort differences: The infants in the present trial were much smaller
and immature than in the previous trial [16]. We speculate that the diversity is more important in
ELBW than in VLBW infants. Additionally, HMO composition may vary between different countries.
Interestingly, Swedish mothers had the lowest DSLNT levels in a previous worldwide study [17].
Human milk oligosaccharides have the potential to influence many of the mechanisms
attributed to NEC development such as the immaturity of the immune system, regulation of the
microvascular circulation, gut motility, reduced intestinal epithelial barrier function, and aberrant
gut microbiota [35,36]. Thus, HMOs have been shown to reduce neutrophil infiltration and activation
in vitro [37] and stimulate anti-inflammatory responses in the intestinal epithelium ex vivo [12,13].
The secretor-dependent 2FL modulated CD14 expression in human enterocytes and attenuated
LPS-induced inflammation ex vivo [38], and also attenuated the severity of experimental NEC by
enhancing mesenteric perfusion in the neonatal intestine via endothelial nitric oxide activation in a
murine model [30]. In a murine ex vivo model on gut motility, fucosylated, but not sialylated HMOs
diminished colon motor contractions [39]. Moreover, HMOs have structural homology to many cell
surface glycans and thus act as decoys by binding to luminal bacteria that are then unable to bind
to the surface of the enterocyte [40]. They can mimic carbohydrate-binding motifs of certain enteric
pathogens, such as enteropathogenic E. coli by acting as a receptor decoy, and prevent adhesion to the
apical surface of enterocytes [11]. Low microbial diversity [33] and high abundance of Proteobacteria
and Enterobacteriaceae, and low abundance of Bacteroidetes have been related to the development of
NEC [41]. Bifidobacteria and Bacteroidetes species become dominant intestinal bacteria in healthy
breast-fed term infants due to their ability to digest and utilise HMOs via specific glycosidases,
while most pathogenic Enterobacteriaceae lack these enzymes and are unable to utilize HMOs as a
food source [42]. Interestingly, preterm infants to secretor-negative mothers have been shown to have
increased abundance of Proteobacteria [43].
Group B Streptococcus (GBS) is the most common pathogen causing neonatal sepsis. The neutral
oligosaccharide LNT inhibited growth of GBS in vitro [19], and infants to Lewis-positive mothers were
less colonised with GBS in a study in The Gambia [31]. Our study did not confirm these findings.
Breastfeeding has been associated with weight development in infants [44]. There were many
but quite weak correlations between growth indices and single HMO in the present study, although
some of our findings were consistent throughout the neonatal period. The sialylated LSTa correlated
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positively to the growth of weight, length and head circumference, which is consistent with a Malawian
study in which sialylated HMOs were less abundant in breast milk from mothers to severely stunted
infants [18]. Supplementation with sialylated bovine milk oligosaccharide also increased growth in
a gnotobiotic animal model [18]. However, not all sialylated HMOs seem to increase growth. In a
Gambian study, the sialylated oligosaccharides 3SL and LSTc were positively and negatively correlated,
respectively, to weight development [45], while 6SL and LSTc were negatively associated to weight
gain in the present study.
Our study has many strengths. It is the largest trial of its kind, although the non-significant
associations between NEC and several of the HMOs, such as DSLNT and 2FL, still might be due to
insufficient statistical power. Also, the study included only ELBW infants, which is the patient group
with the highest risk of developing NEC. The prospective design ensured well-controlled data and
precise diagnoses, and samples were obtained longitudinally at three time points during the entire
neonatal period. The breast milk sampling was standardised and included all mothers with sufficient
breast milk. Fifteen of the most abundant HMOs [46] were measured with an established method,
HPAEC-PAD [23,24]. A limitation of the study was the fact that no infants receiving donor milk or
formula were included. Moreover, since we collected breast milk samples only at three fixed time
points, the duration between sampling and use of the breast milk and the NEC and sepsis onset varied
between cases, although most cases started before day 28 of life. However, the variability in HMO
composition was higher between mothers than within the same mother over time, and the difference
in HMO diversity and LNDH I levels were significantly associated with NEC at all three sampling
points. These findings implicate that the duration between the sampling and NEC onset was of minor
importance. Like the previous human trial [16], the analyses purely focused on HMO concentrations
and not on the absolute HMO amounts received, which depended on the amount milk the infant
received. Male gender was significantly more common among the NEC-cases, but there were no
differences in HMO diversity in breast milk from mothers of singleton boys and girls. No other potential
confounder that we measured differently between NEC and non-NEC cases. However, this does
not preclude that some other factors could have influenced the result. A randomized-controlled
intervention is needed to prove causality.
5. Conclusions
Our results suggest that the HMO composition in breast milk may be an important factor
explaining why exclusively breast milk fed ELBW infants develop NEC. Low HMO diversity and low
levels of the HMO LNDH I was associated with NEC development in ELBW infants. A preventive
effect of supplementation with single or multiple HMO compounds still needs to be confirmed in
future randomised-controlled trials.
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Abstract: Constipation often begins in the first year of life. The aim of this study was to assess the
effect of fructooligosaccharides (FOS) in the treatment of infants with constipation. This randomized,
double-blind, placebo-controlled clinical trial included infants with constipation who were randomly
assigned to one of two parallel groups: FOS or placebo. Either the FOS supplement or the placebo
was added to the infant formula. Thirty-six infants completed the 4-week intervention. Therapeutic
success occurred in 83.3% of the FOS group infants and in 55.6% of the control group infants (p = 0.073;
one-tailed test). Compared with the control group, the FOS group exhibited a higher frequency of
softer stools (p = 0.035) and fewer episodes of straining and/or difficulty passing stools (p = 0.041).
At the end of the intervention, the mouth-to-anus transit time was shorter (22.4 and 24.5 h, p = 0.035),
and the Bifidobacterium sp. count was higher (p = 0.006) in the FOS group. In conclusion, the use
of FOS in infants with constipation was associated with significant improvement in symptoms, but
the results showed no statistical significance regarding the success of the therapy compared with the
control group. FOS was associated with reduced bowel transit time and higher counts of the genus
Bifidobacterium in the stool.
Keywords: constipation; prebiotic; intestinal transit time; infant; Bifidobacterium
1. Introduction
Constipation occurs frequently in childhood and accounts for approximately 25% of visits to
pediatric gastroenterology outpatient clinics [1–3]. In most cases, symptoms appear during the first
year of life [3–5]. This stage of life involves significant changes to the infant’s diet, including the
introduction of complementary feeding and inappropriate early interruption of breastfeeding [6].
Breastfeeding protects against the development of constipation and is associated with higher stool
frequency and softer stools during the first six months of life [5,7,8]. The lower constipation frequency
among breastfed infants might be due to the ingestion of prebiotic oligosaccharides, which are the third
largest component of breast milk and are absent from nonhuman milk [9]. Oligosaccharides have a
bifidogenic effect (contributing to the growth of beneficial bacteria from the genera Bifidobacterium and
Lactobacillus) and modify intestinal metabolic activity by reducing the pH and increasing the short-chain
fatty acid concentration. This modulation of the gut microbiota may contribute to increasing the stool
bulk and intestinal motility, thus facilitating the passage of stool [10,11].
Nutrients 2018, 10, 1602; doi:10.3390/nu10111602 www.mdpi.com/journal/nutrients118
Nutrients 2018, 10, 1602
Considering that human breast milk contains large amounts of oligosaccharides, a mixture of
prebiotic oligosaccharides (galactooligosaccharides and fructooligosaccharides) has been added to
some infant formulas. The effect of this mixture on the gut microbiota and bowel pattern was assessed.
The results indicated an increased stool frequency [12–17] and softer stools [12–17] in the infants who
were fed the prebiotic mixture. In addition, the number of fecal Bifidobacteria was higher in the group
fed the prebiotic mixture than in the control group [13,17]. A recent clinical study conducted in Brazil
assessed the effect of galactooligosaccharides on constipation among 6 to 14-year-old children and
adolescents. The results showed higher stool frequency, less straining and softer stools during the
prebiotic intake period [18].
Although several studies have demonstrated the influence of prebiotics on stool frequency and
consistency, no randomized, double-blind, placebo-controlled clinical trial has assessed their use in
treating infants with constipation. Therefore, this clinical trial assessed the effect of prebiotic FOS on
the bowel pattern of infants (6–24 months old) with constipation as well its effects on mouth-to-anus
transit time and stool counts of the genera Bifidobacterium and Lactobacillus.
2. Materials and Methods
2.1. Study Design
This study was a randomized, double-blind, placebo-controlled, parallel trial that complied
with the guidelines formulated by the Consolidated Standards of Reporting Trials (CONSORT) [19].
The trial was registered at the Brazilian Registry of Clinical Trials (registry number RBR-2x8wqc;
registry URL: http://www.ensaiosclinicos.gov.br/rg/RBR-2x8wqc/).
Infants aged 6–24 months were assessed for inclusion in the study at basic health units or daycare
centers in the cities of Osasco and São Vicente (State of São Paulo, Brazil). Constipation was defined as
the elimination of hard stools associated with one of the following characteristics: pain or straining
while passing stools, scybalous stools, cylindrical and cracked or cylindrical and thick stools and stool
frequency less than three times per week, as per the modified international recommendations [20]
used in previous studies [5,21]. After inclusion in the study and before randomization, a daily register
of intestinal habits was tracked in a diary for one week and used to confirm the constipation diagnosis.
Infants who fulfilled any of the following criteria were not admitted to the study: (1) exclusively
or partially breastfeeding; (2) use of antibiotics, dietary fiber or prebiotic supplements in the past
30 days; (3) iron deficiency anemia (hemoglobin < 11.0 g/dL); 4. current use of medications that can
cause constipation (except ferrous sulfate); 5. malnutrition or obesity; 6. infants whose parents were
not able to record the infant’s bowel pattern during follow-up.
Other exclusion criteria were the clinical need for prescribed laxatives, a diagnosis of fecaloma or
FOS or placebo intake below 80%.
2.2. Intervention
Randomization was performed by a health professional who did not participate in the study.
A computer-generated random number table was used, and the participants were assigned to blocks
by body weight (6.0–8.9 kg, 9.0–11.9 kg and over 12.0 kg). In each weight interval, a block of four
participants was assigned to the study and control groups at 2:2 ratios. The prebiotic and placebo
were delivered in identical packaging, and the coding was standardized according to the random
number table. The participants received the corresponding intervention based on their order of
entry into the study. Neither the participants nor the investigators were aware of the intervention
(prebiotic or placebo).
The study lasted five weeks with one week for clinical evaluation before randomization.
During the intervention, participants received a prebiotic composed of 100% FOS (the FOS
polymerization degree ranged from two to six monosaccharide molecules) or a placebo composed
of 100% (flavorless) maltodextrin for four weeks. The FOS and placebo doses were 6, 9 or 12 g
119
Nutrients 2018, 10, 1602
daily based on the infants’ weight groups of 6.0–8.9 kg, 9.0–11.9 kg or over 12.0 kg, respectively.
Both were supplied by the same manufacturer (FQF, Farmoquimica, São Paulo, Brazil). Based on
the randomization, each patient received the FOS or placebo in two doses. The FOS or placebo
supplements were administered in baby bottles and dispersed in infant formula (MilupaR, Danone,
Brazil) or cow’s milk (NinhofortificadoR, Nestlé, Brazil) for infants aged less than 12 months and older
than 12 months, respectively.
2.3. Study Stages
The study involved three stages: baseline, intervention and the last week of the clinical trial.
At baseline (first week), clinical interviews were conducted. The interviews included characterization of
the infants’ bowel patterns and 24-h diet recall; stool samples were also collected, and hemoglobin levels
in capillary blood samples and the carmine dye mouth-to-anus transit time were measured. The infants’
parents received home monitoring diaries. During the baseline week, the participants received infant
formula or iron-fortified cow’s milk without supplemental FOS or the placebo. This procedure
permitted evaluation of the effect of dietary changes on the infants’ bowel patterns. Only infants who
continued to experience constipation at the end of the first week were included in the intervention.
The intervention period was conducted over the following four weeks and included one weekly
clinical evaluation. Participants received FOS or the placebo as indicated by the randomization.
During the intervention, the infants’ guardians recorded the bowel patterns and adverse effects in
their home monitoring diaries.
During the end-of-study period (the last week of the intervention period), a second stool sample
was collected, the carmine dye mouth-to-anus transit time was measured, and 24-h diet recall
was recorded.
2.4. Study Procedures
The infants’ bowel patterns were assessed based on data provided by their guardians at clinical
interviews based on their home monitoring diaries.
Hemoglobin concentration in the capillary blood samples was measured using a photometer
(HemoCue, Angelholm, Sweden). Infants with anemia (hemoglobin concentration less than 11 g/dL
per the World Health Organization [21]) were excluded. Anemia was evaluated and treated by
pediatricians at basic health units. The guardians of infants without anemia who were receiving ferrous
sulfate at prophylactic doses were directed to discontinue the medication during the study period.
The mouth-to-anus transit time, expressed in hours, was measured using carmine dye (Certistain,
Merck, Brazil). The dye was administered at a dose of 0.25 g dissolved in 50 mL of water [22].
Guardians were directed to record the dates and times at which the infants ingested the dye and first
expelled red-stained stools.
The infants’ typical diets were assessed using the 24-h recall method [23]. Energy, macronutrient
(carbohydrate, fat and protein) and micronutrient (calcium and iron) intake estimates were calculated
using Nutrition Decision Making Support System software (version 2.5) (Universidade Federal de São
Paulo, São Paulo, Brazil). Dietary fiber intake was calculated using the Brazilian Food Composition
Table (Tabela Brasileira de Composição de Alimentos) [24], which lists the dietary fiber content of
foods according to the Association of Official Analytical Chemists’ (AOAC) enzymatic-gravimetric
method [25].
Body weight and height were measured at all clinical evaluations. Infants were weighed
without clothes using digital scales (Filizola, São Paulo, Brazil) with 15-kg capacities and 5-g
sensitivities. Body length was measured using a portable, horizontal 100-cm stadiometer with 0.1-cm
precision. The weights and lengths of the infants are expressed as weight-per-age, length-per-age and
weight-per-length z-scores. Z-scores were calculated using the World Health Organization’s Anthro
software, version 3.2.2 (Geneva, Switzerland) [26].
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The guardians who received instructions on delivering the FOS or placebo were also asked to
record the infants’ bowel patterns (stool frequency and consistency, pain, crying, straining or difficulty
passing stools) and adverse effects (excessive crying, regurgitation or vomiting) each day in their home
monitoring diaries. To facilitate description of stool shape and consistency, a scale with four figures
illustrating infant stools was appended to the home monitoring diary.
For determining the number of Bifidobacterium and Lactobacillus, stool samples were collected
by the guardians according to established guidelines. Approximately 1 g of each stool sample was
transferred to a microtube containing ASL buffer from the DNA extraction QIAamp Mini Stool Kit,
and the sample was stored at −20 ◦C until the DNA was to be extracted. The bacterial genomic DNA
was extracted according to the protocol recommended by the extraction kit manufacturer (Qiagen,
Hilden, Germany), and the purified DNA was diluted in a buffer solution to a final volume of 200 μL.
The DNA concentration was measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific,
Waltham, MA, USA). All DNA samples were diluted to a final concentration of 20 ng/μL and stored
at −20 ◦C.
DNA from all fecal samples was subjected to real-time polymerase chain reaction (qPCR).
The primers used were selected to identify and quantify Lactobacillus spp. [27] and Bifidobacterium
spp. [28]. All reactions were performed in duplicate in a final volume of 10 μL that included 5 μL of
Rotor-gene SYBR Green PCR Master Mix (Qiagen, Hilden, Germany). Thermocycling was performed
in a Rotor-gene Q device (Qiagen, Hilden, Germany) with the following parameters: 5 min at 95 ◦C
and 40 cycles of 95 ◦C for 10 s and 60 ◦C for 15 s. The dissociation protocol used to obtain the melting
curve was 95 ◦C for 1 min followed by variation of the temperature from 70 ◦C to 95 ◦C with a
temperature increase of 1 ◦C/s. The negative control contained all the ingredients except the DNA
sample. The standard curve for all of the analyses was created by amplifying a Topo TA plasmid
(Invitrogen, ThermoFisher, Waltham, MA, USA) carrying a fragment of the reference gene previously
amplified by conventional PCR, and its specificity was confirmed by sequencing and BLAST system
alignment. With the molecular mass of the plasmid and insert known, it is possible to calculate the
copy number as follows: mass in daltons (g/mol) = (size of double-stranded (ds) product in base
pairs (bp)) (330 Da × 2 nucleotides (nt)/bp) [29–31]. If the copy number and the concentration of the
plasmid DNA are known, the number of molecules added to subsequent real-time PCR runs can be
calculated, thus providing a standard for determining the copy numbers of specific genes [29–31].
The real-time PCR results are expressed as log CFU per gram of stool (log CFU/g) using the average
number of copies of 16S rRNA genes in each bacterium to normalize the counts [29–31].
2.5. Outcomes
The primary outcome was therapeutic success defined as a normal bowel pattern at the end
of the study, i.e., predominantly soft, amorphous or cylindrical stools without cracks as well as
the absence of pain or difficulty passing stools (a pattern incompatible with the criteria adopted
herein for characterizing constipation). Therapeutic failure was defined as the persistence of a bowel
pattern indicating constipation at the end of the study or a clinical need for laxatives during the
intervention period.
Secondary outcomes were stool frequency, stool consistency, pain and/or crying when passing
stools, and difficulty and/or straining while passing stools during the last week of the clinical trial.
The mouth-to-anus transit time and Bifidobacterium spp. and Lactobacillus spp. counts were measured
before and at the end of the intervention.
2.6. Ethical Issues
The study protocol was approved by the Research Ethics Committee of the Universidade Federal
de São Paulo (Federal University of São Paulo). Written informed consent was obtained from the
parents of the infants prior to inclusion in the study.
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2.7. Statistical Analysis
Sample size was calculated based on the primary outcome (therapeutic success). A success rate
of 70% was assumed for the group that received FOS, and a success rate of 20% was assumed for the
control group. For α = 0.05 and β = 0.20 (power = 0.80), each group should include 19 individuals.
To compare the mean and median values between groups, parametric (Student’s t-test) or
non-parametric (Mann–Whitney U) tests were used based on the data distribution. A chi-squared
test was used to compare proportions. For the variables therapeutic success, stool frequency, stool
consistency, and occurrence of pain and/or crying when passing stools or difficulty and/or straining
when passing stools, the study goal was to establish whether the FOS performed better than the
placebo. Therefore, p-values from one-tailed tests were used to compare those variables. Calculations
were performed using SigmaStat 3.1 (Systat, San Jose, CA, USA) and EpiInfo (CDC, Atlanta, GA, USA).
Differences between groups were considered significant when p < 0.05.
3. Results
3.1. Patients
Seventy-five infants were eligible for inclusion in the study; however, the constipation diagnosis
was unconfirmed in 26 (34.7%) cases during the first week’s assessment, five guardians dropped out
during the baseline period, and six did not consent to participate. Thus, 38 infants were randomly
assigned to the two groups. The study group (n = 19) received FOS, and the control group (n = 19)
received the placebo. No statistically significant differences were found between the groups at the time
of inclusion in the study (after the end of the baseline period) (Table 1). During the intervention period,
one participant in the FOS group dropped out for medical reasons (pneumonia), and one participant
in the control group dropped out due to a family trip. Therefore, 36 infants completed the clinical trial:
18 in the FOS group and 18 in the control group (Figure 1).
Table 1. Demographic and clinical characteristics at baseline.
FOS Group (n = 19) Control Group (n = 19) p
Age (months) 12.77 ± 4.37 13.00 ± 5.19 0.890 †
Sex
Female 10 (52.6%) 10 (52.6%) 1.000 *
Male 9 (47.4%) 9 (47.4%)
Number of bowel movements per week 6.27 ± 1.32 5.66 ± 1.87 0.133 †
Predominant stool shape and consistency
Cylindrical with cracks 13 (68.4%) 8 (42.1%) 0.191 *
Scybalous 6 (31.6%) 11 (57.9%)
Straining and/or difficulty in more than 50%
of bowel movements 16 (84.2%) 16 (84.2%) 1.000 *
Pain and/or crying in more than 50% of
bowel movements 11 (57.9%) 12 (63.2%) 1.000 *
FOS: fructooligosaccharide; Consistency and shape: predominant occurrence (more than four times per week);
* Two-tailed chi-squared test with Yates’ correction; † Two-tailed Student’s t-test, mean ± standard deviation.
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Figure 1. Flowchart showing the study participants. FOS: fructooligosaccharide.
3.2. Primary Outcome
Therapeutic success occurred more frequently in the FOS group (15/18, 83.3%) than in the control
group (10/18, 55.6%); however, this difference was not statistically significant (p = 0.073, one-tailed
chi-squared test).
3.3. Secondary Outcome
For the secondary outcomes, all variables were similar at admission (Table 2). The weekly
stool frequencies in the last week of the study were similar in both groups, and no statistically
significant increment in the number of bowel movements occurred between the baseline and the
last week of the study. Both groups presented fewer (p < 0.05) bowel movements with pain/crying
or straining/difficulty when passing stool and increments (p < 0.05) in the percentages of bowel
movements with soft stool. At the last week of the study, the FOS group presented fewer bowel
movements with straining/difficulty (p = 0.041) and a higher percentage of passing soft stools than the
control group (p = 0.035).
The median mouth-to-anus transit times for the FOS and control groups were similar (p = 0.740,
two-tailed Mann-Whitney test) upon admission in the study, at 23.3 h (percentiles 25 and 75: 22.2; 25.6)
and 23.5 h (percentiles 25 and 75: 21.9; 27.0), respectively. At the end of the study, the mouth-to-anus
transit time was lower (p = 0.035; one-tailed Mann–Whitney test) in the FOS group (median: 22.4 h;
percentiles 25 and 75: 18.3; 25.7) than in the control group (median: 24.5 h; percentiles 25 and 75:
23.0; 33.3).
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Table 2. Clinical secondary outcomes at baseline and at the end of the study (stool frequency, percentage
of straining, difficulty, pain, crying during defecation and percentage of soft stools).
FOS Group (n = 18) Control Group (n = 18) p *
Number of bowel movements per week
Baseline week 6.27 ± 1.32 5.66 ± 1.87 0.133
Last week of the study 6.33 ± 1.28 6.11 ± 1.53 0.320
Pain/crying when passing stools (percent of bowel movements)
Baseline week 55.13 ± 44.07 60.09 ± 44.44 0.369
Last week of the study 14.68 ± 29.15 28.39 ± 43.82 0.138
Straining/difficulty when passing stools (percent of bowel movements)
Baseline week 84.47 ± 29.39 79.47 ± 37.63 0.330
Last week of the study 29.65 ± 41.73 55.07 ± 43.44 0.041
Soft stool consistency (percent of bowel movements)
Baseline week 12.12 ± 15.91 16.92 ± 15.07 0.180
Last week of the study 73.38 ± 29.38 55.38 ± 36.32 0.035
* The data are presented as mean ± standard deviation (One-tailed Student’s t-test).
At the end of the study, the number of bacteria of the genus Bifidobacterium was higher in the FOS
group than in the control group (Table 3).
Table 3. Secondary outcome: Bifidobacterium and Lactobacillus genus counts (log CFU/g).
FOS Group (n = 18) Control Group (n = 18) p
Bifidobacterium
Baseline 6.39 (5.25–8.36) 6.61 (4.48–7.99) 0.301
End of the study 7.37 (5.86–8.43) 5.60 (4.46–6.42) 0.006
Lactobacillus
Baseline 6.27 (4.33–7.54) 6.03 (2.95–7.23) 0.248
End of the study 6.45 (4.83–7.61) 5.39 (3.37–6.73) 0.095
The data are presented as median values with the 25th and 75th percentile values in parentheses (Mann-Whitney test).
The z-scores (weight-for-height, weight-for-age, height-for-age and body mass index-for-age)
and the food intake as per the 24-h food recall method were similar in the FOS and control groups
at baseline and at the end of the study (data not shown). Dietary fiber intake (excluding the FOS
supplement used in the intervention) was 6.6 ± 2.1 g/day and 7.4 ± 2.4 g/day at admission (p = 0.269)
in the FOS and control groups, respectively. At the end of the study, these values were 6.5 ± 2.3 g/day
and 7.1 ± 2.2 g/day (p = 0.457), respectively.
3.4. Adverse Effects
All participants who completed the 4-week intervention (n = 36) consumed more than 80% of
the delivered amount of FOS or placebo. Adverse effects were reported only in the FOS group (two
infants with abdominal distension and flatulence), but the treatment was continued. One of the infants
in the FOS group had two vomiting episodes during the first week of intervention.
4. Discussion
This clinical trial showed that FOS intake contributed to relieving infant constipation (increased
frequency of softer stools) and reducing the number of defecation events with straining and/or
difficulty passing stools. FOS also reduced the bowel transit time and increased the number of
Bifidobacterium in constipated infants who were treated with FOS relative to the control group. The stool
frequencies in the two groups were similar at baseline and at the last week of the study. Although the
difference did not reach statistical significance, therapeutic success was more frequently achieved in
the group treated with FOS than in the control group.
Per the 2014 ESPGHAN/NASPGHAN guideline for constipation, routine use of prebiotics
is not recommended for treating childhood constipation. Recently, a clinical trial performed in
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Brazil [17] showed a positive effect of galactooligosaccharide probiotics on constipation in children and
adolescents aged 4–16 years. That study showed softer stools, increased stool frequency and less pain
or difficulty when passing stools during the prebiotic intake period. The present study showed similar
results except for stool frequency. However, the defecation frequency of constipated infants included
in our study was not reduced; therefore, no increase in the bowel movement frequency was expected.
Prebiotics were administered to healthy bottle-fed infants in previous clinical trials [12–16] to
assess their influence on bowel patterns. Infants who received prebiotic mixtures of galacto- and
fructooligosaccharides exhibited softer stools. Our results agreed with these studies, as the frequency
of softer stools increased after four weeks of intervention only with FOS. Additionally, the mixture
used in the infant formula contained 90% galactooligosaccharides and only 10% FOS.
The increased frequency of softer stools and the consequent reduction in defecation events with
straining and/or difficulty when passing stools in the FOS-treated group might be related to the
effect of this prebiotic on the gut microbiota. Prebiotics are carbohydrates that are not digested in
the gastrointestinal tract and are used as an energy source by the gut bacteria [10]. Other studies
found that consumption of a mixture of galacto- and fructooligosaccharides increased the number
of Bifidobacterium [12,13]. Our results showed that at the end of the study Bifidobacterium numbers
were higher in the FOS group. Thus, only FOS had a prebiotic effect as observed for the galacto-
and fructooligosaccharide mixture. This effect might be associated with the short-chain fatty acids
produced by the fermentation of prebiotics. The modulation of gut microbiota may contribute to
increasing the stool bulk and may stimulate intestinal motility, thus facilitating stool expulsion [10,32].
The daily FOS dose varied between 6 g and 12 g according to the infants’ weights. Infant formula
containing 8 g/L of the galacto- and fructooligosaccharide mixture provides 6 g of prebiotic in 750 mL.
Therefore, the dose of FOS used in the present study was similar to or higher than the amount that
would be provided by regular daily intake of 750 mL of infant formula containing 8 g/L of the galacto-
and fructooligosaccharide mixture. The supplemented FOS was well tolerated since only one infant
presented two vomiting episodes during the first week of intervention. Mild flatulence and abdominal
distension were observed in two FOS group patients; however, the treatment was continued. Therefore,
the FOS supplementation was well tolerated, with mild adverse effects in few infants.
The limitations of the present study include the following. The sample may have been insufficient
to demonstrate statistical significance for therapeutic success in the FOS and control groups.
The therapeutic success observed in the FOS group (83.3%) was similar to the expected value (80%)
used to estimate the sample size. The number of infants included in the trial complied with the
calculated sample size; however, the proportion of constipated infants in the control group who had
therapeutic success (55.6%) was much higher than the value (20%) used in the sample size estimate.
The guidance for healthy eating for infants provided at the time of inclusion in the study and the
substitution of cow’s milk for infant formula in patients younger than 12 months likely had an effect
on improving the constipation. This might also explain the high number of infants (26/75; 34.7%;
Figure 1) who were not confirmed to have constipation after the first week of clinical observation (prior
to randomization). The macronutrient intake, including dietary fiber, assessed by the 24-h food recall
method was similar in the FOS and control groups before and at the end of the intervention. The dietary
fiber intake (soluble and insoluble) varied between 6.5 and 7.4 g/day. The suggested daily intake of
dietary fiber for this age group is 5–10 g [33]. Notably, neither the American Health Foundation [34]
nor the Dietary Recommended Intake [35] recommend specific amounts of dietary fiber intake during
the first year of life. Therefore, the quantity of macronutrients, including dietary fiber, consumed by
the participants in this study may not explain the decreased constipation. Additionally, the type of
milk consumed by all infants was changed at the beginning of the first week, corresponding to the
baseline of the clinical trial. Most infants had been fed cow’s milk containing added starch and sugar,
which is a frequent feeding habit for infants in Brazil [36,37]. The change in infant formula or the use
of fortified cow’s milk in the correct dilution may explain the decreased constipation in the first week
and in the control group during the intervention period. These results should not be extrapolated to
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severely constipated infants since this clinical trial did not include infants requiring other laxatives or
fecal disimpaction.
5. Conclusions
In conclusion, the use of FOS in infants with constipation was associated with significant
improvement in symptoms, but the results showed no statistical significance regarding the success of
the therapy compared with the control group. However, the improved stool consistency, the reduced
number of episodes of straining and/or difficulty passing stools and the reduced bowel transit time
detected among the infants fed FOS are relevant findings that will contribute to preventing more
severe constipation symptoms among constipated infants. Additional clinical trials assessing the effect
of prebiotics on infant constipation are needed to confirm the results of this study and to provide data
for a future meta-analysis.
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Abstract: Probiotics may have immunomodulatory effects. However, these effects in asthma
remain unclear and warrant clinical trials. Here, we evaluated the effects of Lactobacillus paracasei
(LP), Lactobacillus fermentum (LF), and their combination (LP + LF) on the clinical severity,
immune biomarkers, and quality of life in children with asthma. This double-blind, prospective,
randomized, placebo-controlled trial included 160 children with asthma aged 6–18 years (trial
number: NCT01635738), randomized to receive LP, LF, LP + LF, or a placebo for 3 months. Their
Global Initiative for Asthma–based asthma severity, Childhood Asthma Control Test (C-ACT) scores,
Pediatric Asthma Severity Scores, Pediatric Asthma Quality of Life Questionnaire scores, peak
expiratory flow rates (PEFRs), medication use, the levels of immune biomarkers (immunoglobulin E
(IgE), interferon γ, interleukin 4, and tumor necrosis factor α) at different visits, and the associated
changes were evaluated. Compared with the placebo group by generalized estimating equation
model, children receiving LP, LF, and LP + LF had lower asthma severity (p = 0.024, 0.038, and 0.007,
respectively) but higher C-ACT scores (p = 0.005, < 0.001, and < 0.001, respectively). The LP + LF
group demonstrated increased PEFR (p < 0.01) and decreased IgE levels (p < 0.05). LP, LF, or their
combination (LP + LF) can aid clinical improvement in children with asthma.
Keywords: Lactobacillus; probiotics; asthma; Childhood Asthma Control Test; peak expiratory flow
rate; immunoglobulin E
1. Introduction
Asthma, a chronic complex disease of the airways, is characterized by reversible airflow
obstruction, bronchial hyperresponsiveness, and underlying inflammation [1]. The prevalence of
asthma has increased in the past decades. A potential mechanism underlying this high prevalence
is the microbial hypothesis [2], which argues that less microbial exposure upregulates the cytokine
production of T-helper cell type 2 (Th2), leading to an increase in allergic diseases. According to
this hypothesis, probiotic administration is an alternative treatment for atopic disease, which when
administered in adequate amounts, can confer a health benefit to the host [3]. The researchers found
that probiotics have some health effects in atopic disease patients through immunity balancing of
T-helper cell type 1 (Th1) and Th2, particularly in those with atopic dermatitis (AD). However, relevant
studies focusing on asthma patients are limited.
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A meta-analysis found that, although perinatal and early-life probiotic administration reduces
atopic sensitization risk and total immunoglobulin E (IgE) levels in children, it may not reduce their
asthma risk [4]. However, some studies have reported the benefit of using probiotics, in addition to
standard care, for treating children with asthma. A randomized, placebo-controlled trial for 7-week
Enterococcus faecalis treatment demonstrated decreased peak flow variability in children with asthma [5].
Lee et al. also reported significant improvements in the pulmonary function of children with asthma
after a regimen of vegetable, fish oil, and fruit supplementation along with probiotic administration [6].
However, these aforementioned studies were designed as mixed interventions with relatively small
sample sizes.
In the present study, we thus included participants representing a population of school-age
children with asthma randomized to receive pure strains of Lactobacillus paracasei GMNL-133 (BCRC
910520, CCTCC M2011331) (LP), Lactobacillus fermentum GM-090 (BCRC 910259, CCTCC M204055)
(LF), or their mixture (LP + LF). We focused on the therapeutic effects of the probiotics on the disease
severity, quality of life, immune biomarkers, and fecal microbial composition in school-age children
with asthma.
2. Materials and Methods
2.1. Participants
This double-blind, randomized, placebo-controlled trial was conducted between December 2011
and September 2013 at the pediatric outpatient clinics of Taipei Hospital, Ministry of Health and
Welfare. The inclusion criteria were 6–18 years of age with a history of intermittent to moderate
persistent asthma (Global Initiative for Asthma (GINA) steps 1–3) for at least 1 year. We excluded
children who had received immunosuppressants, antibiotics, systemic corticosteroids, or antimycotics
within 4 weeks before study enrolment or antihistamines within 3 days before study enrolment.
The children who had an immunodeficiency disease, other major medical problems, or used probiotic
preparations within 4 weeks before study enrolment were also excluded. We acquired written informed
consent from all the parents in compliance with the principles of the Helsinki Declaration. The Taipei
hospital’s Institutional Review Board ratified the study protocol (TH-IRB-10-14). The study was
registered under trial number NCT01635738.
2.2. Protocol
An investigator enrolled the children and sequentially assigned them a patient number associated
with a code. Capsules were prepared and coded by GenMont Biotech Inc. (in their Current Good
Manufacturing Practice–certified facilities, Tainan, Taiwan) and dispensed by a study nurse. The
children were randomized using computer-generated 4-block design lists created by a statistician, with
stratification according to age, sex, severity, and current medication use. We assessed the eligibility
of 160 recruited children and randomly allocated them to four groups, with 40 participants in each
group (Figure 1). The groups were then randomized to receive LP, LF, LP + LF, or placebo for 3 months.
All the investigators, study nurses, and participants were blinded to treatment assignment over the
study duration. A capsule count was performed monthly to ensure that the capsules were taken as
applicable. Randomization code was deciphered only at the end of the trial.
2.3. Outcome Measures
The primary outcome was the changes in asthma severity and Childhood Asthma Control Test
(C-ACT) scores over 3 months of the intervention compared with baseline. At baseline and follow-up
visits at 0, 1, 2, 3, and 4 months of intervention, we determined GINA-based asthma severity and
recorded C-ACT scores, Pediatric Asthma Quality of Life Questionnaire (PAQLQ) scores, Pediatric
Asthma Severity Scores (PASSs), peak expiratory flow rates (PEFRs), and medication use. Skin prick
test and blood serum analysis were performed at 0 and 3 months of intervention. In addition, fecal
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microbial analysis was performed for comprehensive evaluation before and after the 3-month treatment
course. The changes in PAQLQ score, PASS, PEFR, skin prick test reactivity, serum immune biomarker
levels, and fecal probiotic microbial composition were the secondary outcomes (Figure 2).
2.4. Laboratory Methods
Skin prick tests using commercial extracts were performed to detect asthma-causing allergens,
including mite, cockroach, animal dander, egg, milk, and crab allergens [7]. The levels of IgE and other
serum immune biomarkers, such as interferon (IFN) γ, interleukin (IL) 4, and tumor necrosis factor
(TNF) α, were measured through enzyme-linked immunosorbent assay [8]. Specific intestinal bacterial
strains in the feces were quantified using conventional culture techniques [9].
2.5. Sample Size Estimation
Using nQuery Advisor + nTerim 3.0 (Statistical Solutions Ltd., Cork, Ireland), we calculated
the number of participants required to detect the presence of any significant differences in C-ACT
scores. According to previous data [10], to detect significant differences in the effects of probiotics on
C-ACT scores with 90% power and a 5% significance level, each study group must include at least 22
participants. To allow for a 20% loss from ineligibility or withdrawal, we decided to enroll 30 children
in each group. After power assessment, we estimated that 120 total participants would suffice and
thus scheduled recruitment of 160 children.
2.6. Statistical Analysis
The baseline demographic data of the four groups were compared using analysis of variance.
Intragroup comparisons for severity, C-ACT scores, PASSs, PAQLQ scores, and immune biomarker
levels at baseline and 3 months of treatment were performed using the paired t test. Differences in
outcome variables between the treatment and placebo groups over the five visits were evaluated
using a generalized estimating equation (GEE) model after adjustment for potential confounders.
All children who completed the study were included in the analysis, regardless of their compliance.
All reasons for dropouts or premature withdrawal from the study as well as missing values were
recorded. Significance was set at a two-tailed α at 0.05, and all analyses were performed on SPSS
(version 21).
3. Result
3.1. Baseline Characteristics of Participants
Of 160 recruited children, 152 were finally enrolled and randomly assigned to receive LP, LF, LP +
LF, or placebo. Figure 1 shows the relevant patient consort diagram, and Table 1 presents the baseline
demographic characteristics of 147 children who completed the entire evaluation. The randomization
process ensured adequate comparability between the treatment and placebo groups. No statistically
significant differences were observed for any demographic, clinical, or functional variables. Moreover,
the clinical manifestation of asthma was similar between the two groups. No significant differences
were observed in the severity, total serum IgE level, the rate of sensitization to various allergens, the
PEFR, or other parameters between the groups at baseline (Table 2).
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Figure 1. Consort diagram.
Figure 2. Study protocol.










Male, N (%) 22 (57.9) 24 (63.2) 19 (52.8) 18 (51.4)
Age (years), Mean (SD) 7.68 (2.21) 7.37 (2.34) 7.00 (1.79) 7.86 (2.50)
Height (cm), Mean (SD) 121.24 (18.49) 117.81 (17.21) 117.51 (15.89) 122.23 (18.94)
Weight (Kg), Mean (SD) 26.45 (10.08) 25.14 (10.16) 24.75 (10.29) 26.30 (11.76)
IgE (kU/I), Mean (SD) 611.26 (511.83) 600.23 (739.18) 748.22 (896.40) 493.06 (773.52)
Combine with allergic rhinitis (AR), N (%) 31 (81.6) 31 (81.6) 32 (88.9) 28 (80.0)
Combine with atopic dermatitis (AD), N (%) 15 (39.5) 10 (26.3) 11 (30.6) 9 (25.7)
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Allergic sensitization, N (%)
Mite 33 (86.8) 32 (84.2) 30 (83.3) 29 (82.9)
Cockroach 3 (7.9) 2 (5.3) 1 (2.8) 0 (0)
Animal dander 2 (5.3) 2 (5.3) 1 (2.8) 1 (2.9)
Milk 2 (5.3) 3 (7.9) 1 (2.8) 0 (0)
Egg 2 (5.3) 2 (5.3) 1 (2.8) 1 (2.9)
Crab 2 (5.3) 3 (7.9) 1 (2.8) 0 (0)
Maternal history of atopic disease, N (%) 21 (55.3) 22 (57.9) 12 (33.3) 15 (42.9)
Paternal history of atopic disease, N (%) 21 (55.3) 21 (55.3) 20 (55.6) 17 (48.6)
LP, Lactobacillus paracasei; LF, Lactobacillus fermentum.
Table 2. Subscale measures at baseline (N = 147).
Subscale
LP (n = 38)
Mean (SD)
LF (n = 38)
Mean (SD)
LP + LF (n = 36)
Mean (SD)




Severity 2.16 (0.64) 2.13 (0.62) 2.28 (0.62) 2.20 (0.58) 0.757
C-ACT 19.89 (4.28) 17.87 (5.54) 19.81 (4.72) 20.77 (4.75) 0.074
PAQLQ 5.44 (1.17) 5.40 (1.41) 5.90 (0.85) 5.58 (1.16) 0.268
PASS 16.84 (5.27) 16.29 (5.79) 15.71 (4.85) 15.60 (5.16) 0.738
IFN-γ (ng/uL) 170.73 (188.44) 150.75 (158.12) 156.97 (167.18) 145.28 (162.26) 0.954
IL-4 (ng/uL) 36.05 (29.63) 48.48 (85.06) 61.10 (117.67) 55.38 (86.94) 0.773
TNF-α (ng/uL) 292.95 (425.14) 324.71 (512.82) 231.88 (187.97) 207.51 (340.37) 0.690
IgE (kU/I) 611.26 (511.83) 600.23 (739.18) 748.22 (896.40) 493.06 (773.52) 0.547
Fecal cell count
Log10 (CFU/g)
Lactobacillus 8.07 (0.87) 7.90 (0.95) 7.49 (1.15) 7.71 (0.92) 0.101
Bifidobacterium 8.81 (0.91) 8.74 (0.85) 8.75 (1.12) 8.90 (0.72) 0.872
Clostridium 7.19 (0.78) 6.63 (1.09) 6.84 (1.18) 6.79 (1.11) 0.133
LP, Lactobacillus paracasei; LF, Lactobacillus fermentum; C-ACT, Childhood Asthma Control Test; PAQLQ, Pediatric
Asthma Quality of Life Questionnaire; PASS, Pediatric Asthma Severity Scores.
3.2. Effects of Probiotics on Severity of Asthma and Quality of Life
Significant intragroup differences were detected in C-ACT scores, the primary outcome, in all
groups, except the placebo group (Figure 3). Compared with the placebo group, both asthma severity
and C-ACT scores significantly improved in the LP, LF, and LP + LF groups according to our age- and
sex-adjusted GEE model (Table 3). No significant difference was noted on both asthma severity and
C-ACT scores between the LP + LF and the LP and LF groups, respectively. The PAQLQ scores and
PASSs demonstrated no significant group-by-time effects. In the LP + LF group, PEFRs improved
significantly (p < 0.01).
Table 3. The p values and effect sizes (β) compared with the placebo group (n = 35) using a generalized
estimating equation model.
Measure
LP Group (n = 38) LF Group (n = 38) LP + LF Group (n = 36)
β (95% CI) P Value β (95% CI) P Value β (95% CI) P Value
Severity −0.34 (−0.63, −0.04) 0.024 * −0.30 (−0.59, −0.02) 0.038 * −0.43 (−0.74, −0.12) 0.007 *
C-ACT 3.13 (−0.95, 5.31) 0.005 * 4.54 (2.44, 6.65) < 0.001 * 3.83 (1.78, 5.89) < 0.001 *
PAQLQ −0.32 (−0.86, 0.23) 0.256 −0.30 (−0.89, 0.28) 0.310 −0.43 (−0.96, 0.09) 0.104
PASS −1.39 (−4.09, 1.30) 0.311 −1.14 (−3.79, 1.51) 0.400 −0.48 (−3.17, 2.20) 0.725
PEFR 8.77 (−11.74, 29.27) 0.402 28.83 (−3.55, 61.21) 0.081 33.81 (8.62, 59.00) 0.009 *
Adjusted for age and sex, * p < 0.05. LP, Lactobacillus paracasei; LF, Lactobacillus fermentum; C-ACT, Childhood Asthma
Control Test; PAQLQ, Pediatric Asthma Quality of Life Questionnaire; PASS, Pediatric Asthma Severity Scores;
PEFR, peak expiratory flow rate.
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Figure 3. Intragroup differences in Childhood Asthma Control Test scores. * p < 0.05.
3.3. Effects of Probiotics on Sensitization and Immune Biomarker Levels
At the end of treatment, the total serum IgE levels significantly decreased only in the LP + LF
group (p < 0.05; Table 4). Nevertheless, among all groups, significant intragroup differences, but no
intergroup differences, were noted in the skin prick test reactivity to mite allergens. However, no
such significant differences were noted for other allergens between before and after the intervention
(Table S1). Moreover, serum IFN-γ, IL-4, and TNF-α levels did not demonstrate any significant changes
(Table 4).
Table 4. Immune biomarker levels at baseline and subsequent changes (N = 147).
Subscale Examination
LP (n = 38)
Mean (SD)
LF (n = 38)
Mean (SD)
LP + LF (n = 36)
Mean (SD)




IgE Baseline 611.26 (511.83) 600.23 (739.18) 748.22 (896.40) 493.06 (773.52) 0.547
(kU/I) month 3 482.42 (371.68) 496.40 (622.51) 377.29 (268.51) * 577.81 (705.94) 0.448
IFN-γ Baseline 170.73 (188.44) 150.75 (158.12) 156.97 (167.18) 145.28 (162.26) 0.954
(ng/uL) month 3 158.01 (164.61) 182.75 (373.50) 221.41 (426.21) 166.21 (197.61) 0.886
IL-4 Baseline 36.05 (29.63) 48.4 (85.06) 61.10 (117.67) 55.38 (86.94) 0.773
(ng/uL) month 3 51.16 (85.33) 49.58 (67.82) 55.09 (109.40) 104.13 (215.39) 0.366
TNF-α Baseline 292.95 (425.14) 324.71 (512.82) 231.88 (187.97) 207.51 (340.37) 0.690
(ng/uL) month 3 315.23 (625.85) 777.92 (1731.71) 584.30 (959.98) 550.48 (1059.83) 0.514
LP, Lactobacillus paracasei; LF, Lactobacillus fermentum. * p < 0.05 (Intragroup comparisons).
3.4. Fecal Microbial Composition, Rescue Medication Use and Compliance
All intervention groups showed lower counts of Clostridium than did the placebo group. However,
these intergroup differences were nonsignificant (Table S2). The frequencies of oral steroid (Table S3),
bronchodilator (Table S4), and antihistamine use (Table S5) demonstrated no significant intergroup
differences. The compliance of each group is more than 93% without intergroup differences (Table S6).
4. Discussion
The present study effectively resolves the debate regarding whether pure probiotics are beneficial
to children with asthma. Using a GEE model, we found that LP, LF, and LP + LF interventions along
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with standard asthma therapy effectively reduced asthma severity and increased C-ACT scores.
Furthermore, LP + LF increased both serum IgE levels and PEFRs, implying the existence of a
dose-dependent effect.
Consistent with the present study results, a randomized clinical trial by Chen et al. [10] revealed
the beneficial effects of probiotics on the severity of asthma and clinical symptoms, but they included
participants with asthma accompanied by persistent allergic rhinitis. By contrast, studies have
demonstrated the significant effects of various probiotics on some parameters of asthma, but not
on its clinical severity, in children with asthma [11,12]. In addition to probiotics containing a single
bacterial strain, the clinical advantage of applying a mixture of bacterial strains [13] or using mixed
therapy that includes a probiotic regimen [6] has been demonstrated in asthma patients. The reasons
for inconsistencies in the aforementioned results may be the variabilities in genetic backgrounds,
disease severity, culture, and diet of the participants; moreover, the differences in the study designs,
mixed regimens, and strain doses and combinations may also affect the results because the effects of
probiotics are strain-specific [14].
We selected LP for this trial because it previously demonstrated beneficial effects in airway
hypersensitivity patients [15]. Moreover, it can inhibit related Th2 cytokine production and rebalance
the Th1/Th2 immune response by increasing IFN-γ levels, as noted in murine bronchoalveolar lavage
samples [16]. We also used LF, which can increase IFN-γ levels in patients with AD [17] and ameliorate
oxidative damage, food allergies, and food-derived infections [18,19]. The present study is the first
one in a clinical setting that compared the effects of both single- and mixed-strain probiotics.
Regarding the effects on serum immune biomarker levels, a clinical trial applied single-strain
Lactobacillus gasseri A5 probiotics to school children with asthma and allergic rhinitis and reported a
nonsignificant reduction in total IgE levels [10]. In the current study, the administration of LF + LP
was associated with a significant decrease in IgE levels, while the administration of LP or LF alone
showed a tendency to decrease IgE levels, albeit without reaching statistical significance. Similarly, the
significant decrease was noted in PEFRs in the LP + LF group. These results may be explained by the
synergistic interactions or dose-dependent effects, which were also noted in other probiotic-related
trials [20,21]; however, the mechanisms underlying these effects remain unclear.
Studies reporting intragroup differences in the effects of probiotics on IgE levels in children with
asthma are limited [22]. However, the significance of probiotic-elicited reduction in IgE levels in
children with AD has been reported by several studies [23]. Notably, studies have also revealed that,
in addition to regulating IgE levels, probiotics can regulate cytokine levels in patients with AD. For
instance, in some AD studies [24,25], probiotics significantly reduced serum IL-4 levels, which were
compatible with less Th2 responses. However, such cytokine-related findings in the context of asthma
are required. The few studies mentioning the related measurement lack consistency in results [10,22].
Notably, based on the preceding comparison of different allergic diseases, gastrointestinal
probiotic administration is more efficient at alleviating AD than at alleviating respiratory tract allergic
diseases, namely, asthma and allergic rhinitis. Furthermore, the sensitization pattern for asthma
allergens, as observed in the current study using the skin prick test, was also different from that for AD
allergens. Consistent with previous studies, mites are the predominant aeroallergen of asthma [26–28].
We noted significant postintervention changes in mite sensitization among all groups; however, no
intergroup differences were observed. Due to the difference between AD and respiratory tract allergic
diseases, it might be useful to consider an alternative method for probiotic administration in children
with asthma, such as the intranasal route, which demonstrated effective results in a murine model [29];
however, related human studies are warranted.
Considering the pathogenesis, asthma might be viewed as atopic processes later in life, implying
a more systemic level. A review article summarized current experimental data and gave the
interpretation of the allergy march; epidermal barrier dysfunction in early life was found to
initiate systemic sensitization, which later facilitates the further development of asthma and allergic
rhinitis [30]. Another longitudinal study suggested that children with early atopic AD have higher
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risk of asthma than do those with nonatopic AD [31]. Therefore, the administration of a high probiotic
dose, probiotic strain mixture, or mixed therapy including probiotics appears suitable for children with
asthma compared to other atopic disease; this inference is partly supported by previous trials [6,13].
Regarding fecal intestinal microbiota, the numbers of Lactobacillus, Bifidobacterium, and Clostridium
before and after intervention demonstrated no intergroup differences among all four groups. The LP +
LF group demonstrated a tendency to elevate the fecal colony counts of Lactobacillus and Bifidobacterium
compared to the placebo group, but without reaching statistical significance. It may be explained by the
dose-dependent effect: only the combination group received adequate probiotics against consumption.
In addition to Lactobacillus, we analyzed the numbers of Bifidobacterium and Clostridium because asthma
is associated with a higher amount of Clostridium [32] and a lower level of Bifidobacterium [33] in
previous studies, respectively. We found the numbers of Clostridium in LP group tended to decrease
after intervention, but without reaching statistical significance. This was probably because Lactobacillus
reestablished gut microbiota, as suggested by Durack et al. [34]. The authors asserted that Lactobacillus
supplements may recompose gut microbiota, thus preventing atopy and asthma. Furthermore,
decreases in Clostridium counts may facilitate colonization by other microorganisms, thus increasing
the gut microbial diversity, potentially another protective factor against asthma [35].
This study has some limitations. First, the children with asthma continued receiving standard
therapy along with the probiotics, impeding the potential delineation of the effects of probiotics alone.
However, the interference is ethical and unavoidable. Moreover, no group differences were noted
in oral steroid or bronchodilator use between before and after the intervention. Additionally, these
treatments may mask the therapeutic effects of probiotics, which make the results toward the null
and strengthen our positive finding. Second, the compliance of the children was another concern.
To ensure compliance, we used the capsule counting method rather than the patient record method;
this method was easier and less expensive than detection of the study probiotic strains in the feces.
Finally, some confounders, including selection bias, host factors (e.g., genetic backgrounds and original
microbiota), and environmental factors (e.g., diet and lifestyle) existed. To mitigate this limitation,
randomization was performed.
Nevertheless, our study has several strengths: relatively large sample size, comprehensive
outcome measures (including C-ACT scores, PAQLQ scores, PASSs, and skin prick testing), and
longitudinal repeated measures. We collected different types of data, specifically various serum
biomarker levels and fecal microbial compositions. Moreover, a novelty of our study was that we
combined two probiotic strains (LP + LF) and noted superior effects in lowering IgE and elevating
PEFR than single stain alone. This topic can provide pediatricians, immunologists, and other health
care professionals evidence of Lactobacillus administration for childhood asthma. Furthermore, it can
also inspire public health experts.
5. Conclusions
Our study supports that Lactobacillus is beneficial to children with asthma. We found that
both LP and LF can reduce asthma severity and improve asthma control in school-age children.
The combination of LP plus LF appears to be more effective in childhood asthma than either LP or LF
alone. LP, LF, and their combination were well tolerated with fair compliance and without adverse
effects reported.
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Abstract: Probiotics are living microorganisms that confer a health benefit when administered in
adequate amounts. It has been speculated that probiotics supplementation during pregnancy and in
the neonatal period might reduce some maternal and neonatal adverse outcomes. In this narrative
review, we describe the rationale behind probiotic supplementation and its possible role in preventing
preterm delivery, perinatal infections, functional gastrointestinal diseases, and atopic disorders during
early life.
Keywords: “Probiotics”[Mesh]; “Pregnancy”[Mesh]; “Infant, Newborn”[Mesh]
1. Introduction
Gut microbiota is a heterogeneous microbial community that includes 1014 microorganisms
comprising predominantly bacteria, but also viruses, archaeans, and protozoa, and is considered as a
super-organ that dynamically interacts with the host in a mutual relationship [1,2]. Gut microbiota
plays a significant role in human immunology, nutrition, and pathological processes. Despite
inter-individual variability, in adults, 80% of gut microbiota is composed of three dominant phyla:
Bacteroidetes, Firmicutes, and Actinobacteria [3]. The final composition of the intestinal microbiota
is influenced by multiple factors such as genetic heritage, type of delivery, mode of feeding,
administration of probiotics or antibiotics, stress, and infections [4]. The neonatal microbiota is highly
different compared to the adult one, since the first is characterized by rapid changes [5]. At birth,
the newborn is exposed to a set of bacteria including staphylococci, enterobacteria, and enterococci that
immediately colonize the gastrointestinal tract. In the first days of life, the gut is inhabited mainly by
Bifidobacterium, Lactobacillus, Clostridium, and Bacteroides. From one to five months of life, the population
of the gastrointestinal tract consists of Bifidobacteriales, Lactobacillales, and Clostridiales. At one year of
age, the microbiota is similar to the adult one [6,7]
Traditionally, babies have been considered sterile in utero while microbes colonize their gut
during delivery and after the birth [8]. Several studies suggest that the placenta and amniotic fluid
are involved in this process. In fact, the fetus incorporates an initial microbiome before birth [9,10].
Placental microbiome composition has been recently characterized, and includes non-pathogenic
strains of Bacteroidetes Firmicutes, Fusobacteria, Proteobacteria, and Tenericutes [11]. During pregnancy,
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the ingestion of bacteria present in the amniotic fluid influences the foetal gut microbiome. Further,
maternal microorganisms are present in the meconium and in the cord blood [12,13] in the total absence
of chorioamnionitis.
The microbiota colonizes the host before birth and matures definitively during the twelve months
following delivery [14]. During this moment, the fetus comes into contact with maternal vaginal
bacteria that immediately reach the newborn gastrointestinal tract. The gut of infants born vaginally
are colonized prevalently with Bifidobacterium and Streptococcus. In contrast, caesarean delivery is
associated with a decrease of Bifidobacteria, while Clostridium and Bacteroides prevail [15–17]. There
is some evidence that Bifidobacteria influence the development of very common allergic disorders
such as atopic eczema and asthma [18,19]. Additionally, cesarean sections, especially as elective
procedures, seem to represent a risk factor for autoimmunity and metabolic disorders [20,21]. Moreover,
bifidobacteria are the most represented bacteria in the gastrointestinal tract of healthy infants. Beside
the type of delivery, other factors affect microbial colonization in newborns. The abuse of antibiotics
during pregnancy or after birth seems to reduce the number of bifidobacteria [22]. Schumann at al. have
recently demonstrated a severe decrease of intestinal aerobic and anaerobic bacteria in rats treated
with daily intragastric gavage of amoxicillin [23]. The gestational age at the birth is one of main
factors that delineates the profile of gut microbiota. In fact, preterm newborns, in comparison to term
births, have higher rates of anaerobic bacterial colonization, in particular Enterobacteriaceae [24] and
Enterococcaceae [25,26]. During a premature delivery, it is not guaranteed that close contact with the
vaginal mucosa and a smaller amount of bacteria are ingested. Additionally, in neonatal intensive
care units, the wide use of antibiotics contributes to reduced growth indexes of gut bacteria, creating a
restricted microbial population [27]. Abnormal vaginal microbiota or active bacterial infection during
pregnancy alter the acquisition of neonatal flora promoting preterm delivery [28]. The presence of
pathogenic bacteria in the amniotic fluid activates the innate immune response, and the production of
prostaglandins increases uterine contractility, promoting premature birth [29].
Moreover, breastfeeding is another important determining factor in establishing the gut
microbiome, and is a source of short- and long-term health benefits for the child. In the short term, it
has been observed that it decreases the risk of infections, diarrhoea, type-1 diabetes, and necrotizing
enterocolitis; while the long term benefits of breastfeeding include protection from the development
of diseases like type-2 diabetes, inflammatory bowel disease, and obesity [30]. Breast milk contains
fats, proteins, cytokines, enzymes, antibodies, and nutrients that influence the growth of the child
and the development of his/her immune system [31]. Other components are antimicrobial agents
like lactoferrin, lysozyme, peroxidase, defensins, IgAs, and oligosaccharides. The rich composition of
human milk provides passive immunoprotection against infections and inflammation [32].
Among these components, lactoferrin is an important protein in breast milk, mostly in colostrum,
and is involved in the regulation of the immune system and inflammatory response. A recent study
suggests that during breastfeeding, lactoferrin is transferred to the intestine of the newborn. The fecal
concentration of this protein progressively increases in the first month after birth, promoting the growth
and differentiation of the immature intestine. Therefore, lactoferrin seems to promote the proliferation
of enterocytes and closure of enteric gap junctions regulating the postnatal intestinal development [33].
Finally, lactoferrin is considered as a growth promoter for bifidobacteria, the predominant beneficial
microorganism of human gut [34].
Furthermore, there is accumulating evidence that human milk is not sterile, but contains
maternally-delivered bacteria, i.e., mainly lactobacilli and bifidobacteria. The number of bacteria
ingested by an infant per 800 mL of milk consumed daily is estimated at 1 × 105–1 × 107 [35].
Microorganisms present in the breast milk are transferred from the mother’s intestine to the
mammary gland through the lymphatic system by dendritic cells by openings in the tight junctions of
the intestinal epithelium [36]. The bacteria contained in the breast milk affect the composition of the gut
microbiota in infants, and they could protect against infectious diseases and promote the maturation of
the immune system. [37,38]. Additionally, other factors in breast milk including oligosaccharides, s-IgA,
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and lactoferrin influence the proliferation of healthy microbiota [7,39]. Intestinal bacteria stimulate
endogenous production of s-IgA [40], activation of T regulatory cells [41,42] and anti-inflammation
response [43,44]. Therefore, appropriate gut colonization through breastfeeding is involved in the
correct development of immune system and in prevention of diseases.
Gastrointestinal flora composition differs mostly in breast- and formula-fed infants. Several
studies conducted on stool samples of newborns have shown that bifidobacteria are present in the flora
of both groups, but their number is higher in breastfed infants in comparison to formula-fed infants;
instead, the number of E. coli and Bacteroides is higher in formula-fed infants [6]. These differences
remain, even after breastfeeding is discontinued [7].
Current evidence supports a link between the activity and composition of the gut microbiota
and human health and disease. The correct development of gut microbiota composition affects many
organs, including neural, immune, and gastrointestinal systems. The gut microbiota composition
is altered in many diseases, like disorders of the gut-brain axis [45], immune and gastrointestinal
disorders [46,47], and allergic diseases [48]. The potential modulation of the gut microbiota through
the administration of probiotics is very prominent in the prevention of human diseases starting
from pregnancy.
2. Methods
An exhaustive search for eligible studies was performed in PubMed, Embase, Medline, Cochrane
library and Web of Science database.
The following subject MeSH headings were used: “Probiotics”[Mesh], “Pregnancy”[Mesh],
“Lactation”[Mesh], “Breast Feeding”[Mesh], “Premature Birth”[Mesh], “Infection”[Mesh],
“Gastrointestinal Diseases”[Mesh]. Furthermore, free text for “allergy”, “atopy”, “gut-brain
axis”, and proper Boolean operators “AND” “OR” were also included to be as comprehensive as
possible. Additional studies were sought using references in articles retrieved from searches.
Search limits were set for RCT, involving only human subjects, and published between October
2008 and October 2018. The review was limited to studies written in English.
3. Role of Probiotics Administration in the Prevention of Infection and Preterm Delivery during
Pregnancy
Vaginal microbiota alterations and infections during pregnancy lead to a greater possibility of
preterm delivery; this is related to the development of neonatal infections, sepsis, and necrotising
entercocolitis. The use of probiotics seems to modulate the composition of vaginal microflora.
Vitali et al. have conducted a pilot, non-randomized, controlled, and perspective study that
demonstrated the influence on the vaginal microbiota of pregnant women of dietary supplementation
with a probiotic mixture containing L. paracasei DSM 24733, L. plantarum DSM 24730, L. acidophilus
DSM 24735, and L. delbrueckii subsp. bulgaricus DSM 24734), three strains of bifidobacteria (B. longum
DSM 24736, B. breve DSM 24732, and B. infantis DSM 24737), and one strain of Streptococcus thermophilus
DSM 24731, produced at Danisco-Dupont, WI, USA and currently sold in Continental Europe and
USA under the brand Vivomixx® and Visbiome®, respectively. The characterization of vaginal bacteria
in women supplemented with this multistrain probiotic showed an increase of bifidobacteria and a
reduction of Atopobium vaginae, resulting in the prevention of bacterial vaginosis. Furthermore, IL-4
and IL-10 levels are influenced by alteration in the vaginal microbial environment. The decline of
cytokines involved in the antiphlogistic process were noticed in a control women group that did
not consume the probiotic mixture [49]. In contrast, Gille et al. in a recent trial demonstrated that
the supplementation with Lactobacillus rhamnosus GR-1 and L reuteri RC-14 for two months during
pregnancy does not improve the normal composition of vaginal microbiota compared to the placebo
group [50].
Group B Streptococcal (GBS) vaginal colonization is considered a principal cause of neonatal
sepsis, pneumonia, and meningitis [51]. The Centres for Disease Control and Prevention (CDC) suggest
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parenteral antibiotic administration during delivery as preventive therapy for women diagnosed with
GBS at 35 and 37 weeks of gestation [52]. The possible impact of probiotic administration on prevention
of infections during pregnancy has been investigated.
Recently, Olsen at al. performed a randomized pilot study to determine a potential causal
relationship between probiotic administration during pregnancy and vaginal Group B Streptococcal
(GBS) colonization. There was no significant difference in the incidence of GBS vaginal infections
between the women supplemented with probiotics and the control group. However, a greater
proportion of commensal bacteria was found in pregnant women who had used probiotics [53]. Besides
Ho M. et al. conducted a randomized controlled trial to examine the effect of the oral administration
of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 in pregnant women with a vaginal
and rectal GBS colonization. Compared to the placebo group, women treated with probiotics had
significantly-reduced rectal and vaginal GBS colonization rates [54].
Bacterial vaginosis increases the risk of spontaneous preterm delivery and neonatal
complications [55]. Few studies have tested the efficacy of probiotics in the prevention of preterm
births. A prospective cohort study recently showed that the administration of a milk supplemented
with probiotics during pregnancy reduced preeclampsia and preterm delivery risk [56]. Furthermore,
a randomised controlled trial tested the early administration effect of Lactobacillus rhamnosus GR-1 and
Lactobacillus reuteri RC-14 in women during gestation affected by low/intermadiate grade of vaginosis,
to have a reduce premature delivery risk [57].
In a randomized clinical trial, the use of a yoghurt that contained Lactobacillus bulgaris, Streptococcus
thermophilus, Probiotic lactobacillus, and Bifidobacterium lactis has been investigated in pregnant women in
the treatment of bacterial vaginosis versus the use of clindamycin. Compared to the use of clindamycin,
the administration of probiotics has a significant effect only on the reduction of vaginal pH, which
seems to be associated with a lower risk of preterm delivery [58]. Therefore, there is no determinant
evidence from clinical trials that confirms role of probiotics in the prevention of preterm delivery
(Table 1). A recent metanalysis including 21 studies confirms that there is no evidence that the
administration of probiotics in pregnant women reduces the risk of preterm delivery [59].
The potential role of probiotics in the prevention of infections during pregnancy and in preterm
infants remains unclear, and requires further research.
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4. Role of Probiotics Administration in the Prevention of Allergic Diseases
At birth, the lymphoid system of the newborn is not yet mature and Th1 response is inhibited.
Therefore, it is necessary that the immune system clear the gap between Th1 and Th2 response.
Microbiota has a crucial role during this critical phase [60]. There is a relationship between gut
microbiome patterns and the potential role of modulation of innate immune signaling in the prevention
of allergic diseases. West et al. have shown that after the birth, the maturation of the intestinal
microbiota influences the innate immune response and the development of atopic eczema. This
study suggests that alteration of gut microbial population increases the risk of the development of
atopic-eczema due to a lack of modulation on inflammatory cytokines mediated by the microbiome [61].
Moreover, antibiotics, caesarean section, and infant formula are factors that modify microbiome
composition and are related to the development of allergic diseases [62].
Probiotic supplementation to mothers during breastfeeding positively influences the microbial
composition of breast milk and positively modulates the neonatal immune system mainly through the
regulation of both Th1- and Th2-type response and by the stimulation of tolerance [63]. It has been
observed that administration to mothers of a probiotic mixture containing L. paracasei DSM 24733,
L. plantarum DSM 24730, L. acidophilus DSM 24735, and L. delbrueckii subsp. bulgaricus DSM 24734),
three strains of bifidobacteria (B. longum DSM 24736, B. breve DSM 24732, and B. infantis DSM 24737),
and one strain of Streptococcus thermophilus DSM 24731 (Danisco-Dupont, WI, USA and currently sold
in Continental Europe and USA under the brand Vivomixx® and Visbiome®, respectively) resulted
in an increase of lactobacilli and bifidobacteria in both colostrum and mature milk [7]. This probiotic
mixture seems to play a key role in the regulation of the immune response which is influenced by
the type of delivery; by comparing women with vaginal delivery under probiotics or placebo, an
increase in bifidobacteria and lactobacilli was observed in the colostra and mature milk in the first
group; no difference, however, was observed between the two groups of women who underwent
caesarean section [63]. Maternal probiotic supplementation before and after delivery seems to prevent
atopic eczema in children (Table 2), but further studies are requested to confirm this relation with other
allergic disorders.
In a randomized, double-blind trial, women were given probiotic milk or placebo from the 36th
week of gestational age to 3rd month after delivery during breastfeeding. At 2 years of age, all infants
were tested for atopic dermatitis, asthma, and other allergic diseases. The study demonstrates that
administration of probiotics to mothers during pregnancy decreases the incidence of atopic dermatitis,
but has no effect on asthma [64]. Enomoto et al., in an open trial, confirmed that the administration of
a combination of Bifidobacteria from 1 month before delivery to mothers and 6 months after birth to
babies significantly reduced the incidence of cutaneous allergic diseases (eczema/atopic dermatitis).
Moreover, women in the study group exhibit lower fecal Proteobacteria concentrations; this is related
to higher children fecal concentration of Bacterioidetes at 4 months of age [65].
In contast, a recent randomized placebo-controlled trial demonstrated that the administration
of Lactobacillus rhamnosus HN001 to pregnant woman before and after delivery during breastfeeding
seems not to prevent the development of infant eczema, wheeze, and atopic sensitization during the
first year of life [66]. In addition, another clinical trial shows that the supplementation of Lactobacillus
GG in women from the 6th month of pregnancy and after birth (to mothers during breastfeeding or to
infants for 6 months) does not reduce the incidence of developing allergic diseases in children followed
up to 36 months of age [67].
Rautava et al. found that maternal supplementation of a mixture of probiotics 2 months before
delivery and 2 months after lactation reduces the risk of developing eczema in infants in the first 2
years of life [68]. Furthermore, Kim et al. prove that the maternal supplementation of Bifidobacterium
bifidum, B. lactis, and Lactobacillus acidophilus 4–8 weeks before delivery and until 6 months after the
birth reduces the prevalence of eczema in the first year of life in children [69].
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In a pAnda study, a mixture of probiotics (Bifidobacterium bifidum, Bifidobacterium lactis, and
Lactococcus lactis) administrated to mothers before delivery and to infants for the first year of life
reduced the incidence of eczema during the first 3 months of life compared to placebo group [70].
Simpson et al. have confirmed the long-term protective effect on the baby of probiotic maternal
administration: children assessed at 6 years of age have a lower incidence of the development of atopic
dermatitis, while this has not been confirmed for other allergic diseases [71]. Therefore, several studies
have confirmed the role of probiotics in the early prevention of eczema in children, and these benefits
were shown to persist over time. A recent randomized, controlled study (Probiotics in the Prevention
of Allergy among Children in Trondheim, ProPACT) in part explains how perinatal maternal probiotics
supplementation can play a protective role in the development of atopic dermatitis. In this study
T-regs, Th-1, Th-2, and Th-17 lymphocyte or the Th-1/Th-2 ratio seem not to be influenced by a mixture
of LGG, La-5, and Bb-12, but this reduces the proportion of Th-22 number [72].
The World Allergy Organization (WAO) convened a guideline panel to develop evidence-based
recommendations about the use of probiotics in the prevention of allergies. The WAO guideline panel
suggests:
• that by using probiotics in pregnant women at high risk for allergy in their children, there is a
net benefit resulting primarily from prevention of eczema (conditional recommendation, very
low-quality evidence).
• that by using probiotics in women who breastfeed infants at high risk of developing allergy, there
is a net benefit resulting primarily from prevention of eczema (conditional recommendation, very
low-quality evidence).
• using probiotics in infants at high risk of developing allergies, because there is a net benefit
resulting primarily from prevention of eczema (conditional recommendation, very low-quality
evidence).
Currently-available evidence does not indicate that probiotic supplementation reduces the risk of
developing allergies in children, but there is a net benefit primarily in the prevention of eczema [73].
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5. Brain-Gut Microbiota Axis
The microbiota plays an important role in the interaction between the brain and the enteric nervous
system, known as the “brain-gut microbiota axis”. Thanks to this axis, information from the Central
nervous system can influence the motor, secretory, and sensitive functions of the gastrointestinal tract;
conversely, visceral signals from the gut can modulate brain activity, mood, and behavior [7]. The
gut-brain dialogue involves neuro-immuno-endocrine mediators [74].
It is believed that alterations in the microbiota gut-brain axis are associated with the onset
of irritable bowel syndrome (IBS) or functional gastrointestinal (GI) disorders [75], and might be
implicated in autism spectrum disorders (ASDs) [76–78], anxiety-depressive behaviors [76,79–81], and
chronic pain [82]. However, the sites, the pathways and molecular mechanisms responsible for these
alterations must be better defined.
Different models have been used to define the gut brain axis (GBA), including gut microbial
perturbation by antibiotics and probiotics, fecal microbial transplantation, and mice who lived without
any exposure to microorganisms (germ-free, GF) [83]. GF animals were born by Caesarean section and
lived in aseptic conditions.
There is supporting evidence that metabolites derived from maternal gut microbiome modulate
the neurotransmitter, synaptic, and neurotrophic signaling systems, thus influencing fetal brain
development [84]. Petterson et al. underline that “healthy” intestinal microbiota is crucial for the
programming of mammalian neurodevelopment and later adult behavior. This study suggests that
early microbial colonization influences the expression of synaptic-related proteins (e.g., synaptophysin,
which is an indicator of synaptogenesis), signaling pathways, and neurotransmitter turnover, that could
modulate the synaptic transmission influencing motor control and emotional behavior in adults [85].
It has also been reported that maternal separation (MS) in rodents induced dysbiosis and
brain and behavioral changes [86]. MS triggers depression and anxiety-like behavior [87,88],
hyper-responsiveness of the HPA axis [89], increased intestinal permeability [90–92], and visceral
hypersensitivity [93].
Maternal stress and MS might be implicated with modifications of gut brain axis [94,95] and
probiotics seem to improve those gut and brain changes caused by perinatal stressors [96–98]. In
different studies, it was observed that postnatal microbial colonization regulates an adequate HPA
response to stress [99] and the hippocampal serotoninergic system [100]. It was also described
a decrease in depression and anxiety-like behavior after the administration of oral probiotics in
mice [96,101,102] and humans [103,104] with normal gut microbiota.
Furthermore, the short-chain fatty acids (SCFA s) generated by the colonic microbiota represent a
significant source of energy for the gastrointestinal cells. In this regard, colonocytes from germ-free
C57BL/6 rodents showed lower energy statuses than normally-raised mice [105].
Additionally, the loss of intestinal-generated SCFAs induces metabolic changes that may affect
neurodevelopment and alter mechanisms associated with feeding behavior and metabolism [83].
Indeed, recent studies compare ingestive behavior between mice with gut microbial composition
and GF, suggesting that gut microbioma modulate feeding behavior. GF mice showed lower blood
levels of leptin and ghrelin, and a higher inclination for lipids, justified by the increased expression of
oral receptors for fats and a decreased one for gut fatty-acid receptors [106].
Furthermore, it was observed that bifidobacterium B. longum 1714 improves cognition in mice [107].
Additionally, the administration of a probiotic mixture containing L. paracasei DSM 24733, L. plantarum
DSM 24730, L. acidophilus DSM 24735, and L. delbrueckii subsp. bulgaricus DSM 24734), three strains of
bifidobacteria (B. longum DSM 24736, B. breve DSM 24732, and B. infantis DSM 24737), and one strain
of Streptococcus thermophilus DSM 24731 (Danisco-Dupont, WI, USA, currently sold in Continental
Europe and USA under the brand Vivomixx® and Visbiome®, respectively) to aged animals induced
a reduction of the age-related attenuation of LTP through modifications of the gut microbiota [108].
These results are interesting but translational studies in humans are necessary.
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6. Probiotics and Functional Gastrointestinal Disorders
Probiotics have an important role in the maturation and health of the intestinal tract. The
composition of gut microbiota is involved in the development of gastrointestinal functions, particularly
in the gut-brain axis, and participates in emitting and receiving signals to and from the brain [109].
This connection occurs with different mechanisms: through the release of cytokines and chemokine
(immune pathway), through neural pathways, and through the production of intestinal neuroendocrine
factors (endocrine pathway) [6]. Therefore, through changes of the microbiota, bidirectional
relationships between the gut and brain are modified, thus influencing the pathogenesis of functional
gastrointestinal disorders. The most common diseases in early life are infantile colic, a benign and
functional gastrointestinal disorder that affects around 20% of young infants. Colic is associated with
parental frustration and anxiety, and resolves spontaneously after the first three to four months of life.
Although infantile colic is a self-resolving condition, it implies long-term effects on a child’s behavior,
sleep, and allergies [110].
According to the Rome IV criteria for functional gastrointestinal disorders, infantile colic is
diagnosed in infants younger than 4 months of age if the following symptoms occur: paroxysms of
irritability, fussing or crying that starts and stops without obvious cause; episodes lasting 3 or more
hours per day and occurring at least 3 days per week for at least 1 week; and no failure to thrive [111].
Infantile colic presents a multifactorial aetiology, but the cause remains unclear. However, some
causative mechanisms have been suggested like behavioral, food allergies and hypersensitivities,
immaturity of gut function, and dysmotility [112].
An extensive number of possible factors have been hypothesized, like increased painful intestinal
contractions, lactose intolerance, food hypersensitivity, gas, parental misinterpretation of the normal
crying pattern, and altered gut microbiota (dysbiosis). In the management of infantile colic, many
therapies are used, such as dietary, pharmacological, and behavioral interventions. However, data on
their effectiveness are limited. Dysbiosis may play an important role in the pathogenesis of infantile
colic, and gut microbiota modification with probiotics can have advantages on the management of
infantile colic [113].
Partty et al. have conducted a randomized, double-blind, prospective study based on the
administration of L. rhamnosus GG (ATCC 53103) or placebo to mothers daily for 4 weeks before
expected delivery, and subsequently to the child or the mother, if breast-feeding, for 6 months, to
evaluate the influence on the appearance of functional gastrointestinal disorders.
They hypothesized that colic crying, typical of the perinatal period, was associated with functional
gastrointestinal disorders later in childhood.
Their 13-year follow-up study showed that administration of L. rhamnosus GG (ATCC 53103) does
not affect the appearance of functional gastrointestinal disorders later in childhood, but suggests that
different probiotics or probiotic combinations may be needed [114]. (Table 3).
It has been shown that probiotic administration to women during pregnancy and
lactation can change the composition of breast milk, and consequently, its immunomodulatory
molecular composition, bestowing benefits on the child in the form of reduced instances of
gastrointestinal disorders.
A study conducted in 2013 showed an increase in breast milk of anti-inflammatory molecules
such as TGF-B and IL-10 in supplemented mothers compared to the control group. Indeed, maternal
probiotic supplementation leads to an increase of the TGF-B, which stimulates gut maturity, influencing
IgA production and oral tolerance induction, and that seems to improve gastrointestinal functional
symptoms in infants [115].
In a recent study, Baldassarre et al. have demonstrated that the use of a probiotic mixture
(L. paracasei DSM 24733, L. plantarum DSM 24730, L. acidophilus DSM 24735, and L. delbrueckii subsp.
bulgaricus DSM 24734), three strains of bifidobacteria (B. longum DSM 24736, B. breve DSM 24732,
and B. infantis DSM 24737), and one strain of Streptococcus thermophilus DSM 24731, Vivomixx®,
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Danisco-Dupont, WI, USA) appears safe and reduces inconsolable crying in exclusively breastfed
infants with infantile colic [116].
Many studies have also been conducted on the prophylactic use of probiotics in the first months
of life to treat breastfed infants with colic. In particular, benefits of the use of Lactobacillus reuteri on
functional gastrointestinal disorders have been studied.
Gutiérrez-Castrellón et al. [117] have demonstrated the superiority of the use of L. reuteri DSM
17938 with a dose of 108 CFU/day for 21 to 28 days to significantly reduce the duration of crying
episodes during the day.
Recently, Indrio et al. [118] have suggested that oral supplementation of L. reuteri, for the
first three months of life, not only reduces the probability of colic episodes and other functional
gastrointestinal disorders, like gastroesophageal reflux and constipation, but also the number of visits
and hospitalizations.
In conclusion, L. reuteri DSM17938 is effective, and may be recommended for breastfed infants
with colic, while its role in formula-fed infants requires further study [119].
7. Safety of Probiotics in Pregnancy and Neonatal Period
The early supplementation of probiotics in the perinatal and postnatal periods seems to have
a positive impact on future health of infants. In this article we have shown the beneficial effects
of probiotics in preventing infections before and after delivery and atopy in children. However, to
define the possible role of the early administration of probiotics on the development of the nervous
system of newborns, future studies and randomized trials are required. The use of probiotics is usually
considered safe, even in first months of life. Despite the large use of probiotics during pregnancy and
perinatal period, there are few studies that tested their safety during this period. Development of
infections or other adverse effects in adult patients after the use of probiotics are rarely reported and
often involve immunocompromised patients [120,121]. Allen et al., in a randomized, double-blinded,
placebo-controlled trial, have tested the possible adverse effects of the administration of a probiotics
mixture to pregnant women and to their infants after the birth. In this study, none of the adverse
effects was attributed to the supplementation of probiotics [122]. Moreover, Baldassarre et al., in a
prospective, double-blinded, randomized, controlled trial, confirmed that the early administration of
probiotics during pregnancy has no side effects in mothers or in infants [115]. In addition, Luoto et al.
in a clinical trial, involving 256 pregnant women and their offspring, showed no side effects in mothers
and children after the administration of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12
probiotics mixture [123]. In contrast, Kuitunen et al. have suggested that the early supplementation of
probiotics negatively influences hematologic values in infants. In this trial, children supplemented
with probiotics before and after the birth have significantly lower haemoglobin levels compared to the
placebo group at 6th month of life. This effect is transient, and may be due to a potential inflammation
of the intestinal mucosa probably caused by probiotics [124] (Table 4). Future studies are needed to
confirm the total safety of the use of probiotics during pregnancy and in the early stages of life.
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8. Conclusions
In the last 20 years, it has been shown that the constitution of the human microbiome is
conditioned by multiple elements such as genetic heritage, prematurity, cesarean section, kind of
infant nutrition, administration of probiotics or antibiotics, perinatal stressors, and infections. Further
studies demonstrated that a normal intestinal microbiota takes part in the induction of the immune
tolerance [125,126]. Alterations of the microbiota are associated with the development of many
pathological states like infantile colic, inflammatory bowel disease, necrotizing enterocolitis, asthma,
atopic diseases, celiac disease, diabetes, mood disorders, and autism spectrum disorders. Additional
studies are needed to attest that probiotics could have a protective function against the onset and
the progression of these diseases. Nowadays there is no standard recommendation for performing
targeted supplementation in individual patients.
Studies suggest that the microbiota may influence immunologic and inflammatory systemic
responses, and thus, modulate the onset of sensitization and allergy.
In 2015, the WAO guidelines on the prevention of allergies recommends using probiotics in: (a)
pregnant women at high risk for having an allergic child; (b) women who breastfeed infants at high
risk of developing allergies; and (c) infants at high risk of developing allergies [73].
These are the only recommendations by the Scientific Community for using probiotics as a
preventive intervention for diseases during pregnancy and perinatal period, despite the many studies
demonstrating clinical benefits from the administration of probiotics in pregnancy and the perinatal
period. So, it is important to obtain more data about the exact composition of microbiomes and
the alterations which occur in specific diseases. It is also important to underline that the security
and effectiveness of findings attributable to one single probiotic product cannot be applied to
other probiotic formulations, especially if the product is administered to patients such as pregnant
women and newborns; this is a serious task, and therapeutic discomfort that multi-strain probiotic
formulations lack generic names, because they are food supplements. Many clinicians and patients are
unaware that deficiencies in the regulation of probiotics mean that the formulations sold under these
medically-recognized brand names may no longer be the same as the original products on which the
clinical efficacy and safety evidence is based. FAO/WHO guidelines for probiotics state that proper
nomenclature and strain designation are required on a probiotic product. Without proper identification
of the strains and/or of the clarification of the origin of the product such as manufacturing site, the
clinical evidence is erroneously transferred from one product to another. This is the reason why
limiting the information to probiotic genera/species is not the best choice [127], and more stringent
quality control of probiotics is required [128].
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Abstract: The human intestinal microbiota, establishing a symbiotic relationship with the host, plays a
significant role for human health. It is also well known that a disease status is frequently characterized
by a dysbiotic condition of the gut microbiota. A probiotic treatment can represent an alternative
therapy for enteric disorders and human pathologies not apparently linked to the gastrointestinal
tract. Among bifidobacteria, strains of the species Bifidobacterium breve are widely used in paediatrics.
B. breve is the dominant species in the gut of breast-fed infants and it has also been isolated from
human milk. It has antimicrobial activity against human pathogens, it does not possess transmissible
antibiotic resistance traits, it is not cytotoxic and it has immuno-stimulating abilities. This review
describes the applications of B. breve strains mainly for the prevention/treatment of paediatric
pathologies. The target pathologies range from widespread gut diseases, including diarrhoea and
infant colics, to celiac disease, obesity, allergic and neurological disorders. Moreover, B. breve strains
are used for the prevention of side infections in preterm newborns and during antibiotic treatments
or chemotherapy. With this documentation, we hope to increase knowledge on this species to boost
the interest in the emerging discipline known as “therapeutic microbiology”.
Keywords: Bifidobacterium breve; probiotics; paediatrics; therapeutic microbiology
1. Introduction
The use of microorganisms to treat or prevent targeted diseases was conceived at the end of the
last millennium. This concept has rapidly evolved giving rise to a new branch of applied microbiology
known as “therapeutic microbiology” [1]. Since human organisms and gut microbiota establish an
intimate symbiotic relationship that is fundamental for the maintenance of the host’s health, the
administration of beneficial microorganisms may represent a key determinant of the general health
status and diseases susceptibility. The choice for the most suitable species for a certain pathology
requires extensive studies, both in vitro and in vivo. Moreover, it is known that strains belonging
to the same species may express different functions in vivo [2]. It has also been demonstrated that
blending different microbial strains, species or even genera, may lead to a final effect that is not
predicted by results from using each single microorganism. Several Bifidobacterium species are largely
used as probiotics for their capability of reaching and colonizing the gastrointestinal tract and their
documented history of safety. Among them, Bifidobacterium breve, originally isolated from infant faeces,
represents one of the most used probiotics in infants. The multiple studies in which B. breve strains have
been successfully used in diseased humans, especially children and newborns, witness the potentiality
of strains belonging to this species for the prevention or treatment of human diseases. The aim of this
Nutrients 2018, 10, 1723; doi:10.3390/nu10111723 www.mdpi.com/journal/nutrients162
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review is to show the various applications of B. breve for preventing and treating paediatric diseases
starting from in vitro and mice model assessment of efficacy to the clinical use. To the best of our
knowledge, this work represents the first collection of works focused on the application in paediatrics
of strains belonging to the B. breve species and is aimed to shed light on the role of this Bifidobacterium
species in the scenario of “therapeutic microbiology.” Moreover, this paper explores the effectiveness
of B. breve used both as a single strain and combined with other microorganisms with a final short
outcome of its application in adulthood.
2. The Human Intestinal Microbiota
The human intestinal microbiota is a complex ecosystem that includes not only bacteria but
also fungi, Archaea, viruses and protozoans; bacteria concentration increases from the stomach and
duodenum throughout the intestinal tract and in the large intestine it rises to 1011–1012 CFU/g of lumen
content [3]. It has been estimated that at least 1800 genera and a range of 15,000–36,000 bacterial species,
depending on whether species are conservatively (97% OTUs) or liberally (99% OTUs) classified, can
be found in the large intestine [4].
The symbiotic mutualistic relationship that the gut microbiota establishes with the host exerts
several beneficial roles, the main of which are the maintenance of the gut epithelial barrier, the inhibition
of pathogen adhesion to intestinal surfaces, the modulation and proper maturation of the immune
system, the degradation of otherwise non-digestible carbon sources such as plant polysaccharides
and the production of different metabolites including vitamins and short chain fatty acids (SCFAs) [5].
Furthermore, intestinal microorganisms seem to be responsible for a bidirectional interaction between
the gut and the Central Nervous System (CNS) via the gut-brain axis [6]. Dysfunction in this
interaction may be implicated in the development and prognosis of some neurological diseases,
including autism [7], multiple sclerosis [8] or Parkinson disease [9]. Because of this symbiotic
relationship, the human organism can be seen as a “superorganism,” which consist of not only
the microbial cells but also their genomes, that is, the microbiome and the related microproteome
and micrometabolome [10]. The microbiome represents more than 100 times the human genome
(1,000,000 genes vs. 23,000 genes) [10]. Indeed, the gut microbiome is influenced by external factors,
such as diet, health status and xeno-metabolome. These factors shape the individual intestinal
microbiota that can be considered as a “fingerprint” of the hosting organism.
Recently, the realization of global-collaborative projects has enriched the knowledge about the gut
microbiota, such as the MetaHit project [11], the Human Microbiome project [12] and the MyNewGut
project [13]. Moreover, the large amount of data from high throughput gene sequencing technology
has allowed us to gain deeper insights in the composition of the “typical” human gut microbiota. The
two principal bacterial phyla are Firmicutes and Bacteroidetes, followed by Actinobacteria, Proteobacteria
and Verrucomicrobia. Fungi and Archaea constitute approximately 1% of the species of the intestinal
microbiota [14,15]. The predominant fungal phyla are Ascomycota and Basydiomicota; some of the most
abundant genera, that is, Saccharomyces, Debaryomyces and Kluyveromyces, are found in food, confirming
the influence of diet habits also on the fungal intestinal population [16]. From the 80s some archaeal
species belonging to Methanobrevibacter genus have been identified. Methanobrevibacter is the only
genus detected in the gut probably due to the use of 16S primers not having sufficient resolution for
Archaea. Within this genus, the species’ composition depends on diet and host’s health status, as for
the entire microbiota [17,18].
Microbiologists’ attention has been also focused on bacteriophages, which, living at bacteria
expense and being vehicles of genetic transfer, could have an important role in shaping the biodiversity
of the gut ecosystem. The first metagenomic analysis of an uncultured viral community from human
faeces using partial shotgun sequencing suggested a large diversity of phages in gut microbiota [19].
The same authors investigated the viral community in the infant intestine using metagenomic
sequencing: 72% of the detected viral community resulted to be siphoviruses and prophages and over
25% resulted to be phages that infect lactic acid bacteria; faecal viral sequences were not identified
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in breast milk, suggesting a non-dietary initial source of viruses [20]. The entire viral community
composition changed dramatically between the first and the second week of age [20], remaining then
stable during host’s life [21].
Gut colonization begins at birth, although recent evidences suggest the existence of an intrauterine
transmission of maternal bacteria to the foetus [22]. The first colonizer are facultative anaerobes
(Staphylococcus spp., Enterobacteriaceae and Streptococcus spp.), followed by strict anaerobes, such as
members of Bifidobacterium, Bacteroides and Clostridium genera [23,24]. The mode of delivery exerts a
strong influence on the first microbial colonization of newborns’ gut. Children born by natural delivery
have an intestinal microbiota profile similar to their mother’s vaginal one, characterized by Lactobacillus
and Prevotella spp., while children born by caesarean section develop a microbiota similar to that of
mother’s skin (Streptococcus, Corynebacterium and Propionibacterium spp.) [25]. In addition, the type of
feeding has a crucial role on the colonization of microbial groups in the gut. Indeed, the gut microbiota
of formula-fed infants contains a higher amount of Escherichia, Veillonella, Enterococcus and Enterobacter
members and the concentration of Lactobacillus and Bifidobacterium is lower with respect to in breast-fed
infants [26]. The abundance of these genera can be due to a more acidic pH in the colon of breast-fed
infants [27]. The prevalence of bifidobacteria in breast-fed infants is also due to their capability of
fermenting oligosaccharides (referred to as human milk oligosaccharides, HMO) [28]. Diet continues
to exert a crucial influence in the gut microbiota composition also in adulthood: De Filippis et al. [29]
showed an association between plant-based diet and a prevalence of Lachnospira and Prevotella and
a positive correlation between Ruminococcus and omnivore diet. Animal-based diets increase the
abundance of bile-tolerant microorganism (Alistipes, Bilophila and Bacteroides) and decreases the levels
of Firmicutes [30].
The use of antibiotics influences the gut microbiota composition, determining a significant
decrease of the microbial diversity in the digestive tract [31,32]. However, the microbiota is a resilient
system and tends to return to the pre-treatment state within 1 to 2 months after the end of the
administration [33]. Moreover, the use of perinatal antibiotics, such as in the intrapartum prophylaxis,
influences the establishment of a normal gut microbial composition and function, in particular reducing
the levels of bifidobacteria and increasing potential pathogens [34–36].
It is well established that a functional and balanced microbiota reflects a healthy condition of the
host; on the other hand, an unhealthy status may be associated with a compromised gut microbiota
displaying a decrease of beneficial bacteria and increase of harmful ones.
3. Probiotics with a Special Emphasis on Bifidobacterium breve
“Probiotic” means “for life” and it is currently used to name bacteria associated with beneficial
effects for humans and animals. In 2001 the Food and Agriculture Organization of the United
Nations (FAO)/World Health Organization (WHO) defined them as “live microorganism which,
when administered in adequate amounts confer a health benefit on the host” [37]. This definition has
been revised in 2014 by the International Scientific Association for Probiotics and Prebiotics, including
in the term probiotic “microorganism for which there are scientific evidence of safety and efficacy” and
excluding “live cultures associated with fermented foods for which there is no evidence of a health
benefit” [38].
Probiotics that have been largely studied in humans include species of the Lactobacillus and
Bifidobacterium genera. Probiotic administration in the first stage of life results to be more effective
in prevention and treatment of disorders, leading to a correct microbial colonization when the gut
microbiota is still in a period of establishment. Several studies have shown the beneficial effects of
Lactobacillus reuteri, one of the most used probiotics in infants, for the prevention and treatment of
infant gastrointestinal disorders, including colics, regurgitation, vomit, constipation [39–41]. This
species has been demonstrated to improve symptoms and reduce the number of anaerobic Gram
negative bacteria, Enterobacteriaceae and enterococci in colicky infants [42,43]. Furthermore, L. reuteri
ATCC 55730 was effective in children with distal active ulcerative colitis (UC) improving mucosal
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inflammation and modulating mucosal expression levels of some cytokines involved in the bowel
inflammation [44]. Lactobacillus and Saccharomyces strains (L. casei CG, L. reuteri ATCC 55730 and a
strain of S. boulardii) exerted positive effects as supplement for rehydration therapy for infectious
diarrhoea in children by reducing the duration and stool frequency [45].
Several data are available for the use of bifidobacteria as probiotics for therapeutic purposes in
infants [46]. As an example, Bifidobacterium strains belonging to the animalis (BB-12 strain) and
longum species proved their efficacy against acute rotavirus diarrhoea in hospitalized children,
particularly by increasing the immune response and decreasing duration of disease [47–49]. In addition,
administration of Bifidobacterium bifidum and B. animalis strains in preterm and low birth weight infants
demonstrated clinical positive effects for treatment of necrotizing enterocolitis (NEC) [50–52].
Among the different species belonging to the Bifidobacterium genus, Bifidobacterium breve, is the
dominant one in breast-fed newborns [53] and one of the most used in infants. The species B. breve was
firstly described by Reuter [54], who isolated from breast-fed infant faeces and named seven species of
Bifidobacterium, including B. parvulorum and B. breve. The two species were then combined under the
name of B. breve [55]. B. breve strains are also found in the vagina of healthy women [54]. Their presence
in extra-body environments is a consequence of faecal contamination and the species is a useful
indicator of human and animal faecal pollution [56]. B. breve, like other Bifidobacterium species, possess
an array of enzymes for the utilization of different carbohydrates. These enzymes, useful to adapt
and compete in an environment with changing nutritional conditions, are inducible in the presence
of specific substrates. Amongst them, glycosidases, neuraminidases, glucosidases, galactosidase
are included as well as extracellular glycosidases that degrade intestinal mucin oligosaccharides and
glycosphingolipids [57]. B. breve also possess a glucosidase with a β-D-fucosidase activity, useful for the
utilization of fucosilated HMO [58]. B. breve is included in the list of Qualified Presumption of Safety
(QPS) biological agents [59]. Furthermore, recent studies have shown that human milk, traditionally
considered as sterile, contains commensal, mutualistic and/or potentially probiotic bacteria for the
infant gut. Among the different Bifidobacterium species found in human milk, B. breve strains have been
detected with DNA-based techniques and also isolated and characterized [60]. These bacteria from
human milk rapidly colonize the newborn’s gut, protect the infant against infections and contribute to
the maturation of the immune system [60].
Early studies by Akiyama et al. [61] showed that B. breve administration soon after birth was
effective in developing a normal intestinal microbiota and, furthermore, B. breve showed a stronger
affinity for immature bowel than other species, such as B. longum, evidencing its strong capabilities as
probiotic. These achievements stimulated the development of further studies that gave new insights to
the importance of this species as probiotic in infants.
Aloisio et al. [62] screened 46 Bifidobacterium strains for their capability of inhibiting the growth of
gut pathogens including coliforms isolated from colicky infants. The most interesting strains belonged
to the B. breve species, namely B632 strain (DSM 24706), B2274 strain (DSM 24707) and B7840 strain
(DSM 24708). In addition to the antimicrobial activity against coliforms and other pathogenic bacteria,
the strains did not possess transmissible antibiotic resistance traits and were not cytotoxic for gut
epithelium, which are important pre-requisites for their use as probiotics. B. breve B632 was also able
to stimulate the activity of mitochondrial dehydrogenases of macrophages and the production of IL-6,
linked to a considerable activation of macrophages and endothelial cells in inflammatory condition.
The potential of B. breve B632 as probiotic was also evidenced by Simone et al. [63]: it was able to inhibit
the growth of Enterobacteriaceae in an in vitro gut model system stimulating the intestinal microbiota
of a 2-month colicky infant, supporting the possibility to move to an in vivo study. Another strain
of B. breve, BR03 (DSM 16604), revealed to be effective, as well as B632, in inhibiting the growth of 4
E. coli biotypes [64]. Mogna et al. [65] also underlined the validity of these two B. breve strains (B632
and BR03) in an in vivo study. The administration of both strains for 21 consecutive days as an oily
suspension (daily dose of 100 million live cells of each strain) to healthy children was effective in
obtaining gut colonization and in decreasing total faecal coliforms.
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A biotechnological approach could improve the gastric transit survival, gastrointestinal
persistence and therapeutic efficacy of the strain B. breve UCC2003, isolated from infant stool, via
the heterologous expression of the listerial betaine uptake system gene, BetL [66]. In addition to the
improved capability of colonizing the intestine of inoculated mice, the strain was also able to reduce
Listeria proliferation in the organs of the infected mice. Although the introduction of genes from
pathogens into probiotic cultures is unlikely to meet approval from regulatory authorities, this study
underlined that probiotic characteristics can be susceptible to improvements. Future perspectives
include the obtainment of BetL homologues from Generally Recognized as Safe (GRAS) organisms
and natural selection of probiotic cultures with elevated expression of such homologues.
B. breve strain Yakult (BBG-01) is another widely used probiotic strain. It was one of the first
B. breve strain shown to possess the ability to modulate the intestinal microbiota by reducing the
count of several pathogenic bacteria, such as Campylobacter, Candida and Enterococcus spp., after oral
administration [67,68]. This strain has also displayed an anti-infective activity against
Shiga-toxin-producing E. coli (STEC) O157:H7 in infected mice [69].
For its valid properties as probiotic, B. breve has also found a notable place in food technology in
the fermentation of milk. In this regard, the positive effects associated to B. breve-fermented soymilk
has been reported in several studies, demonstrating to improve lipid metabolism, alcohol metabolism
and mammary carcinogenesis in mice models [70–72].
Moreover, a strain of B. breve has been included in a widespread of commercial high concentrated
probiotic preparation, known as VSL#3, which contains 1011–1012 viable lyophilized cells of different
bacterial species that are usual component of human gut microbiota. Specifically, the formulation
contains four strains of Lactobacillus (L. paracasei, L. plantarum. L. acidophilus and L. delbrueckii subsp.
bulgaricus), three strains of Bifidobacterium (B. longum, B. breve and B. infantis) and one strain of
Streptococcus salivarius subsp. thermophilus. VSL#3 exhibited an immunomodulatory capacity in in vitro
studies by increasing the production of anti-inflammatory cytokines and inhibiting the production of
pro-inflammatory cytokines [73].
4. B. breve Effectiveness in Mice Models
The strong evidence of the immune modulating capability of B. breve strains has been consolidated
and well documented in a large number of animal models studies, which are the basis for human
clinical trials.
The oral administration of B. breve YIT4064 strain, isolated from faeces of a healthy breast-fed
infant, in mice immunized orally with an influenza virus was able to increase anti-influenza virus
IgG levels in serum, thus protecting mice against infection. The authors concluded that the oral
administration of this strain may enhance antigen-specific IgG against various pathogenic antigens
taken orally and induce protection against various viral infections [74]. This conclusion was also
supported by the study of Yasui et al. [75] that proved that the same strain stimulated anti-influenza
virus hemagglutinin IgA by Peyer’s patch cells in response to addition of hemagglutinins. These
antibodies may reach the mucosal tissue and prevent influenza virus infection.
B. breve UCC2003 possessed a cell surface exopolysaccharide (EPS) able to play an important
role in immunomodulation in B cell response. Administration for 3 consecutive days of EPS+ B. breve
strains in mice infected with Citrobacter rodentium, a diarrheagenic pathogen related to human E. coli, is
effective in reducing the pathogen colonization, differently from mice fed with EPS− B. breve [76]. EPS
was involved in the production of a biofilm on the gut epithelium [77] preventing the attachment of
C. rodentium.
Natividad et al. [78] illustrated the relationship between B. breve NCC2950 and regenerating (REG)
III proteins, molecules belonging to the family of C-type lectins, which are expressed in the intestine
and involved in maintaining gut homeostasis. The group REGIII-γ was measured in the ileum and
colon of germ-free (GF) mice, mice colonized with specific pathogen free (SPF) microbiota and with a
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low diversity microbiota (altered Schaedler flora–ASF). Monocolonization with the probiotic B. breve
NCC2950 but not with the commensal E. coli JM83, significantly induced REGIII-γ expression.
B. breve MRx0004, isolated from faeces of healthy humans, possessed a protective action in a
severe asthma condition [79]. The study remarked an important decrease of neutrophil and eosinophil
infiltration in lung bronchoalveolar lavage fluid in a mouse model of severe asthma after the probiotic
treatment. This result, together with the demonstrated reduction of pro-inflammatory cytokines and
chemokines involved in neutrophil migration, showed that B. breve MRx0004 effectiveness in reducing
the above-mentioned inflammation condition paves the way for next-generation drug for management
of severe asthma.
Many B. breve strains played an important role in prevention and treatment of various allergy
conditions. Oral administration of B. breve M-16V, isolated from faecal sample of a healthy infant, in
ovalbumin (OVA)-immunized mice significantly reduced the serum levels of total IgE, OVA-specific
IgE and OVA-specific IgG1 and ex vivo production of IL-4 by the splenocytes [80]. Schouten et al. [81]
showed that an intervention with a synbiotic formulation, comprising B. breve M-16V and a GOS/FOS
mixture, was protective against the development of symptoms in mice orally sensitized with
whey. The promising effect was confirmed by Kostadinova et al. [82] demonstrating the partially
prevention of skin reaction due to cow’s milk allergy, following the probiotic administration in
combination with specific β-lactoglobulin—derived peptides and a specific blend of short- and
long-chain fructo-oligosaccharides in mice. Particularly, the treatment, besides increasing the cecal
content of propionic and butyric acid, determined an increase of IL-22 expression, which plays an
antimicrobial role in the innate immunity response and of the anti-inflammatory cytokine IL-10 in the
Peyer’s patches. This outcome agrees with Jeon et al. [83], who demonstrated that the administration
of the B. breve Yakult strain increased the number of IL-10-producing CD4+ T cells in the large intestine
of murine models and an increased production of acetic acid [69].
B. breve was also involved in protective mechanisms against obesity; the orally administration of
B. breve B-3 in a mouse model with diet-induced obesity could suppress the increase of body weight
and epididymal fat, with improved serum levels of total cholesterol, fasting glucose and insulin and
act by regulating gene expression pathways involved in lipid metabolism and response to stress in the
liver [84,85].
Increasing evidence suggests that a brain–gut–microbiome axis exists, although its role in
cognition remains relatively unexplored [6,86]. Bifidobacteria were found to improve the behavioural
deficits and to possess a potential action on stress-related disorders in model mice [87]. B. breve strains
potential has also been investigated for the capability of conferring beneficial effects on neurological
diseases. Savignac et al. [88] showed that 6 weeks feeding of B. breve 1205 strain resulted in positive
effects on compulsive behaviour in marble burying test, anxiolytic effects in the elevated plus maze
and reduced body weight gain in model mice, contributing to a general amelioration of anxiety and
metabolism. Kobayashi et al. [89] showed that oral administration of B. breve A1, isolated from faeces of
human infants, prevented cognitive decline in Alzheimer disease (AD) model mice, with a reduction of
neural inflammation; they observed that the probiotic provided ameliorations in both working memory
and long-term memory. Furthermore, they found an increase of plasma acetate levels after the probiotic
treatment and the neural inflammation reduction can be considered as a consequence of this increase
due to B. breve administration, since SCFAs have been shown to have immune modulatory functions
in model mice [90]. This evidence suggests that B. breve A1 has therapeutic potential for preventing
cognitive impairment in Alzheimer disease and the necessity to move to a clinical intervention to
evaluate the effects on diseased humans.
B. breve supplementation can affect the metabolism of fatty acids. Among them, eicosapentaenoic
acid (EPA), which derives from α-linolenic acid metabolization, is an essential constituent of the cell
membrane, plays an important role in brain and nervous system development and in inflammatory
response [91]; docosahexanoic acid (DHA), which derives from EPA metabolization, is one of the
major n-3 polyunsaturated fatty acids (PUFA) in the brain and is essential for a correct development
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of foetal encephalon [92]. Some studies revealed that human commensal microorganisms are able
to synthetize bioactive isomers of conjugated linoleic acids (CLA) from free linoleic acid [93]; CLA
was proven to possess antiatherosclerotic, antidiabetic and immunomodulatory properties [94,95].
Wall et al. [96] demonstrated that oral administration for 8 weeks to different animals (pigs and mice)
of B. breve NCIMB 702258, a CLA producer strain, in combination with linoleic acid as substrate,
increased the concentration of the predominant CLA isomer found in nature (c9, t11) in the liver.
Furthermore, this supplementation in mice increased EPA and DHA levels in the adipose tissue
and reduced proinflammatory cytokines tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ)
levels. The same authors demonstrated that a 8 weeks administration with the same B. breve strain
and α-linolenic acid, the precursor of EPA, resulted in an increase in the liver EPA and brain DHA
concentrations in mice. These results outline that the B. breve strain is a notable candidate for the
treatment of inflammatory and neurodegenerative being able to modulate the hippocampal expression
of brain-derived neutrophic factor (BDNF), a neurotrophin involved in development of the nervous
system [97,98]. Particularly, the probiotic treatment reduced the expression of BDNF exon IV, which
has been described as being highly responsive and increased by stress [99].
5. B. breve Application in Clinical Trials in Paediatrics
The use of B. breve strains for treatment and prevention of human diseases have been increasingly
expanding in the last decade. Being bifidobacteria the most abundant bacterial group in infant gut,
most of the studies are focused on paediatric subjects. Figure 1 summarizes the main applications of
B. breve in paediatric diseases.
 
Figure 1. Paediatric diseases in which an amelioration of symptoms has been obtained upon B. breve
strains administration.
Therapeutic and protective role for human health of B. breve strains both as single strain or as
a mixture of two strains of the same species has been demonstrated. As already mentioned, several
researchers account for the improved efficacy of multi-species and multi-strain formulations that acting
with a synergic effect, may enhance the effectiveness of each single strain [100,101].
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5.1. Preterm Infants and Necrotising Enterocolitis (NEC)
A consistent number of preterm infants, especially those of very low birth weight, are subjected
to episodes of systemic infection caused by antibiotic resistant bacteria and fungi that can lead to
chronic diseases and brain injuries [102,103]. These episodes can result from a combination of factors,
including immature gastrointestinal tract mucosal barrier and undeveloped gastrointestinal tract
immune system, which may predispose premature infants to bacterial translocation, causing systemic
infection and necrotising enterocolitis (NEC) [104,105]. In addition, preterm infants have revealed
an altered microbiota composition, resulting in almost undetectable bifidobacteria counts during the
first and second week of life, differently for those at term [106–108]. This observation has allowed the
formulation of the hypothesis that a bifidobacteria treatment could lead to a reintegration of beneficial
bacteria in the intestinal environment and a reduction of bacterial translocation to other districts,
stimulating researches in this sector. One of the first study that investigated the effects of a B. breve
supplementation in preterm neonates reported that the strain YIT4010, administered as a suspension
of distilled water containing 0.5 × 109 bacterial cells for 28 days, was able to colonize efficiently the
intestinal tract, to reduce abnormal abdominal symptoms and to improve the weight gain [109]. A later
study compared the effects of the administration of a B. breve strain a few hours after birth and 24 h
after birth; the supplement was prepared by dissolving 1.6 × 108 cells in 0.5 mL of 5% glucose solution
and administered twice a day for all the duration of hospitalization [110]. In newborns administered
with the probiotic soon after birth, bifidobacteria were detected significantly earlier and the number of
Enterobacteriaceae at 2 weeks after birth was significantly lower, compared to the infants treated 24 h
after birth demonstrating that a very early probiotic intervention may contribute to the establishment
of a beneficial gut microbiota and the prevention of infectious diseases [110].
A more recent work proved the suitability of B. breve M-16V administration for routine use in
preterm infants in order to control the gut microbiota colonization and shift it towards a healthy
profile [111]. Moreover, a retrospective cohort study was performed with the purpose of evaluating
whether the supplementation with the same probiotic to preterm neonates would reduce the risk of
NEC [112]. NEC represents the most life-threatening pathology of preterm neonates with incidence
and mortality of 10–12% and 40–45%, respectively. It is characterized by gastrointestinal dysfunction
progressing to pneumatosis intestinalis, systemic shock and rapid death in severe cases [113,114].
NEC is categorized into 3 different stages based on the severity of the disease, from stage I,
a suspicion for disease, to stage III, corresponding to a severe progression of the disease [115].
Although the pathogenesis of this condition remains obscure, some important prevention strategies
have been adopted, such as the use of antenatal glucocorticoids, early preferential feeding with
breast-milk, prevention and treatment of infections [116]. Since preterm infants have shown an
intestinal reduction of total bifidobacteria and a predominance of facultative anaerobes, some of
which potentially pathogens, until the 20th day of life, it has been suggested that a major etiological
factor for NEC could be an altered microbiota composition [117]. Therefore, a probiotic treatment
can be an additional strategy for NEC prevention. A 3-week B. breve M-16V supplementation
(3 × 109 CFU/day) has been associated with a lower incidence of NEC (≥stage II) in very low
birth weight infants born before 34 weeks; the incidence in those born before 28 weeks resulted lower
but not statistically significant [112]. Satoh et al. [118] had already demonstrated the efficacy of B. breve
M-16V administration in preventing NEC in extremely low and very low birth weight infants: the
probiotic was daily supplemented at a dose of 1 × 109 CFU dissolved in breast milk or breast-mixed
with formula milk several hours after birth and continued until discharge from hospital (achievement
of body weight 2300 g or gestational age of 37 weeks); the treatment led to a significant reduction of
infection and mortality rate.
Various studies suggested that an overproduction of SCFAs in the intestinal environment can
lead to mucosal injuries, which may evolve in NEC in premature infants [119,120]. Wang et al. [121]
demonstrated that a 4 weeks B. breve M-16V supplementation (1.6 × 108 cells suspended in 0.5%
glucose solution) was associated with a reduction of butyric acid levels in very and extremely low
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birth weight newborns. Since butyric acid increases the IL-8 secretion in enterocytes, condition that
may lead to neutrophil invasion, a known hallmark of NEC, B. breve administration can be considered
protective against NEC onset.
Immediately after delivery, some physiological changes, especially in the immunologic system,
occur in newborns in order to adapt themselves to the new environment. B. breve M-16V, administered
at 109 cells in 0.5 mL of 5% glucose solution starting several hours after birth, can increase the
transforming growth factor β1 (TGF-β1) signals in preterm infants [122]. This increase has a relevant
importance as it is known to induce oral tolerance, exert anti-inflammatory effects, express mucosal
IgA and promote epithelial cell proliferation and differentiation [123]. A further study investigated the
preventive effects of the same B. breve strain against infections and sepsis in extremely and very low
birth weight newborns. The probiotic consisted on a freeze-dried preparation with a dose of 109 CFU
dissolved in breast- or formula-milk; the development of infection and sepsis resulted significantly
lower in the supplemented group compared with the non-supplemented one [124], highlighting once
more the efficacy of a B. breve treatment in the prevention of developing infections, sepsis and NEC.
According to Braga et al. [125] the combined use of B. breve Yakult and L. casei was able to reduce
the occurrence of NEC and was associated with an improvement in intestinal motility in newborns.
The intervention started at the second day of life and continued for 30 days, provided L. casei and
B. breve mixed to human milk in a daily dosage of 3.5 × 107 and 3.5 × 109 CFU, respectively. The
number of NEC confirmed cases (≥stage II) was reduced upon probiotic treatment.
5.2. Gastrointestinal Disorders
A disorder that affects up to 30% of newborns in the first months of life is infant colic. It is
characterized by paroxysmal, excessive and incontrollable crying without identifiable causes [126]
representing a serious problem for the family and, in many cases, it can cause disorders later in
life [127,128]. The aetiology remains obscure but an unbalanced intestinal microbiota has been
suggested to play a role in the disease pathogenesis. Several studies support the use of probiotics
as therapeutic or preventive agent against colics but very few clinical trials have been performed on
bifidobacteria application. A mixture of B. breve strains (BR03 and B632), whose probiotic potential,
as already highlighted in Section 3, has been extensively demonstrated in vitro, was prepared as oily
suspension and administered at a daily dosage of 5 drops containing 108 CFU of each strain to 83 infants,
involving both breast and bottle-fed subjects [129]. Preliminary results showed that administration
was effective in reducing minutes of daily crying. The clinical trial was then completed (155 infants,
130 breast- and 25 bottle-fed), as described in Aloisio et al. [130]; the B. breve mixture was able to
prevent gastrointestinal disorders in healthy breast-fed infants, principally by reducing 56% of daily
vomit frequency, decreasing 46.5% of daily evacuation over time and improving stool consistency. The
strength of this study is the interrelation among a prolonged probiotic treatment, several clinical and
anthropometric parameters (e.g., crying time, stool frequency, colour and consistency, regurgitation,
vomits, weight, length, head circumference of newborn, delivery mode, type of feeding, gestational age)
and main gut microbial groups. Epidemiological data have shown the predisposition of neonates born
by caesarean section to develop obesity later in life [131,132]. However, the B. breve supplementation
in infants born by caesarean section [130] resulted in a lower catch-up growth in weight, thus allowing
the authors to speculate a protective effect of the probiotic strains against the risk to develop metabolic
disturbance later in life.
Another common disease in childhood related to the intestinal tract is functional constipation,
a chronic condition characterized by infrequent defecation (less than three times per week) and
more than two episodes of faecal incontinence per week [133]; the pathogenesis, undoubtedly
multifactorial, has not a well-defined aetiology. It has been shown that, despite intensive medical and
behavioural therapy, 25% of patients developing constipation before the age of 5 years continue
to have constipation upsets beyond puberty [134]. A pilot study showed the beneficial effects
of 4 weeks treatment with B. breve Yakult (BBG-01) in constipated children: daily administration
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of 108–109 CFU led to a significantly increase in defecation frequency and amelioration of stool
consistency, frequency of episodes of faecal incontinence and abdominal pain [135]. There is a debate
of whether it is more effective the use of single strains or an association of them for constipation
treatment; however, the mentioned study demonstrated that the intake of only one B. breve strain
is even effective. Giannetti et al. [136] investigated the effects deriving from the administration of a
mixture of 3 bifidobacteria, namely B. infantis M-63, B. breve M-16V and B. longum BB536, in children
suffering from irritable bowel syndrome (IBS). IBS is a functional bowel disorder characterized
by chronic abdominal pain, discomfort, bloating and altered bowel habits including diarrhoea or
constipation [137]. The daily dose was about 109 cells for each strain administered as bacterial powder
and the treatment lasted 6 weeks. The bifidobacteria mixture intake resulted in a significant decrease
in prevalence and frequency of abdominal pain and an improvement of the quality of life, assessed by
an interview-administered validated questionnaire.
The commercial formulation VSL#3, already described in Section 3, was used in several clinical
studies targeted to different diseases in paediatrics resulting in an amelioration of the health status of
children suffering from IBS [138]. In this randomized, double-blind, placebo-controlled, multicentre
trial, patients were treated with one sachet (twice in those 12–18 years old) of probiotic mixture
containing 4.5 × 1012 bacteria for 6 weeks. The preparation was effective in improving the overall
perception of symptoms, the severity and frequency of abdominal pain, abdominal bloating and family
assessment of life disruption, leading to a general improving of quality of life in children suffering
from IBS.
Miele et al. [139] carried out the first paediatric, randomized, placebo-controlled trial using VSL#3
for the treating of ulcerative colitis (UC). This disorder belongs to the chronic inflammatory bowel
disease (IBD) category, has a prevalence of about 100 cases per 100,000 children [140] and occurs as
diffuse mucosal inflammation in the colon; it is characterized by periods of remission and relapse
episodes, not all the patients tolerate the existing treatment to induce remission for their adverse effects
and in 20–30% of paediatric patients failure of the treatment occurs [141]. Since the pathogenesis, beside
genetic susceptibility, is linked to compromised immune response and alteration in gut microbiota
composition, the idea beyond the study was that 1 year of VSL#3 administration might improve the
health status of patients. Subjects with an average age of 10 were supplemented with a weight-base
dose of probiotic (4.5 × 1011–1.8 × 1012 bacteria per day); treated patients showed a significantly
higher rate of remission compared to placebo and a significantly lower incidence of relapse within
1 year of follow-up. According to the authors, this success may be related to the use of a mixture of
various probiotics, which might have a strong synergic action and to the high bacterial concentration
of viable cells contained in the mixture. Furthermore, the probiotic preparation showed to be safe and
well tolerable by children with a diagnosis of UC.
The efficacy of VSL#3 in paediatric diseases was also evaluated by Dubey et al. [142], who
conducted a double-blind, randomized, placebo-controlled trial treating acute rotavirus diarrhoea in
children. VSL#3, containing a total of 9 × 109 bacteria/dose and administered for 4 days, significantly
reduced, already on day 2, mean stool frequency and improved stool consistency; these results were
also reflected in the lower volume of oral rehydration salts administered in children who received
the probiotic. The functional role of VSL#3 was investigated by Sinha et al. [143], who focused on the
prevention of neonatal sepsis in low birth weight infants, one of the infections which evolves more
rapidly in this paediatric category. The mixture, containing 109 bacteria/dose, was administered for
30 days. VSL#3 intake in low birth weight was associated with a non-significant 21% reduction in the
risk of suspected sepsis; nevertheless, in the sub-group of infants weighing 1.5–1.99 kg, the reduction of
the risk of suspected sepsis was statistically significant, differently from newborns weighing 2.0–2.49 kg.
The results of the study allowed to conclude that the intervention may be useful for the most vulnerable
subjects of low birth weight.
As infant feeding has a crucial role in developing infant gut microbiota and consequently intestinal
immunity, fermented formula milk containing probiotics or prebiotics has been developed. This
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approach is aimed at protecting infants from various gastrointestinal disorders by modulating gut
microbial composition. The first study that evaluated the effects of a fermented formula milk with
B. breve C50 and Streptococcus thermophilus 065 on the incidence of acute diarrhoea in healthy infants
was a randomized, double-blind, placebo-controlled multicentre study, which involved 971 subjects
belonging to three different areas of France [144]. The trial was planned to occur in a high risk predicted
period for diarrhoea incidence in France (from October to January) and the supplementation lasted
5 months. Although no reduction in the incidence and duration of diarrhoea episodes were observed
after the intervention, a lower number of dehydration cases, a lower number of medical consultation
cases with fewer oral rehydration solution prescriptions and changes of formula were registered. These
outcomes can be considered as indicators of probiotic positive effects on the severity of the disease.
According to the authors, these results may be related to the bifidogenic and immunomodulatory
properties of fermentation products contained in formula-milk.
5.3. Celiac Disease
The efficacy of the probiotic mixture containing B. breve B632 and B. breve BR03 was also shown
in children affected by celiac disease. In this case, the strains were administered as lyophilized
powder at a daily dosage of 109 CFU of each strain for 3 months in celiac children on a gluten free
diet (GFD). A preliminary important outcome obtained from the intervention was the reduction of
pro-inflammatory cytokine TNF-α in blood samples of celiac children on GFD [145]. The gut microbiota
composition was also studied with Next Generation Sequencing (NGS) technology. Unexpectedly, the
intervention did not cause changes at the level of the genus or phylum to which the administered
probiotics belong but the probiotic acted as a “trigger” element for the increase of Firmicutes and the
restoration of the physiological Firmicutes/Bacteroides ratio that was altered in celiacs with respect to
healthy subjects. Moreover, the intervention restored the normal amount of Lactobacillaceae members,
reaching almost the same values of healthy subjects [146]. Besides modulating inflammatory condition
and gut microbiota composition of celiac children, B. breve supplementation influenced the SCFAs
profile; acetic acid had a negative correlation with Verrucomicrobia, Euryarcheota and particularly
Synergisestes [147]. Although Synergisestes is a minor phylum in human faeces (abundance of 0.01%) of
healthy subjects, it was found to have a considerable role for human health because of its negative
correlation with TNF-α that may indicate an anti-inflammatory role [148,149]. In the study of
Primec et al. [147], the Synergisestes phylum clearly confirmed its anti-inflammatory role negatively
correlating with pro-inflammatory acetic acid after three months of probiotic treatment.
5.4. Paediatric Obesity
Another pathology in which the gut microbiota may play a notable role is obesity. Although it
is accepted that obesity results from disequilibrium between energy intake and expenditure, it is a
complex disease and not completely understood. Nowadays, obesity prevalence is spreading especially
among children and adolescents and it can be considered a worldwide epidemic. Obesity has been
associated with a chronic inflammation that may conduct to insulin resistance [150,151]. Recently,
obesity has been associated with a specific profile of the gut microbiota characterized by lower levels of
bacteria belonging to Bacteroides and Bifidobacterium genera compared to that of lean individuals [152].
In addition, bifidobacteria were shown to be higher in children maintaining normal weight at 7 years
old than in children developing overweight and their administration was able to reduce serum and
liver triglyceride levels and to decrease hepatic adiposity [153,154]. The mixture of B. breve already
mentioned (BR03 and B632) was used in a cross-over double-blind randomized controlled trial in
order to re-establish metabolic homeostasis and reduce chronic inflammation in obese children [155].
Although the study is still on-going, preliminary results related to the part previous the cross-over
demonstrated that a B. breve administration in obese children is promising: 8 weeks treatment seems
to ameliorate glucose metabolism and could help in weight management by reducing BMI, waist to
height ratio and waist circumference [155].
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5.5. Allergies
There are increasing evidences that the intestinal microbiota plays an important role in the
development of allergic diseases, in particular, low bifidobacteria levels appear to be associated with
atopic dermatitis [156]; in the previous section, the potential of B. breve in preventing and treating
allergy conditions was reported and this impressive role has been confirmed in clinical studies. B. breve
M-16V revealed to be effective in the treatment of cow’s milk hypersensitivity infants with atopic
dermatitis [157]. B. breve, added to the casein-hydrolysed milk formula at the dosage of 5 × 109 CFU
or 15 × 109 CFU per day, increased the proportion of bifidobacteria in the gut microbial composition
and ameliorated allergic symptoms by interacting with the immune system and no remarkable dose
dependent differences were detected [157]. The synergetic combination of probiotics and prebiotics,
known as synbiotic, seems also to be promising in atopic dermatitis treatment. In this regard,
Van der Aa et al. [158] studied the effects of a synbiotic mixture on atopic dermatitis in formula-fed
infants; the formulation consisted of B. breve M-16V at a dose of 1.3 × 109 CFU/100 mL and a mixture of
90% short-chain galactooligosaccharides (scGOS) and 10% long-chain fructooligosaccharides (IcFOS),
0.8 g/100 mL added to formula milk. Although the formulation, administered for 12 weeks, had
no effect on atopic dermatitis severity, it significantly modulated the composition and the metabolic
activity of gut microbiota, leading to a decrease of pH, high lactate and low butyric levels resembling
the metabolic profile of breast-fed infants [159]. The same synbiotic mixture has demonstrated to
reduce the prevalence of asthma-like symptoms and the prevalence of asthma medications use after
the fulfilment of a 1-year follow-up [160].
The effects of a formulation containing B. breve M-16V and B. longum BB536 for the prevention
of allergies in infants enrolling both mothers and newborns was studied [161]. The formulation was
provided as powder daily doses containing 5 × 109 CFU/g of each strain. Pregnant women begun the
supplementation 4 weeks before the expected date of delivery and the newborns received the probiotic
mixed to water, breast- or formula-milk starting 1 week after birth and continuing for 6 months. The
study revealed that prenatal and postnatal supplementation with a bifidobacteria mixture reduced the
risk of developing eczema and atopic dermatitis in infants. NGS analyses of newborns’ faecal samples
showed significant differences of the major intestinal microbial phyla (Actinobacteria, Bacteroidetes,
Proteobacteria) of allergic and non-allergic infants at 4 months of age. However, these differences were
lost at 10 months of age, highlighting that the microbiota of early stages is particularly important in
regulating allergies upset in infants.
5.6. Surgical Procedures
Surgical procedures can also alter gut microbiota composition and functions and disrupt intestinal
barrier function, inducing the patient in a condition at risk for infection [162]. A probiotic therapy
may be functional for patients improving the immunological function of the intestine and competing
against harmful bacteria infection. A pilot study demonstrated that daily administration of B. breve
Yakult BBG-01 (109 freeze-dried cells per day) to children younger than 15 years 7 days before
surgery until discharge from hospital, simultaneously to intravenous antibiotics postoperatively
treatment, reduced the incidence of bacteria in blood samples. Moreover, the intestinal microbial
composition was improved by increasing Bifidobacterium spp. and reducing potential pathogens such
as Clostridium difficile, Pseudomonas and Enterobacteriaceae. Higher concentrations of faecal acetate and
lower faecal pH levels were detected in children who received the probiotic 2 weeks after surgery [163].
Improvement of intestinal environment resulting from a perioperative supplementation with the same
strain was also observed in neonates undergoing surgery for congenital heart disease [164]. Daily
dosage of 3 × 109 CFU of B. breve Yakult (BBG-01) was administered starting 1 week before surgery and
ending 1 week after the operation; infants who received the probiotic supplement showed significantly
higher bifidobacteria levels and lower Enterobacteriaceae, Staphylococcus and Pseudomonas levels in faecal
microbiota compared to infants not receiving the supplement. Moreover, probiotic treated infants
exhibited significantly higher concentration of total organic acids levels compared to non-treated ones,
173
Nutrients 2018, 10, 1723
in particular acetic acid increased immediately and 1 week after surgery; furthermore, the faecal pH
tended to decrease with the probiotic intervention.
Kanamori et al. [165] documented in a case-report the efficacy of a synbiotic therapy, consisting
in a combination of B. breve Yakult (BBG-01), L. casei Shirota and galactoolicosaccharides as prebiotic
components, in a newborn with short bowel syndrome resulting from a consistent bowel resection
performed soon after delivery. Patients affected from this pathology are subjected to an intestinal
bacteria overgrowth due to their dilated intestine [166]; this condition can lead to a bacteria
translocation in other districts inducing catheter sepsis, compromised carbohydrates fermentation
resulting in high level of lactate, with consequent acidosis [167] and a possible incontrollable growth
of intestinal pathogens. One year of synbiotic therapy, consisting in 3 g of bacteria (1 × 109 bacteria/g
per each strain) and 3 g of prebiotic per day, improved the nutritional state, prior compromised, by
increasing the intestinal motility and suppressed the intestinal pathogen overgrowth, in particular
E. coli and Candida spp.
The same synbiotic combination was used as a therapy for refractory and repetitive
enterocolitis [168]; this disorder often occurs in paediatric surgery patients and the severe type may
be fatal. The 7 recruited patients, having short bowels as a result of surgical resection and suffering
from repetitive enterocolitis, were administered with 1 g of probiotic (109 bacteria/g) 3 times daily for
36 months. All patients had an altered gut microbial composition prior to the therapy characterized by
low levels of anaerobic bacteria and high levels of resident pathogenic bacteria. In spite of the frequent
antibiotic treatments to which patients were exposed, the long synbiotic administration was effective
in highly increasing bifdobacteria and lactobacilli levels, which were almost undetectable before the
supplementation and incrementing faecal SCFAs, inducing a more normal ecosystem profile in the
intestine. Moreover, most of patients accelerated their body weight gain and showed increased serum
rapid turnover, with a general amelioration of their health status.
With the developing of therapies and surgeries in the field of perinatal and foetal cares, neonate
survival outcomes have extraordinary increased; newborns that are subjected to these interventions
need prolonged intensive care periods, which include use of antibiotics, respiratory care and restriction
of enteral feeding. All these factors may affect the normal microbial gut colonization leading to
severe infection and malnutrition [169]. A synbiotic therapy, including B. breve, as already observed,
could be effective in preventing or correcting an abnormal microbial colonization in intensive care
newborns. The same synbiotic therapy, largely and positively tested, including B. breve Yakult, L. casei
Shirota and galactooligosaccharides, was applied to newborns with diagnosis of severe congenital
anomalies [169]. The product contained 109–1010 bacteria/g and was administered immediately after
birth via a nasogastric tube, as soon as intestinal feeding was possible, first at a dose of 0.12 g per day
in four equal dose and then, when the amount of milk increased, at 3 g per day in three equal doses.
As results of the therapy, none of patients manifested enterocolitis, they showed an improvement in
their clinical course and reached a body weight gain equivalent to that of normal infants. This last
outcome has been hypothesized to be linked to the potential metabolic activity of the administered
probiotics to promote liver lipogenesis and fat storage in the peripheral fat tissue contributing to the
growth observed in these infants despite the congenital disorders [170].
5.7. Coadjuvant in Chemotherapic Treatment
A condition in which the use of probiotics may have a reliving effect is chemotherapy. The cancer
itself and the drug-therapy inducing bone marrow suppression lead to an immunocompromising
state in which an infectious could be fatal. Since the main source of infection is endogenous intestinal
harmful bacteria [171], a probiotic treatment can certainly benefit the patient’s state by not only
competing against pathogens for nutrients and attachments sites but also by stimulating gut immunity,
producing organic acids and improving transepithelial resistance [172]. A study conducted in 2009
evaluated the effect of B. breve Yakult (BBG-01) strain in cancer paediatric subjects, administered with
109 freeze-dried cells, corn starch and hydroxipropyl cellulose in 1 g of formulation. The administration
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was found to be effective in reducing febrile episodes, which may be the only sign of infection and the
use of intravenous antibiotics by stabilizing the intestinal microbial composition [173].
An overview in chronological order of B. breve applications as a single strain and as a component
of a multi-strain/multi-species formulation is reported in Tables 1 and 2, respectively.
Table 1. Overview of B. breve strains applications in in vitro studies, mice model and paediatric trials.
B. breve Strains Reported Effect(s) References
B. breve B632
Strong antimicrobial activity against pathogens, stimulation of mitochondrial
dehydrogenase activity of macrophages, stimulation of proinflammatory cytokines
production in in vitro study
[62]
B. breve BR03 Inhibition of the growth of 4 E. coli biotypes in in vitro study [64]
B. breve B632 +
B. breve BR03
Reduction of total faecal coliforms in healthy children [65]
Reduction of pro-inflammatory TNF-α in blood samples of celiac children [145]
Reduction of minutes of daily crying in healthy infants [129]
Restoration of the healthy percentage of main gut microbial components in celiac children [146]
Improvement of glucose metabolism and weight management in obese children [155]
Reduction of daily vomit frequency, daily evacuation, improved stool consistency,
protection against developing metabolic disturbance in healthy infants [130]
Modulation of faecal SCFAs profile in celiac children [147]
B. breve Yakult
(BBG-01)
Anti-infective activity against Shiga-toxin-producing E. coli in mice model [69]
Reduction of febrile episodes and use of intravenous antibiotics in cancer
paediatric subjects [173]
Improvement of composition and metabolic activity of gut microbiota and reduction of
incidence of bacteria in blood in paediatric surgery subjects [163]
Increased defecation frequency, improvement of stool consistency, frequency episodes of
faecal incontinence and abdominal pain in constipated children [133]
Stimulation of anti-inflammatory IL-10-producing CD4+T cells in mice model [83]
Improvement of composition and metabolic activity of gut microbiota in paediatric
surgery infants with congenital heart disease [164]
B. breve YIT4064
Stimulation of anti-influenza virus hemagglutinin IgA production by Peyer’s patch cells in
mice model [75]
Stimulation of antigen-specific IgG production against pathogenic antigens in mice model [74]
B. breve UCC2003 Reduction of Citrobacter rodentium gut colonization in mice model [76]
B. breve NCC2950 Induction of REGIII-γ expression in mice model and REGIII-α in in vitro study [78]
B. breve MRx0004 Reduction of pro-inflammatory cytokines and lung neutrophil and eosinophil infiltrationin severe asthma mice model [79]
B. breve M-16V
Improvement of allergic symptoms associated to cow’s milk hypersensitivity in infants [157]
Immunomodulation activity by increasing TGF-β1 in preterm infants [122]
Reduction of infections and mortality for NEC in extremely and very low birth
weight infants [118]
Reduction of faecal butyric acid in extremely and very low birth weight infants [121]
Reduction of total IgE, OVA-specific IgE and OVA-specific IgG in mice model [80]
Protection against developing of whey allergy symptoms in model mice [81]
Reduction of infections and sepsis incidence in extremely and very low birth
weight infants [124]
Improvement of composition and metabolic activity of gut microbiota in infants with
atopic dermatitis [158]
Reduction of asthma-like symptoms prevalence and asthma medication use prevalence in
infants with atopic dermatitis [160]
Shifted gut microbiota towards a healthy profile in preterm infants [111]
Low incidence of NEC (≥stage II) in very low birth weight infants [112]
Partially protection against developing skin reaction due to cow’s milk allergy, increased
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Table 1. Cont.
B. breve Strains Reported Effect(s) References
B. breve B-3 Suppression of epididymal fat and body weight gain in mice model withdiet-induced obesity [84,85]
B. breve 1205 Amelioration of anxiety condition and general metabolism in mice model [88]
B. breve A1 Prevention of cognitive decline in Alzheimer disease and reduction of neuralinflammation in mice model [89]
B. breve NCIMB
702258
Increased CLA isomer (c9, t11), EPA and DHA in adipose tissue and reduced
proinflammatory cytokines in mice model [96]
B. breve YIT4010
Reduced abdominal symptoms and improved weight gain in preterm infants [109]
Establishment of beneficial gut microbiota and prevention of infections in preterm infant [110]
Table 2. Overview of applications of B. breve strains combined to other bacterial strains in
paediatric trials.




Reduction of developing eczema and atopic




Reduction of abdominal pain prevalence and







Improvement of composition and metabolic
activity of gut microbiota and of overall health
status in infants with short bowel syndrome
[165,168]
Prevention of enterocolitis, improvement of





Reduction of NEC incidence and improvement
of intestinal motility in infants [125]
B. breve C50 B. breve C50S. thermophilus 065
Reduction of number of dehydration cases and
medical consultation cases in children exposed
to risk of developing acute diarrhoea
[144]
B. breve DSM 24732 VSL#3
Reduction of stool frequency and improving of
stool consistency in children with acute
rotavirus diarrhoea
[142]
Manifestation of high rate of remission and low
incidence of relapse in UC children [139]
Improvement of symptoms, severity and
frequency of abdominal pain and bloating and
family assessment of life disruption in
IBS children
[138]
Reduction of the risk of suspected sepsis in
most vulnerable very low birth weight infants [144]
6. B. breve Administration in Adults: A Short Outcome
The use of B. breve has been largely investigated in paediatric scenery and its therapeutic role
has been strongly supported by significant and solid outcomes; its use is not limited to paediatric
supplementation but it is also involved in improving health condition in briefly outlined.
Minami et al. [174] investigated the use of B. breve B-3 at a daily dosage of 5 × 1010 CFU/capsule
for 12 weeks in adults with a tendency for obesity. A significant decrease of the fat mass
and an amelioration of blood parameters were observed, in particular a significant reduction of
γ-glutamyltranspeptidase (γ-GTP), a marker used to evaluate liver injury and high-sensitivity protein
C-reactive (hCRP), a marker used to evaluate the inflammatory reaction, were detected. Interestingly,
a significant negative correlation between the value of fat mass and 1,5-anhydroglucitol, a marker
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that closely reflect short-term glucose status and glycaemic variability, was recorded suggesting the
potential role of B. breve in the improvement of diabetes.
Ishikawa et al. [175] showed the effects of one year of B. breve Yakult treatment, in association
with galactooligosaccharides as prebiotic, in patients diagnosed with UC. The probiotic, containing
109 CFU/dose of freeze-dried powder, was administered immediately after every meal 3 times a
day and the prebiotic, at a dosage of 5.5 g, was administered once a day. The synbiotic intervention
improved the endoscopic score by decreasing the values of severity mucosa damage [176] and reduced
the level of myeloperoxidase, which is secreted by neutrophils and macrophages accumulated in the
inflamed lesions and positively correlated with the disease severity [177]. Regarding gut environment
results, the synbiotic treatment significantly reduced Bacteroidaceae counts and faecal pH, which may
be connected to an increment of faecal SCFAs.
An interesting relationship was evaluated by Kano et al. [178]: since a Japanese 2007 survey
evidenced that women who suffer from abnormal bowel movements also showed skin disorders,
they conducted a double-blind, placebo-controlled, randomized trial to investigate the effects of
probiotic and prebiotic fermented milk on skin of healthy adult women. The fermented milk contained
galactooligosaccharides, polydextrose, B. breve Yakult, Lactococcus lactis and S. thermophilus at a daily
dose of 6 × 1010, 5 × 1010, 5 × 1010 CFU/100 mL of milk, respectively. The synbiotic intake, which
lasted 4 weeks, resulted to prevent hydration level decreases in the stratum corneum. The intervention
increased cathepsin L-like protease activity, which can be considered as an indicator of keratocyte
differentiation, as proteolysis of cathepsin L activates transglutaminase 3, which plays an important
role in the stratum corneum formation [179]. Moreover, the administration reduced phenol levels in
serum and urine and since the production of phenols is inhibited at low intestinal pH, an increase of
intestinal organic acid levels might be occurred after the treatment.
The probiotic preparation VSL#3 has been extensively used for the treatment of IBD in adulthood.
Brigidi et al. [180] investigated the effects of 20 days VSL#3 administration in patients with diarrhoea
predominant-IBS or functional diarrhoea; the probiotic intake caused changes in gut microbiota
composition with a significantly increase of total lactobacilli, total bifidobacteria and S. thermophilus,
which are component of VSL#3. The treatment led also to an improvement of some enzymes
functions, whose actions are compromised in IBD, by reducing urease activity, whose products
usually allow pathogenic bacteria to survive in the gastrointestinal tract and contribute to mucosal
tissue damages [181] and by increasing β-galactosidase activity, which is involved in the metabolism
of unabsorbed carbohydrates. Pronio et al. [182] confirmed the positive role of VSL#3 upon treatment
of patients undergoing ileal pouch anal anastomosis for ulcerative colitis. The probiotic intervention
reduced signs and symptoms of inflammation inducing a significant expansion of cells associated to an
improvement of the inflammatory condition of the pouch mucosa. An interesting microbial outcome
was evidenced by Kühbacher et al. [183]: the UC remission maintained by VSL#3 administration was
accompanied by a higher bacterial diversity actually not related to the probiotic intake. However,
the increase of bacterial diversity may represent a therapeutic mechanism that supports the VSL#3
activity in maintaining UC remission. Bibiloni et al. [184] showed that 6 weeks administration with
the probiotic mixture improved UC remission and response in patients not responding to traditional
therapy. Since VSL#3 has been demonstrated to maintain remission in UC patients intolerant or allergic
to 5-aminosalicylic acid (5-ASA), known also as mesalazine [185], Tursi et al. [186] demonstrated the
efficacy on UC of another therapeutic combination: VSL#3, in association with balsalazide, 5-ASA
prodrug, was shown to be significantly superior to balsalazide alone and to mesalazide in the treatment
of active mild-to-moderate UC. One of the key points of the study is the low dosage of balsalazide used
(2.25 g/day), usually not effective in reducing UC symptoms and inducing remission. Therefore, the
low dosage appeared to be effective only in combination with VSL#3. In this regard, a more recent study,
involving a larger number of patients, highlighted the superior ability of VSL#3 to improve relapsing
mild-to-moderate UC when added to standard UC treatment with respect to patients on standard
treatment only, confirming the potential synergic action exerted by standard UC pharmacological
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treatments and VSL#3 [187]. The reason for this synergic action may be a combined effect of the
chemotherapic on the disease and of the probiotic on the general well-being of the host. Clinical
studies proved that this probiotic mixture was particularly effective in the treatment of IBD, improving
abdominal pain duration and distention severity score in patients suffering from IBS [188]. Moreover,
it was effective in clinical condition of diarrhoea-predominant IBS subjects [189,190].
7. Conclusions
This review has outlined the large number of cases in which B. breve strains, mainly as single
strains but also in combination with other Bifidobacterium species or Lactobacillus strains, are used
for therapeutic and prevention purposes and/or to prevent further complications of the disease in
the paediatric sector. The analysis of the outlined results allows to conclude that, whereas in vitro or
animal-model study are performed with a large number of different B. breve strains, clinical studies
are performed with a restricted number of strains (mainly B. breve YIT4010, M-16V, the associations
B632/BR03 and Yakult BBG-01). Therefore, there is the opportunity of expanding the potentialities of
the strains used in clinical studies on the basis of the positive results obtained in pre-clinical studies
and, therefore, more opportunities for a further development of “therapeutic microbiology.” A second
interesting aspect outlined in this review is the frequent association of the B. breve administration
with traditional chemotherapeutic treatment. This is particularly important in the treatment of very
serious diseases in which stopping the traditional therapies may be considered risky for the patient.
The probiotic can act as a supplement to prevent complication and improve the general health status
of the patient. We are all confident that the improvement in the “therapeutic microbiology” sector will
be a great aid to medical approach in the near future.
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Mičetić-Turk, D.; Langerholc, T. Clinical intervention using Bifidobacterium strains in celiac disease children
reveals novel microbial modulators of TNF-α and short-chain fatty acids. Clin. Nutr. 2018, 4, 95–101.
[CrossRef] [PubMed]
148. Horz, H.-P.; Citron, D.M.; Warren, Y.A.; Goldstein, E.J.C.; Conrads, G. Synergistes Group Organisms of
Human Origin. J. Clin. Microbiol. 2006, 44, 2914–2920. [CrossRef] [PubMed]
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Abstract: Iron deficiency anemia (IDA) occurs in 15–46% of patients with celiac disease (CD), and in
some cases, it may be its only manifestation. Studies in animal models have shown that prebiotics,
including inulin, may help to increase intestinal absorption of iron. The aim of this study was to
evaluate the effect of a prebiotic, oligofructose-enriched inulin (Synergy 1), on iron homeostasis
in non-anemic children and adolescents with celiac disease (CD) in association with a gluten-free
diet (GFD). Thirty-four CD patients (4–18 years old) were randomized into two groups receiving
Synergy 1 (10 g/day) or a placebo (maltodextrin) for three months. Before and after intervention,
blood samples were collected from all patients for assessment of blood morphology, biochemical
parameters and serum hepcidin concentration. We found that serum hepcidin concentration after the
intervention was significantly decreased by 60.9% (p = 0.046) in the Synergy 1 group, whereas no
significant difference was observed in the placebo group. No differences in morphological and
biochemical blood parameters (including ferritin, hemoglobin and C-reactive protein (CRP)) were
observed after intervention in either group. Given that hepcidin decrease may improve intestinal iron
absorption, these results warrant further investigation in a larger cohort and especially in patients
with IDA.
Keywords: celiac disease; iron deficiency anemia; gluten-free diet; inulin; prebiotics;
iron absorption; hepcidin
1. Introduction
Celiac disease (CD) is a small intestine enteropathy that is triggered by the ingestion of storage
proteins (gluten) from wheat, barley or rye. It occurs in genetically predisposed individuals at any age,
at a frequency of 1:100 [1–4]. Characteristic features of CD include a massive lymphocytic infiltration
of the lamina propria and atrophy of intestinal villi. Consequently, there is a significant reduction of
the intestinal absorption surface, leading to malabsorption of macro- and micronutrients [2,4,5].
Iron deficiency anemia (IDA) is a common finding in children and adults with CD, with an
estimated prevalence at diagnosis between 15% and 46% [6]. Anemia may accompany the intestinal
presentation of CD, but it can also be the only manifestation of the disease. As such, the possibility
Nutrients 2018, 10, 1818; doi:10.3390/nu10111818 www.mdpi.com/journal/nutrients189
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of CD should be considered in patients with refractory anemia after other possible causes have been
excluded [7]. Iron absorption and distribution is tightly controlled. Hepcidin, a 25-amino-acid peptide
hormone produced in the liver, is a central regulator of systemic iron homeostasis. Iron deficiency
and hypoxia can decrease hepcidin production, while the pro-inflammatory cytokine IL-6 increases
hepcidin expression. Increased serum levels of hepcidin contribute to anemia in chronic diseases [8,9].
Previous studies have shown that the main cause of IDA in CD patients is the limited iron
absorption, as a consequence of chronic damage of the intestinal mucosa [6]. Other authors have
highlighted the role of chronic mucosal inflammation [10], and the presence of mutations in genes
encoding proteins involved in iron absorption [11,12].
The only known therapy for celiac disease is a lifelong gluten-free diet (GFD). Adherence to a
GFD leads to recovery of the intestinal mucosa, thereby normalizing nutrient absorption. In most
patients, a 6-month period is adequate for nutritional absorption to improve [13]. Normalization of
iron and hemoglobin levels depends on the severity of the disease at presentation, compliance to GFD,
and bioavailability of dietary iron. In the majority of patients, anemia resolves after approximately one
year of a GFD, but persistent IDA is observed in about 8% of patients despite a GFD and even up to
20.5% according to some reports [14,15]. Evaluation of serum CD-associated antibodies, such as
anti-tissue transglutaminase antibodies, and the assessment of clinical symptoms, are the most
commonly used methods to assess CD patients during follow-up. However, these antibodies often
decrease and/or disappear regardless of histological healing and GFD adherence [16]. In one study,
complete histological recovery after one year of well-followed GFD in adults was only obtained in 66%
of patients [17]. Moreover, GFD itself may result in further deficiencies, including fibre, B vitamins,
iron, and trace minerals [18,19]. Decreased iron intake while following a GFD has been reported [20].
All abovementioned clinical circumstances can influence the availability and absorption rate of iron
and result in prolonged iron deficiency. Thus, additional safe and easily accepted therapeutic options
to improve the iron status in CD patients are needed.
Prebiotics, typically oligosaccharides, such as fructo- and galactooligosaccharides (FOS and GOS)
or inulin, have been shown to improve bioavailability of minerals, and to enhance iron absorption in
animal studies [21,22].
The aim of this study was to evaluate the effect of oligofructose-enriched inulin (Synergy 1) on
iron homeostasis in CD children following a GFD. We posited that Synergy 1 supplementation would
result in an improvement of blood morphology and other parameters relative to iron homeostasis.
2. Materials and Methods
2.1. Study Design
We performed a single-center, randomized, placebo-controlled, double-blind study in
patients diagnosed with CD and treated with a GFD. The intervention consisted of introducing
oligofructose-enriched inulin (Synergy 1) into the diet for 12 weeks. We assessed the impact of
the intervention on nutritional status, morphological and biochemical blood parameters and gut
microbiota. Details of the study protocol have been previously described by Krupa-Kozak et al. [23].
Results regarding nutritional status, gut microbiota composition, and short-chain fatty acids
concentration in the stool have been previously reported elsewhere [24].
2.2. Participants Selection
Participants were enrolled among consecutive patients with celiac disease, aged 4–18 years,
treated with a gluten-free diet for at least 6 months prior to enrolment, treated and followed-up at the
Department of Paediatrics, Gastroenterology and Nutrition Medical Faculty of University of Warmia
and Masuria in Children’s Hospital, Olsztyn, Poland. CD was diagnosed according to criteria created
by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN 2012
criteria) [25]. All patients had positive (≥8 AU/mL) anti-transglutaminase 2 antibodies at the time
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of diagnosis. To confirm the diagnosis, endoscopy with small bowel biopsies was performed in
all patients and the specimens were interpreted according to the Marsh criteria [25]. Among the
96 patients who met the inclusion criteria (Table 1), a consent to participate in the study was obtained
for 34 patients.
Table 1. Participant selection criteria.
Inclusion Criteria Exclusion Criteria
Diagnosed Celiac Disease
Gluten-free diet for at least 6 months
Age: 4–18 years old
Normalization of Tissue Transglutaminase Antibody
(TTGA) level
Written consent from parents/caregivers
Iron deficiency anemia 1
Iron deficiency 2
Immunoglobulin A (IgA) deficiency
Treatment with oral formulas in the 2 months prior to
the study
Therapy by antibiotics or probiotics/prebiotics in the
2 months prior to the study
Chronic inflammatory disorders
1 Iron deficiency anemia was defined as a hemoglobin level below WHO range for sex and age. 2 iron deficiency
was defined as a ferritin level <12 ng/mL [26].
2.3. Ethics
Parents and caregivers were informed about potential benefits and risks and signed a written
consent form during the enrollment visit. Experimental design and all procedures were approved by
the Bioethics Committee of the Faculty of Medical Sciences of the University of Warmia and Mazury
in Olsztyn (permission No. 23/2015 of 16 June 2015). The study was registered in the ClinicalTrials
database (NCT03064997) [27].
2.4. Intervention
Patients (n = 34) were randomly assigned to the placebo group (n = 16) or the Synergy 1 group
(n = 18) [23]. The intervention lasted 3 months. Participants in the control group received maltodextrin
(7 g orally/day; Maltodextrin DE 20, Hotrimex, Konin, Poland), while participants in the examination
group received oligofructose-enriched inulin (10 g orally/day; Orafti® Synergy 1, Beneo, Tienen,
Belgium). Patients, parents/caregivers, and all investigators except N.D. (who was in charge of
the treatment distribution) were blinded to the allocated experimental group. Maltodextrin was
the placebo of choice, as it is digested in the small intestine and thus does not exert local effects in
the colon, contrarily to prebiotics. During the study, patients were required to record adherence to
supplementation, side effects, if any, and the intake of other substances, i.e., antibiotic, probiotic,
or prebiotic. The nutritional value of the diet during study and adherence to GFD were monitored
using a validated food frequency questionnaire (FFQ-6) [28].
2.5. Sample Collection
Blood samples were collected from all participants at two time points: before and after the
intervention. Complete blood count and biochemical parameters (C-reactive protein (CRP) and
ferritin) were analyzed according to standard procedures of the hospital laboratory, as previously
described [23]. Serum hepcidin levels were measured using a commercial ELISA kit (FRG Instruments
GmbH, Nuremberg, Germany).
2.6. Statistical Analysis
All below analyses were performed in duplicate and the data were analyzed using the Statistica
12 software (StatSoft, Tulsa, OK, USA). A difference with a p-value < 0.05 was considered statistically
significant. Normality of quantitative variables was tested by the Shapiro–Wilk W test. Quantitative
variables with a normal distribution were expressed as mean ± SD, while quantitative variables which
showed a non-normal distribution were expressed as a median (P25-P75). Differences in characteristics
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between groups were tested with the parametric Student’s t-test or the non-parametric Mann–Whitney
U test, as appropriate. Differences within groups before and after intervention were determined with
the Student’s t-test for paired samples or the Wilcoxon signed-rank test, as appropriate.
3. Results
3.1. Study Population
Thirty-four children and adolescents (mean age 10 years; 62% females; all anthropometric details
summarized in Table 2), were included in the study. The duration of the GFD prior to enrolment
ranged between seven months to nine years but showed no significant difference between Synergy 1
and the placebo group (p = 0.608). Thirty patients completed the study (88.2%), while four children
were excluded from the analysis due to non-compliance in the test protocol.






N 30 17 (56.6%) 13 (63.4%)
Gender
(G–girls, B–boys)
G = 18 (60%) G = 10 (58.8%) G = 8 (61.5%)
B = 12 (40%) B = 7 (41.2%) B = 5 (38.5%)
Age (years) 4–18 4–18 4–16
Average = 10 Average = 10 Average = 10
T0 a T1 b T0 T1 T0 T1
Weight (kg) 15.0–78.0 15.7–77.5 15.0–78.0 15.7–77.5 16.3–66.8 17.0–71.5
Av = 35.8 Av = 37.6 Av = 35.8 Av = 37.6 Av = 33.7 Av = 36.2
Height (cm) 103.0–183.0 104.5–184.5 104.5–183.0 108.0–184.5 103.0–172.0 104.5–172.6
Av = 139.6 Av = 141.4 Av = 141.5 Av = 142.4 Av = 137.1 Av = 139.7
BMI (kg/m2)
12.5–28.4 12.7–29.0 12.5–23.5 12.7–23.6 13.7–28.4 13.4–29.0
Av = 17.1 Av = 17.3 Av = 17.1 Av = 17.3 Av = 17.0 Av = 17.3
a T0—baseline; b T1—after three-month intervention.
The safety profile and side effects of Synergy 1 in this trial have been previously described [24].
Briefly, no severe side effects were noted during the three-month intervention with Synergy 1 and there
was no significant difference in the frequency of reported symptoms between the two experimental
groups. The levels of anti-tissue transglutaminase antibodies (tTGA) were measured before and after
intervention. In all patients, tTGA titers before and after intervention were within the recommended
level (<8.0 AU/mL). All patients had adequate adherence to GFD according to the FFQ-6 questionnaire.
3.2. Morphological and Biochemical Parameters of Blood
Morphological and biochemical blood parameters at baseline were comparable between the
Synergy 1 and the placebo group. No statistically significant difference in those parameters was
observed before and after intervention in either of the two experimental groups (Table 3).
3.3. Hepcidin
Serum hepcidin concentrations at baseline (T0) were comparable between the two groups (p =
0.547). Hepcidin levels in the Synergy 1 group were significantly lower after 3-months intervention
than at baseline (median: 1.73 (1.31–3.14) versus 4.42 (1.89–8.64), respectively; p = 0.046), accounting
for a 60.9% decrease. Conversely, no significant difference in hepcidin concentration was observed
between T1 and T0 in the placebo group (median: 2.43 (0.91–3.87) versus 2.99 (1.23–5.09), respectively)
(Figure 1). There was no significant difference between the Synergy 1 and placebo group after the
intervention (p = 0.645).
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Figure 1. Serum hepcidin concentration before (T0) and after (T1) intervention, expressed as a median
(cross) (P25-P75) (box). * p = 0.046.
4. Discussion
To our knowledge, this is the first prospective, randomized, placebo-controlled, double-blind
study of the effects of oligofructose-enriched inulin (Synergy 1) on iron homeostasis in CD patients
treated with a GFD. Our key finding was a significant decrease in plasma hepcidin concentration
after 3 months of treatment with Synergy 1 (10 g daily), whereas no such effect was observed in
the placebo group. Hepcidin downregulates duodenal iron absorption and decreases iron storage
release by modulating cellular export via ferroportin [11]. Hepcidin production disorders result in
impaired iron homeostasis: Hepcidin deficiency may cause iron overload, while excess is associated
with IDA [8,9]. Thus, the observed decrease in hepcidin levels upon the Synergy 1 treatment could
potentially help improve iron absorption in CD children and adolescents.
To confirm this hypothesis, a positive effect of Synergy 1 on ferritin levels would need to be
demonstrated. Plasma ferritin concentration is the most sensitive indicator of iron storage capacity
in IDA. In our study, the Synergy 1 treatment did not alter ferritin or haemoglobin levels. However,
in patients with normal iron stores, ferritin levels are finely regulated to avoid excessive iron absorption
and accumulation in the organism [7]. Given that the present study was conducted on non-anemic
children and adolescents, the potential effect of Synergy 1 on ferritin and on haemoglobin levels cannot
be properly evaluated. Further prospective studies are warranted, focusing on CD children with
IDA and especially on those with refractory IDA, to verify whether Synergy 1 can indeed increase
iron absorption and whether it could have a clinical benefit in this setting. As a secondary finding,
our results show that Synergy 1 does not cause excessive iron accumulation or iron deficiency in
non-anemic CD patients, thus supporting a safe profile of this prebiotic in regards to iron homeostasis
in non-anemic individuals.
One possible explanation of the observed decrease in hepcidin is the potential anti-inflammatory
effect of prebiotics, which has been previously reported in animal models. In a study by
Marciano et al. [22], supplementation of anemic growing rats with oligofructose, but not with inulin,
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led to decreased TNF-α, IL-6 and IL-10 expression in the cecum and to a decrease in urinary
hepcidin. In another study, inulin and oligofructose supplementation led to a downregulation of
pro-inflammatory genes in colonic tissue of young anemic pigs [29]. Although the Synergy 1 treatment
did not influence CRP levels in our study, pro-inflammatory cytokines were not measured.
The beneficial role of prebiotics on iron absorption could have important clinical implications,
but so far, results from different model systems have been discrepant. Many animal studies suggest
a positive effect [22,29,30]. For example, in rats, a beneficial effect of FOS supplementation on iron
absorption was observed in both iron-deficient animals [22,31] and in growing rats with a normal iron
status [32]. In vitro experiments on the human cell line Caco-2, a widely-used model for studying
absorptive proprieties of the intestinal mucosa, have yielded inconsistent results: in two studies,
prebiotics did not improve iron bioavailability from milk- or soy-based yogurts [33,34], while in two
other studies, iron bioavailability from iron-fortified cereal biscuits [35] and from the commercial Young
Child Formula® [36] were significantly improved by prebiotic supplementation. In humans, no positive
results are available to date. In healthy men aged 20–30 years, iron absorption measured using a
stable isotope technique was 20% higher in individuals supplemented daily with FOS (15 g/day for
21 days) than in the control group, but the results did not reach statistical significance [37]. In women
with anemia, supplementation with 20 g of inulin per day for four weeks did not cause an increase
of iron absorption, although changes in gut microbiota composition and a decrease of fecal pH were
observed [38].
Although our work reveals a potential link between prebiotic supplementation and hepcidin
levels, prebiotics may also enhance iron absorption in other ways, including a direct effect on iron
transporter expression [22] and their potential to decrease systemic inflammation [22,29]. Moreover,
fermentation of indigestible oligosaccharides increases the production of fatty acids by Bifidobacteria spp.
and lowers the fecal pH, which in turn can improve iron solubility and enhance its absorption [21,38].
The potential effect of prebiotics on iron status could also be a more complex process, affecting not
only absorption but also the stage of transfer, storage, and recycling [22,29,30].
Healing of the intestinal mucosa is a critical step towards recovering normal absorption of macro-
and micro-nutrients. However, CD patients with anemia usually show a more severe enteropathy than
non-anemic patients and their intestinal mucosa may take longer to heal [38].
Our study has some limitations, including a small cohort size, inclusion of patients within a wide
age range, and a relatively short intervention duration. Thus, these findings need to be validated
on a larger cohort, including patients with IDA, and measuring additional parameters, such as
pro-inflammatory cytokines, with the potential to elucidate the mechanisms of hepcidin changes in
this setting. Intestinal histological healing in children after GFD has also been shown to occur earlier
and to a greater extent than in adults [39]. Thus, further research is needed to establish the potential
role of Synergy-1 in iron hemostasis in adult CD patients.
5. Conclusions
We have previously shown that oligofructose-enriched inulin (Synergy 1) was a safe and
well-tolerated prebiotic in children and adolescents with CD in association with a GFD. Here, we found
that a three-month intervention with Synergy 1 (10 g orally/day) led to a significant decrease of
serum hepcidin concentrations by 60.9% (p = 0.046) in those patients, whereas no significant difference
was observed in the placebo group. Given that hepcidin decrease may improve iron absorption,
these promising results warrant further investigation in a larger cohort, including patients with iron
deficiency anemia, who represent the potential target group for this type of treatment.
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biscuits as affected by enrichment with pseudocereal/inulin mixtures. Acta Aliment. 2011, 40, 480–489.
[CrossRef]
35. Christides, T.; Ganis, J.C.; Sharp, P.A. In vitro assessment of iron availability from commercial Young Child
Formulae supplemented with prebiotics. Eur. J. Nutr. 2018, 57, 669–678. [CrossRef] [PubMed]
36. Van den Heuvel, E.G.H.M.; Schaafsma, G.; Muys, T.; Van Dokkum, W. Nondigestible oligosaccharides do
not interfere with calcium and nonheme-iron absorption in young, healthy men. Am. J. Clin. Nutr. 1998, 67,
445–451. [CrossRef] [PubMed]
37. Petry, N.; Egli, I.; Chassard, C.; Lacroix, C.; Hurrell, R. Inulin modifies the bifidobacteria population,
fecal lactate concentration, and fecal pH but does not influence iron absorption in women with low iron
status. Am. J. Clin. Nutr. 2012, 96, 325–331. [CrossRef] [PubMed]
197
Nutrients 2018, 10, 1818
38. Abu Daya, H.; Lebwohl, B.; Lewis, S.K.; Green, P.H. Celiac disease patients presenting with anemia have
more severe disease than those presenting with diarrhea. Clin. Gastroenterol. Hepatol. 2013, 11, 1472–1477.
[CrossRef] [PubMed]
39. Rubio-Tapia, A.; Rahim, M.W.; See, J.A.; Lahr, B.D.; Wu, T.T.; Murray, J.A. Mucosal recovery and mortality in
adults with celiac disease after treatment with a gluten-free diet. Am. J. Gastroenterol. 2010, 105, 1412–1420.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Probiotics in Celiac Disease
Fernanda Cristofori 1, Flavia Indrio 2, Vito Leonardo Miniello 2, Maria De Angelis 3 and
Ruggiero Francavilla 2,4,*
1 Paediatric Department, “SS Annunziata” Hospital, 74100 Taranto, Italy; fernandacristofori@gmail.com
2 Department of Paediatrics, Paediatric Hospital Giovanni XXIII, Via Amendola 207, 70126 Bari, Italy;
flaviaindrio1@gmail.com (F.I.); vito.miniello@libero.it (V.L.M.)
3 Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, 70126 Bari, Italy;
maria.deangelis@uniba.it
4 Pediatric Section, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
* Correspondence: rfrancavilla@gmail.com or ruggiero.francavilla@uniba.it; Tel.: +39-080-5592063
Received: 30 September 2018; Accepted: 15 November 2018; Published: 23 November 2018 	
Abstract: Recently, the interest in the human microbiome and its interplay with the host has exploded
and provided new insights on its role in conferring host protection and regulating host physiology,
including the correct development of immunity. However, in the presence of microbial imbalance and
particular genetic settings, the microbiome may contribute to the dysfunction of host metabolism and
physiology, leading to pathogenesis and/or the progression of several diseases. Celiac disease (CD) is
a chronic autoimmune enteropathy triggered by dietary gluten exposure in genetically predisposed
individuals. Despite ascertaining that gluten is the trigger in CD, evidence has indicated that intestinal
microbiota is somehow involved in the pathogenesis, progression, and clinical presentation of CD.
Indeed, several studies have reported imbalances in the intestinal microbiota of patients with CD
that are mainly characterized by an increased abundance of Bacteroides spp. and a decrease in
Bifidobacterium spp. The evidence that some of these microbial imbalances still persist in spite of a
strict gluten-free diet and that celiac patients suffering from persistent gastrointestinal symptoms have
a desert gut microbiota composition further support its close link with CD. All of this evidence gives
rise to the hypothesis that probiotics might play a role in this condition. In this review, we describe
the recent scientific evidences linking the gut microbiota in CD, starting from the possible role of
microbes in CD pathogenesis, the attempt to define a microbial signature of disease, the effect of a
gluten-free diet and host genetic assets regarding microbial composition to end in the exploration
of the proof of concept of probiotic use in animal models to the most recent clinical application of
selected probiotic strains.
Keywords: probiotics; microbiota; celiac disease; gluten free diet
1. Introduction
Celiac disease (CD) is a lifelong immune mediated enteropathy initiated by exposure to dietary
gluten in individuals carrying human leucocyte antigen (HLA)-DQ2 or DQ8 [1]. Loss of gluten
tolerance may occur at the time of its introduction into the diet or at any time in life, and the underlying
mechanism is still under research. The role for an environmental component in CD pathogenesis
is supported by: (a) HLA and non-HLA genes explain only 55% of disease susceptibility, (b) the
concordance of celiac disease in monozygotic twins is around 80%, and (c) the incidence on this
condition is rapidly increasing [2–4].
Intestinal microbiota could be somehow involved in the pathogenesis of CD and/or in its
progression and/or in the development of clinical manifestation [5–9]. Briefly, gut microbiota can
impact on the pathogenesis of CD in different ways: (a) modulating the digestion of gluten peptides
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both generating toxic and/or tolerogenic peptides that might impact on the acquisition of dietary
tolerance to antigen, (b) influencing the intestinal permeability through zonulin release and tight
junction expression, (c) promoting the maturation of the mucosal epithelium, and (d) regulating the
activity of the immune system via expression of cytokines and pro-inflammatory or anti-inflammatory
peptides [10].
In the last decade, several studies have reported imbalances in the intestinal microbiota of patients
with CD, even though the literature shows that there is not a univocal microbial signature of CD [11].
It is also matter of debate whether dysbiosis plays a role in the pathogenesis of the disease, or whether
it is just a consequence of CD inflammation; however, the intestinal dysbiosis often persists irrespective
of the adherence to a gluten-free diet (GFD), and in part is also related to this particular diet. Finally,
the identification of intestinal dysbiosis in CD, with the evidence supporting a role for gut microbiota
in regulating key aspects of innate and adaptive immunity and the persistence of dysbiosis despite a
prolonged GFD, have led to a hypothesis suggesting the clinical use of probiotics.
The aim of this review is to describe the recent scientific evidence on the role of gut microbiota in
CD, and the proof of concept for the use of probiotics in CD patients.
2. Gut Microbiota and Risk of Developing Celiac Disease
Microbiota has a crucial role in the maturation of the immune system, being pivotal for
the development of protective/tolerogenic immune responses [12]. Current evidence shows that
environmental agents and/or endogenous signals may cause dysbiosis, which is responsible for a
breakdown of immune homeostasis and an increase in the risk of immune conditions such as CD,
among others [13].
There are several early life events that may prime a dysregulated gut microbiota, starting from
the mode of delivery. After vaginal delivery, the colonization of the newborn is characterized mainly
by Lactobacilli, Prevotella, and Bifidobacteria [14,15], while after cesarean section (C-section), the infant
flora is mainly influenced by environmental and maternal skin bacteria [16]. This might explain an
increased risk of CD in C-section newborns, as reported by previous studies [17,18].
Breastfeeding is a second factor that might impact gut microbiota composition; indeed,
the presence of human maternal oligosaccharides supports the survival and growth of a healthy
microbiota. Retrospective studies have shown that the duration of breastfeeding and particularly
gluten introduction during breastfeeding reduce or delays CD onset [19]. However, both these evidence
have been recently questioned and not confirmed, so the issue is still debated [20–22], and the issue may
be more complicated than initially thought. De Palma et al. studied 164 newborns (born in a family
with a first-degree relative with CD) divided according to HLA genotype and modality of feeding
(breast versus formula), and found a different gut colonization according to with the type of feeding.
Overall, they showed that carrying the HLA predisposition was associated with increased numbers of
Bacteroides fragilis and Staphylococcus, and decreased Bifidobacterium, and that these differences were
increased by formula as compared to breastfeeding. These results support the idea that gut microbiota
composition is a multiplayer game where both feeding type and HLA genotype are key regulators [23].
Another variable can complicate this issue: evidence that breast milk samples from mothers with CD
as compared to those without CD have lower titers of interleukin12p70, transforming growth factor-β1,
and secretory immunoglobulin A (IgA), and a decrease in the Bifidobacterium and Bacteroides fragilis
groups. This study supports the hypothesis that the reduction of immune-protective compounds and
Bifidobacterium species can reduce the protection conferred by breastfeeding, thus increasing the child’s
risk of CD [24].
That a particular genetic asset could play a role in shaping gut microbiota in early life is further
supported by a recent study. De Palma et al. studied the faecal microbiota of 22 breastfed infants
(born in a family with a first-degree relative with CD), and found that carrying a high (HLA-DQ2)
as compared to a low genetic risk (non-HLA-DQ2/8) was followed by the presence of higher
proportions of Firmicutes and Proteobacteria (Corynebacterium, Gemella, unclassified Clostridiaceae,
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unclassified Enterobacteriaceae, and Raoultella) and lower proportions of Actinobacteria (Bifidobacterium
and unclassified Bifidobacteriaceae). These results highlight that a specific host genotype might
modulate the gut microbiota composition of infants and contribute to an increasing disease risk [25].
The possibility that a particular genotype can shape the gut microbial composition is supported by
genome-wide association studies that have identified 39 non-HLA CD risk loci. Interestingly, some
of these genes related to immune functions and bacterial colonization and disease-associated single
nucleotide polymorphism (SNPs) involved in the regulation of microbiota handling may explain the
role of genes in gut microbiota composition [26].
In order to investigate the role of gut microbiota (and their products—metabolome) as contributory
factors leading to the onset of CD, a large international study: “Celiac Disease Genomic, Environmental,
Microbiome, and Metabolomic Study (CDGEMM) is ongoing in the United States (USA), Italy and
Spain. CDGEMM is a prospective, longitudinal observational cohort study of infants with a first-degree
family member with CD that aims to investigate if the time of gluten introduction, microbiota
composition, and genetic asset are involved in the loss of gluten tolerance, and identify and validate
specific microbiota and metabolic profiles that are mechanistically linked to gut functions (including
permeability, immune function, and stem cell niche biology) and can anticipate a loss of gluten
tolerance in genetically predisposed individuals. This study will be the proof of concept to plan
preventive interventions to induce gluten immune tolerance and possibly prevent CD [27].
3. Microbiota in Celiac Patient
As shown in Table 1, in the last 10 years, several studies [28–51] have been performed evaluating
fecal, salivary, and duodenal microbiota in CD patients. Interestingly, Collado et al. have shown a
correlation between bacterial species found in both biopsies and feces of CD patients indicating that the
fecal microbiota is comparable to the small intestine microbiota, and may have a diagnostic value [31].
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Sanz et al. [29] 10 CD vs. 10 HC Children No No Yes CultureDGGE
L. curvatus, Leuconostoc
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PCR
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↓ Bifidobacteria
Di Cagno et al.
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Bacteroides and enterobacteria
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↑ Bacteroides vulgatus and
Escherichia coli
De Palma et al.
[35]
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CD-GFD vs. 20 HC Children No No Yes
FISH flow
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↓ Gram-positive to Gram-negative
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↓ Bifidobacterium, Clostridium
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Sanchez et al.
[36]
20 CD vs. 12
CD-GFD vs. 8 HC Children No Yes No DGGE
↑ Bacteroides dorei





Bifidobacterium animalis subsp lactis
Di Cagno et al.
[37] 19 CD vs. 15 HC Children No Yes Yes DGGE
↓ Lactobacillus, Enterococcus, and
Bifidobacteria
Nistal et al. [38] 10 CD vs. 11CD-GFD vs. 11 HC Adults No No Yes DGGE ↑ B. bifidum and catenulatum
Nistal et al. [39] 13 CD vs. 5CD-GFD vs. 10 HC
Children
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Sanchez et al.
[40]
20 CD vs. 20






Acar et al. [41] 35 CD vs. 35 HC Children Yes No No CRT Bacteria ↓ Salivary mutans streptococci andlactobacilli colonization







32 CD vs. 17


















↑ Proteobacteria, such as
Acinetobacter and Neisseria, in
patient with GI symptoms.
↓ microbial diversity in GI
symptoms or anemia
Cheng et al [45] 10 CD vs. 9 HC Children No Yes No qRT-PCR
No differences Haemophilus ssp.
and Serratia ssp. had relatively
higher abundance in CD
Francavilla et al.
[46]
13 CD-GFD vs. 13























11 A-CD vs. 11 HC Children No Yes No DGGE Lactobacillus genus
D’Argenio et al.
[49]
20 A-CD vs. 6





↑ Proteobacteria ↓ Firmicutes and
Actinobacteria
↑ Neisseria genus (Neisseria
flavescens)
Quagliariello et













Bacteroidetes (CD > RCD),
Actinobacteria (CD < RCD),
Fusobacteria (CD > RCD)
A-CD: active celiac disease, CD-GFD: celiac disease on gluten-free diet, GI: gastrointestinal, RCD: refractory celiac
disease, HC: healthy controls, FISH: fluorescent in situ hybridization, TTGE: temporal temperature gradient gel
electrophoresis, DGGE: denaturing gradient gel electrophoresis; qPCR: quantitative PCR; qRT-PCR: quantitative
reverse-transcriptase-PCR; ↓ Decrease; ↑ Increase.
Among the various studies, results may vary, which is due to huge differences in terms of
microbiological methods, sample sizes, and patients’ characteristics. Nevertheless, there is substantial
agreement on the presence of an imbalance between pro-inflammatory and anti-inflammatory species,
with a prevalence of the former.
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We investigated the fecal microbiota of children with active CD (A-CD) and after (T-CD) GFD and
of healthy children (HC) showing a reduction of Lactobacillus in A-CD, but not in T-CD, that was similar
to that of HC. Using gas chromatography mass spectrometry solid-phase microextraction analysis,
we found a profound variation of the mean concentrations of volatile organic compounds with short
chain fatty acids being more represented in HC [32]. In a subsequent study, we analyzed the duodenal
microbiota of 19 T-CD and 15 HC, and found a higher diversity of Eubacteria and lower counts of
Bifidobacteria in T-CD as compared to HC children. According to the most recent scientific evidences,
the CD patients’ microbiota seems to be characterized by an increased abundance of Bacteroides spp.,
E. Coli, Proteobacteria, and Staphylococcus and a decrease in Bifidobacterium spp. and Lactobacillus [52].
This result supports the knowledge that a long-lasting GFD did not completely restore the microbiota
of CD children [37].
A study by Wacklin et al. suggested that the microbiota might have a role in the clinical
manifestation of the disease. Indeed, the authors demonstrated that CD patients with gastrointestinal
symptoms compared to those without and controls have different microbiota compositions (more
abundant in Proteobacteria phylum versus more abundant in Firmicutes phylum, respectively) [44].
Moreover, alterations of microbiota may have pathogenic implication, leading to persistent
gastrointestinal symptoms, despite a strict GFD. Indeed, the same group found that CD patients
on a GFD who are still symptomatic have a reduced microbial richness and a different duodenal
microbiota colonization in comparison with asymptomatic patients (higher relative abundance of
Proteobacteria and a lower abundance of Bacteroidetes and Firmicutes), showing that intestinal dysbiosis
might be responsible for the persistence of symptoms, even while adhering to a strict GFD [47].
4. Gluten-Free Diet and Gut Microbiota
At present, a strict GFD is the only available treatment [53] and, although evidence exists on
the comparison between the gut microbiota of CD patients on a GFD or a gluten-containing diet
(GCD) and/or controls, very few data are available in prospectively followed CD patients before and
after GFD.
GFD is only partially effective in restoring the gut microbiota: indeed, while higher numbers
of Enterobacteria or Staphylococci are restored, other alterations such as decreased Bifidobacteria and
Lactobacilli and increased Bacteroides, Enterobacteriaceae and virulent E. coli still are persistent [54].
On the other hand, a GFD can itself influence gut microbiota composition. De Palma et al. studied
the effects of a month of GFD on the composition of the gut microbiota in 10 healthy subjects, and
found a significant decrease of Bifidobacterium, Clostridium lituseburense, and Faecalibacterium prausnitzii,
and an increase of Enterobacteriaceae and Escherichia coli counts [54]. The analysis of the daily energy
and nutrient intake before and after the GFD found no significant differences in dietary intake, except
for a significant reduction in polysaccharide intake, leading the authors to conclude that a natural
reduction in polysaccharide intake (fructans), which have prebiotic action and constitute one of
the main energy sources for commensal components of the gut microbiota [55], might explain the
reductions in beneficial gut bacteria populations. Therefore, a GFD itself rather than CD may be
responsible for gut microbiota unbalance.
5. Probiotics Supplementation
Most of the evidence on the effect of probiotics in CD comes from animal models. Experiments
using transgenic non-obese diabetic-DQ8 mice are the proof of concept that the microbiota shape
the gluten-related immune-mediated mucosal damage. In germ-free conditions, mice develop a
more aggressive gluten-induced pathology as compared with mice colonized with altered Schaedler
flora (benign microbiota) that is deprived of opportunistic pathogens. However, in the presence of
a microbiota with opportunistic pathogens or in the case of perturbations secondary to antibiotic
use, mice develop gluten-induced severe pathology. These results reinforce the pivotal effect of gut
microbiota in the inflammatory response that is associated with gluten ingestion [56].
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Mouse models have demonstrated that probiotics can modulate innate and adaptive immunity,
and reduce gliadin-induced inflammation [57–59].
Lindfors K et al. studied whether Lactobacillus fermentum or Bifidobacterium lactis are able to reduce
the toxic effects of gluten-derived peptides in intestinal cell culture (Caco-2) conditions. They showed
that Bifidobacterium lactis was able to inhibit the gliadin-induced derangement of epithelial permeability,
and speculated that this probiotic could counteract the harmful effects of toxic gliadin epitopes [60].
Papista C et al. investigated the influence of probiotics in a model of gluten sensitivity (BALB/c
mice); the authors were able to show that the Saccharomyces boulardii KK1 strain hydrolyzed the
gliadin toxic peptides, and its consumption was followed by improved enteropathy and a decrease of
histological damage and pro-inflammatory cytokine production [59].
Laparra J.M. et al. studied the use of Bifidobacterium longum CECT 7347 in an animal model of
gliadin-induced enteropathy. The authors showed that the administration of this particular strain
reduces the production of pro-inflammatory cytokines and the mediated immune response [61].
The idea that the effect played by probiotics is strain-specific is supported by the work of
D’Arienzo et al., who studied the effect of Lactobacillus and Bifidobacterium lactis strains in transgenic
mice expressing human DQ8, and found an increased antigen-specific tumor necrosis factor (TNF)
secretion showing that probiotics may have pro-inflammatory rather than suppressive effects [62].
Despite the encouraging data deriving from in vitro studies, few in vivo data are available on
probiotics supplementation in patients with CD (Table 2).
Table 2. Main evidence on the use of probiotics in patients with celiac disease.
Author RCT Population Used Strain
Time of
Administration
Findings in Probiotics Group
Smecuol et al. [63] Yes 22 A-CD (12 probioticvs. 10 placebo)
Bifidobacterium infantis Natren
life start 3 weeks
Improvement in GI symptoms
(indigestion, constipation, and
gastroesophageal reflux)
↓ Final/baseline IgA tTG and IgA
DGP antibody concentration ratios
↑ Serum macrophage
inflammatory protein-1β
No differences in intestinal
permeability




24 A-CD no treatment




life start 3 weeks
↓ Paneth cell counts
↓ α-defensin-5
Olivares et al. [65] Yes
36 A-CD (18 B. longum
+ GFD vs. 18 placebo
+ GFD)
Bifidobacterium longum
CECT 7347 3 months
↑ Height percentile
↓ Peripheral CD3+ T lymphocytes
concentration
↓ TNF-α levels
↓ Bacteroides fragilis and
Enterobacteriaceae
↑ Harmless to potentially harmful
bacteria ratio
No differences in GI symptoms
Quagliarello et al.
[50] Yes
40 A-CD children (20
probiotic and 20
placebo) vs. 16 HC
Bifidobacterium breve strains
(B632 and BR03) 3 months
↑ Actinobacteria Re-establishment
Firmicutes/Bacteroidetes ratio.

















No differences in the fecal
microbiota counts
No differences in symptoms
severity
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Table 2. Cont.
Author RCT Population Used Strain
Time of
Administration
Findings in Probiotics Group





(BR03 and B632) 3 months ↓ TNF-alpha levels (not persistent)
Primec et al. [68] Yes
40 CD (20 probiotic
and 20 placebo) 16
HC
Bifidobacterium breve strains














subsp. lactis Bi1 LMG P-17502,
Bifidobacterium breve Bbr8 LMG
P-17501 Bifidobacterium breve
Bl10 LMG P-17500
6 weeks Improvement in GI symptoms↑ Bifidobacteria (persistent)
A-CD: active celiac disease; CD-GFD: celiac disease on gluten-free diet; HC: healthy controls; GI: gastrointestinal,
IgA: immunoglobulin A; tTG: antitransglutaminase; DGP: deamidated gliadin peptide; TNF: tumor necrosis factor;
↓ Decrease; ↑ Increase.
Smecuol et al. investigated the effects of Bifidobacterium infantis Natren life start strain (NLS-SS),
randomizing 22 patients with A-CD to receive the probiotic or placebo while on a GCD, showing that
this probiotic led to a significant improvement in GI symptoms. However, they found no effect on
cytokines and growth factors, neither on celiac serology nor gut permeability [63].
The same group speculated that the favorable effect that was observed could be due to its influence
on innate immunity. Thus, they tested the effect of Bifidobacterium infantis NLS-SS by assessing Paneth
cells and macrophage counts and human α-defensin 5 (HD5) expression in duodenal biopsies of
CD patients on a GFD. The results of this second study demonstrated that patients that assumed
Bifidobacterium infantis NLS-SS experience a decrease in the expression of the antimicrobial peptide
HD5, which is paralleled by a decrease in Paneth cells counts [64].
In a recent randomized control trial, Olivares at al. demonstrated in children with a new diagnosis
of CD that the administration of Bifidobacterium longum CECT 7347 for three months, when associated
with a GFD, was able to determine a height percentile increase compared with a placebo, as well as
lower peripheral CD3+ T lymphocytes concentration and slightly reduced TNF-α levels; moreover,
the treatment with Bifidobacterium longum CECT 7347 was associated with a significant decrease in the
Bacteroides fragilis group and Enterobacteriaceae and a higher ratio of harmless to potentially harmful
bacteria. However, the authors did not find any improvement of gastrointestinal symptoms [65].
Quagliarello et al. performed a RCT in 49 CD children to evaluate the efficacy of three months of
administration of two Bifidobacterium breve strains (B632 and BR03) on the re-establishment of eubiosis
in CD children on a GFD, demonstrating that supplementation induces an increase of Actinobacteria
as well as a restoration of the Firmicutes/Bacteroidetes ratio [50].
On the contrary, Harnett et al. randomized 45 CD patients on a GFD, with persistent symptoms,
to receive VSL#3 (5 g) or placebo, and found no differences in the fecal microbiota counts, and symptoms
severity after two weeks of supplementation [66].
Klemenak et al. investigated the effect of two Bifidobacterium breve strains (BR03 and B632) on
serum interleukin-10 and TNF-α levels in 49 children with CD on GFD, demonstrating lower levels of
TNF-α after three months of daily use; no difference was found for interleukin (IL)-10 levels [67].
In 2018, Primec M. et al. performed a double-blind placebo-controlled study enrolling 40 CD and
16 healthy children. CD children were randomized to receive placebo or a mixture of two Bifidobacterium
breve strains (DSM 16604 and DSM 24706) for three months. The authors showed that this probiotic
mixture was able to modulate the production of acetic acid and total short-chain fatty acids (SCFAs),
promoting a potential role in microbiome restoration [68].
Finally, our group recently performed a large prospective, randomized study in 109 CD
patients strictly adherent to a GFD with irritable bowel syndrome (IBS) symptoms. Enrolled patients
were randomized to probiotics (mixture of five strains of lactic acid bacteria and bifidobacteria:
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Lactobacillus casei LMG 101/37 P-17504 (5 Å~ 109 CFU/sachet), Lactobacillus plantarum CECT 4528
(5 Å~ 109 CFU/sachet), Bifidobacterium animalis subsp. lactis Bi1 LMG P-17502 (3.4 Å~ 109 CFU/sachet),
Bifidobacterium breve Bbr8 LMG P-17501 (3.4 Å~ 109 CFU/sachet), Bifidobacterium breve Bl10 LMG
P-17500 (3.4 Å~ 109 CFU/sachet)), or placebo for six weeks, and then followed up for six more
weeks. Our results showed that the probiotic mix under study is effective in ameliorating the
severity of IBS symptoms measured by IBS severity score (IBS-SS). After six weeks of treatment,
we found a significantly higher proportion of treatment success (a decrease of at least 50% of IBS-SS),
at both intention-to-treat (14.8% versus 3.6%; p < 0.04) and per protocol analysis (15.3% versus 3.8%;
p < 0.04) [69]. A recent meta-analysis has shown that CD patients with GI symptoms have a higher
prevalence of small intestinal bacterial overgrowth (SIBO) as compared to controls (28% versus 10%),
although the difference does not reach statistical significance, and the analysis is affected by the large
heterogeneity of the studies [70]. At present, no studies have been conducted to investigate whether
probiotic administration might have an impact on SIBO in CD patients, nor have we explored this in
our trial. However, we were able to show a positive modulation of gut microbiota with an increase of
bifidobacteria still detectable six weeks after the discontinuation of probiotics [69].
6. Conclusions
Gut microbiota is an essential mediator of health, and its imbalance might be followed by an
alteration of microbiota functions with a negative impact on health. Research in the last 10 years
has shed new light on the role of the gut microbiota in CD and the complex relation between its
composition, genetic background, GFD, and the persistence of clinical symptoms. Although many
critical issues remain to be defined, some aspects are now clear. (a) Gut microbiota participate and
mediate the gluten related inflammation. (b) As of yet, there is not a definite microbial signature
of disease, although some microbial alterations are consistently reported, both in biopsies and fecal
samples (abundance of Bacteroides spp., a decrease in Bifidobacterium spp.). (c) Some alterations of gut
microbial composition revert to normal, while others are sustained by a GFD, and might be in part
responsible for the persistence of symptoms in this population. (d) Selected probiotics with clinical
proven efficacy might be of help in controlling gluten-mediated inflammation and ameliorating clinical
symptoms (Figure 1).
With the increasing prevalence of people that adopt the gluten-free regimen, it is mandatory to
define the intimate link between gut microbiota and gluten-related disorders in order to explore new
possible avenues to offer a valid dietetic counseling to this expanding population and possibly in the
future to identify new strategies for prevention and treatment.
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Figure 1. Mechanism of action of probiotics in controlling GI symptoms in celiac patients. Recent
data have shown that patients with celiac disease (CD) have an altered gut microbiota (GM), (1) and
that carrying the genetic predisposition (HLA-DQ-2 or DQ-8) may predispose individuals to a state of
dysbiosis. (2) Patients with CD usually have GI symptoms (3) that can persist to a strict gluten-free diet
(GFD); moreover, the alteration of GM can be one of the main causes of the persistence of GI symptoms.
(4) CD requires that a patient follow a rigorous GFD (5) and a natural reduction in polysaccharide intake
(fructans), which have prebiotic action, and constitute one of the main energy sources for commensals
of the GM that might further worsen gut dysbiosis. (6) In turn, this reinforces the persistence of GI
symptoms. (7). If we consider that most of the variables of this complex equation are fixed (genetic
predisposition, CD, need for a GFD, the presence of GI symptoms), the only variable on which we can
operate is the GM: therefore, the adoption of a probiotic supplementation that restores the imbalance
in the GM of a celiac patient might be a reasonable therapeutic option.
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Abstract: The potential association between gut microbiota perturbations and childhood functional
gastrointestinal disturbances opens interesting therapeutic and preventive possibilities with
probiotics. The aim of this review was to evaluate current evidence on the efficacy of probiotics
for the management of pediatric functional abdominal pain disorders, functional constipation and
infantile colic. Thus far, no single strain, combination of strains or synbiotics can be recommended for
the management of irritable bowel syndrome, functional abdominal pain or functional constipation
in children. However, Lactobacillus reuteri DSM 17938 may be considered for the management of
breastfed colic infants, while data on other probiotic strains, probiotic mixtures or synbiotics are
limited in infantile colic.
Keywords: probiotics; functional gastrointestinal disorders; functional abdominal pain disorders;
functional constipation; infantile colic
1. Introduction
The role of the intestinal microbiota in health and disease has been the focus of intensive research
during the past decades. This interest has largely resulted from studies indicating differences in
gut microbiota between healthy individuals and patients afflicted with non-communicable disease.
Particularly, various chronic gastrointestinal disorders such as functional gastrointestinal disorders
(FGID), colic crying, inflammatory bowel disease, and celiac disease have been associated with
perturbations in gut microbiota composition. While these associations offer no proof of causality
or direction, they serve as starting points for research aiming to establish whether gut microbiota
disturbances might predispose one to or be involved in the causal complex leading to disease.
The association between dysbiosis and functional gastrointestinal disorders in children and infants
has raised great interest in modulating the gut microbiota composition and activity as a promising
therapeutic and preventive option. The aim of this review was to evaluate current evidence on the
efficacy of probiotic interventions for the management and prevention of functional gastrointestinal
disorders, especially focusing on pediatric functional abdominal pain disorders, functional constipation
and infantile colic.
2. Intestinal Microbial Colonization in Early Life
Neonatal gut colonization is a stepwise process which is affected by genetic and maternal
influences and, perhaps more profoundly, by environmental and dietary exposures. Recent reports
from clinical and experimental studies suggest that intestinal colonization may begin already during
fetal life by microbes present in the intrauterine environment [1,2]. These findings, while extremely
interesting, need further confirmation in large clinical studies with methodological rigor to exclude
Nutrients 2018, 10, 1836; doi:10.3390/nu10121836 www.mdpi.com/journal/nutrients212
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the possibility of contamination during sample acquisition and all steps during sample preparation,
processing and analysis.
Human neonates receive an important inoculum of colonizing microbes during vaginal delivery.
While maternal vaginal microbes, primarily lactobacilli, transiently colonize the neonatal gut [3], it is
evident that the maternal gut is the most important source of early colonizing bacteria to the neonate [4].
The significance of vaginal delivery to healthy gut colonization is underscored by data suggesting
aberrant gut colonization patterns in infants born by caesarean section delivery as compared to those
born vaginally [5]. After birth, gut colonization progresses in a stepwise manner and bifidobacteria
soon dominate the gut microbiota of breastfed infants [6,7]. This is thought to primarily result
from breast milk components, including glycoproteins and particularly human milk oligosaccharides
(HMOs), which selectively enhance the growth of bifidobacteria [8]. This notion is supported by the
fact that Bifidobacterium longum subspecies infantis, a microbe capable of utilizing a variety of HMOs,
is practically universally encountered in breastfed infant microbiota throughout the world [9–11].
Moreover, the gut microbiota of infants fed with cow’s milk-based formula devoid of HMOs exhibits
more diversity and a lower abundance of bifidobacteria [12]. While breastfeeding is associated with
reduced risk of chronic non-communicable diseases including type II diabetes mellitus and obesity [13],
the contribution of gut microbiota modulation to these health impacts is currently not known.
The infant and child gut microbiota gradually shifts to resemble that of adults and a stable, adult-like
gut microbiota is thought to be established by the age of 2–3 years. The introduction of solid foods and
particularly the cessation of breastfeeding are major driving forces of gut microbiota maturation [4]. It is
noteworthy, however, that the mature gut microbiota exhibits considerable differences depending on
geographical area [14]. The contribution of dietary practices most likely outweighs the effect of genetic
differences in explaining this phenomenon. Throughout the maturation process, detrimental exposures
and particularly antibiotic use may cause profound disturbances in gut microecology. The potential
clinical significance of these temporary perturbations is illustrated by epidemiological studies suggesting
an association between early-life antibiotic exposure and chronic disorders including overweight and
obesity, asthma and inflammatory bowel disease [15].
3. Functional Gastrointestinal Disorders and Gut Microbiota
Since the early 1990s, the Rome foundation, a group of experts in functional gastrointestinal disorders
(FGIDs), has collected the summary of knowledge among the FGIDs into the Rome criteria [16]. The most
recent version, the Rome IV criteria, categorizes FGIDs among children and adolescents into three
main classes based on the prime symptoms, i.e., functional nausea and vomiting disorders, functional
abdominal pain disorders and functional defecation disorders. Functional nausea and vomiting
disorders include cyclic vomiting syndrome, functional nausea and vomiting, rumination syndrome,
and aerophagia. Functional abdominal pain disorders are classified into four groups: functional
dyspepsia, irritable bowel syndrome (IBS), abdominal migraine, and functional abdominal pain
(FAP)—not otherwise specified, whereas functional constipation and non-retentive fecal incontinence
belong to the functional defecation syndromes [17].
According to the Rome IV criteria, infant colic is recurrent and presents with prolonged periods
of crying, fussing or irritability in otherwise healthy infants under the age of 5 months. Colic crying
resolves by the first five months of life and occurs without obvious cause and cannot be prevented
or resolved [18]. However, the most widely accepted definition was penned by Wessel in 1954 as
“paroxysms of irritability, fussing or crying lasting for a total of more than three hours a day and
occurring on more than three days in any one week” in an otherwise healthy and thriving infant (19).
Since the Rome criteria are based on a systemic review of the literature and are widely adopted,
we decided to concentrate here on only randomized clinical probiotic studies where the criteria have been
used. However, in most of the colic studies, the “Wessel rule of three” has been used as the diagnostic
criteria of infantile colic [19], and thus we included studies using those criteria as well. Moreover, the focus
is on functional abdominal pain disorders, functional constipation and infantile colic since clinical trials
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in the field have been done almost exclusively with children with those disorders, as recently systemically
reviewed [20,21]. In addition, in this review, we focused on the studies where these disorders were the
primary outcome.
Given the association between early gut microbiota composition and chronic disease later in
childhood, it is intriguing to hypothesize that disturbances in gut colonization might also play a
role in the etiology and pathogenesis of childhood functional gastrointestinal disorders. The data
regarding gut microbiota perturbations related to irritable bowel syndrome (IBS) and other functional
gastrointestinal disorders in adults are not easy to interpret due to discrepant findings, despite attempts
to adhere to generally accepted diagnostic criteria. The extrapolation of results obtained from an
adult population to apply to children should always be done with caution. Only a few studies
have systematically investigated gut microbiota composition or activity in children with functional
gastrointestinal disorders.
In a case-control study of 22 school-aged children with IBS as defined by the Rome III criteria
and 22 healthy controls, a fecal microbiota analysis by sequencing the 16S ribosomal RNA gene
revealed that IBS was associated with a greater relative abundance of Proteobacteria, and particularly
Gammaproteobacteria [22]. Rigsbee and colleagues [23] reported significant differences in gut
microbiota composition between 22 school-aged children newly diagnosed with diarrhea-prominent
IBS (IBS-D) fulfilling the Rome II criteria and 22 healthy children. Using several molecular methods
(microarrays, 16S rRNA gene sequencing, quantitative PCR and fluorescent in situ-hybridization) they
showed differing abundances of several bacterial genera between children with and without IBS-D.
In contrast, no significant differences in fecal microbiota profiles or relative abundances of specific taxa
were detected between 76 children aged between 4 and 17 years with functional constipation as defined
by the Rome III criteria as compared to 61 healthy children of similar age [24]. Nonetheless, the children
with functional constipation could be distinguished from the healthy matched controls by the ridge
regression analysis of the fecal microbiota.
Whilst some studies suggest gut microbiota differences between pediatric patients with IBS
and healthy children, it is not at all certain whether the gut microbiota plays a causal role in the
pathogenesis of IBS. We are not aware of any reports with fecal samples obtained before the onset of
IBS. However, a recent register-based study of more than 2 million individuals, of whom more than
14,000 had been diagnosed with IBS [25], suggests that caesarean section delivery is associated with a
slightly increased risk of developing IBS (adjusted odds ratio (OR) 1.09, 95% confidence interval (CI)
1.03–1.16). This increase in risk, albeit small on an individual level, may at least in part be attributable to
the aberrant gut colonization associated with caesarean section delivery. More circumstantial evidence
for the connection between early gut microbiota perturbations and later functional gastrointestinal
disorders may be drawn from a birth cohort study of more than 2700 children from Sweden [26],
in which antibiotic use in the first or second year of life was associated with increased risk of recurrent
abdominal pain in later childhood in girls. However, the association was not detected in boys.
The most comprehensive data on the association between gut microbiota alterations and functional
gastrointestinal disorders are currently those regarding infantile colic. As early as 1994, Lehtonen and
colleagues have reported based on culture methods that infants with colic were more often colonized
by clostridia than healthy age-matched control infants, and that the difference was no longer detectable
later at the age of three months [27]. Through the use of a modern microarray method in a case-control
study of 12 infants with colic and 12 healthy age-matched controls with serial fecal samples, de Weerth
and co-workers demonstrated that gut microbiota alterations are detectable already in the first weeks
of life in infants who later develop colic [28]. Colic was specifically associated with the enrichment
of Proteobacteria including Escherichia, Klebsiella and Pseudomonas, whereas the phyla Firmicutes and
Actinobacteria were more prevalent in infants who did not develop colic. A decreased abundance of
Actinobacteria and especially Bifidobacteria in the feces of infants with colic was recently confirmed
by the 16S rRNA gene sequencing of fecal samples obtained from 37 infants with colic and 28 healthy
controls [29]. Taken together, these data suggest not only that infantile colic is associated with altered gut
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microbiota composition but also that aberrant gut colonization precedes and may be causally related
to the development of colic. This notion is corroborated by a recent report suggesting that maternal
intrapartum antibiotic treatment, which is known to affect neonatal gut colonization, is more prevalent
in infants who later develop colic [30].
4. Probiotics
The potential association between gut microbiota perturbations and functional gastrointestinal
disturbances in children opens interesting therapeutic and preventive possibilities. The modification
of the gut microbiota composition and activity by dietary interventions is currently an active area of
research. Probiotics are one of the most commonly used treatment modalities.
Probiotics have been defined as live micro-organisms that, when administered in adequate
amounts, confer a health benefit to the host [31]. It is important to note that, in order to be named a
probiotic, the microbe in question must have evidence-based health effects. It is equally important to
realize that probiotic effects are strain and species-specific. Clinical or mechanistic probiotic effects
cannot be extrapolated to apply to other, even closely related microbes. This should also be borne in
mind when devising or interpreting systematic reviews and meta-analyses of clinical probiotic studies.
The mechanisms of action of probiotics appear to be complex. It is often assumed that probiotics
function by modulating the gut microbiota, but the evidence for this conjecture is sparse and the
definition of probiotics cited above makes no reference to the gut microbiota. Specific probiotics
have been shown to effective in reducing the risk and treatment of gastrointestinal disorders such
as childhood infectious diarrhea [32,33], but it is not evident that these beneficial effects entail an
impact on gut microecology. Moreover, there are clinical trials indicating that probiotic intervention on
the pregnant and breastfeeding mother significantly reduces the occurrence of atopic dermatitis in
high-risk infants with no effect on the infant gut microbiota composition [34,35]. Intriguingly, clinical
and experimental studies have demonstrated that specific probiotics have direct effects on host
physiological processes involving digestion and gut barrier function, immune responses, metabolism,
nociception and behavior. It is therefore not surprising that probiotics have in some clinical trials
shown clinical benefit in reducing the risk of diseases such as respiratory tract infections or otitis
media [36], which have little to do with the gut microbiota. Based on all of this, it is paramount
that determining the efficacy of probiotic interventions should be based on clinical criteria and not
surrogate outcomes such as effects on gut microbiota.
4.1. Probiotics in the Management Pediatric Functional Abdominal Pain Disorders
Several clinical observations suggest that dysbiosis is a hallmark of IBS. First, symptoms in a
substantial proportion of IBS patients are preceded by gastroenteritis or a round of antibiotics [37,38].
Moreover, rifaximin, the nonabsorbable antibiotic, has been shown to be effective in the treatment
of adult patients with diarrhea-predominant irritable bowel syndrome (IBS-D) [39], although it was
ineffective in children with chronic abdominal pain [40]. Indeed, gut microbiota alterations have
found both in adults (reviewed in [41]) and children (reviewed above), thus offering a rationale for the
therapeutic manipulation of gut microbiota in this group of patients.
Lactobacillus reuteri DSM 17938 has been the most widely studied probiotic in the field. Its effect
has been investigated in 5 randomized clinical studies in children with FAP or IBS. In the first study,
Romana et al. [42] compared the Lactobacillus reuteri with a placebo in 60 children. A significant
reduction in pain intensity was found only in the probiotic group whereas a comparable significant
reduction in pain frequency was shown in both groups. However, all these data were only
graphically shown, without numeric presentation, limiting the interpretation of the findings [43].
Eftekhari et al. [43] did not find any significant differences between probiotic and placebo groups in
severity of pain in 80 children with FAP despite a similar significant decrease within the groups as
compared to the baseline. These studies both consisted of four weeks of intervention and follow-up.
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Weizman et al. [44] evaluated the effect of Lactobacillus reuteri DSM 17938 with placebo in
101 children with FAP. At the end of the 4-week intervention, both the frequency and severity of
pain were significantly lower in the probiotic group than in the placebo arm. After the 4-week
follow-up, only the latter difference remained significant between the groups [44]. Jadresin et al. [45]
studied Lactobacillus reuteri DSM 17938 in comparison to placebo in 55 children with FAP or IBS during
a 16-week trial. Children in the probiotic group had more days without pain as compared to the placebo
group during the study period. The intensity of pain was also less severe in the second and fourth
month among the former group. However, absence from school or activities did not differ between
the groups [45]. In the most recent study, Maragkoudaki et al. [46] compared Lactobacillus reuteri DSM
17938 to placebo in 54 children with FAP. Both the probiotic and placebo significantly reduced pain
intensity and frequency from the baseline, but there was no significant difference between the groups.
In addition, absence from school and use of analgesics were comparable between the groups [46].
The use of Lactobacillus rhamnosus GG in the management of pediatric FGIDs has been evaluated
in three randomized clinical studies [17]. Bauserman et al. [47] found no difference in the change of
abdominal pain severity between probiotic and placebo groups in 64 children with IBS. The number
of responders was also similar between the groups. Abdominal distension was the only remaining
symptom which was significantly less often present in the probiotic than the placebo group at the end of
the 6-week study [47]. Gawronska et al. [48] investigated the effect of Lactobacillus GG versus placebo
in 20 children with functional dyspepsia, 37 children with IBS and 47 children with FAP. Comparable
amounts of patients (25% in probiotic and 9% in placebo group) reported no pain at the end of the 4-week
study period. However, IBS patients receiving the probiotic were significantly more often without pain
than patients on placebo (33% versus 5%) [48]. In the largest trial so far, Francavilla et al. [49] compared
Lactobacillus GG versus placebo in 83 patients with IBS and 58 patients with FAP. They found that after a
4-week run-in and 8-week intervention, both pain intensity and frequency were significantly smaller in
children with probiotic than those with placebo. These differences remained stable during the 8-week
follow-up. Moreover, treatment was more often successful (i.e., at least 50% decrease both in pain
intensity and frequency from the baseline) in the probiotic than the placebo group (72% vs. 53%) [49].
In addition to the above-mentioned studies, three trials have been conducted where other probiotic
strains or combination of strains have been tested against placebo in children with functional abdominal
disorders. Guandalini et al. [50] evaluated VSL#3 (a mixture of 8 strains) versus placebo in a crossover
study of 67 children with IBS. Abdominal pain had decreased in both groups by the end of the 6-week
intervention, but significantly more in the VSL#3 group. At week 6, the last week of the intervention,
disruption of family life was assessed to be decreased more in the probiotic than placebo group [50].
Basturk et al. [51] investigated the effect of Bifidobacterium lactis B94 versus prebiotic inulin versus a
synbiotic (inulin and Bifidobacterium lactis B94) in 71 children with IBS. The resolution of all symptoms
during a 4-week trial was found in comparable amounts in the probiotic (39%) and synbiotic (29%) groups,
but less often in those on inulin (12%). Giannetti et al. [52] studied a mixture of Bifidobacterium infantis
M63, Bifidobacterium breve M16-V and Bifidobacterium longum BB36 in a crossover study of 50 children
with IBS and 28 children with functional dyspepsia. They reported that abdominal pain disappeared
significantly more often in the probiotic than placebo group in patients with IBS but not in those with
functional dyspepsia. Again, quality of life improved significantly more often only in IBS patients on
probiotics as compared to the same patients on placebo [52].
4.2. Probiotics in the Management of Pediatric Functional Constipation
Banaszkiewicz and Szajewska [53] investigated the effect of Lactobacillus rhamnosus GG versus
placebo as an adjunct to lactulose in 84 children with constipation. Treatment success (at least 3
spontaneous bowel movements per week) was comparable between the groups both at the end of
the 12-week intervention and 12 weeks later. Bu et al. [54] compared Lactobacillus casei rhamnosus
Lcr35, magnesium oxide and placebo in 45 children with constipation in a 4-week trial. Lactulose and
glycerin enema were allowed if stool passage was not noted for 3 and 5 days, respectively. The patients
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on probiotic and magnesium oxide had a higher defecation frequency, higher treatment success and
fewer hard stools and less need for glycerin enema as compared to the placebo group [54].
Coccorullo et al. [55] studied the effect of an oil suspension with Lactobacillus reuteri DSM 17,938 or
placebo in 44 infants with constipation in an 8-week intervention. Significantly more patients passed
at least 5 stools a week in the probiotic than the placebo group at weeks 2, 4 and 8. Stool consistency
did not differ between the groups [55]. Guerra et al. [56] evaluated a goat yogurt containing
Bifidobacterium longum versus the yogurt alone in 59 children with constipation in a 10-week crossover
intervention. When all the crossover data were analyzed, significant differences were observed between
the groups in defecation frequency, defecation pain and abdominal pain. However, the authors did not
state whether the difference was in favor of the probiotic goat yogurt or goat yogurt alone. In addition,
all the results were presented graphically only [56]. Tabbers et al. [57] compared the effect of a fermented
milk containing Bifidobacterium lactis DN-173 010 with a non-fermented milk-based dairy product in
159 constipated children. The rate of responders was similar in both groups. Moreover, stool frequency,
pain during defecation, abdominal pain and bisacodyl use were comparable between the groups.
However, flatulence was reported significantly less often during the 3-week study among those on the
probiotic product [57].
Sadeghzadeh et al. [58] investigated the effect of lactulose plus a mixture of 7 probiotic strains
versus lactulose plus placebo in 56 children with functional constipation during a 4-week intervention.
Stool frequency and stool consistency improved in both groups, but significantly more so in those
on lactulose plus probiotic. Russo et al. [59] studied polyethylene glycol 4000 plus a combination of
three Bifidobacteria versus polyethylene glycol 4000 alone in 55 constipated children during an 8-week
intervention. They reported that stool frequency and stool consistency improved in both groups as
compared to baseline. However, no significant differences were detected between the groups [59].
Wojtyniak et al. [60] compared Lactobacillus casei rhamnosus LCR35 to a placebo in 94 children with
constipation. Treatment success (at least 3 spontaneous stools per week without fecal soiling) was
comparable between the groups although stool frequency was significantly lower in the probiotic
group [60]. In the latest trial, the effect of Lactobacillus reuteri DSM 17938 and macrogol versus macrogol
and matching placebo were studied in 129 constipated children for 8 weeks [61]. Stool frequency
increased in almost all the patients and in comparable amount in both groups. Moreover, there were
no significant differences between the groups in the number of patients with hard stools, painful
defecation, large stools, fecal soling or abdominal pain [61].
In their comprehensive systemic reviews, Wegh et al. [20] and Wojtyniak and Szajewska [21]
assessed the methodological quality and potential risks of bias of most of the studies reviewed
above [42–60]. All in all, a relatively high risk of bias was found [20,21]. In addition, interventions and
follow-up were short-term, the study populations were fairly small and heterogeneous as to their study
design, probiotic strain and dose, duration of intervention and follow-up, and outcome measures.
Therefore, no single strain or combination of strains can be recommended in the management of
IBS, FAP or functional constipation in children. This is in accordance with a recent systematic review
where potential dietary, pharmacological and psychological interventions of functional abdominal pain
disorders in children were evaluated [62]. Probiotics were found to be effective if all the studies with
different strains or combinations of them were pooled together: the odds ratio for improvement in pain
was 1.61 (95% CI 1.15–2.27) for probiotics compared to placebo. When different strains were analyzed
separately, the effect was not as clear, making a recommendation for clinical practice unjustified [62].
4.3. Probiotics in the Management of Infantile Colic
As altered gut microbiota, dysbiosis has been proposed to play a part in the pathophysiology
of colic, probiotic bacteria have been suggested as a promising treatment for colic crying.
Most intervention studies have examined the role of one specific probiotic, Lactobacillus reuteri DSM
17938. However, there are a handful of studies examining the role of other Lactobacillus spp. or mixture
of different probiotics or synbiotics.
217
Nutrients 2018, 10, 1836
A recent systematic review and meta-analysis included altogether seven randomized controlled
trials (471 participants) with a low risk of bias [63]. Five included randomized controlled trials (RCTs)
involving 349 infants evaluated the effect of L. reuteri DSM 17938 at daily dose of 108 colony-forming unit
(CFU) given for 21 or 28 days [64–68]. L. reuteri was associated with treatment success (relative risk (RR)
1.67, 95% CI 1.10–2.81, number needed to treat (NNT) 5, 95% CI 4–8) and reduced crying times at the end
of intervention (mean difference (MD)-49 min, 95% CI−66–33), nevertheless the effect was mainly seen
in exclusively breastfed infants.
In accordance, an individual participant data meta-analysis (IPDMA), pooling raw data from
four individual trials involving 345 infants [64–67] to create sufficient power for sub-group analysis,
suggests that L. reuteri DSM 17,938 is effective in treating breastfed infants with colic, but not
formula-fed infants [69]. The probiotic group was almost twice as likely than the placebo group
to experience treatment success and averaged less crying and/or fussing time than the placebo group.
Moreover, the intervention effects were dramatic in breastfed infants (NNT 2.6, 95% CI 2.0–3.6),
but were insignificant in formula-fed infants. All the infants included in the meta-analysis were
exclusively or predominantly breastfed, except the infants participating in the largest Australian trial,
which included both breast and formula-fed infants. The gut microbiota composition of breastfed and
formula-fed infants is distinct, and this might therefore explain the better effectiveness of probiotic
intervention in breastfed infants. On the other hand, the superior effectiveness of L. reuteri in breastfed
infants might also be explained by the direct effects of microbes or oligosaccharides in breast milk.
After publishing these two meta-analyses, two more RCTs with L. reuteri DSM 17938 in treating
infantile colic in breastfed infants have been published [70,71]. A study with 60 colic infants showed
L. reuteri significantly decreasing daily crying time during a 30-day intervention period [70], while a
small trial with only 20 colic infants found no significant difference in daily crying time between the
probiotic and placebo group [71].
Only one small RCT has examined the role of Lactobacillus rhamnosus GG (LGG) in treating infant
colic during a 28-day intervention [72]. A study with 30 breast and formula-fed colic infants found
no difference in daily crying time between infants receiving probiotic or placebo. However, it is
interesting to note that the study suggested LGG to be effective by parental report, but not by the
validated prospectively recorded Baby Day Diary. This finding emphasizes the importance of using
uniform validated methods in measuring infant crying.
A recent RCT with a mixture of 8 different probiotic bacterial strains in 53 exclusively breastfed
colic infants showed that the probiotic-mixture group had less crying per day than the placebo group at
the end of 3-week treatment period [73]. In addition, a higher rate of infants from the probiotic-mixture
group responded to treatment at end of the study. Interestingly, the probiotic intervention did not
modify the gut microbiota composition compared to placebo in this study. However, the observation
from a metabolomics perspective showed that the fecal molecular profile differed in connection with
the treatment. Dupont et al. investigated the effect of a probiotic-supplemented (L. rhamnosus and
B. infantis) and alpha-enriched formula versus standard formula on daily crying in 66 colic infants
during a 1-month intervention period [74]. The study found no differences for crying duration between
the probiotic and placebo groups.
There are two RCT investigating the role of synbiotics—the combination of probiotics and
prebiotics—in treating infant colic. A trial with 50 breastfed colic infants receiving a synbiotic
(containing L. casei, L. rhamnosus, S. thermophiles, B. breve, L. acidophilus, B. infants, L. bulgariucs and
fructo-oligosaccharides) or placebo for 30 days demonstrated that treatment success was significantly
higher in the synbiotic group compared with placebo at day 7 and 30 [75]. Another trial with 60 colic
infants investigated the effect of intervention formula (containing B. lactis BB12, galacto-oligosaccaharides
combined with reduced lactose and partial whey hydrolysate) on daily crying amount compared to
standard formula [76]. During the 1-month intervention period, daily crying duration decreased
significantly more in infants receiving synbiotics than standard formula.
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Taken together, the role of mixtures of probiotics and synbiotics in the treatment of colic crying
is promising, but still indefinite, due to the variation in the used probiotic strains, and more data is
therefore needed before any conclusions can be drawn.
Thus far, two studies have examined the role of pro- and prebiotics in preventing infant colic
as the primary outcome. A large RCT with 589 term infants studied the effect of L. reuteri 17938 or
placebo during the first 90 days of life in preventing the onset of colic, gastroesophageal reflux and
constipation [77]. The study concluded that daily administration of L. reuteri significantly reduces daily
crying duration at an age of 1 monthcompared to the placebo, and the effect was sustained at 3 months.
In addition, the number of regurgitations per day was significantly lower and the number of evacuations
per day higher in infants receiving L. reuteri compared to placebo. Another randomized controlled trial
of 94 preterm infants (gestational age 32–36 weeks) investigated the effects of L. rhamnosus GG versus
galacto-ologosaccharides versus placebo in preventing infant colic during the first 2 months of life [78].
A total of 27 out of 94 infants were classified as excessive criers at the age of 2 months, while this was
significantly less in the probiotic and prebiotic group than in the placebo group (19% vs. 19% vs. 47%).
5. Conclusions
Infantile colic seems to be both associated with and preceded by altered gut microbiota composition,
suggesting that dysbiosis may be causally related to the development of the condition. As regards older
children’s FGIDs, gut microbiota alterations have only been described in children with IBS, although their
exact role in the pathogenesis remain unclear. So far, in addition to Lactobacillus reuteri DSM 17938 in
the treatment of breastfed infant’s colic, no other probiotic or combination of them for the management
of pediatric FGIDs can be recommended (Table 1). Further clinical studies among children with these
disorders should preferably focus both on relevant clinical outcomes and gut microbiota composition
and function together in order to get a more comprehensive view of the role of the gut microbiota in
these common maladies.
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Abstract: Infant colic is a common condition of unknown pathogenesis that brings frustration to
families seeking for effective management. Accumulating evidence suggests that some single strains
of lactobacilli may play a positive dietary role in attenuation of colic in exclusively breastfed infants.
The objective of this study was to evaluate a mixture of two Lactobacillus strains in decreasing infant
cry and fuss in this population. Infants aged 4–12 weeks received L. rhamnosus 19070-2 and L. reuteri
12246 in a daily dose of 250 × 106 CFU, 3.33 mg of fructooligosaccharide, and 200 IU of vitamin
D3 (84 infants, probiotic group) or just vitamin D3 (84 infants, control group) for 28 days. Cry and
fuss time were measured with validated Baby’s Day Diary on days 0 and 28. At baseline, mean (SD)
duration of cry and fuss time was comparable in the probiotic and control groups: 305 (81) vs. 315
(90) min., respectively (p = 0.450). On day 28, mean cry and fuss time became statistically different:
142 (89) vs. 199 (72), respectively (p < 0.05). Mean change in cry and fuss time from day 0 through
day 28 was −163 (99) minutes in the probiotic and −116 (94) minutes in the control group (p = 0.019).
Our findings confirm that lactobacilli decrease cry and fuss time and provide a dietary support in
exclusively breastfed infants with colic.
Keywords: infant; colic; lactobacilli
1. Introduction
Infant colic (IC) represents a temporary self-limited condition, which occurs in about one of five
infants within the first months of life, and is characterized by inconsolable cry and fuss of unknown
cause [1]. Wessel et al., who coined and brought the term into a wide medical use, defined IC as a stable
symptomatic pattern with timing as a rule of three threes in an infant “who is otherwise healthy and
well-fed, has paroxysms of irritability, fussy or cry, lasting for a total of three hours a day, occurring
on more than three days in any one week for a period of three weeks” [2]. Despite its benign nature,
IC serves a significant source for maternal anxiety, and depression [3], impaired family functioning [4],
and the most common reason for seeking medical advice in this age group [1]. Infant colic had been
linked to poor sleep and disorders in mental health in school age [5]. Due to universal prevalence,
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economic burden associated with IC is great for the healthcare system. In the UK, annual estimates
for financial losses due to IC has been 65 million pounds [6]. At the same time, there is no consensus
on the treatment of IC. Most of the current interventions have been found ineffective, unequivocal,
or unsafe [7].
There is accumulating evidence that lactobacilli may play a role in IC. Earlier findings showed that
infants with IC had more gas-forming Clostridium difficile, Klebsiella pneumoniae, and Escherichia coli in
their intestines and lesser microbial diversity than their non-colic counterparts [8–10]. Probiotic bacteria
can also theoretically influence sulfate reducing bacteria, methanogens and/or acetogens playing an
important role in the functioning of the gut [11]. It was hypothesized that inoculation of antagonizing
probiotic species into the gut of such infants could potentially decrease gas production, thereby
alleviating abdominal distress. However, probiotic supplementation studies are not fully consistent,
and their results ranged from significant and meaningful effects through the absence of efficacy [12–17].
Meta-analysis of personal data from randomized clinical trials showed that exclusively breastfed
infants significantly benefited from probiotic supplementation, while this effect in the formula-fed
infant was not evident [18].
The objective of our study was to explore the effect of Lactobacillus rhamnosus 19070-2 and
Lactobacillus reuteri 12246 on the course of colic in the hypothetically susceptible population of
exclusively breastfed infants.
The rationale for selecting a combination of L. rhamnosus 19070-2 and L. reuteri 12246 was based
on its safety and clinical efficacy in a series of pediatric studies. Two randomized clinical studies
concluded that the combination of the mentioned strains significantly reduced the duration of acute
diarrhea [19,20], and results of two other studies reported a reduction in atopic dermatitis relapse
rate together with a decrease of associated intestinal permeability, and reduction of gastrointestinal
symptoms [21,22]. These studies, which involved 196 children aged six months to thirteen years,
suggested that use of L. rhamnosus 19070-2 and L. reuteri 12246 for five days to six weeks was safe
and effective.
2. Materials and Methods
This was a phase II randomized parallel group prospective controlled multi-center dietary study.
The case of IC was defined as cry and/or fuss lasting > 3 h a day, occurring > 3 days for the last
seven days [23]. Other inclusion criteria were as follows: Informed consent form signed by parents,
gender males and females, age on enrollment 4–12 weeks; gestational age 37–42 weeks; birth weight
2500–4200 g, stated availability throughout the study period, stated availability of mobile phone or
phone with answering machine. Excluded from the study were infants who received any amount of
formula feeding, those who failed to thrive (weight gain less than 100 g per week as averaged from the
birth weight to the weight at entry) and those with present intake of antibiotics, prebiotics or probiotics
by infant or mother. Also excluded were mothers with current maternal smoking, known moderate
or severe disease of any systems (neural, skeletal, muscular, cutaneous, gastrointestinal, respiratory,
genital, urinary, immune), difficulty of parents to comprehend study requirements as judged by
physician, suspected parental alcohol or drug addiction as judged by physician. There were no
changes made to eligibility criteria or other methods after the study commencement.
The study was performed at six (6) clinical centers, where data was collected: Three centers—
tertiary care state or city children hospitals (Dnipro State Children Hospital, Dnipro; Ivano-Frankivsk
State Children Hospital, Ivano-Frankivsk; Lviv City Children Hospital; Lviv), two centers—out-patient
community clinic or out-patient department at hospital (Chernihiv Pediatric Outpatient Clinic #1,
Chernihiv; Pediatric Outpatient Clinic at Lviv Community 4 Clinical Hospital, Lviv); one center—
University Medical Center (Lviv National Medical University, Lviv). All centers were in Ukraine.
Methods of advertisement included social media, verbal information and brochure given during
hospital, outpatient visits and regular newborn visits. During newborn visit families were also
supplied with a leaflet with study announcement and normal immunization schedule.
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Infants in the probiotic group were administered L. rhamnosus 19070-2 and L. reuteri 12246 in a dose
of 125 × 106 CFU (both strains), 2.5 mcg (100 IU) of vitamin D3, and 1.667 mg of fructooligosaccharides
(FOS) in sunflower oil drops (0.25 mL). Subjects in the control group received 2.5 mcg (100 IU) of
vitamin D3 per dose. Both probiotic and control groups were given a dose of the test dietary supplement
(TDS) two times daily: One dose (0.25 mL) during the first morning (from 06:00) breastfeeding, and one
dose (0.25 mL) during one of the evening (18:00−24:00) breast feedings. As a result, the probiotic
group received a daily dose of 250 × 106 CFU of lactobacilli (125 × 106 CFU each strain) with 5 mcg
(200 IU) of vitamin D3, and 3.33 mg of FOS, while the control group received only 5 mcg (200 IU) of
vitamin D3. The TDS was dripped behind the gums just before feeding. Compliance was assessed
with phone calls (days 12, 26) and 28-Day Study Diary (28-DSD), where caregivers checked morning
and evening TDS intakes. The 28-DSD was also designed to screen for mothers’ diet (cow’s milk, eggs,
chocolate, nuts), exclusive breast-feeding status, and adverse events that might be linked to infant
TDS intolerance (regurgitation, vomiting, constipation, diarrhea, skin rash). To evaluate background
conditions that might interfere with the assessment of intolerance events, parents were questioned
whether infant ever experienced the above disorders.
The primary outcome measure was changed in mean cry/fuss time (min/day) from day 0
through day 28. Cry was not specifically defined, while fuss was defined as “behavior that is not quite
cry but not awake and content either” [24]. The secondary outcomes included: Time to treatment
success, a day when more than or equal to 25% and 50% reduction in cry/fuss time from difference
between baseline value and 180 min, a cutoff for definition of IC; recovery success (percent) at 7, 14,
21, 28 days, defined as reduction in duration of cry/fuss time less than 3 h per day (unmet Wessel
criteria). For calculation of time to treatment success, data obtained on the days 6–7, 13–14, 20–21,
and 27–28, was averaged and means were ascribed to days 7, 14, 21, and 28, respectively. Based on
mean values, for every infant we found a day on which cry/fuss time decreased more than 25% or
50% as compared with baseline—180 min value. These days were averaged and mean weekly time to
25% or 50% improvement was calculated for active and control groups. Tertiary outcome measures
included: Infant sleep duration (min/day) on days 0, 7, 14, 21, 28; change in maternal depression score
from day 0 through 28. There were no changes made to outcomes after the trial commencement.
Cry, fuss, and sleep time were assessed with Baby’s Day Diary (BDD), a validated tool for
the observation of infant activity [24]. Briefly, the BDD had four, six-hour time-rulers printed on
a single page, used to capture babies’ behaviors on a 24-h basis. Instructions were given verbally
by investigators and pre-printed on each BDD. Parents ticked the start and end time of successive
periods of behavior on the time rulers, painted these periods with relevant schematic patterns against
a scale showing five-minute increments of time. The BDD was completed nine times: On day 0 (before
inclusion), and then on pairs of consecutive days 6–7, 13–14, 20–21, 27–28 after the commencement of
TDS intake. To improve compliance with BDD recording, parents received two phone call reminders
(days 12, 26), and two text messages (SMS) (days 5, 19). During phone calls parents were also asked
about their impression of colic (“better”, “worse”, “no changes”). Maternal depression score was
estimated with the Edinburgh Postnatal Depression Scale (EPDS) [25]. The scale was linguistically
validated. [26]. Formal permissions to use these assessment tools were obtained from copyright holders.
To detect a difference in change of cry/fuss time of 40 min between the probiotic and control
groups on day 28, with power of 80% and confidence of 0.05, 140 infants should be enrolled. At a
dropout rate of 20%, the final sample size was 140 × 1.2 = 168. The rationale for the number of infants
stemmed from the five published reports on the efficacy of probiotics in IC. It has been estimated
weighted mean difference in change of cry and fuss time (40 min) between probiotic and control arms,
and population variance (7456) [12–15,27]. There were no interim analyses and stopping guidelines in
this study.
Random numbers were generated by the Random Allocation Software v. 1.0.0 [28]. Randomization
was restricted to a 4-block system to secure an equal number of infants in the probiotic and control
groups. Random allocation was implemented by sticking the labels with sequential random numbers
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and sequential selection of packs by the investigator. Random numbers were generated by the
technician who did not participate in the distribution of packs among centers or data analysis.
Investigators and families were blinded to which supplement was given. The supplements looked the
same on appearance, smell and consistency and differed only by the randomization numbers on packs.
Absolute number and percent were used to describe baseline characteristics of boys/girls,
proportion of caesarean delivery, family history of atopy, proton pump inhibitor use. Mean and
standard deviation described age at study entry (weeks), birth weight (g), gestation (weeks), duration
(days) of IC before randomization, total daily cry/fuss time (min/day), fuss time (min/day), cry time
(min/day), infant sleep duration (min/day), maternal mental health (EPDS score). Difference
between the groups in percent data was assessed in z-test, and between means—in a two-tailed
t-test. Distribution of data was checked with Kolmogorov-Smirnov test. Recovery from IC was plotted
using the Kaplan-Meier method, and the difference in recovery rates was assessed with Cox’s F-test.
If not otherwise specified, data in the text is present as mean (SD), and the difference between means is
assessed in a two-tailed t-test. Tests were performed with Statistica 9 (StatSoft., Inc., Tulsa, OK, US).
The study received positive decisions of Ethical committees at clinical centers (Dnipro State
Children Hospital, protocol #6.4 of 29 June 2016; Ivano-Frankivsk State Children Hospital protocol #12
of 6 May 2016; Lviv City Children Hospital protocol #3 of 22 June 2016; Chernihiv Pediatric Outpatient
Clinic #1 protocol #11 of 8 September 2016; Pediatric Outpatient Clinic at Lviv Community 4 Clinical
Hospital protocol #8 of 21 March 2017; Lviv National Medical University protocol #3 of 14 March 2016).
Before enrollment, parents signed an informed consent form. The study protocol was registered by the
protocol registration system at Clinicaltrial.gov NCT02839239.
3. Results
Screening and enrollment of infants occurred continuously from October 2016 to February
2018. Of 323 initially screened infants, 22 met exclusion criteria (formula feeding, present intake
of probiotics, current maternal smoking, failure to thrive), and 129 declined to participate because of
the investigational nature of the trial (Figure 1). During continuous evaluation of data, nine infants
who finished the trial, were excluded from the analysis due to carelessly drawn BDDs, or failure to
return BDD. One hundred seventy-two infants were randomized and evenly allocated into probiotic
or control supplementation groups (86 infants/group). During the study, four infants were lost to
follow-up with no further wish to participate. Four infants started formula feeding, three infants
had carelessly recorded or absent BDD, one infant in the probiotic group started prebiotics, and one
infant in the control group had poor compliance with intake of TDS These infants were excluded from
the analysis and replaced with newly enrolled infants to secure pre-determined sample size. Finally,
data from 168 infants were evaluable for study purposes.
3.1. Baseline Description of Study Participants
Probiotic and control groups were comparable on major demographic and medical data (Table 1).
A small percent of mothers and infants used probiotics and antibiotics in the past. No statistical
difference was found between the groups, except for the duration of mother use of antibiotics and
duration of infant use of probiotics, which were both longer in the control group. All probiotic and
antibiotic treatments were stopped seven days before enrolment of the infant in the study. The most
common past medical condition was hypoxic ischemic encephalopathy. In all cases, the diagnosis
was made 1–3 days after delivery. The disease had mild severity and resolved by the time of
enrollment. Functional jaundice was observed in approximately 5% (probiotic group) to 10% (control
group) of newborns with no significant difference between the groups. Cephalo-hematoma was
observed in one newborn in the probiotic and two newborns in the control group. At the time of
inclusion, no finding of neurological consequences for the condition was found. Hemolytic disease,
arthrogryposis, and lymphadenopathy were all documented in the probiotic group. Diaper dermatitis
was observed in two infants in the probiotic group and one infant in the control group. None of
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the past medical conditions were moderate or severe, or was clinically active at time of enrollment,
except for arthrogryposis that represents life-long congenital pathology of extremities.
Allocated to control supplement (n = 86) 
♦ Received control supplement (n = 86) 
Evaluable (n = 84) 
Excluded (n = 151) 
♦ Met exclusion criteria (n = 22) 
♦ Declined to participate (n = 129) 
Lost to follow-up (n = 2) 
♦ No wish to continue (n = 2) 
Excluded from analysis (n = 4) 
♦ Formula feeding (n = 2) 
♦ Careless or absent BDD (n = 1) 
♦ Use of prebiotics (n = 1)  
 
Allocated to probiotic supplement (n = 86) 
♦ Received probiotic supplement (n = 86) 
Lost to follow-up (n = 2) 
♦ No wish to continue (n = 2) 
Excluded from analysis (n = 5) 
♦ Formula feeding (n = 2) 
♦ Careless or absent BDD (n = 2) 
♦ Insufficient intake (n = 1)  
 
Evaluable (n = 84) 
Randomized (n = 172) 
Assessed for eligibility (n = 323) 
Allocation 
Allocated to probiotic supplement (n = 4) 
♦ Received probiotic supplement (n = 4) 
Allocated to probiotic supplement (n = 5) 
♦ Received probiotic supplement (n = 5) 
Replacement 
Figure 1. The Consolidated Standards of Reporting Trials flow diagram of the study participants. BDD:
Baby‘s Day Diary.
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(n = 84) p-Value
Age, days, mean (SD) 44 (15) 45 (15) 0.666 1
Gender male, n (%) 40 (48) 44 (52) 0.605 2
Respiratory rate, mean (SD) 34 (3) 34 (3) 1.000
Heart rate, mean (SD) 132 (9) 132 (8) 1.000
Body weight, g, mean (SD) 4530 (637) 4581 (581) 0.588
Body length, cm, mean (SD) 55.9 (2.9) 56.6 (2.9) 0.119
Postnatal characteristics
Weight at birth, g, mean (SD) 3427 (288) 3465 (278) 0.386
Length at birth, cm, mean (SD) 52.0 (2.0) 52.3 (1.9) 0.320
Head circumference, cm, mean (SD) 35.1 (1.7) 35.0 (1.5) 0.687
Gestation age, weeks, mean (SD) 39.4 (1.2) 39.5 (1.2) 0.589
Apgar score at 5 min., mean (SD) 8.3 (1.0) 8.2 (1.0) 0.518
Cesarean section, n (%) 7 (8.3) 9 (10.7) 0.597
Use of antibiotics and probiotics
Use of antibiotic by mother, n (%) 7 (8.3) 8 (9.5) 0.785
Use of antibiotic by mother, days, mean (SD) 5.3 (2.1) 6.0 (1.1) 0.008
Use of probiotics by mother, n (%) 6 (7.1) 7 (8.3) 0.771
Use of probiotics by mother, days, mean (SD) 10.8 (5.4) 10.0 (6.2) 0.374
Use of antibiotics by infant, n (%) 3 (3.6) 2 (2.4) 0.649
Use of antibiotics by infant, days, mean (SD) 5.7 (1.5) 5.0 (9.4) 0.501
Use of probiotics by infant, n (%) 6 (7.1) 7 (8.3) 0.771
Use of probiotics by infant, days, mean (SD) 9 (3.3) 13 (9.3) 0.003
Hypoxic-ischemic encephalopathy, n (%) 11 (13.1) 16 (19.0) 0.299
Diagnoses
Functional jaundice, n (%) 4 (4.8) 9 (10.7) 0.154
Umbilical hernia, n (%) 3 (3.6) 2 (2.4) 0.649
Cephalo-hematoma, n (%) 1 (1.2) 2 (2.4) 0.559
Hemolytic disease of a newborn, n (%) 1 (1.2) 0 (0.0) 0.315
Diaper dermatitis, n (%) 2 (2.4) 1 (1.2) 0.559
Arthrogryposis, n (%) 1 (1.2) 0 (0.0) 0.315
Lymphadenopathy, n (%) 1 (1.2) 0 (0.0) 0.315
Fever of unknown origin, n (%) 3 (3.6) 2 (2.4) 0.649
1 Difference between the groups in the Student’s t-test for means. 2 Difference between the groups in the z-test for
proportions. SD, standard deviation; GIT, gastro-intestinal tract.
It was found that around half of the sample size had a history of regurgitation (Table 2).




(n = 84) p-Value
1
Regurgitation, n (%) 2 46 (55) 53 (63) 0.293
Vomiting, n (%) 9 (11) 10 (12) 0.839
Constipation, n (%) 26 (31) 29 (35) 0.582
Diarrhea, n (%) 18 (21) 16 (19) 0.746
Rash, n (%) 9 (11) 10 (12) 0.839
1 Difference between the groups in the z-test for proportions. 2 At least one episode of the listed events reported by
parents was included in analysis.
More than one third of infants suffered from constipation, and fewer infants were observed to
have a vomiting-like episode, diarrhea or skin rash. There was no significant difference in prevalence
of these conditions between the groups before the study enrollment, and none of these conditions had
criteria sufficient for diagnosis. They were commonly described as occasional events, not clinically
meaningful, and did not influence the condition of the infant. In all cases these infants were included
in the study, and per investigator judgment, an occasional and mild episode of these conditions could
not serve a confounder.
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One forth to one third of infants received treatments with claims for infant colic (Table 3).




(n = 84) p-Value
1
Simethicone, n (%) 17 (20.2) 22 (26.2) 0.358
Dimethicone, n (%) 3 (3.6) 3 (3.6) 1.000
Lactase, n (%) 9 (10.7) 7 (8.3) 0.597
L. rhamnosus, n (%) 2 (2.4) 2 (2.4) 1.000
L. reuteri, n (%) 3 (3.6) 3 (3.6) 1.000
Fennel tea, n (%) 1 (1.2) 0 (0.0) 0.315
Homeopathic, n (%) 0 (0.0) 1 (1.2) 0.315
B. subtilis, n (%) 1 (1.2) 2 (2.4) 0.559
Prior treatment of colic, n (%) 26 (31.0) 31 (36.7) 0.436
1 Difference between the groups in the z-test for proportions.
One fifth to one fourth of infants tried simethicone or dimethicone drops with no effects.
Other treatments included probiotic dietary supplements, homeopathic drugs or fennel contained tea.
All treatments were considered as ineffective by parents and finished at least seven days before entry
in the study and were assumed not confounders for study outcomes.
3.2. Compliance
Generally, families complied well with the administration of the TDS and keeping the study
diaries. During phone calls three families (3.6%) in the probiotic group reported one or more doses
missed with a reference that this was due to forgetting and heavy daily routine. Two families (2.4%)
in the control group reported doses missed for the same reasons. There was no statically significant
difference in the number of infants who missed doses (p = 0.649). According to 28-DSD, of the total
4704 doses to be taken in one group (84 infants), only 11 doses (0.2%) were missed in the probiotic and
13 doses (0.3%)—in the control group (p = 0.331).
During phone calls, five families in the probiotic group and eight families in the control group
reported significant troubles with recording in the BDD. In five cases in the probiotic group and four
cases in the control group, the reason was difficulty in drawing graphical pictures. One family reported
“difficulty to comprehend” on how to record in the BDD. Review and discussion of BDD in these
families found consistent records.
3.3. Mother’s Diet
All infants in the probiotic and control were breast fed during the entire study period. Cumulative
groups daily intake by mother of foods that suspected to produce IC revealed no statistical difference
between the groups (Table 4).





(n = 84) p-Value
2
Cow’s milk, days, n (%) 973 (41.4) 1 937 (39.8) 0.264
Eggs, days, n (%) 499 (21.2) 474 (20.2) 0.397
Chocolate, days, n (%) 260 (11.1) 267 (11.4) 0.745
Nuts, days, n (%) 232 (9.9) 234 (9.9) 1.000
1 Data present as total days of intake of a specific food in the group (days of intake × number of mothers in the
group) and percent days of all days of the study in the group (study duration (28) × size of the group (84) = 2352).
2 Difference between the groups in the z-test for proportions.
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The most common food used in both groups was cow’s milk that was consumed for approximately
40% of the study period. Approximately every 5th day mothers ate hen eggs, and approximately every
10th day chocolate and nuts.
3.4. Outcomes
There was no difference between the probiotic and control groups at baseline on the duration of
fuss and cry (Figure 2).
After day 7, the probiotic group started demonstrating a faster reduction in cry and fuss time
than the control group (upper boxes). Statistically significant results were found on days 14, 21, and 28
(p < 0.05). Mean change (SD) in cry/fuss time from day 0 through day 28 was −163 (99) minutes in
the probiotic and −116 (94) minutes in the control group (p = 0.019). Success in controlling IC was
more evident in the probiotic exposure group. Twenty-five percent reduction in cry/fuss times in the
probiotic group was on day 8.2 (4.9) and day 9.6 (4.8) in the control group (p = 0.063). Fifty percent
reduction in cry/fuss times in the probiotic group occurred after 8.9 (6.1) day and after 11.8 (7.4) day
in the control group (p = 0.006).
Recovery from IC was illustrated in Kaplan-Meier analysis (Figure 3). Twenty-one infant (25%)
in the probiotic group and 57 infants (68%) in the control group continued to have IC (p < 0.001).
A significant difference between the groups was confirmed in Cox’s F-test.
Figure 2. Cry and fuss time over study period. Data present as means (box mark – active; triangle
mark - control group) and 2 standard errors (solid whiskers – active; dash whickers - control group).
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Figure 3. Recovery from colic. Solid line and round marks denote active group. Dash line and triangle
marks denote control group.
Mean (SD) sleep duration did not change due to study intervention. On enrollment it was 770
(87) vs. 773 (112) minutes (p = 0.847); on day 28th—795 (104) vs. 805 (82) minutes (p = 0.489) in the
probiotic and control group, respectively.
Both groups showed marginal changes in EPDS. On enrollment, EPDS was 6.2 (3.3) vs. 6.0 (2.5)
(p = 0.603); on day 28th—5.1 (1.8) vs. 5.4 (2.8) (p = 0.391) in the probiotic and control group, respectively.
Mean EPDS changed −1.0 (2.9) in the probiotic and −0.4 (2.9) in the control group (p = 0.247) over the
duration of the study period.
On follow-up calls, parents in the probiotic group reported better course of IC than parents in the
control group (Table 5).




(n = 84) p-Value
1
Phone call 1
Better, n (%) 58 (69.0) 39 (46.4) 0.035
Worse, n (%) 2 (2.4) 4 (4.8) 0.405
No changes, n (%) 24 (28.6) 41 (48.8) 0.008
Phone call 2
Better, n (%) 78 (92.9) 66 (78.6) 0.008
Worse, n (%) 3 (3.6) 1 (1.2) 0.311
No changes, n (%) 3 (3.6) 17 (20.2) 0.001
Phone call 1 and 2 were made on 12 and 26 days of TDS intake. 1 Difference between the groups in the z-test
for proportions.
Phone call 1 elicited a greater number of infants with “better” colic in the probiotic group and
fewer infants with “no changes” colic on day 12th of the study. Two infants from the probiotic
group and four infants from the control group had worsening colic, however, the difference was not
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statistically significant. After phone call 2, the number of infants with a better condition was still
greater, as well as fewer cases without changes. Three infants from the probiotic group and one infant
from the control group had worsening colic, and the difference was also not statistically significant.
3.5. Intolerance Events
As reported by investigators, both probiotic and control interventions were tolerated well (Table 6).




(n = 84) p-Value
1
Diarrhea, n (%) 1 (1.2) 3 (3.6) 0.311
Constipation, n (%) 0 (0.0) 1 (1.2) 0.315
Intense cry, n (%) 1 (1.2) 4 (4.8) 0.173
Regurgitation, n (%) 1 (1.2) 3 (3.6) 0.311
Intolerance events total, n (%) 3 (3.6) 11 (13.1) 0.027
1 Difference between the groups in the z-test for proportions.
The most common intolerance in the control group was the intensification of cry, followed by
diarrhea and regurgitation. In the probiotic group these events were evenly presented by one infant
per event, except for constipation. Eleven total intolerance events were observed in the control group
compared to three total events in the probiotic group (p = 0.027).
4. Discussion
Study participants were between the ages of 30 to 60 days with equal representation of male and
female gender. The age at entry was comparable with previous studies and averaged the age when the
manifestation of colic was the most severe [29]. Earlier age at entry might theoretically underestimate
the role of any intervention as infant cry/fuss, as well as cry/fuss in colic normally intensifies from
the 4th to the 6th week of life, remaining relatively stable for the next two weeks. If infant cry/colic
includes congenital/inherited component, infants entering the study before two weeks or after eight
weeks might not respond to probiotic treatment. This might explain why studies with less or greater
mean/median age failed to show probiotic effect [13,16].
In this study we showed that the combination of L. rhamnosus 19070-2 and L. reuteri 12246
was effective in alleviation of colic in breast fed infants. Our results are consistent with the recent
meta-analysis of four randomized trials that differentiated outcomes of probiotic intervention in infants
with different types of feeding. Generally, breast-fed infants receiving probiotics had a mean change in
cry and/or fuss time from day 0 to day 21 of −156.0 min compared to −101.9 min in the control group
(p < 0.05) [18]. In our study, the mean change was −163 and −116 min, respectively (p = 0.019). Lack of
standard deviation figures in the mentioned study did not allow for study comparisons however
trends were similar. Difference between the probiotic and control groups was −47 min (−163 − 116 =
−47 min) with −40 min difference was planned during calculation of the sample size. The real time
difference outnumbered the planned one, and this secured statistical power of the data obtained.
In the meta-analysis data, the effect of lactobacilli assumed statistical significance from day 7,
while in our research the difference was evident from day 14 [18]. This discrepancy at least partly can
be explained by different approaches to collect primary data. In the referenced trials, only two used
validated BDD on fixed days [13,15], while two others used non-standard scales with no indication
on when these scales were used [12,17]. Even in the case of using a validated instrument, one may
encounter a variability of data caused by the number of measurements. In a sample of 20 mothers,
it was found that adequate monitoring of baby’s activity required at least a 3-day period [30]. As per
correlation coefficient, the reliability of measurement of cry increased 0.329, 0.546, 0.989 with the
incremental number of days (1, 2, or 3, respectively) the activity was recorded [30]. In the latter trial,
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mothers kept diaries only once for three days, while multiple measurements were planned in our
study. To improve compliance, we requested parents to fill in the BDD one day before enrollment, and,
thereafter, on pairs of consecutive days 6, 7, 20, 21, 27, 28. The double-day approach was also used in
the study by Sung et al. to reduce daily variability of cry and fuss time [18].
Treatment success, defined as a 50% reduction of colic manifestation, was statistically significant
in the breast-fed infants that received lactobacilli [18]. We followed a different methodology for the
assessment of treatment success: (1) We calculated a mean time (days) when 25% or 50% reduction in
cry and fuss was achieved, while other researchers assessed percent of infants experienced 50%
reduction of cry/fuss at the end of intervention period; (2) We calculated 25% or 50% relative
reduction in presentation from baseline 180 min, which is a cut-off for the diagnosis. As a result,
50% relative reduction of cry and fuss time was observed almost three days earlier in the probiotic
group. In Kaplan-Meier analysis we found significantly faster total recovery from colic in the probiotic
group as well. As with previous studies, it was not possible to determine the precise time to treatment
success, as measurements were made weekly and not daily.
The effect of lactobacilli was documented at a daily dose significantly lower than one advocated
by some regulatory authorities for probiotics [31]. In our study, the daily dose was 0.25 × 108 CFU,
while the minimum recommended number had been 1 × 109 viable cells per day [I]. The rationale for
the higher dose of probiotic in this statement was largely based on the results of studies in adults that
cannot be directly translated for young infants. In IC, other investigators reported the positive effects
of probiotics at daily doses of 108 CFU [12,15,17,27]. Conversely, there had been a report that a dose as
high as 109 CFU/day did not exert the effect in IC [16], suggesting a lack of consensus on the dose.
Sleep duration, as a tertiary outcome measure, did not change in the study and was within normal
limits for age [32]. Three of the present probiotic intervention studies did not report sleep duration as
an outcome measure [12,15,17]. One study found no changes during probiotic or control feedings [13].
This could be due to extreme biological importance and dominance of sleep over other infant activities.
It might be for the same reason that the feeding duration was not changed significantly as well.
The role of breast-feeding modality on the positive effect of lactobacilli in infant colic is not
understood. The situation is aggravated with the fact that breast-feeding itself did not affect the
occurrence of colic [33,34] despite the fact it serves excellent nutrition medium for bifido- and
lactobacilli [35,36]. The study performed by the Medical University of Vienna (Austria) also found a
positive effect of probiotics on prevention of necrotizing colitis in the group of breast-fed infants [37].
Authors postulated that the effect can be explained by the presence of unique oligo-saccharides that
promote optimal growth of lactobacilli, but direct studies comparing the potential of native human
milk and herbal oligo-saccharides are not available. An alternative explanation of the lack of probiotic
effect in formula fed infants may be due to a less “comfortable” physical and/or chemical environment
of freeze-dried milk reconstituted in water for lactobacilli, however, direct data is also lacking.
The strength of our study was the randomized double blind controlled prospective parallel
group design and the use of validated EPDS for measurement of maternal depression, and BDD for
monitoring infant cry and fuss. The BDD tool was checked across sound records and found a reliable
method for observation of infant cry and fuss [24]. Despite, there was not linguistic adaptation and
validation of BDD, we believed that the translation of simple nouns, or combination of few words
with clear meaning, could not significantly affect primary outcome measure. Linguistic validation
of EPDS was available in the local language before the study started [26]. We retained almost all
families primarily included in the trial, with phone calls and SMS notification messages. This gave
an opportunity for evaluation and reassurance of the product storage, use of TDS, controlling for
intolerance events, and timely filling the BDD.
The study limitation was the inclusion of infants that were treated with antibiotics or/and received
probiotics before inclusion in the study. The number of such infants was small (5 and 13 cases in
the probiotic and control group, respectively), and all these interventions were finished more than
seven days before study enrollment. The effect of this was known neither in our study nor in the
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referenced literature. Any history of antibiotic or probiotic use served exclusion criteria in the Canadian
study [15]. In two studies, infants, who were treated with antibiotics or probiotics on the week before
study enrollment, were excluded [12,17], while in another one only current intake of probiotics and
antibiotics was an exclusion criterion [13]. No data was available for infants who received these
treatments before the week of enrollment in any study, except for the study of Australian group,
which reported that 22 infants took any probiotic before entry to the study [13].
The weakness of the study was the use of not validated 28-day study diary. The diary contained
questions about maternal diet and possible gastro-intestinal upset symptoms in the infant. It was not
known how much this truly reflected real life events.
None of the infants received any treatments for colic during the study period. However, prior to
the study more than 30% of infants received any type of treatment of colic that included simethicone
or a similar drug, lactase, herbal medicine or homeopathic formulation. No consistent results were
obtained for the efficacy of all the listed interventions except for fennel tea [7]. Only one randomized
study successfully compared a herbal tea containing fennel with some other herbs with placebo.
After one week of treatment, 57% of the infants in the active and 26% of the infants in the placebo
group got rid of colic [38]. In our study, we had only one infant in the probiotic group who received a tea
with fennel with no effect, and who stopped this treatment earlier than seven days before enrollment.
Another limitation was due to the inclusion of infants with hypoxic-ischemic encephalopathy,
whose brain injure may obscure colic or otherwise interfere with cry and fuss patterns in infants.
Particularly, these infants may present transient behavioral abnormalities, such as poor feeding,
irritability, or excessive crying or sleepiness in an alternating pattern. However, we included
only infants with a mild course of the pathology, which recovers within a few days without
consequences. [39]. Potentially, infants with cephalohematoma could influence the study results, as it
sometimes presents with behavioral changes, such as increased sleepiness, and increased crying [40].
However, we included infants, who were fully asymptomatic, and at the discretion of investigator
did not have any symptoms linked to this condition before enrollment. The criterion for this was
symptom free interval before colic commenced. Other background health conditions as being all mild
or producing no constitutional symptoms could not confound the study results.
Notably, that in this study we assessed pre-existed functional conditions/episodes to avoid
labelling them as intolerance events. Indeed, regurgitation was seen in 55% and 63% of all infants
before enrollment the study, in the probiotic and control groups, respectively. According to previous
estimates, the infant may have functional regurgitation in up to 67% that meet our data [41]. As per
the Rome criteria prevalence of functional constipation was 12.1%, vomiting 1.7%, and diarrhea 2.4%
vs. in our study rates for constipation 31%/35%, vomiting 11%/12%, and diarrhea 21%/19% in
the probiotic/control groups, respectively. The difference in rates of these conditions could occur
due to different definitions of the cases. We defined the conditions once only one episode was seen,
while according to Rome criteria, these conditions should last more than four weeks and occur more
frequently than one time for the past period [42]. These functional conditions were similar in rates at
baseline. However, analysis of total symptom load showed fewer days with regurgitation, constipation,
or rashes in the probiotic group. Indrio F. et al., demonstrated that infants with functional regurgitation
benefited from the use of lactobacilli [43]. In the probiotic group infants had fewer episodes of
regurgitation that correlated with an increase of the gastric emptying rate and reduction of median
fasting antral area. Later the same researchers reported more frequent stools in infants with functional
constipation [44]. There were no identifiable reports about the efficacy of probiotics in pediatric
functional diarrhea. Studies in adults with irritable bowel syndrome and diarrhea showed a decrease
in stool frequency, but it is not known if this finding can be extrapolated for infants [45,46].
The significance of our findings is difficult to assess, as the frequency of gastro-intestinal symptoms
was not pre-screened. It remains unknown if this was due to probiotic effect, or pre-study features of
infants in two groups.
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Finally, our study design did not permit ascribing positive effect of L. reuteri 12246, L. rhamnosus
19070-2, and FOS mixture to its separate constituents or their combinations. Most of previous studies
explored a role of L. reuteri [12,15,17,27], L. rhamnosus [16], and FOS separately [47]. While L. reuteri-
based showed consistent beneficial effects in breastfed infants, the study with L. rhamnosus showed no
effect in nonhomogeneous group of breast- and formula-fed infants. Our infants were all exclusively
breastfed, so the role of L. rhamnosus is difficult to discuss. Reduction in the manifestation of IC in the
study of infants fed with FOS fortified formula also prevents from extrapolation of beneficial results
obtained [47]. In this study, we calculated that one-month old infants received approximately 576 mg
of FOS per day, assuming concentration of FOS of 0.8 g/100 mL and the normal daily volume of
formula, of 720 mL. In our study amount of FOS was 3.33 mg, more than 170 times less of that in the
mentioned study. However, we cannot exclude that FOS played a role in the propagation of lactobacilli
in an infant’s intestines [48].
5. Conclusions
Our findings confirm that oral use of a mixture of L. rhamnosus 19070-2 and L. reuteri 12246
decreases cry and fuss time, and provides useful dietary support in exclusively breastfed infants
with colic.
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Dear Editor,
We have read with interest the article published by Diaz et al. about the effects of extensively
hydrolyzed cow’s milk formulas (eHF) or vegetable formulas (soy and rice) on the microbiota in
children with a non-IgE mediated (NIM) cow’s milk protein allergy (CMPA) under a restrictive diet [1].
Although we believe it is a very interesting topic, we do not agree on some points and conclusions that
are derived from this study, as explained below.
Guidelines and recommendations on the nutritional treatment of infants diagnosed with a mild
to moderate cow’s milk protein allergy (CMPA) advise the use of eHF formulas as the first option,
whereas elemental formulas based on free amino acids are recommended in case of failure of the eHF
formulas. Soy formulas (SF) are an option in CMPA infants older than six months, due to the presence
of phytoestrogens.
In recent years, hydrolyzed rice protein formulas (HRFs) have been included in the protocols and
guidelines as a first option in the treatment of CMPA, as rice is one of the less allergenic foods (<1%)
and does not contain phytoestrogens [2,3]. Moreover, HRFs have a better palatability and are a good
option in children who reject the eHF formulas or in vegetarian or vegan families, with efficacy and
nutritional safety similar to eHF [4]. Therefore, according to the latest published recommendations on
CMPA, HRFs are a first line option in infants with CMPA from the first day of life, at the same level of
eHF, in those countries where HRFs are available.
The research topic in the study of Diaz et al. is interesting, but the number of infants both in the
study group (n = 17), as well as in the control group of healthy children of same sex and age (n = 10),
is too low. Moreover, if we look at the number of infants in each formula group, the number of cases
studied is even lower: n = 12 in the eHF group, n = 2 in the SF group and n = 3 in the HRF group.
Since this is a cohort study, it is assumed that infants were not randomly assigned to each
formula, and we think this is an important limitation for the interpretation of the results of the study,
particularly with regard to causality between the type of formula ingested, the observed pattern of
the microbiota and tolerance acquisition to cow’s milk proteins. The authors neither explain what the
criteria to allocate the infants to the eHF were, nor what the vegetable (soy or hydrolyzed rice) formula
groups were.
Secondly, the authors do not provide enough information about the diet of the infants before their
inclusion in the study. The study was carried out in infants with non IgE mediated CMPA with ages
between 13 and 23 months, with a mean age of 17 months. Considering that diagnosis of NIM-CMPA
is usually performed at ages below six months, the authors should provide information about the
type of diet they received from diagnosis until the beginning of the study. We think this is a key factor
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because it can clearly influence the pattern of the microbiota in these infants, and this factor could
explain, at least in part, the observed differences in the acquisition of tolerance between infants in the
eHF, SF, and HRF groups; that is, none of the three infants who were fed with HRF acquired tolerance,
whereas the infants fed eHF and SF acquired tolerance by the end of the study. Another important
difference between controls and infants with NIM-CMPA is that the latter followed a diet free of dairy
products for six months. Indeed, this can be a factor modifying the microbiota (e.g., fermented dairy
products are an important source of lactobacillus at this age).
Another important missing piece of information in the article is related to the type of formula
eHF used in the study. The authors do not provide information about the type of milk hydrolysate
used in the eHF group (casein or whey proteins), and whether they were lactose free or with added
lactose (with prebiotic effect of undigested lactose). All these factors may have a strong impact on the
microbiota of the children.
The third point is related to the analysis of microbiota composition in the infants. Diaz et al. find
that those infants who do not become tolerant in the study (those fed HRF) present less abundance of
Coriobacteriaceae and Bifidobacteriaceae than those who become tolerant. However, they also mention
that infants fed vegetal protein formulas, both rice and soy, have less Coriobacteriaceae than those
fed eHF formulas. They do not provide any hypothesis to the fact that infants fed SF with lower
Coriobacteriacea levels become tolerant (unfortunately, they do not provide details on the levels per
feeding group). Also, the authors do not explain the fact that Coriobacteriaceae are also less abundant
in healthy controls and vegetal formula in comparison with NIM-CMPA infants. Ultimately, the lack
of data on diet composition in the different feeding groups, as well as the lack of longitudinal data
on microbiota composition, makes it difficult to interpret or make conclusions about the microbiota
results in this study.
Finally, the authors suggest in the discussion of the article that the use of vegetable formulas may
impair the acquisition of tolerance due to the absence of exposure to immunomodulatory peptides.
We believe that this conclusion cannot be drawn from the results of the study from Diaz et al., given
the small number of infants in each study group, as well as the other confounding factors, mentioned
in the previous paragraphs, that were not controlled in the present study and may have influenced
the obtained results. The role of immunomodulatory peptides in the acquisition of tolerance was
suggested in the study performed by Canani et al., which is a non-randomized study, with an eHF
formula with LGG (Lactobacillus Rhamnosus GG) [5,6].
Contrary to the suggestion of the authors, several clinical trials in infants have found similar
rates for the acquisition of tolerance between infants with CMPA fed extensively hydrolyzed cow’s
milk protein formulas and hydrolyzed rice formulas [7], besides being effective for the treatment of
CMPA [7,8]. Moreover, a study published by Terracciano et al. in 2009 found that infants and children
with CMPA who received hydrolyzed rice or a soy-based formula for the dietary management of their
condition achieved tolerance earlier than their peers on an extensively hydrolyzed cow’s milk formula.
This fact led to the consideration that the elimination from the diet of any cow’s milk protein residue
may accelerate the induction of tolerance and would be adequate for the management of CMPA [9].
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The objective of this letter of reply is to provide answers to the doubts and critical issues that
Martín Martinez and López Liñan [1] raised in their letter to the editor with respect to the work
published last year in Nutrients in the field of microbiota, diet and non-IgE cow’s milk protein allergy
(NIM-CMPA).
As authors of this publication, we understand and welcome the controversial issues that
unavoidably surround any novel research results with implications for the dietary management
of cow’s milk protein allergy (CMPA).
First, we would like to point out that in the latest published recommendations on CMPA, the
allergologic and nutritional safety of hydrolyzed rice protein formulas (HRF) according to DRACMA
(Diagnosis and Rationale for Action against Cow’s Milk Allergy) guidelines are clearly stated. However,
according to this review it is advisable that debate is ongoing about the best substitute for infants with
CMPA, and it concludes that “in the substitute choice, clinicians should be aware of recent studies
that can modify the interpretation of the current recommendations” [2]. The letter to the editor of
Martín Martinez and López Liñan argues in favor of the use of HRF, which is a reasonable position but
which must be open to debate in the light of new data. As mentioned in our publication, “the data
found in this pilot study need to be confirmed in a larger population” [3], thus, we cannot disagree
with Martín Martinez and López Liñan that the main limitation of our study is the small number of
patients included. Nonetheless, this limitation is already mentioned in our paper. Further research
studies are of course needed and we remain open-minded, but a lack of consensus does not represent
a lack of evidence.
With respect to the first questionable aspect of our study; as stated in the publication [3], our
work is a prospective cohort study, so infants were not randomly assigned to each formula, however,
we really do not think this constitutes a limitation of the study since it was an observational, not an
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interventional study. In this case, randomization was not intended in the study, which focused on the
description of what was happening (microbiota and biochemical parameters of fecal samples) at the
intestinal level in non-IgE mediated cow’s milk protein allergy (NIM-CMPA) infants as compared with
healthy controls, for the first time as far as we know. Infants with proven NIM-CMPA determined
by positive standardized oral challenge (SOC) and negative IgE tests to cow´s milk proteins (CMP)
were included in our study when they were on a cow´s milk elimination diet for at least 6 months. The
substitution formula was decided by the attending physician, and therefore, the number of infants
on each formula simply reflects the formula selection by pediatric gastroenterologists in Spain. In a
recently published survey, extensively hydrolyzed whey or casein formulas were those of choice,
followed by amino acid-based formulas, HRF and soy formulas [4]. Furthermore, formula selection
was not the primary variable outcome of our study.
Secondly, Martín Martinez and López Liñan [1] mentioned that the authors did not provide
enough information about the diet of the infants before inclusion, and because the studied infant ages
ranges between 13 and 23 months, we should provide information about the type of diet that infants
received from diagnosis until the beginning of the study. Probably we did not make these points clear
enough in our manuscript. The age of the infants was recorded at the time of fecal sampling, after a
period of at least 6 months using therapeutic hypoallergenic formulas as the main dietary food, and
matching with the age of the control group (median 18 months versus 17 months in the NIM-CMPA
group). That means that at the time of diagnosis, the NIM-CMPA infants were at least 6 months
younger than at sampling. In their letter [1], Martín Martinez and López Liñan argue that “another
important difference between controls and infants with NIM-CMPA is that the latter followed a diet
free of dairy products for 6 months. Indeed, this can be a factor modifying the microbiota”. We believe
that their interpretation overlooks important points of our study. Control infants are healthy infants
that consume milk and dairy without restriction, and of course, infants with NIM-CMPA are on a
restricted diet for at least 6 months. Hence, we did not conclude that differences in microbiota are only
due to the allergic condition of the infants, and of course, we think that a milk restricted diet is at least
partially responsible for the observed differences.
It is also suggested that another missing piece of information in our study is related to the type
of formula, which has a strong impact on microbiota. It is true that we have not provided detailed
information on the type of hydrolyzed formula used in our study (trademarks) apart from extensively
hydrolyzed formula (EHF), soy protein-based formulas, and HRF, and maybe this has contributed to
some of the confusion. Nevertheless, significant differences in microbiota composition were found
between those infants fed with vegetable protein-based formulas and those consuming EHF, but not
among the last group. Additionally, regarding the argument focusing on lactose, it is important to
underline that in infants with IgE mediated CMPA, formulas containing lactose are sometimes used.
However, in NIM-CMPA cases, these formulas are usually avoided.
Surprisingly, another point that is criticized is the analysis of the microbiota. Our microbial
sequences are deposited in a public database and openly available [3], allowing further analyses by
other authors. We found that those infants who do not become tolerant in the study (fed HRF) present
significant differences and less abundance of Coriobacteriaceae and Bifidobacteriaceae members
than those who become tolerant. It is also noticeable in our study, that infants fed vegetal protein
formulas, both rice and soy, have significantly less Coriobacteriaceae than those fed EHF formulas.
The details on the levels are displayed on page 5: “Coriobacteriaceae were significantly diminished in
NIM-CMPA infants consuming vegetable protein-based formulas (n = 5), both rice and soy, (mean of
0.64% of total assigned reads, range 0.02–2.38%) compared to those infants fed with EHF (mean of
4.45%, range 0.08–13.44%)”, and in Table 1 (Coriobacteriaceae mean abundance in infants consuming
HRF = 0.26%) [3]. A potential explanation for these observations is mentioned in the discussion section
of our article in relation to cross-feeding mechanisms among lactate microbial users and butyrate
producers, although it is true that the exact role of the Coriobacteriaceae in the infant gut microbiota
is still unknown. Moreover, we do not have a clear response to the authors of this letter as to why
245
Nutrients 2019, 11, 476
these Coriobacteriaceae members are enriched in those infants fed with EHF, as compared also with
healthy controls infants, although, a positive significant correlation was found between this family and
butyrate levels [3]. In addition, a statistical association was detected between this important microbial
metabolite and the excretion of the mediator TGF-β, implicated in tolerance, so there is a potential
relationship among all these factors.
Regarding the comment on the use of vegetable formulas and the possible impairment of tolerance
acquisition, Martín Martinez and López Liñan [1] indicate that “this conclusion cannot be drawn from
the results of the study from Diaz et al”. However, although these issues are discussed within the
discussion section, our manuscript does not establish such a conclusion. Actually, our conclusions
are that type of formula can determine microbiota composition, and that this, through the production
of microbial metabolites and modulation of immune mediators, may influence tolerance acquisition.
Of course, in the discussion we are allowed to comment on possible explanations for our results, based
on current knowledge such as exposure to immunomodulatory peptides.
We hope this letter will help to clarify the points raised by Martín Martinez and López Liñan
and appreciate the interest of these authors and the opportunity to engage in a dialogue around
NIM-CMPA tolerance, diet and microbiota.
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